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General introduction
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In the last century, cancer has become one of the most important health issues 
worldwide.1 With increasing incidence and total number of deaths, it is currently 
one of the leading causes of death before the age of seventy in the Western World.2 
Simultaneously,  there has been a significant rise in the number of treatment options 
with an exponential growth in the last twenty to thirty years, starting with radiotherapy 
and surgery as treatment options in the early 1900’s. Nowadays there are multiple 
treatment options, among which intravenously administered chemotherapy and orally 
administered targeted drugs (e.g. tyrosine kinase inhibitors).1, 3 Despite the still growing 
arsenal of therapeutic options there remains an urgent need for optimalisation of the 
already registered drugs to guarantee the most optimal treatment for each individual 
patient.
In case of treatment with anti-cancer drugs, one of the most important parameters to 
ensure optimal treatment efficacy is the systemic exposure to that particular anti-cancer 
drug. Optimal systemic drug exposure, or bioavailability, is determined by several 
individual factors (e.g. organ function, body size-measures),  disease (tumor burden, 
etc.), (pharmaco-) genetic factors and environmental factors (e.g. co-medication).4 
Most of these factors may influence systemic drug exposure by interacting with either 
drug ‘pharmacokinetics’ and/or ‘pharmacodynamics’. Pharmacokinetics describe the 
process of how the body affects a drug. This process globally consists of four major 
components: absorption, distribution, metabolism and excretion, which together 
illustrates the journey of a drug throughout the body.5-7 Pharmacodynamics describe 
the biochemical and physiologic effects (e.g. effect and toxicity) of drugs on both the 
body and the disease.6 Alterations in pharmacodynamics or pharmacokinetics, due to 
the earlier mentioned patient and environmental factors, may have a significant impact 
on treatment efficacy in cancer patients, and patient may be deprived from optimal 
anticancer therapy 8, 9
This thesis describes pharmacokinetic and pharmacodynamic drug-interaction studies 
for several (commonly used) anti-cancer agents. It is important to investigate these 
drug-interactions to either gain knowledge about possible interaction mechanisms 
in general and to find ways to avoid or deal with these drug-interactions, therefore 
assuring an optimal treatment for every individual patient.
12
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PART I: DRUG-DRUG INTERACTIONS
Together with the increase in treatment modalities, there has also been an significant 
increase in the overall quality of life and life expectancy of cancer patients.10, 11 Despite 
this prolonged survival time, many patients suffer from comorbidities and side-effects 
caused by both the disease and the treatment, often forcing them to use multiple co-
medications. Therefore, cancer patients are at major risk for polypharmacy, i.e. the use 
of multiple drugs concomitantly with the anti-cancer drugs. Polypharmacy is associated 
with an increased risk of drug-drug interactions, which may lead to treatment failure 
and/or increased toxicity.12, 13 Pharmacokinetic drug interactions influence the 
pharmacokinetics and therefore exposure to certain drugs at several levels (figure 
1).14 Absorption is the uptake of a drug from the gastro-intestinal tract into the blood 
stream. This is a complex process, which is mainly driven by several ‘pumps’ or drug-
transporters. After the absorption phase, the drug is distributed to the liver where a 
complex enzyme driven process (mainly by enzymes of the cytochrome P450 enzyme 
system) breaks down the drug into several metabolites; these metabolites can be 
both active and inactive. This breakdown process is called drug metabolism. After the 
metabolism phase, a drug is distributed further through the body by the blood stream 
and eventually excreted through the bile or urine. Medication may have an influence 
on every of these four steps of drug pharmacokinetics. Nonetheless, most (important) 
drug-drug interactions appear in the absorption and metabolism phase.9
Chapter 2 gives a detailed overview of several clinically relevant drug-drug interactions 
on both the absorption and metabolism level involved with orally administered small 
molecule kinase inhibitors (SMKIs). SMKIs are a relatively new class of drugs used for 
the treatment of various malignancies. SMKIs includes the group of tyrosine kinase 
inhibitors (TKIs). SMKIs and TKIs target specific so-called tyrosine kinases, that activate 
several cellular pathways involved in (cancer)cell growth, differentiation, death and a 
series of biochemical and physiological processes among other things.15 These drugs 
inhibit the phosphorylation (activation) of these tyrosine kinases, leading to blockage 
of these cellular pathways, thereby preventing tumor growth and stimulating tumor 
death. SMKIs are administered orally, and as a consequence, are therefore highly 
prone to drug-drug interactions, since they also have to undergo the absorption step 
of the pharmacokinetic process in contrast to intravenously administered drugs, which 
bypass this step.16
13
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FIGURE 1: Mechanism of pharmacokinetic drug-interactions 14
Another example of a drug-drug interaction --involving the absorption phase-- is the 
concomitant use of proton pump inhibitors (PPIs). PPIs are used extensively by cancer 
patients for the treatment of, for example gastroesophageal reflux disease, counting 
up to 33% of all cancer patients.17 Co-administration of PPIs can cause a significant 
decrease in drug-exposure (area under the curve; AUC) of several SMKIs, even up to 
61% for dasatinib.18 Since many anti-cancer drugs among which the SMKIs dissolve 
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better in an acidic environment, the decrease in drug-exposure can be explained 
by the increase in stomach pH following PPI administration, which has a significant 
impact on drug absorption and thus drug exposure.9, 16 Since drug exposure decreases 
significantly with PPIs this may have an impact on overall survival, as was proven for 
several drugs like pazopanib.19 Furthermore, Olivier et al. and Chu et al. have shown that 
the use of PPIs in general next to the regular anticancer treatment leads to a significant 
decrease in survival for patients using sunitinib or capecitabine, respectively, which 
may be explained by the drug-drug interaction with PPIs leading to a decrease in anti-
cancer drug exposure.20, 21 In chapter 3 a comment to the research from Chu et al. is 
described about the pitfalls in their work. Despite the interesting results of this study, 
the lack of data on type of PPI used, PPI dose, and period of time the combination was 
used, makes the interpretation of the data difficult.
An example of a more optimal research strategy to study drug-drug interactions 
with PPIs in cancer patients is presented in chapter 4. Here, the possible drug-drug 
interaction between regorafenib, a new multi-kinase inhibitor that targets angiogenic, 
stromal and oncogenic receptor tyrosine kinases (e.g. VEGFR, KIT, BRAF, PDGFR and 
FGFR), and the PPI esomeprazole is described. Regorafenib is used in the treatment 
of metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal 
tumor. We concluded (chapter 2) that regorafenib is unlikely to result in a clinically 
relevant drug-interaction with PPIs. However this interaction has not been studied 
in a clinical setting. Therefore this study investigated whether there is a significant 
interaction between the PPI esomeprazole and regorafenib, or not.
Drug-drug interactions involving drug metabolism are the most important and most 
prevalent drug-drug interactions in clinical practice.22 Most drugs are extensively 
metabolized in the liver in active (e.g. tamoxifen, sorafenib) and inactive metabolites 
(e.g. afatinib) by cytochromes of the P450 (CYP) system. Drug interactions involve either 
induction or inhibition of a certain enzyme resulting in decreased or increased drug 
concentrations respectively.9 In chapter 5 a study is described in which a metabolic 
drug-drug interaction (docetaxel with prednisone) is investigated. Docetaxel, a 
chemotherapeutic agent in the class of taxanes, is used in the regular treatment of 
several cancer types such as breast cancer, but also showed an important survival 
benefit in the first line treatment of metastatic hormone sensitive prostate cancer 
(mHSPC).23 In this TAX327 study, docetaxel was combined with prednisone to equally 
compare it to mitoxantrone therapy, which is also combined with prednisone. Two 
large clinical trials (CHAARTED and STAMPEDE) assessed the survival benefit of 
docetaxel compared to standard of care resulting in a comparable survival benefit of 
10.4 and 16.0 months in the CHAARTED and STAMPEDE respectively. 24, 25 However, 
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one of the main differences between these trials was the absence of prednisone in the 
CHAARTED trial whereas the STAMPEDE trial added prednisone to the treatment. There 
was no significant difference in toxicity between the CHAARTED and STAMPEDE trial, 
which raised the question whether prednisone could be removed from the treatment 
regimen to prevent (long-term) toxicity in these patients. Furthermore prednisone 
is a mild CYP3A4 inducer and may theoretically alter docetaxel pharmacokinetics, 
since docetaxel is primarily metabolized by CYP3A4.26 To clarify this, this interaction is 
investigated and described in chapter 5 of this thesis.
Anticancer drugs, and especially some SMKIs, are known for their narrow therapeutic 
window, which is the balance between side-effects on one hand and underdosing and 
ineffective dosing on the other.8 In this case a drug-interaction may have a significant 
impact on both patient wellbeing and therapy efficacy. When two agents with a small 
therapeutic window have to be combined for clinical reasons, and metabolic pathways 
overlap, the risk for a significant drug-interaction increases significantly since only a small 
alteration may have a major impact on toxicity or efficacy of such a drug. For instance 
patients who receive immunosuppressants after undergoing a liver transplantation for 
HCC may develop a recurrent tumor in the transplant liver in approximately 20% of the 
cases.27, 28 The first line of treatment in this case is the SMKI sorafenib, which also has 
a narrow therapeutic window and is associated with many side-effects. Furthermore, 
most patients who underwent a liver transplantation receive immunosuppressants, 
which are usually strong inhibitors of several metabolizing enzymes such as CYP3A4 
and may therefore alter sorafenib pharmacokinetics and theoretically also efficacy and 
toxicity.29 Vice versa, sorafenib may also alter immunosuppressant pharmacokinetics 
as well by inhibiting CYP3A4, which is the main metabolic enzyme for many 
immunosuppressants. In chapter 6 a case-series is presented in patients using this 
combination of agents.
Sorafenib is associated with many side-effects of which hand-foot skin reaction 
(HFSR) is one of the most common and debiliating.30, 31 HFSR is a particularly painful 
complication seen most frequently during the early weeks of treatment with SMKIs, 
such as sorafenib, sunitinib, and pazopanib, in which hyperkeratotic plaques develop 
predominantly over sites of pressure or friction. Unfortunately, there is currently 
no effective treatment option for HFSR besides dose-reduction or discontinuation. 
However, the finding by Zimmerman et al. that a drug transporter (OAT6) in keratinocytes 
is responsible for the uptake of sorafenib in the skin might potentially offer a possibility 
to prevent this side-effect.32 The preclinical study showed that by selectively inhibiting 
OAT6 with probenecid, a drug used in the treatment of gout, HFSR was prevented in 
16
Chapter 1
mice. However, probenecid may also alter sorafenib metabolism and/or excretion.33 
Therefore, a clinical study investigating the possible interaction between sorafenib and 
probenecid and the influence of this combination on HFSR was performed (chapter 7).
Another example of an important pharmacodynamic drug-drug interaction is the 
prolongation of the QTc-interval, which gives a significant risk of cardiac arrhythmias 
and sudden cardiac death.34, 35 The QTc-interval is determined as the time on an 
electrocardiogram (ECG) from the start of the QRS complex, to the end of T wave, as 
it returns to baseline.36 A group of agents that is known to prolong the QTc-interval 
includes the serotonin reuptake inhibitors (SRIs), used in the treatment of depression 
and anxiety disorders.37 These drugs are often prescribed to patients with cancer, 
because of their high prevalence of depressive complaints.38 Among these, breast cancer 
patients experience the highest prevalence of depression.39 Many of these patients use 
antihormonal therapy, most often the selective estrogen receptor inhibitor tamoxifen, 
which may also prolong the QTc-interval by itself.40 Therefore, Chapter 8 describes the 
effect on the QTc-interval of the combination of these two classes of agents compared 
to tamoxifen monotherapy.
PART II FOOD-DRUG INTERACTIONS
Besides the use of multiple drugs, and the risk for drug-drug interactions, there is 
also an increasing trend in the use of complementary and alternative medication.41 
Nowadays, the use of food and herbs is becoming more and more popular among 
(cancer) patients as an alternative strategy for the treatment of cancer and the treatment 
of cancer and treatment related symptoms (e.g. pain and nausea).41 About 48-88% of 
all cancer patients use alternative medication including food supplements.41 Besides 
the potentially favorable effects, food and supplements may also have an impact on 
the pharmacokinetics of several drugs and may therefore deprive patients from an 
optimal therapy.42 For example, the intake with a fat meal increases the exposure of 
abiraterone; a drug used in the treatment of castrate resistant prostate cancer by 10-
fold, compared to intake in a fasted state.43 Since food or supplements may also have a 
significant impact on the pharmacokinetics of drugs like SMKIs, an extensive review is 
presented in chapter 9 about important currently known food-drug interactions with 
SMKIs.
As mentioned in part I of this introduction, significant drug-interactions between PPIs 
and SMKIs exist, resulting in a significant and clinically relevant reduction in drug 
exposure, and therefore potential reduction in therapy efficacy. Because of its low 
acid dissociation constant (pKa-value; resulting in a rapidly decreasing solubility at 
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higher pH), erlotinib, a SMKI used in the treatment of non-small cell lung cancer, is 
also highly prone for a drug-drug interaction with PPIs. Concomitant use of erlotinib 
with esomeprazole results in a decrease of AUC of almost 50%.44, 45 Cancer patients 
often have a hard indication for the use of a PPI and therefore cannot stop or decrease 
their PPI therapy. Therefore, a practical way to bypass this interaction with the popular 
beverage cola is presented in chapter 10. Coca-Cola is a very acidic beverage (pH=2.5). 
By taking erlotinib simultaneously with cola --instead of water-- the negative effects on 
erlotinib absorption may theoretically be bypassed, caused by a temporarily decrease 
in stomach pH and therefore an increase in erlotinib solubility.
Although intake of erlotinib with cola possibly offers a clear advantage over intake 
with water, when erlotinib is used concomitantly with a PPI, cola also knows many 
disadvantages. Erlotinib is often administered in the morning at an empty stomach, 
which makes ingestion with cola difficult for many patients. Many SMKIs, like erlotinib, 
have the ability to dissolve better in a fatty environment compared to water. Therefore, 
intake with (fat) food alters the exposure of several SMKIs as described in chapter 9 of 
this thesis. Consequently, intake of a SMKI with a fatty drink, such as full cow’s milk, 
may potentially be another and healthier alternative, compared to cola to increase 
the systemic exposure to erlotinib (chapter 11). This chapter studies the effects of 
coadministration of a PPI on erlotinib plasma exposure. Furthermore the influence of 
full cow’s milk, as a fatty beverage, on erlotinib exposure in patients using erlotinib with 
or without a PPI is described.
Since the use of food and herbs (and supplements) is becoming increasingly popular 
among cancer patients, the risk of a relevant food-drug interaction is also increasing. 
One of the most popular herbs among cancer patients, especially breast cancer 
patients, is curcumin, which is derived from the root of the curcuma longa and is used 
in traditional Asian cuisine and medicine. Curcumin is believed to induce several 
health benefits and to also possibly have an additional anti-tumor effect.46, 47 However, 
curcumin itself may also have an effect on drug pharmacokinetics in rats as was 
demonstrated by Cho et al.48 They showed a 33%-64% increase in the area under the 
curve (AUC) or exposure of tamoxifen. However, since these data were preclinical, 
the translation to a clinical setting --especially in cancer patients-- remains difficult. 
Tamoxifen is a prodrug and has to be metabolized first, mainly by the cytochrome 
P450 enzymes CYP2D6 and CYP3A4, into active metabolites of which endoxifen is the 
most potent. Furthermore, tamoxifen shows a large interindividual variability in drug 
exposure.49 These characteristics make tamoxifen prone for drug interactions, which 
is of major relevance, as there is a suggested threshold for endoxifen efficacy, and a 
drug interaction might potentially lead to subtherapeutic endoxifen concentrations.50 
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Since many breast cancer patients use both tamoxifen and curcumin in daily practice, 
a clinical study in breast cancer patients is described in chapter 12.  Here, this possible 
pharmacokinetic interaction with regards to curcumin and tamoxifen with or without 
the bio enhancer piperine, is studied.
Next to curcumin, one of the other supplements that is becoming more and more 
popular among (breast) cancer patients is green tea, which contains high amounts of 
epigallocatechin gallate (EGCG). EGCG is a flavonoid compound (i.e. an organic nitrogen-
free organic structure often found in plants) with a proposed anti-cancer effect.51 
However, flavonoids may also cause a drug-interaction as was shown by Misaka et 
al. for nadolol.53, 53 They found a 85% decrease in nadolol plasma levels, when nadolol 
was administered with green tea. EGCG may potentially also influence tamoxifen 
metabolism. Chapter 13 describes the interaction between green tea extract capsules 
and tamoxifen in breast cancer patients.
In conclusion, this thesis gives an overview of different pharmacokinetic and 
pharmacodynamic aspects in the field of drug-drug and drug-food interactions. 
However, this is just a tip of the iceberg and more research is needed to fully 
understand the mechanisms, the complexity and impact of drug-interactions in daily 
clinical oncology practice. Recognition of drug-drug and drug-food interactions may 
improve therapy efficacy, reduce side-effects and therefore increase the quality of life 
of (cancer) patients, and should have a more prominent place in both clinical research 
and practice.
19
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ABSTRACT
Multi-kinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have 
rapidly become an established factor in daily (hemato-) oncology practice. Although 
the oral route of administration offers improved flexibility and convenience for the 
patient, challenges arise in the use of MKIs. As MKIs are prescribed extensively, 
patients are at increased risk for (severe) drug-drug interactions (DDIs). As a result of 
these DDIs, plasma pharmacokinetics of MKIs may vary significantly, thereby leading 
to high interpatient variability and subsequent risk for increased toxicity or diminished 
therapeutic outcome.
Most clinically relevant DDIs with MKIs concern altered absorption and metabolism. The 
absorption of MKIs may be decreased by concomitant use of gastric acid suppressive 
agents (e.g. proton pump inhibitors) as many kinase inhibitors show pH-dependent 
solubility. In addition, DDIs concerning drug (uptake and efflux) transporters  may be 
of significant clinical relevance during MKI therapy. Furthermore, since many MKIs are 
substrates for cytochrome P450 isoenzymes (CYPs), induction or inhibition with strong 
CYP inhibitors or inducers may lead to significant alterations in MKI exposure.
In conclusion, DDIs are of major concern during MKI therapy and need to be monitored 
closely in clinical practice. Based on the current knowledge and available literature, 
practical recommendations for management of these DDIs in clinical practice are 
presented in this review.
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INTRODUCTION
Although cancer is still the leading cause of death among men and women worldwide, 
novel treatment options are rapidly evolving. In order to improve treatment efficacy and 
minimize toxicity more specific targets have been identified. One of the most promising 
classes of targeted anticancer agents are the multi-kinase inhibitors (MKIs), including 
the tyrosine kinase inhibitors (TKIs). MKIs target specific tyrosine kinases within the 
tumor cell, where they play a key role in the signal transduction, gene transcription, 
and DNA synthesis.1 MKIs like osimertinib (for lung cancer) and cabozantinib (for 
kidney cancer) rapidly gained a place in standard of care treatment for multiple or 
new indications [e.g. regorafenib in primary liver cancer, after earlier approvals for 
gastrointestinal stromal tumor (GIST) and colorectal cancer.
MKIs include both small molecule MKIs and large molecule MKIs. In this review we 
will solely focus on the small molecule MKIs. Small molecule MKIs are administered 
orally, which gives them a clear advantage over conventional chemotherapy in terms 
of flexibility and patient convenience. Many MKIs show a narrow therapeutic window, 
whereas intra- and interpatient exposure is highly variable and multifactorial.2-4 
Also factors like food, beverages, lifestyle, and pharmacogenetic polymorphisms 
may alter MKI bioavailability significantly.5 For example, as MKIs are predominately 
metabolized through phase I (e.g. CYP enzymes) or phase II enzymes (e.g. UDP-
glucuronosyltransferase) or almost exclusively by phase II enzymes (e.g. in the case of 
afatinib), this makes them highly prone for drug-drug interactions (DDIs) involving drug 
metabolism.6 Moreover, since cancer patients often use multiple drugs concomitantly 
with their anticancer therapy, they are even more at risk for DDIs, compared to other 
patient groups.7
DDIs can be classified as pharmacodynamic or pharmacokinetic.8 Pharmacokinetic 
DDIs are defined as drug interactions regarding drug absorption, metabolism, 
distribution and elimination leading to altered plasma concentrations of a drug and 
possible unfavorable outcomes (e.g. increased toxicity and reduced treatment efficacy). 
A pharmacodynamic interaction is the altered response in terms of toxicity and efficacy 
when two or more drugs affect similar molecular targets (e.g. membrane receptors). 
Pharmacodynamic DDIs can be additive, antagonistic or synergistic. For instance, 
epidermal growth factor receptor (EGFR) kinase inhibitors often show synergistic 
antitumor effects when combined with chemotherapy.9
Both the United States Food and Drug Administration (US FDA) and the European 
Medicines Agency (EMA) present guidelines for the interpretation of DDIs. However, 
28
Chapter 2
because of discrepancies between recommendations, currently no clear general 
consensus for the management of DDIs is available. Therefore, the management of 
DDIs is challenging for clinicians and the need for a general consensus is urgent.
This review-article presents an overview of known pharmacokinetic DDIs regarding 
orally taken MKIs currently approved by the US FDA and EMA. Moreover, if possible, 
practical recommendations are given for the management of DDIs during MKI therapy 
in clinical practice.
METHODS
We conducted a search in PubMed and the Embase databases for English language 
studies published until 2 July 2018 for randomized clinical trials, observational studies, 
and reviews about US FDA and EMA-approved MKIs. We used the following search 
MESH terms: ‘(Drug interactions) OR (Drug combination) AND (Drug name)’. In Embase, 
we used ‘clinical studies’, ‘humans’ and ‘only in English’ as additional search limits. The 
search results were manually screened for relevance. In addition, all MKI (US FDA and 
EMA) assessment reports were screened on the latest updates regarding DDIs in the 
scientific updates available at the EMA and US FDA website until 2 July 2018. We included 
clinical drug–drug interaction studies in human and preclinical pharmacokinetic 
studies investigating possible interactions. We excluded studies which did not focus on 
pharmacokinetics or drug interactions. Clinical relevance of the interaction was scored 
on the basis of the US FDA-classification of the effect of drug interactions and the level 
of available evidence as a ‘major’, ‘moderate’ or ‘minor’ interaction. If there was no 
clinical pharmacokinetic study performed, the interaction potential was estimated 
on the basis of the inhibitory concentration or pKa and the advice in the assessment 
reports.10
ABSORPTION
Intragastric pH
The absorption of MKIs can be significantly affected by altered intragastric pH. When 
intragastric pH is elevated (e.g. due to proton pump inhibitors; PPIs), the MKI solubility, 
bioavailability, and eventually treatment efficacy may be significantly influenced (Figure 
1).8,11–13 The impact of this ‘pH effect’ is highly variable per MKI and the clinical relevance 
of the DDI between MKIs and acid-suppressive agents (e.g. PPIs, H2-antagonists and 
antacids) must be assessed on an individual basis. A complete overview can be found 
in Table 1.14–35
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Indecisive guidelines and the fact that 20–30% of all cancer patients have an indication 
for the use of acid-suppressive agents (ASAs) complicate the management of this DDI.36 
The general consensus is, if possible, to avoid the combination between MKIs and ASAs.37 
However, if there is a distinct indication for an ASA (e.g. Barrett’s esophagus), a clear and 
practical advice to manage the DDI between MKIs and ASAs is essential to safeguard 
optimal MKI therapy. Based on the pharmacokinetics and pharmacodynamics of both 
MKIs and ASAs, practical advice can be given for the management of the DDI between 
MKIs and PPIs, H2-antagonists (H2As) and antacids (see Figure 1 and Table 1).13 This 
advice may be extrapolated to newly introduced MKIs with a known or suspected drug 
interaction with gastric suppressive agents and thus with a great impact of the ‘pH 
effect’ as mentioned in Figure 1 and Table 1.
ASA
MKI
DDI:
• Ceritinib
• Gefitinib
• Erlotinib
• Dasatinib
• Pazopanib
• Nilotinib
• Lapatinib
• Bosutinib
• Alectinib
• Sunitinib
• Nintedanib
• Tivozanib
No DDI
• Cobimetinib
• Crizotinib
• Cabozantinib
• Imatinib
• Osimertinib
• Vandetanib
• Axitinib
• Dabrafenib
• Ponatinib
• Regorafenib
• Ibrutinib
• Lenvatinib
• Sorafenib
• Vemurafenib
• Trametinib
• Afatinib
• Ruxolitinib
+
pH    
Absorption    
FIGURE 1. Working mechanism of the drug–drug interaction with an ASA: MKIs are arranged according to the 
clinical relevance and magnitude of the interaction in a descending order, with the most relevant interactions on 
top of the list. A PPI increases stomach pH after intake and thereby decreases absorption of MKIs and therefore 
bioavailability of MKIs. Abbrevations: ASA, acid-suppressive agent; DDI, drug–drug interaction; MKI, multikinase.
MKIs and PPIs. Since PPIs do not elevate intragastric pH over the full 24 h-range, a window 
of relatively low intragastric pH may be used to manage the DDI.38 If there is a hard 
indication for PPI use, MKIs should be taken at least 2h before the PPI in the morning 
in a once-daily regimen, since MKIs can be absorbed completely within this window.13,38 
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Clinically relevant drug interactions with multikinase inhibitors
2
Another possibility is to administer a MKI with an acidic beverage such as cola (pH = 
2.5) to manage the DDI, since the acidic beverage temporarily decreases stomach pH 
resulting in better MKI solubility and absorption.23 Furthermore, the influence of other 
acidic beverages [e.g. sprite (pH = 3.4) or orange juice (pH = 3.3)] on the absorption of 
MKIs has not been studied yet.
MKIs and H2-antagonists. Since most H2-antagonists show a short plasma half-life and 
are administered in a twice daily regimen (e.g. ranitidine), MKIs should be taken at 
least 2h before or 10h after the H2-antagonist intake according to US FDA and EMA 
guidelines.14,15
MKIs and antacids. Antacids are relatively short-acting agents (e.g. magnesium 
hydroxide). MKIs should be administered at least 2h before, or 4h after antacid intake, 
to manage this DDI.14,15
Drug transporters and intestinal enzymes
As mentioned previously, MKI absorption is a multifactorial process mediated and 
affected by passive diffusion, active transport through multiple drug transporters, and 
intestinal metabolism.7 The activity of these drug transporters and intestinal enzymes 
may significantly influence MKI bioavailability.
Drug transporters are located throughout the body, especially in the gut, bile ducts, 
kidneys and the blood–brain barrier (Figure 2).39 The US FDA states: ‘membrane 
transporters can have clinically relevant effects on the pharmacokinetics and 
pharmacodynamics of a drug in various organs and tissues by controlling its absorption, 
distribution, and elimination. In contrast to drug metabolizingenzymes that are largely 
expressed in the liver and small intestines’.10 Therefore, the effect of a DDI considering 
drug transporters may be of greater clinical relevance then is assumed so far.
Furthermore, efflux drug transporters like P-glycoprotein, or P-gp (ATP-binding cassette 
subfamily B member 1, ABCB1) and also breast cancer resistance protein (BCRP; 
ATP-binding cassette subfamily G member 2, ABCG2) may play a crucial role in drug 
absorption and enterohepatic recirculation. Enterohepatic recirculation is the process 
in which foreign chemicals are absorbed into the portal blood stream and metabolized 
by hepatocytes, secreted into the bile and eventually are reabsorbed after secretion 
of bile in the gut lumen.40 In this multi-step process drug transporters like P-gp and 
BCRP play a significant role. Other drug efflux transporters that may influence MKI 
bioavailability are the multidrug resistance protein subfamily (ATP-binding cassette 
subfamily C member 1 to 12, ABCC1 to 12, like MRP1) and the multi-antimicrobial 
34
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extrusion protein (MATE), while several uptake transporters may be involved as well 
[e.g. organic anion transporting peptides (OATPs), organic anion transporters (OATs), 
and organic cation transporters (OCTs), see Figure 2].
P-gp
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BCRP
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UGT1A6
UGT1A8
UGT1A10
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FIGURE 2. Distribution of drug transporters and metabolizing enzymes: A complete overview of all the drug 
transporters and metabolizing phase I and phase II enzymes are presented in this figure for the main organs 
involved in the pharmacokinetics of drugs. BCRP, breast cancer resistance protein (ABCG2); CYP, cytochrome 
P450 iso-enzyme, MATE, multi-antimicrobial extrusion protein; MRP, multidrug resistance associated protein; 
OAT, organic anion transporters; OATP, organic anion  ransporting peptides; OCT, organic cation transporters; 
P-gp, P-glycoprotein (ABCB1); UGT, UDP-glucuronosyltransferase.
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Clinically relevant drug interactions with multikinase inhibitors
2
Many drugs are known P-gp inhibitors (e.g. verapamil) or act as a strong P-gp-inducer 
(e.g. rifampicin). Drugs like cyclosporine, an inhibitor of several OATPs (e.g. OATP1B1 
and BCRP) and cimetidine (OCT2 inhibitor) may influence other drug transporters 
as well.41 For example, nintedanib showed a decrease in both area under the curve 
(AUC) and maximum concentration (Cmax) when co-administered with rifampicin. Since 
nintedanib is almost exclusively metabolized by phase II enzymes, this effect on AUC 
and Cmax is most likely due to P-gp induction.
42 In general the use of strong P-gp or BCRP 
inhibitors or inducers is discouraged when MKIs are substrates for these transporters. 
Furthermore, many MKIs show inhibition of several drug transporters by themselves 
(Table 2).14,15,18,21,35,41,43–59 When a MKI acts like an inhibitor of these transporters and is 
co-administered with drug transporter substrates with a narrow therapeutic window 
(e.g. digoxin), close monitoring of side effects (e.g. severe arrhythmia for digoxin) is 
warranted. For some MKIs the clinical relevance of DDIs regarding drug transporters is 
negligible and the combination with inhibitory or inducing compounds is considered to 
be well tolerated (e.g. bosutinib).14,15
In contrast with the above mentioned unwanted adverse effects, mostly found in 
preclinical studies, DDIs concerning drug transporters and MKIs may also be used 
in a beneficial way. For example, MKIs may potentially increase chemotherapy 
concentrations through P-gp or BCRP inhibition (e.g. increased paclitaxel plasma 
concentration resulting from P-gp inhibition by nilotinib or increased nilotinib 
concentrations as a result of P-gp inhibition by imatinib).60,61
In conclusion, we found only a limited number of clinical studies, which investigated the 
effects of inhibition or induction of drug transporters by MKIs, since this is a relatively 
novel field of DDI research. Combinations between strong drug transporter inhibitory 
or inducing compounds should be avoided for most MKIs as mentioned in Table 2.
Intestinal metabolism
Another important factor in drug absorption is intestinal metabolism. Many MKIs are 
metabolized in the gut wall through intestinal CYP3A4, which is often in close proximity 
of drug transporters, such as P-gp. When a MKI is given concomitantly with an intestinal 
CYP3A4 inducer (e.g. rifampicin) or inhibitor (e.g. grapefruit juice) this may significantly 
change MKI bioavailability.62 However, in contrast, Van Erp and colleagues failed to 
show a significant increase in sunitinib exposure, when co-administered with grapefruit 
juice.63 Moreover, since many MKIs undergo extensive first-pass metabolism and are 
thus dependent of both intestinal and hepatic metabolism, it is difficult to determine 
whether intestinal metabolism or hepatic metabolism is the main contributor to an 
altered drug bioavailability.
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el
ev
an
t c
on
ce
nt
ra
tio
ns
 a
re
 
un
lik
el
y.
 If
 n
ec
es
sa
ry
 a
 2
0m
g 
do
se
 
al
te
ra
tio
n 
m
ay
 b
e 
ap
pl
ie
d.
 C
lo
se
 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 w
ar
ra
nt
ed
 
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
M
RP
2 
in
hi
bi
to
rs
 (e
.g
. c
yc
lo
sp
or
in
e)
. 
M
od
er
at
e
14
, 1
5
37
Clinically relevant drug interactions with multikinase inhibitors
2
TA
BL
E 
2.
 C
on
tin
ue
d
M
KI
Su
bs
tr
at
e
In
hi
bi
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C m
ax
A
U
C
Cl
in
ic
al
 im
pl
ic
at
io
ns
In
te
ra
ct
io
n 
po
te
nt
ia
l
Re
fe
re
nc
es
Ce
ri
tin
ib
P-
gp
P-
gp
, B
CR
P
N
A
N
A
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 o
f P
-g
p 
m
us
t b
e 
av
oi
de
d 
si
nc
e 
pl
as
m
a 
co
nc
en
tr
at
io
n 
of
 c
er
iti
ni
b 
m
ig
ht
 b
e 
al
te
re
d.
 C
lo
se
 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 w
ar
ra
nt
ed
 
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
P-
gp
 
or
 B
CR
P 
su
bs
tr
at
es
. H
ow
ev
er
 C
YP
 
D
D
Is
 a
re
 o
f g
re
at
er
 in
flu
en
ce
.
M
in
or
, s
in
ce
 
in
te
ra
ct
io
ns
 
re
ga
rd
in
g 
CY
P 
en
zy
m
es
 a
re
 
of
 g
re
at
er
 
cl
in
ic
al
 
im
po
rt
an
ce
14
, 1
5
Co
bi
m
et
in
ib
P-
gp
in
 v
itr
o:
 B
CR
P,
 O
AT
P1
B1
, 
O
AT
P1
B3
, O
CT
1
N
A
N
A
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 
st
ro
ng
 P
-g
p 
in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 m
us
t 
be
 a
vo
id
ed
. A
pp
ro
pr
ia
te
 m
on
ito
ri
ng
 
is
 r
ec
om
m
en
de
d 
w
he
n 
us
in
g 
BC
RP
, 
O
AT
P1
B1
, O
AT
P1
B3
, O
CT
1 
su
bs
tr
at
es
.
M
od
er
at
e
14
, 1
5,
 2
1
Cr
iz
ot
in
ib
P-
gp
in
 v
itr
o:
 P
-g
p,
 O
CT
1,
 O
CT
2
N
A
N
A
Ap
pr
op
ri
at
e 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d 
w
he
n 
us
in
g 
co
nc
om
ita
nt
 P
-g
p 
su
bs
tr
at
es
, i
nh
ib
ito
rs
 
an
d 
in
du
ce
rs
. F
ur
th
er
m
or
e 
cl
os
e 
m
on
ito
ri
ng
 is
 r
ec
om
m
en
de
d 
w
he
n 
us
in
g 
P-
gp
, O
CT
1,
 O
CT
2 
su
bs
tr
at
es
.
M
in
or
, 
si
nc
e 
CY
P 
in
te
ra
ct
io
ns
 
ar
e 
of
 g
re
at
er
 
cl
in
ic
al
 
im
po
rt
an
ce
14
, 1
5
D
ab
ra
fe
ni
b
P-
gp
, B
CR
P
in
 v
itr
o:
 O
AT
P1
B1
, 
O
AT
P1
B3
, B
CR
P
Ro
su
va
st
at
in
: 
16
0%
  i
nc
re
as
e
Ro
su
va
st
at
in
: 
7%
 in
cr
ea
se
D
ab
ra
fe
ni
b 
is
 n
ot
 li
ke
ly
 to
 h
av
e 
a 
cl
in
ic
al
ly
 r
el
ev
an
t i
nt
er
ac
tio
n 
w
ith
 
O
AT
P1
B1
, O
AT
P1
B3
 a
nd
 B
CR
P.
 
Co
nc
om
ita
nt
 u
se
 w
ith
 s
ub
st
ra
te
s 
of
 th
es
e 
tr
an
sp
or
te
rs
 is
 c
on
si
de
re
d 
sa
fe
. T
he
 in
flu
en
ce
 o
f P
-g
p 
an
d 
BC
RP
 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 is
 c
on
si
de
re
d 
to
 b
e 
sm
al
l s
in
ce
 th
e 
bi
oa
va
ila
bi
lit
y 
of
 
da
br
af
en
ib
 is
 h
ig
h 
(9
5%
), 
on
ly
 li
m
ite
d 
ph
ar
m
ac
ok
in
et
ic
 e
ff
ec
ts
 c
an
 b
e 
ex
pe
ct
ed
M
in
or
14
, 1
5
D
as
at
in
ib
P-
gp
, B
CR
P
N
A
N
A
N
A
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 o
f P
-g
p 
an
d 
BC
RP
 m
us
t b
e 
av
oi
de
d 
or
 s
id
e-
ef
fe
ct
s 
m
us
t b
e 
m
on
ito
re
d 
cl
os
el
y 
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
.
M
in
or
14
, 1
5,
 4
6
38
Chapter 2
TA
BL
E 
2.
 C
on
tin
ue
d
M
KI
Su
bs
tr
at
e
In
hi
bi
ts
C m
ax
A
U
C
Cl
in
ic
al
 im
pl
ic
at
io
ns
In
te
ra
ct
io
n 
po
te
nt
ia
l
Re
fe
re
nc
es
Er
lo
tin
ib
P-
gp
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 v
itr
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 O
CT
2,
 O
AT
3
N
A
N
A
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 
st
ro
ng
 in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 o
f P
-g
p 
or
 B
CR
P 
m
us
t b
e 
av
oi
de
d 
si
nc
e 
an
 
al
te
re
d 
pl
as
m
a 
co
nc
en
tr
at
io
ns
 p
os
si
bl
e.
 
Ad
m
in
is
tr
at
io
n 
w
ith
 O
CT
2 
an
d 
O
AT
3 
su
bs
tr
at
es
 s
ho
ul
d 
be
 a
vo
id
ed
.
M
od
er
at
e
14
, 1
5,
 
47
-4
9
G
ef
iti
ni
b
P-
gp
, B
CR
P
in
 v
itr
o:
 B
CR
P,
 P
-g
p
N
A
In
 v
itr
o 
Ir
in
ot
ec
an
: A
U
C 
ir
in
ot
ec
an
 6
3%
 in
cr
ea
se
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 
P-
gp
 a
nd
 B
CR
P 
su
bs
tr
at
es
 s
ho
ul
d 
be
 a
vo
id
ed
. B
CR
P 
in
hi
bi
tio
n 
is
 
10
-f
ol
d 
st
ro
ng
er
 th
an
 P
-g
p 
in
hi
bi
tio
n.
 
So
 e
sp
ec
ia
lly
 b
e 
ca
re
fu
l w
he
n 
ge
fit
in
ib
 
is
 c
om
bi
ne
d 
w
ith
 B
CR
P 
su
bs
tr
at
es
. 
Av
oi
d 
th
e 
us
e 
of
 s
tr
on
g 
BC
RP
 o
r 
P-
gp
 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 s
in
ce
 g
ef
iti
ni
b 
pl
as
m
a 
co
nc
en
tr
at
io
n 
m
ay
 b
e 
al
te
re
d.
M
od
er
at
e
14
, 1
5,
 5
0
Ib
ru
tin
ib
N
A
in
 v
itr
o:
 P
-g
p,
 B
CR
P
N
A
N
A
W
he
n 
P-
gp
 o
r 
BC
RP
 s
ub
st
ra
te
s 
ar
e 
us
ed
, 
th
ey
 s
ho
ul
d 
be
 ta
ke
n 
at
 le
as
t 6
 h
ou
rs
 
be
fo
re
 o
r 
af
te
r 
ib
ru
tin
ib
 in
ta
ke
. I
nh
ib
ito
rs
 
or
 in
du
ce
rs
 o
f t
ra
ns
po
rt
er
s 
ar
e 
no
t 
lik
el
y 
to
 r
es
ul
t i
n 
cl
in
ic
al
ly
 m
ea
ni
ng
fu
l 
ch
an
ge
s 
in
 ib
ru
tin
ib
 p
ha
rm
ac
ok
in
et
ic
s 
an
d 
ca
n 
be
 u
se
d 
co
nc
om
ita
nt
ly
.
M
in
or
14
, 1
5,
 5
1
Im
at
in
ib
P-
gp
, B
CR
P
In
 v
itr
o:
  B
CR
P
N
A
N
A
A 
cl
in
ic
al
 r
el
ev
an
t i
nt
er
ac
tio
n 
w
ith
 
P-
gp
 o
r 
BC
RP
 in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 
m
ay
 b
e 
po
ss
ib
le
. C
lo
se
 m
on
ito
ri
ng
 o
f 
su
bs
tr
at
e 
sp
ec
ifi
c 
si
de
-e
ff
ec
ts
 is
 a
dv
is
ed
 
w
he
n 
us
ed
 c
on
co
m
ita
nt
ly
 w
ith
 B
CR
P 
su
bs
tr
at
es
. A
lth
ou
gh
 th
e 
in
te
ra
ct
io
n 
po
te
nt
ia
l i
s 
co
ns
id
er
ed
 to
 b
e 
lo
w
.
M
in
or
14
, 1
5,
 5
2
La
pa
tin
ib
P-
gp
, B
CR
P
in
 v
itr
o:
 P
-g
p,
 B
CR
P,
 
O
AT
P1
B1
D
ig
ox
in
 (P
-g
p 
su
bs
tr
at
e)
: 
10
0%
 in
cr
ea
se
 (d
ig
ox
in
)
D
ig
ox
in
 (P
-g
p 
su
bs
tr
at
e)
: 6
0-
80
%
 
in
cr
ea
se
 (d
ig
ox
in
)
La
pa
tin
ib
 is
 h
ig
hl
y 
su
sc
ep
tib
le
 
fo
r 
in
te
ra
ct
io
ns
re
ga
rd
in
g 
dr
ug
 tr
an
sp
or
te
rs
. 
W
he
n 
us
in
g 
P-
gp
, B
CR
P,
 O
AT
P1
B1
 
su
bs
tr
at
es
 c
lo
se
 m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
 T
he
 u
se
 
of
 s
tr
on
g 
P-
gp
 a
nd
 B
CR
P 
in
hi
bi
to
rs
 
or
 in
du
ce
rs
 s
ho
ul
d 
be
 a
vo
id
ed
.
M
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, 1
5,
 5
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te
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nt
ia
l
Re
fe
re
nc
es
Le
nv
at
in
ib
P-
gp
, 
BC
RP
, 
M
D
R1
in
 v
itr
o:
 P
-g
p,
 B
CR
P,
 
O
AT
P1
B3
Ke
to
co
na
zo
le
: 
19
%
 in
cr
ea
se
si
ng
le
-d
os
e 
ri
fa
m
pi
ci
n:
 
33
%
 in
cr
ea
se
Ke
to
co
na
zo
le
: 
15
%
 in
cr
ea
se
si
ng
le
-d
os
e 
ri
fa
m
pi
ci
n:
 
31
%
 in
cr
ea
se
Cl
in
ic
al
 r
el
ev
an
t i
nt
er
ac
tio
ns
 w
ith
 
st
ro
ng
 in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 o
f P
-g
p,
 
BC
RP
 a
re
 n
ot
 li
ke
ly
 to
 a
pp
ea
r, 
bu
t c
lo
se
 
m
on
ito
ri
ng
 fo
r 
le
nv
at
in
ib
 s
pe
ci
fic
 s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
. C
on
co
m
ita
nt
 
ad
m
in
is
tr
at
io
n 
w
ith
 P
-g
p,
 B
CR
P 
 a
nd
 
O
AT
P1
B3
 s
ub
st
ra
te
s 
sh
ou
ld
 b
e 
av
oi
de
d.
M
in
or
14
, 1
5,
 
54
, 5
5
N
ilo
tin
ib
P-
gp
, B
CR
P
in
 v
itr
o:
 P
-g
p,
 B
CR
P
N
A
Im
at
in
ib
 (C
YP
3A
4/
P-
gp
 
in
hi
bi
to
r)
: n
ilo
tin
ib
 A
U
C 
in
cr
ea
se
d 
w
ith
 1
8-
40
%
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
P-
gp
 o
r 
BC
RP
 in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 m
us
t 
be
 a
vo
id
ed
 s
in
ce
 a
n 
al
te
re
d 
pl
as
m
a 
co
nc
en
tr
at
io
n 
is
 p
os
si
bl
e 
ot
he
rw
is
e 
si
de
-e
ff
ec
ts
 s
ho
ul
d 
be
 m
on
ito
re
d 
cl
os
el
y.
M
in
or
14
, 1
5,
 5
6
N
in
te
da
ni
b
P-
gp
in
 v
itr
o:
 P
-g
p,
 O
CT
1,
 B
CR
P
Ke
to
co
na
zo
le
: 
83
%
 in
cr
ea
se
Ri
fa
m
pi
ci
n:
 6
0%
 
de
cr
ea
se
Ke
to
co
na
zo
le
: 
61
%
 in
cr
ea
se
Ri
fa
m
pi
ci
n:
 5
0%
 
de
cr
ea
se
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
P-
gp
 in
hi
bi
to
rs
 a
 1
00
m
g 
st
ep
-w
is
e 
do
se
 r
ed
uc
tio
n 
m
us
t b
e 
co
ns
id
er
ed
. 
Th
e 
du
ra
tio
n 
of
 th
er
ap
y 
w
ith
 
st
ro
ng
 in
du
ce
rs
 m
us
t b
e 
m
in
im
iz
ed
 
si
nc
e 
in
ad
eq
ua
te
 p
la
sm
a 
le
ve
ls
 o
f 
ni
nt
ed
an
ib
 m
ig
ht
 o
cc
ur
. C
on
co
m
ita
nt
 
ad
m
in
is
tr
at
io
n 
w
ith
 P
-g
p,
 B
CR
P 
an
d 
O
CT
1 
su
bs
tr
at
es
 s
ho
ul
d 
be
 a
vo
id
ed
.
M
aj
or
14
, 1
5
O
si
m
er
tin
ib
P-
gp
, B
CR
P
in
 v
itr
o:
 P
-g
p,
 B
CR
P
Ro
su
va
st
at
in
 (B
CR
P 
su
bs
tr
at
e)
: 7
2%
 in
cr
ea
se
Ro
su
va
st
at
in
 (B
CR
P 
su
bs
tr
at
e)
: 3
5%
 in
cr
ea
se
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 
st
ro
ng
 P
-g
p 
an
d 
BC
RP
 in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 m
us
t b
e 
av
oi
de
d 
si
nc
e 
an
 
al
te
re
d 
pl
as
m
a 
co
nc
en
tr
at
io
n 
is
 li
ke
ly
. 
W
he
n 
co
-a
dm
in
is
te
re
d 
w
ith
 B
CR
P 
or
 P
-g
p 
su
bs
tr
at
es
 c
lo
se
 m
on
ito
ri
ng
 
of
 s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
M
in
or
14
, 1
5
Pa
zo
pa
ni
b
P-
gp
, B
CR
P
in
 v
itr
o:
 O
AT
P1
B1
, 
P-
gp
, B
CR
P
La
pa
tin
ib
 (P
-g
p 
an
d 
BC
RP
 in
hi
bi
to
r)
 
60
%
 In
cr
ea
se
La
pa
tin
ib
(P
-g
p 
an
d 
BC
RP
 in
hi
bi
to
r)
: 
50
%
 in
cr
ea
se
Co
-a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
P-
gp
 
or
 B
CR
P 
in
hi
bi
to
rs
 m
us
t b
e 
av
oi
de
d.
 
Cl
os
e 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 
ad
vi
se
d 
w
he
n 
us
ed
 c
on
co
m
ita
nt
ly
 
w
ith
 P
-g
p 
or
 B
CR
P 
su
bs
tr
at
es
.
M
od
er
at
e
14
, 1
5
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U
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Cl
in
ic
al
 im
pl
ic
at
io
ns
In
te
ra
ct
io
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te
nt
ia
l
Re
fe
re
nc
es
Po
na
tin
ib
P-
gp
, B
CR
P
in
 v
itr
o:
 P
-g
p,
 B
CR
P
N
A
N
A
Ap
pr
op
ri
at
e 
m
on
ito
ri
ng
 is
 r
ec
om
m
en
de
d 
w
he
n 
co
-a
dm
in
is
te
re
d 
w
ith
 P
-g
p 
or
 
BC
RP
 s
ub
st
ra
te
s.
 A
ls
o 
th
e 
us
e 
of
 s
tr
on
g 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 o
f P
-g
p,
 B
CR
P 
m
us
t 
be
 a
vo
id
ed
, a
lth
ou
gh
 D
D
I p
ot
en
tia
l i
s 
co
ns
id
er
ed
 to
 b
e 
lo
w
 s
in
ce
 p
on
at
in
ib
 is
 
on
ly
 a
 w
ea
k 
su
bs
tr
at
e 
fo
r 
P-
gp
 a
nd
 B
CR
P.
M
in
or
14
, 1
5
Re
go
ra
fe
ni
b
P-
gp
, B
CR
P
In
 v
itr
o:
 B
CR
P
Re
go
ra
fe
ni
b 
ha
s 
no
 
ef
fe
ct
 o
n 
di
go
xi
n 
AU
C
Ro
su
va
st
at
in
 
(B
CR
P 
su
bs
tr
at
e)
: 
36
0%
  i
nc
re
as
e
Ro
su
va
st
at
in
 
(B
CR
P 
su
bs
tr
at
e)
: 
28
0%
 in
cr
ea
se
 
BC
RP
 s
ub
st
ra
te
s 
sh
ou
ld
 b
e 
us
ed
 
w
ith
 c
au
tio
n.
 W
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 
of
 P
-g
p 
an
d 
BC
RP
 c
lo
se
 o
bs
er
va
tio
n 
of
 s
id
e-
ef
fe
ct
s 
is
 w
ar
ra
nt
ed
.
M
aj
or
14
, 1
5
Ru
xo
lit
in
ib
N
A
in
 v
itr
o:
 P
-g
p,
 B
CR
P
N
A
N
A
W
he
n 
ru
xo
lit
in
ib
 is
 a
dm
in
is
te
re
d 
w
ith
 
P-
gp
 o
r 
BC
RP
 s
ub
st
ra
te
s 
cl
os
e 
m
on
ito
ri
ng
 
is
 a
dv
is
ed
 fo
r 
th
es
e 
su
bs
tr
at
es
. 
D
D
I p
ot
en
tia
l c
an
 b
e 
m
in
im
iz
ed
 
if 
tim
e 
be
tw
ee
n 
ad
m
in
is
tr
at
io
n 
is
 
ke
pt
 a
pa
rt
 a
s 
lo
ng
 a
s 
po
ss
ib
le
.
M
in
or
14
, 1
5
So
ra
fe
ni
b
P-
gp
, 
O
AT
P1
B1
, 
O
AT
P1
B3
, 
M
RP
2-
3
P-
gp
N
A
N
A
Co
nc
om
ita
nt
 a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 o
f P
-g
p,
 O
AT
P1
B1
, 
O
AT
P1
B3
(r
ifa
m
pi
ci
n)
 a
nd
  M
RP
2-
3 
sh
ou
ld
 
be
 a
vo
id
ed
. A
dm
in
is
tr
at
io
n 
w
ith
 P
-g
p 
su
bs
tr
at
es
 s
ho
ul
d 
be
 d
on
e 
w
ith
 c
au
tio
n.
M
od
er
at
e
14
, 1
5,
 5
7
Su
ni
tin
ib
P-
gp
in
 v
itr
o:
 P
-g
p,
 B
CR
P
co
ad
m
in
is
tr
at
io
n 
w
ith
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Chapter 2
Metabolism
In the liver, MKIs are predominately metabolized by CYP enzymes into either active 
or inactive metabolites. For some MKIs, like nintedanib, phase II metabolism through 
UDP-glycosyltransferases (UGTs), glutathione S-transferases and sulfotransferases 
(SULTs) is dominant in their metabolism.6,64,65 Inhibition or induction of these phase 
I and II enzymes by coadministered medication may lead to either (severe) toxicity or 
loss of effective MKI therapy, respectively.
As DDIs with strong CYP3A4 inhibitors and inducers (e.g. ketoconazole and rifampicin, 
respectively) play a significant role in MKI therapy, they are usually well described 
and clear recommendations for the management of these DDIs are presented in the 
assessment report. There are many (strong) inducers or inhibitors of CYP enzymes 
for which a complete overview can be found at the FDA and EMA websites.41,66 
Moreover, some MKIs (e.g. imatinib, pazopanib) also displayed inhibitory or inducing 
activity by themselves.67–70 The general advice is to avoid concomitant administration 
with strong inhibitors or inducers of CYP enzymes. If this is not possible, a MKI dose 
adjustment, based on the advice given in the assessment report is recommended. For 
strong inducers a gradual dose escalation of the prescribed dose is advised with close 
monitoring of MKIspecific side effects. For an overview of clinically relevant DDIs and 
for practical recommendations see Table 3.14,15,41,43,44,67-69,71–93
Interactions with novel MKIs
In the last decade there has been a significant increase in the development of and 
treatment with MKIs resulting in more than a doubling of registered MKIs in the past 5 
years. Earlier, we described the DDIs with MKIs which were approved before 1 August 
2013.6 Here, we give an extensive overview of the DDI potential and management of 
the novel MKIs, which have been approved after August 2013. A complete overview 
including all (new and older) MKIs is presented in Tables 1–3.
Afatinib.
Afatinib is used in the treatment of nonsmall cell lung cancer (NSCLC). It is a substrate 
of P-gp and BCRP and is mainly metabolized through enzyme-catalyzed Michael adduct 
formation (phase II) and only in a minor extent to phase I enzymes like CYP3A4 and 
FMO (2%).14,15 Concomitant administration with ritonavir (a P-gp inhibitor) showed a 
48% increase in AUC and 39% increase in Cmax.43 Treatment with a potent P-gp inducer 
(rifampicin) prior to singledose afatinib showed a moderate effect on both afatinib 
AUC and Cmax (34% and 22% decrease respectively).
43 When afatinib is administered 
with strong P-gp and BCRP inhibitors, staggered dosing may be used, preferably 6h 
43
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or 12h apart from afatinib intake. When afatinib is administered with strong P-gp 
inducers the dose may be increased with 10mg with close monitoring of side effects. 
Administration with strong CYP inducers or inhibitors is considered safe, since no CYP 
enzymes are involved in afatinib metabolism. Furthermore in vitro studies showed 
afatinib itself to be an inhibitor of P-gp and BCRP, so close monitoring of side effects 
when administered with substrates for these transporters with a narrow therapeutic 
window is recommended.14,15
Alectinib.
The anaplastic lymphoma kinase (ALK) inhibitor alectinib is used in the treatment of 
metastatic lung cancer. Alectinib as well as its M4 metabolite are considered equally 
active. Alectinib is primary metabolized by CYP3A4.14,15 Co-administration with the 
strong CYP3A4 inhibitor posaconazole resulted in a 75% increase of AUC, while co-
administration with rifampicin led to a 73% decrease in alectinib AUC.44 Since alectinib 
and M4 are equally active, a dose modification is not necessary (unless patients 
experience a significant increase in toxicity) when alectinib is administered with strong 
inhibitors or inducers of CYP3A4. Since alectinib is a P-gp and BCRP inhibitor, close 
monitoring of side effects of these substrates is recommended, especially for drugs 
with a narrow therapeutic window (e.g. digoxin).
Bosutinib.
Bosutinib is used in the treatment of chronic myeloid leukemia (CML). Although 
bosutinib is a P-gp substrate and inhibitor, DDIs are not likely to appear, since clinical 
studies demonstrated no significant effect on dabigatran (P-gp substrate) or bosutinib 
(when administered with the P-gp inhibitor lansoprazole) pharmacokinetics.18,45 
Therefore no bosutinib dose reductions are necessary, when administered with strong 
P-gp inducers or inhibitors. Bosutinib is mainly metabolized through CYP3A4 and 
coadministration with the strong inhibitor ketoconazole resulted in 420% increase in 
Cmax and 760% increase in AUC.
74 Administration with rifampicin showed a significant 
86% reduction in Cmax and a 92% decrease in AUC of bosutinib. Administration with the 
moderate inhibitor aprepitant also showed an increase in AUC and Cmax.
73 In conclusion; 
strong inhibitors or inducers of CYP3A4 must be avoided or a gradual 20% dose 
reduction should be applied, when co-administered with strong inhibitors of CYP3A4. 
Increasing the bosutinib dose is not useful, when co-administered with strong CYP3A4 
inducers, since a maximal tolerated bosutinib dose of 600mg is often not sufficient to 
compensate for the relatively large loss of exposure.14,15
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gr
ad
ua
lly
 
in
cr
ea
se
d 
de
pe
nd
in
g 
on
 to
xi
c 
si
de
-e
ff
ec
ts
. 
W
he
n 
ad
m
in
is
te
re
d 
w
ith
 C
YP
2D
6,
 C
YP
2C
8 
or
 
CY
P3
A4
, C
YP
2C
9,
 U
G
T1
A1
 s
ub
st
ra
te
s 
cl
os
e 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
M
aj
or
14
, 1
5,
 8
5
ri
fa
m
pi
ci
n
64
%
 
de
cr
ea
se
80
%
 
de
cr
ea
se
N
in
te
da
ni
b
H
yd
ro
ly
si
s 
du
e 
to
 e
st
er
as
es
U
G
T1
A1
, 
U
G
T1
A7
, 
U
G
T1
A8
, 
U
G
T1
A1
0,
 
CY
P’
s 
(5
%
)
N
A
N
A
ke
to
co
na
zo
le
83
%
 
in
cr
ea
se
61
%
 
in
cr
ea
se
N
in
te
da
ni
b 
co
-a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
CY
P 
in
du
ce
rs
 o
r 
in
hi
bi
to
rs
 is
 c
on
si
de
re
d 
sa
fe
 
si
nc
e 
on
ly
 a
 s
m
al
l p
ar
t i
s 
m
et
ab
ol
iz
ed
 b
y 
CY
P 
en
zy
m
es
 a
nd
 th
e 
in
te
ra
ct
io
n 
is
 m
or
e 
lik
el
y 
th
ro
ug
h 
P-
gp
 in
hi
bi
tio
n 
or
 in
du
ct
io
n.
M
in
or
14
, 1
5
ri
fa
m
pi
ci
n
60
%
 
de
cr
ea
se
50
%
 
de
cr
ea
se
O
si
m
er
tin
ib
CY
P3
A4
CY
P3
A5
, 
CY
P1
A2
, 
CY
P2
A6
, 
CY
P2
C9
, 
CY
P2
E1
CY
P1
A2
, C
YP
2C
8,
 U
G
T1
A1
(in
 
vi
tr
o)
 C
YP
3A
4,
 C
YP
3A
5
Si
m
va
st
at
in
 A
U
C 
an
d 
C m
ax
 
de
cr
ea
se
d 
w
ith
 9
%
 a
nd
 
23
%
 r
es
pe
ct
iv
el
y
CY
P3
A4
, 
CY
P1
A2
 
itr
ac
on
az
ol
e
20
%
 
de
cr
ea
se
24
%
 
in
cr
ea
se
Ad
m
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
f C
YP
3A
4 
is
 
co
ns
id
er
ed
 s
af
e.
 S
tr
on
g 
in
du
ce
rs
 o
f C
YP
3A
4 
m
us
t 
be
 u
se
d 
w
ith
 c
au
tio
n 
w
ith
 c
lo
se
 m
on
ito
ri
ng
 o
f 
si
de
-e
ff
ec
ts
. W
he
n 
ad
m
in
is
te
re
d 
w
ith
 C
YP
3A
4/
3A
5,
 
CY
P1
A2
, C
YP
2C
8 
an
d 
U
G
T1
A1
 s
ub
st
ra
te
s 
cl
os
e 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
M
od
er
at
e
14
, 1
5 
,8
6,
 8
7
Ri
fa
m
pi
ci
n
73
%
 
de
cr
ea
se
78
%
 
de
cr
ea
se
Pa
zo
pa
ni
b
CY
P3
A4
CY
P1
A2
, 
CY
P2
C8
In
 v
itr
o:
 C
YP
3A
4,
 C
YP
2B
6,
 C
YP
2C
8,
 
CY
P2
D
6,
 C
YP
2E
1,
 U
G
T1
A1
m
id
az
ol
am
 A
U
C 
an
d 
C m
ax
 
in
cr
ea
se
d 
bo
th
 w
ith
 
30
%
 r
es
pe
ct
iv
el
y
de
xt
ro
m
et
ho
rp
ha
n 
(C
YP
2D
6 
su
bs
tr
at
e)
 A
U
C 
an
d 
C m
ax
 in
cr
ea
se
d 
w
ith
 3
3%
 a
n 
64
%
 r
es
pe
ct
iv
el
y
pa
cl
ita
xe
l (
a 
CY
P2
C8
 s
ub
st
ra
te
) 
AU
C 
an
d 
C m
ax
 in
cr
ea
se
d 
w
ith
 
26
%
 a
nd
 3
1%
 r
es
pe
ct
iv
el
y
Ca
ff
ei
ne
 (C
YP
1A
2 
su
bs
tr
at
e)
, 
W
ar
fa
ri
n 
(C
YP
2C
9 
su
bs
tr
at
e)
 
an
d 
om
ep
ra
zo
le
 (C
YP
2C
19
 
su
bs
tr
at
e)
 A
U
C 
di
d 
no
t c
ha
ng
e
N
A
ke
to
co
na
zo
le
45
%
 
in
cr
ea
se
66
%
 
in
cr
ea
se
W
he
n 
a 
st
ro
ng
 C
YP
3A
4 
in
hi
bi
to
r 
is
 a
dm
in
is
te
re
d
 a
 5
0%
 p
az
op
an
ib
 d
os
e 
re
du
ct
io
n 
m
ay
 b
e 
ap
pl
ie
d.
 F
or
 s
tr
on
g 
in
du
ce
rs
 c
lo
se
 m
on
ito
ri
ng
 o
f 
si
de
-e
ff
ec
ts
 m
us
t b
e 
ap
pl
ie
d 
an
d 
th
er
ap
y 
w
ith
 
in
du
ce
rs
 m
us
t b
e 
lim
ite
d.
 C
lo
se
 o
bs
er
va
tio
ns
 fo
r 
CY
P2
C8
, C
YP
2D
6,
 C
YP
2E
1,
 U
G
T1
A1
 a
nd
 C
YP
3A
4 
w
ith
 n
ar
ro
w
 th
er
ap
eu
tic
 w
in
do
w
s 
m
us
t b
e 
ap
pl
ie
d 
w
he
n 
co
-a
dm
in
is
te
re
d 
w
ith
 p
az
op
an
ib
.
M
in
or
14
, 1
5,
 8
3
Ph
en
yt
oi
n 
or
 
ca
rb
am
az
ep
in
e
50
%
 
de
cr
ea
se
30
%
 
de
cr
ea
se
48
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3.
 C
on
tin
ue
d
M
KI
M
aj
or
 C
YP
M
in
or
 C
YP
s 
an
d 
ot
he
rs
In
hi
bi
to
ry
 a
ct
iv
it
y
In
du
ci
ng
 
ac
ti
vi
ty
In
hi
bi
to
ry
 
co
m
po
un
d
In
du
ci
ng
 
co
m
po
un
d
Ch
an
ge
 
in
 C
m
ax
Ch
an
ge
 
in
 A
U
C
Cl
in
ic
al
 r
ec
om
m
en
da
ti
on
s
Cl
in
ic
al
 
re
le
va
nc
e
Re
fe
re
nc
e
Po
na
tin
ib
CY
P3
A4
CY
P2
D
6,
 
CY
P2
C8
, 
CY
P3
A5
N
A
N
A
ke
to
co
na
zo
le
47
%
 
in
cr
ea
se
78
%
 
in
cr
ea
se
W
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
CY
P3
A4
 in
hi
bi
to
rs
 
a 
do
se
-r
ed
uc
tio
n 
to
 3
0m
g 
m
ay
 b
e 
ad
m
in
is
te
re
d.
 
Th
e 
co
-a
dm
in
is
tr
at
io
n 
of
 s
tr
on
g 
in
du
ce
rs
 s
ho
ul
d 
be
 
av
oi
de
d 
or
 th
er
ap
y 
du
ra
tio
n 
sh
ou
ld
 b
e 
m
in
im
iz
ed
.
M
od
er
at
e
14
, 1
5,
 
88
, 8
9
Ri
fa
m
pi
ci
n
42
%
 
de
cr
ea
se
62
%
 
de
cr
ea
se
Re
go
ra
fe
ni
b
CY
P3
A4
U
G
T1
A9
In
 v
itr
o:
 U
G
T1
A1
, U
G
T1
A9
, 
CY
P2
C8
, C
YP
2B
6,
 C
YP
2C
9,
 
CY
P2
C1
9,
 C
YP
3A
4
Ir
in
ot
ec
an
 m
et
ab
ol
ite
 (S
N
-
38
) (
su
bs
tr
at
e 
of
 U
G
T1
A1
) 
AU
C 
in
cr
ea
se
d 
w
ith
 4
4%
N
A
ke
to
co
na
zo
le
40
%
 
in
cr
ea
se
33
%
 
in
cr
ea
se
Co
-a
dm
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 o
f C
YP
3A
4 
an
d 
U
G
T1
A9
 s
ho
ul
d 
be
 
av
oi
de
d.
 In
flu
en
ce
 o
n 
re
go
ra
fe
ni
b 
pl
as
m
a 
le
ve
ls
 
is
 r
el
at
iv
el
y 
sm
al
l. 
Re
go
ra
fe
ni
b 
do
se
 m
us
t b
e 
gr
ad
ua
lly
 in
cr
ea
se
d 
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 
st
ro
ng
 C
YP
3A
4 
in
hi
bi
to
rs
 a
nd
 c
lo
se
 m
on
ito
ri
ng
 o
f 
si
de
-e
ff
ec
t i
s 
re
co
m
m
en
de
d 
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
CY
P3
A4
 in
du
ce
rs
. T
ox
ic
ity
 m
us
t 
be
 m
on
ito
re
d 
fo
r 
U
G
T1
A1
, U
G
T1
A9
, C
YP
2C
8,
 
CY
P2
C9
, C
YP
2C
19
 o
r 
CY
P3
A4
 s
ub
st
ra
te
s,
 
ho
w
ev
er
 p
ha
rm
ac
ok
in
et
ic
 d
at
a 
di
d 
no
t r
es
ul
t 
in
 c
lin
ic
al
ly
 m
ea
ni
ng
fu
ll 
in
te
ra
ct
io
ns
.
M
od
er
at
e
14
, 1
5
Ri
fa
m
pi
ci
n
20
%
 
de
cr
ea
se
50
%
 
de
cr
ea
se
Ru
xo
lit
in
ib
CY
P3
A4
CY
P2
C9
In
te
st
in
al
 C
YP
3A
4
N
A
ke
to
co
na
zo
le
er
yt
hr
om
yc
in
33
%
 
in
cr
ea
se
8%
 
in
cr
ea
se
91
%
 
in
cr
ea
se
27
%
 
in
cr
ea
se
W
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
f C
YP
3A
4
an
d 
CY
P2
C9
 a
 5
0%
 d
os
e 
re
du
ct
io
n 
m
ay
 b
e 
ap
pl
ie
d 
if 
th
er
e 
is
 r
el
ev
an
t t
ox
ic
ity
. F
or
 m
od
er
at
e 
in
hi
bi
to
rs
 a
 d
os
e 
re
du
ct
io
n 
is
 n
ot
 n
ec
es
sa
ry
. 
Fo
r 
st
ro
ng
 C
YP
3A
4 
an
d 
CY
P2
C9
 in
du
ce
rs
 
si
de
-e
ff
ec
ts
 s
ho
ul
d 
be
 c
lo
se
ly
 m
on
ito
re
d.
M
od
er
at
e
14
, 1
5,
 9
0
Ri
fa
m
pi
ci
n
52
%
 
de
cr
ea
se
71
%
 
de
cr
ea
se
So
ra
fe
ni
b
CY
P3
A4
U
G
T1
A9
U
G
T1
A9
, U
G
T1
A1
Ad
m
in
is
tr
at
io
n 
w
ith
 
cy
cl
op
ho
sp
ha
m
id
e 
(a
 C
YP
2B
6 
su
bs
tr
at
e)
, w
ar
fa
ri
n,
 m
id
az
ol
am
, 
de
xt
ro
m
et
ho
rp
ha
n,
 o
m
ep
ra
zo
el
 
or
 p
ac
lit
ax
el
 d
id
 n
ot
 r
es
ul
t 
in
 a
ny
 s
ig
ni
fic
an
t c
ha
ng
es
 in
 
AU
C 
of
 th
es
e 
su
bs
tr
at
es
. 
N
A
ke
to
co
na
zo
le
26
%
 
in
cr
ea
se
11
%
 
in
cr
ea
se
So
ra
fe
ni
b 
ad
m
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 o
f C
YP
3A
4 
is
 c
on
si
de
re
d 
sa
fe
. F
or
 U
G
T1
A1
 
an
d 
U
G
T1
A9
 s
ub
st
ra
te
 s
pe
ci
fic
 s
id
e-
ef
fe
ct
s 
sh
ou
ld
 
be
 c
lo
se
ly
 m
on
ito
re
d.
 T
he
 u
se
 o
f s
tr
on
g 
U
G
T1
A9
 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 s
ho
ul
d 
be
 a
vo
id
ed
.
M
in
or
14
, 1
5
Ri
fa
m
pi
ci
n
no
 
si
gn
ifi
ca
nt
 
di
ff
er
en
ce
37
%
 
re
du
ct
io
n
Su
ni
tin
ib
CY
P3
A4
CY
P1
A2
N
A
N
A
ke
to
co
na
zo
le
49
%
 
in
cr
ea
se
51
%
 
in
cr
ea
se
D
os
e 
re
du
ct
io
n 
is
 a
dv
is
ed
 w
he
n 
co
-
ad
m
in
is
te
re
d 
w
ith
 s
tr
on
g 
CY
P3
A4
 in
hi
bi
to
rs
 
to
 a
 m
in
im
um
 o
f 3
7.
5m
g 
fo
r 
G
IS
T 
an
d 
m
et
as
ta
tic
 r
en
al
 c
el
l c
ar
ci
no
m
a 
or
 2
5m
g 
fo
r 
ne
ur
o-
en
do
cr
in
e 
tu
m
or
s 
ba
se
d 
on
 m
on
ito
ri
ng
 
of
 to
le
ra
bi
lit
y.
 F
or
 s
tr
on
g 
CY
P3
A4
 in
du
ce
rs
 
an
 in
cr
ea
se
 in
 1
2.
5 
m
g 
in
cr
em
en
ts
 m
ay
 b
e 
ap
pl
ie
d 
w
ith
 m
on
ito
ri
ng
 o
f t
ol
er
ab
ili
ty
.
M
in
or
14
, 1
5
Ri
fa
m
pi
ci
n
23
%
 
de
cr
ea
se
46
%
 
de
cr
ea
se
49
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TA
BL
E 
3.
 C
on
tin
ue
d
M
KI
M
aj
or
 C
YP
M
in
or
 C
YP
s 
an
d 
ot
he
rs
In
hi
bi
to
ry
 a
ct
iv
it
y
In
du
ci
ng
 
ac
ti
vi
ty
In
hi
bi
to
ry
 
co
m
po
un
d
In
du
ci
ng
 
co
m
po
un
d
Ch
an
ge
 
in
 C
m
ax
Ch
an
ge
 
in
 A
U
C
Cl
in
ic
al
 r
ec
om
m
en
da
ti
on
s
Cl
in
ic
al
 
re
le
va
nc
e
Re
fe
re
nc
e
Ti
vo
za
ni
b
CY
P3
A4
U
G
T1
A,
 
CY
P1
A1
CY
P2
B6
, C
YP
2C
8
N
A
Ke
to
co
na
zo
le
3%
 
de
cr
ea
se
5%
 
in
cr
ea
se
Ad
m
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
f C
YP
3A
4 
Is
 c
on
si
de
re
d 
sa
fe
. T
he
 u
se
 o
f s
tr
on
g 
CY
P3
A4
 
in
du
ce
rs
 m
us
t b
e 
m
in
im
iz
ed
 a
nd
 c
lo
se
 m
on
ito
ri
ng
 
of
 s
id
e-
ef
fe
ct
 is
 r
ec
om
m
en
de
d.
 A
ls
o 
cl
os
e 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d 
w
he
n 
ad
m
in
is
te
re
d 
w
ith
 C
YP
2B
6 
or
 C
YP
2C
8 
su
bs
tr
at
es
.
M
od
er
at
e
14
, 1
5,
 9
1
Ri
fa
m
pi
ci
n
9%
 
in
cr
ea
se
52
%
 
de
cr
ea
se
Tr
am
et
in
ib
D
ea
ce
ty
la
tio
n 
an
d 
 
gl
uc
ur
on
id
at
io
n
CY
P3
A4
CY
P2
C8
, C
YP
2C
9,
 
CY
P2
C1
9 
(in
 v
itr
o)
CY
P3
A4
 
(in
 v
itr
o)
N
o 
st
ud
ie
s 
av
ai
la
bl
e
N
A
N
A
Ad
m
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 o
r 
in
du
ce
rs
 o
f C
YP
 e
nz
ym
es
 is
 c
on
si
de
re
d 
sa
fe
 
si
nc
e 
pr
im
ar
y 
m
et
ab
ol
is
m
 is
 n
ot
 d
ue
 to
 
m
et
ab
ol
is
m
. D
D
I p
ot
en
tia
l i
s 
lik
el
y 
to
 b
e 
lo
w
.
M
in
or
14
, 1
5
no
 s
tu
di
es
 
av
ai
la
bl
e
N
A
N
A
Va
nd
et
an
ib
CY
P3
A4
FM
O
1,
 
FM
O
3
CY
P2
D
6
CY
P1
A2
, 
CY
P2
C9
, 
CY
P3
A4
M
id
az
ol
am
 
AU
C 
di
d 
no
t 
ch
an
ge
Itr
ac
on
az
ol
e
4%
 
de
cr
ea
se
9%
 
in
cr
ea
se
Ad
m
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
hi
bi
to
rs
 a
nd
 in
du
ce
rs
 
of
 C
YP
3A
4 
is
 c
on
si
de
re
d 
sa
fe
. C
on
co
m
ita
nt
 
ad
m
in
is
tr
at
io
n 
w
ith
 s
tr
on
g 
in
du
ce
rs
 m
us
t b
e 
av
oi
de
d 
or
 d
os
e 
m
ay
 b
e 
gr
ad
ua
lly
 in
cr
ea
se
d.
 
W
he
n 
ad
m
in
is
te
re
d 
w
ith
 s
ub
st
ra
te
s 
fo
r 
CY
P2
D
6,
 C
YP
1A
2,
 C
YP
2C
9 
an
d 
CY
P3
A4
 c
lo
se
 
m
on
ito
ri
ng
 o
f s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
M
in
or
14
, 1
5,
 9
2
ri
fa
m
pi
ci
n
3%
 
in
cr
ea
se
40
%
 
de
cr
ea
se
Ve
m
ur
af
en
ib
CY
P3
A4
U
G
T
In
 v
itr
o:
 C
YP
1A
2,
 C
YP
2C
8,
 C
YP
2C
9
15
0%
 in
cr
ea
se
 in
 c
af
fe
in
e 
(C
YP
1A
2 
su
bs
tr
at
e)
 e
xp
os
ur
ew
as
 s
ee
n
W
ar
fa
ri
n 
(C
YP
2C
9 
su
bs
tr
at
e)
 
ex
po
su
re
 in
cr
ea
se
d 
w
ith
 1
8%
CY
P3
A4
, 
CY
P2
B6
M
id
az
ol
am
 
AU
C 
de
cr
ea
se
d 
w
ith
 3
2%
no
 c
om
pl
et
ed
 
cl
in
ic
al
 s
tu
dy
N
A
N
A
Th
e 
in
flu
en
ce
 o
f C
YP
3A
4 
or
 U
G
T 
in
hi
bi
to
rs
 
or
 in
du
ce
rs
 is
 c
on
si
de
re
d 
m
in
im
al
. W
he
n 
ad
m
in
is
te
re
d 
w
ith
 C
YP
1A
2,
 C
YP
2C
8,
 C
YP
2C
9,
 
CY
P3
A4
 o
r 
CY
P2
B6
 s
ub
st
ra
te
s 
cl
os
e 
m
on
ito
ri
ng
 
of
 s
id
e-
ef
fe
ct
s 
is
 r
ec
om
m
en
de
d.
M
in
or
14
, 1
5
ri
fa
m
pi
ci
n
un
kn
ow
n
40
%
 
de
cr
ea
se
Le
ge
nd
: C
lin
ic
al
 r
el
ev
an
ce
 is
 s
co
re
d 
by
 m
ea
ns
 o
f 
th
e 
FD
A 
Cl
in
ic
al
 D
ru
g 
In
te
ra
ct
io
n 
St
ud
ie
s 
—
 S
tu
dy
 D
es
ig
n,
 D
at
a 
An
al
ys
is
, a
nd
 C
lin
ic
al
 Im
pl
ic
at
io
ns
 G
ui
da
nc
e 
fo
r 
In
du
st
ry
, f
or
 in
du
ce
rs
 a
s 
M
aj
or
 (A
U
C 
de
cr
ea
se
 ≥
80
%
), 
M
od
er
at
e 
(A
U
C 
de
cr
ea
se
 ≥
 5
0%
 t
o 
< 
80
%
), 
M
in
or
 (A
U
C 
de
cr
ea
se
 ≥
20
%
 to
 <
50
%
) o
r 
un
kn
ow
n 
an
d 
fo
r 
in
hi
bi
to
rs
 a
s 
M
aj
or
 (A
U
C 
in
cr
ea
se
 ≥
 4
00
%
), 
M
od
er
at
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Cabozantinib.
Cabozantinib is used in the treatment of medullary thyroid carcinoma and renal cell 
carcinoma (RCC). Since cabozantinib is a P-gp and BCRP inhibitor, close monitoring of 
side effects of substrates with a narrow therapeutic window is recommended when 
co-administered with cabozantinib.14,15 A study with ketoconazole and rifampicin 
showed a significant change in AUC (38% increase and 77% decrease, respectively).75 
There was no significant effect of cabozantinib on rosiglitazone (a CYP2C8 substrate) 
plasma pharmacokinetics, indicating no inhibitory effect on CYP2C8 in contrast to the 
in vitro data.75 The product label recommends minimizing the risk of a DDI by avoiding 
co-administration with strong inducers or inhibitors of CYP3A4. If necessary, a dose 
adjustment (decrease or increase) of 20mg following a step-by-step approach may be 
warranted.
Ceritinib.
Ceritinib is used in the treatment of ALK-positive NSCLC. Ceritinib is a substrate and 
inhibitor for P-gp. Furthermore, ceritinib is mainly metabolized by CYP3A4. Treatment 
with ketoconazole resulted in 190% and 20% increase in ceritinib AUC and Cmax, 
respectively.14,15 Coadministration with rifampicin showed a 70% and 44% decrease in 
AUC and Cmax, respectively.
14,15 If concomitant administration with strong inhibitors of 
CYP3A4 is unavoidable a dose reduction by one third of the initial dose is necessary 
(rounded to units of 150mg). For strong CYP3A4 inducers gradual dose escalation is 
possible with close monitoring of MKI-specific side effects.
Cobimetinib.
Cobimetinib is a BRAF inhibitor used in the treatment of melanoma. It is a substrate for 
P-gp and inhibits BCRP, OATP1B1, OATP1B3, and OCT1.14,15 Therefore, close monitoring 
of side effects is warranted when cobimetinib is administered with BCRP (e.g. 
rosuvastatin), OATP1B1, OATP1B3 (e.g. atorvastatin) or OCT1 substrates (metformin) 
with a narrow therapeutic window. Cobimetinib is primarily metabolized by CYP3A4 
and UGT2B7. When co-administered with itraconazole 570% and 220% increase in 
AUC and Cmax was seen, respectively.
14,15 A physiologically based pharmacokinetic 
(PBPK) model demonstrated rifampicin to decrease cobimetinib AUC by 83% and Cmax 
by 63%.76 So, the co-administration with strong inhibitors or inducers of CYP3A4 and 
P-gp must be avoided.  However, rabeprazole (a P-gp inhibitor) showed no effects on 
the pharmacokinetics of cobimetinib.21 If concomitant use of cobimetinib and strong 
CYP3A4 inhibitors is unavoidable, the cobimetinib dose should be decreased with 
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20mg (33%) following a step-by-step approach. Furthermore, since cobimetinib is a 
CYP1A2 inhibitor, concomitant use with CYP1A2 substrates (e.g. haloperidol) may lead 
to altered plasma concentrations of these substrates.14,15
Dabrafenib.
Dabrafenib is a BRAF inhibitor used in the treatment of advanced melanoma and NSCLC. 
Dabrafenib was shown to be a substrate for P-gp and BCRP. Since the bioavailability 
of dabrafenib is high (95%), only limited pharmacokinetic effects can be expected with 
inhibitors and inducers of these drug transporters. Dabrafenib is metabolized by both 
CYP3A4 (24%) and CYP2C8 (67%). Administration of dabrafenib with ketoconazole, 
gemfibrozil (a CYP2C8 inhibitor), and rifampicin showed significant changes in AUC, 
however these effects were mostly relatively small.14,15 Furthermore, dabrafenib is 
known to auto-induce CYP3A4 mediated metabolism.14,15 In conclusion, concomitant 
administration with strong CYP3A4 and CYP2C8 inhibitors or inducers must be avoided. 
Furthermore, a study with warfarin showed a 37% and 33% decrease in AUC and an 
18% and 19% decrease in Cmax for S-warfarin (a CYP2C9 substrate) and R-warfarin (a 
CYP3A4/CYP1A2 substrate), respectively.78 Therefore, dabrafenib is characterized as a 
moderate CYP3A4 inducer and a weak CYP2C9 inducer and as a result concomitant use 
of substrates for these enzymes must be avoided.78
Ibrutinib.
Ibrutinib is used as treatment for chronic lymphatic leukemia (CLL) and mantle 
cell lymphoma. Ibrutinib is an inhibitor of P-gp and BCRP.14,15 Ibrutinib is mainly 
metabolized by CYP3A4. Ketoconazole gave 2800% and 2300% increase in Cmax and 
AUC respectively.14,15,51 Furthermore concomitant administration with rifampicin 
showed 92% and 90% decrease in Cmax and AUC respectively.
14,15 Administration with 
a moderate inhibitor of CYP3A4 (e.g. erythromycin) led to 240% and 200% increase in 
Cmax and AUC respectively.
14,15,82 Overall concomitant administration with strong CYP3A4 
inhibitors or inducers must be avoided. If ibrutinib is administered with moderate 
and strong CYP3A4 inhibitors the ibrutinib dose should be reduced to 280mg and 
140mg respectively. When ibrutinib is administered with substrates of P-gp and BCRP 
monitoring of side effects of these substrates is warranted. When toxicity appears the 
dose of these substrates may be decreased.
Lenvatinib.
Lenvatinib is used in the treatment of RCC and advanced thyroid carcinoma. It was 
shown to be a MDR1 substrate, a P-gp and BCRP substrate and inhibitor and an 
OATP1B3 inhibitor in vitro.14,15 When lenvatinib is administered with ketoconazole or 
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rifampicin, only marginal changes in AUC and Cmax were observed.
54,55 Since lenvatinib 
is mainly metabolized through several phase II mechanisms (e.g. aldehyde oxidase 
and glutathione conjugation) into less active metabolites and only for a small part by 
CYP3A4, these changes were most likely due to an interaction with P-gp.14,15 Lenvatinib 
has an overall low DDI potential and dose modifications are currently not considered 
necessary.
Nintedanib.
Nintedanib is used in the treatment of NSCLC. It is a substrate and weak inhibitor of 
P-gp.14,15,94 When nintedanib is administered with a strong P-gp inhibitor, a 100mg 
(25%) step-wise daily dose reduction must be considered with close monitoring of 
side effects. Use of strong P-gp inducers must be avoided, since nintedanib plasma 
concentrations may decrease. Nintedanib is mainly metabolized due to hydrolysis by 
esterases and glucuronidated by UGT with only a minor involvement of CYP enzymes 
(CYP3A4; 5%).14,15 Administration with ketoconazole resulted in 61% and 83% increase in 
AUC and Cmax respectively and administration with rifampicin demonstrated a decrease 
in AUC of 50% and 60% of Cmax respectively.
42 These differences were probably due 
to a DDI with P-gp. Therefore, concomitant administration with strong inhibitors or 
inducers of CYP3A4 is considered safe.
Osimertinib.
Osimertinib is used in the treatment of NSCLC.14,15 Osimertinib is a substrate and 
inhibitor for P-gp and BCRP.14,15 A study with rosuvastatin (a sensitive BCRP substrate) 
showed an increase in AUC and Cmax of 35% and 72% of rosuvastatin respectively.
87 
Osimertinib is mainly metabolized by CYP3A4 and CYP3A5, but only rifampicin resulted 
in a significant change in both AUC and Cmax in contrast to itraconazole.
86 A study 
with simvastatin (a CYP3A4 substrate) resulted in a slight decrease in AUC and Cmax 
of simvastatin of 9% and 23%, but these changes are not considered to be of clinical 
significance.87 In conclusion only strong CYP3A4 inducers must be used with caution 
and close monitoring of side effects of osimertinib is warranted.
Ponatinib.
Ponatinib is used in the treatment of CML and Acute lymphatic leukemia (ALL). 
Ponatinib is a substrate and inhibitor of P-gp and BCRP.14,15 Therefore, concomitant 
use of ponatinib with strong inhibitors or inducers of these transporters should be 
avoided. Ponatinib is mainly metabolized into nonactive metabolites by CYP3A4 and 
to a lesser extent by CYP2D6, CYP2C8 and CYP3A5.14,15 A study with concomitant 
ketoconazole administration showed an increase in Cmax of 47% and 78% in AUC of 
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ponatinib.88 Multiple dosing of rifampicin demonstrated a decrease in AUC and Cmax 
of 42% and 62% respectively.89 As a consequence, concomitant administration with 
inhibitors of CYP3A4 and P-gp should be avoided or a dose reduction to 30mg should 
be applied when administered concomitantly. Moreover, the use of strong CYP3A4 
or P-gp inducers must be avoided or duration must be minimized, since ponatinib 
exposure may change.
Tivozanib.
Tivozanib is used in the treatment of RCC. Tivozanib is an inhibitor of BCRP and is 
metabolized by multiple liver enzymes, including CYP3A4, CYP1A1 and several UGT1A 
enzymes (e.g. UGT1A1, UGT1A3 and UGT1A7).14,15 A study with rifampicin showed a 
52% decrease in tivozanib AUC. Therefore, the administration with strong CYP3A4 
inducers should be avoided. A dose escalation is not necessary since the effect on 
tivozanib exposure is relatively small. Ketoconazole did not result in significant changes 
in tivozanib exposure.14,15,91 Administration with strong CYP3A4 inhibitors is therefore 
considered safe. Furthermore, the concomitant administration with strong UGT 
inhibitors or inducers (e.g. probenecid or ibuprofen) should be avoided since tivozanib 
plasma concentrations potentially may change.
Trametinib.
Trametinib is used in the treatment of melanoma and NSCLC. It is a known inhibitor 
of P-gp, BCRP, OAT1, OAT3, OATP1B1, OATP1B3, OAT2B1, OCT2 and MATE1 and a 
substrate for P-gp.14,15 As a result, the use of strong inhibitors or inducers of P-gp (e.g. 
ketoconazole) must be avoided. Trametinib is metabolized through deacetylation, 
oxidation and glucuronidation pathways.14,15 No drug interaction studies are available 
to date, however since trametinib is not dependent on CYP isoenzymes, no DDIs with 
CYPs are to be expected.
DDI studies with longer available MKIs
In recent years several new studies have been published that investigated DDIs with 
longer available MKIs. Most of these studies are listed in Tables 1–3. There are only 
a few clinical DDI studies concerning drug transporters, since most studies mainly 
focus on CYP interactions. A phase I study investigated the combination of gefitinib 
and irinotecan and found an increase in SN-38 (the active irinotecan metabolite) 
and irinotecan plasma exposure, attributed to an enhanced BCRP activity in the 
gut.50 Moreover, in patients using sorafenib with rifampicin, the concentration of the 
metabolite sorafenib-glucuronide increased, suggesting inhibition of OATP1B1 by 
rifampicin and confirms sorafenib as an OATP1B1 substrate.57
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Several new studies investigated possible DDIs regarding drug metabolism. For a 
complete overview see Table 3. For example: imatinib coadministration caused a 26% 
increase in cyclosporine (CYP3A4 and CYP2C8 substrate) plasma levels, explained by 
CYP3A4 inhibition by imatinib.69 In addition, lapatinib and pazopanib demonstrated an 
increase of 23% and 26% in paclitaxel AUC respectively, suggesting inhibition of CYP2C8 
by these MKIs.83,95 Furthermore, regorafenib significantly increased the exposure to 
irinotecan and its active metabolite SN-38 due to UGT1A1 inhibition.96,97
Although most MKIs are metabolized through CYP enzymes it becomes more apparent 
that MKI metabolism is multifactorial and the inhibition and induction of other 
pathways (such as drug transporters) may also significantly influence MKI exposure. 
More research is needed to fully assess the DDI potential of these new pathways and 
their clinical relevance.
DISCUSSION
Many MKIs have a narrow therapeutic window, with a clear relation between exposure 
and response on one hand and toxicity on the other.98 For example, sunitinib and 
pazopanib show increasing severe toxicity with raising plasma concentration, leading 
to dose reductions and discontinuation of treatment in many patients.99,100 Meanwhile, 
a threshold for efficacy for these drugs is seen.98–100 Therefore, it is important to provide 
the right dose for the individual patient, in order to optimize treatment efficacy and 
minimize toxicity. To accomplish this, there is a shifting paradigm towards personalized 
dosing in oncology practice.5 Along with other factors, DDIs are key factors influencing 
MKI exposure and subsequent clinical outcome. In addition, cancer patients are at 
greater risk for DDIs.7 Therefore, a structured medication review for clinically relevant 
DDIs should take place on a regular basis.
To create a solid base for medication review, more DDI studies are strongly needed and 
results should be weighed on their clinical relevance. Specific and practical guidelines 
must be developed to guide clinicians and pharmacists in the management of DDIs 
in clinical practice. A practical way to reach this goal is by establishing clinical expert 
groups for consensus-based evaluation of clinical significance and management of the 
DDIs.101
ASAs may strongly decrease MKI bioavailability. Since there is no clear general 
consensus on the management of this DDI we presented a practical advice for all 
ASAs. However, another problem is that there is no standard design for clinical DDI 
research with ASAs. Ideally, drug exposure should be compared in a crossover design 
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between MKI monotherapy and during co-administration of the strongest ASA [e.g. the 
PPI esomeprazole (40mg)] 3 h prior to MKI administration, since maximum intragastric 
pH elevating effect of this PPI is reached after this time period.38 In that case, when no 
effects are seen, a DDI between MKIs and PPIs can be ruled out. When a significant DDI 
with H2-antagonists and antacids is expected, a corresponding treatment arm may be 
added. A more standardized study design of these ASA-DDI studies may provide a solid 
basis for practical management of this DDI, since study results could more easily be 
interpreted and compared between different MKIs.
Drug transporters are located throughout the body and thus potentially influence 
pharmacokinetics on multiple levels.39 To date, insufficient attention has been given to 
the clinical relevance of these DDIs concerning drug transporters. Unfortunately, there 
is a lack of clinical studies investigating this type of DDI. Furthermore, many registration 
studies use ketoconazole or rifampicin as an inhibitor or inducer of CYP3A4, but these 
drugs are also strong inhibitors or inducers of P-gp. As a result, the P-gp effect may be 
underestimated or overestimated in the assessment reports. More research is needed 
to fully assess the DDI potential concerning drug transporters.
In contrast, DDIs with drug transporters may also be used for beneficial purposes. 
For instance, inhibition of certain drug transporters (e.g. P-gp) in the blood–brain 
barrier might theoretically lead to altered blood–brain barrier penetration, which may 
result in better brain (metastasis) penetration of a MKI, for example, osimertinib.102 In 
addition, Zimmerman and colleagues demonstrated a protective effect on hand-foot 
skin reaction in mice, a frequently seen side effect of sorafenib, when sorafenib was 
concomitantly taken with the OAT6 inhibitor probenecid.103
Furthermore erlotinib may reduce cisplatin toxicity (e.g. nephrotoxicity and ototoxicity) 
through OCT2 inhibition.48 Such potentially useful applications of DDIs between MKIs 
and drug transporters need to be further explored, and may in the future result in 
more effective MKI therapy.
In current DDI research there is a trend towards a model-based DDI prediction, like 
the PBPKmodels.104,105 PBPK-models are multi-compartmental (often represented as 
single organs or tissues) models which use (in vitro) pharmacokinetic data and human 
physiologically-dependent system parameters to predict DDIs with a mathematical 
model.106 A disadvantage of PBPK modeling is the lack of sufficient in vivo data that adds 
to the uncertainty in the predictions of the PBPK model. Also, the lack of knowledge 
regarding multifactorial physiologic changes in, for instance, enzyme and transporter 
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expression and activity might be a possible confounding factor. Despite the evident 
benefits of PBPK modeling in current DDI research, confirmatory evidence from clinical 
trials in humans is needed to assess a good predicting model.105
Another novel approach in oncology in managing DDIs is therapeutic drug monitoring 
(TDM). For many MKIs there is a clear relationship between exposure, toxicity and 
treatment efficacy (e.g. imatinib, pazopanib and sunitinib).98,100,107 For some MKIs TDM 
could be an alternative way to manage DDIs in MKI therapy, where dose adjustments 
can be made if plasma levels are outside the therapeutic range. Furthermore, TDM has 
the advantage of monitoring MKI treatment, continuously over a longer time period 
which may result in better therapy efficacy. However, further research is needed to 
confirm the clinical relevance of TDM as a tool in DDI management.
In conclusion, most MKIs are highly prone to cause DDIs. Drugs that elevate intragastric 
pH, strong inhibitors or inducers of CYP enzymes and drug transporters can result 
in clinically relevant changes in MKI exposure. For many DDIs the only evidence for 
a potential DDI comes from in vitro data or is predicted based on PBPK modeling. 
Without clinical data it is difficult to determine the exact clinical relevance of these 
possible DDIs. In this review, we present practical recommendations for management 
of MKI interactions in clinical practice. Acknowledging these DDIs by clinicians may 
eventually result in a more personalized and effective treatment with MKIs.
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With interest, we read the report by Chu and colleagues, investigating the influence of 
proton pump inhibitors (PPIs) on capecitabine efficacy in advanced gastroesophageal 
cancer.1 This retrospective analysis revealed a significant difference in treatment 
efficacy in patients treated with capecitabine and oxaliplatin (CapOx) with and without 
concomitant proton pump inhibitor (PPI) use, probably due to an increased intragastric 
pH --and subsequent-- impaired capecitabine absorption.
Although this is a highly clinically relevant finding, the conclusions are preliminary 
in our opinion. One of our main concerns is that the time of PPI intake (in particular 
in relation to the time of capecitabine intake) was not studied. We believe this is of 
importance, since PPIs show a delayed onset of action and reach their maximum 
elevation in intragastric pH only 3-4 hours after administration.2 Furthermore, the 
elevation of intragastric pH by PPIs is only present for approximately 12 hours, which 
theoretically makes it possible to combine these agents with less (or even without) 
negative effects on the exposure of capecitabine.2 Meanwhile, if the PPI is taken 4-16 
hours before capecitabine, the effect on capecitabine exposure (due to the maximal 
elevation of intragastric pH by the PPI) may be larger compared to a simultaneous 
intake. In this particular subgroup, also the effects on outcome may be worse than 
published by Chu et al.
Two other relevant aspects, i.e. PPI dose and type of PPI, have not been taken into 
account in this study either. There is a significant difference in acid suppression 
potential between the various PPI variants.3 In addition, the dose of the PPI used has 
a positive correlation with the magnitude and duration of gastric acid suppression.4 
Therefore, these issues need to be addressed before a general conclusion on the 
(negative) effects of PPI use on capecitabine efficacy can be drawn.
A final concern that needs to be addressed is the lack of sufficient medication verification 
during the study. Along with other factors, drug interactions can significantly alter 
anticancer drug exposure and efficacy. Drug interactions between CapOx and other 
concomitantly taken medications could not be excluded, as was already mentioned 
by Chu et al. However, it cannot be emphasized enough, that drug interactions are 
frequently seen in cancer patients.5
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ABSTRACT
Background. Regorafenib exposure could potentially be influenced by an interaction 
with acid reducing drugs.
Methods. In this cross-over trial, patients were randomized into 2 sequence groups 
consisting of 3 phases: regorafenib intake alone, regorafenib with concomitant 
esomeprazole, and regorafenib with esomeprazole 3 hours prior. Primary endpoint 
was the relative difference (RD) in geometric means for regorafenib AUC0-24h, and was 
analyzed by a linear mixed model in 14 patients.
Results. AUC0-24h for regorafenib alone was 55.9 µg*h/mL (CV: 40%), and for regorafenib 
with concomitant esomeprazole or with esomeprazole 3 hours prior AUC0-24h was 53.7 
µg*h/mL (CV: 34%) and 53.6 µg*h/mL (CV: 43%), respectively. No significant differences 
were identified when regorafenib alone was compared to regorafenib with concomitant 
esomeprazole (RD: -3.9%, 95% CI: -20.5-16.1%, P=1.0) or regorafenib with esomeprazole 
3 hours prior (RD: -4.1%, 95% CI: -22.8-19.2%, P=1.0).
Conclusion. These findings indicate that regorafenib and  esomeprazole can be safely 
combined in clinical practice.
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INTRODUCTION
Regorafenib is an oral multi-kinase inhibitor that targets angiogenic, stromal and 
oncogenic receptor tyrosine kinases (e.g. VEGFR, KIT, BRAF, PDGFR and FGFR).1 It is 
currently registered for metastatic colorectal cancer (mCRC), gastro-intestinal stromal 
tumor (GIST), and hepatocellular carcinoma (HCC).2-4 Regorafenib is the first and 
currently only tyrosine kinase inhibitor (TKI) registered for mCRC, although the median 
overall survival increase for an unselected group in the 3rd or 4th line of treatment is only 
1.4 months compared to placebo.2 For HCC and GIST, regorafenib provides a stronger 
survival benefit as second and third line TKI-based therapy.3,4 For several TKIs, systemic 
exposure has been demonstrated to influence toxicity and efficacy.5,6
After oral administration, regorafenib is rapidly absorbed, with a time of maximum 
concentration (Tmax) reached at 3-4 hours.
6,7 Most TKIs exhibit pH-dependent solubility.8 
For regorafenib a low basic predicted pKa of around 2 suggests influence of the gastro-
intestinal pH on the absorption, however this is not clearly demonstrated.9,10 Although 
the physiochemical properties of regorafenib may not predict significant pH dependent 
solubility, regorafenib absorption is multifactorial and may be affected by the 
concomitant use of acid-reducing drugs.11 For many TKIs, a pharmacokinetic interaction 
with an acid-suppressive agent has already been demonstrated, for example, erlotinib 
combined with omeprazole resulted in 46% decrease in systemic exposure.8 However, 
for some TKIs this interaction could be ruled out. To our knowledge, for regorafenib 
there is no study available yet on a possible drug-drug interaction with acid-reducing 
drugs.
When the exposure is decreased, the efficacy of TKI treatment could potentially also 
decrease, as was demonstrated for sorafenib and pazopanib among other TKIs.6 As 
regorafenib resembles the structure and mechanism of action of sorafenib, an exposure-
response relationship could be suspected for regorafenib as well. In a secondary 
analysis of the phase-3, RESORCE trial in HCC patients, median overall survival and 
time-to-progression tended to be longer in patients with higher regorafenib exposure 
during the first treatment cycle, however after correction for several covariates it did 
not reach statistical significance.12 To our knowledge, this trial is the only available 
evidence on a possible exposure-response relationship for regorafenib; therefore, 
more research is necessary on this point.
Acid-suppressive therapy is frequently used by cancer patients, both as prophylaxis 
for gastro-intestinal bleeding due to drug-drug interactions (DDI) and as treatment 
for gastresophageal reflux disease (GERD).13 In 2013, Smelick et al reported that up 
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to 33% of all anticancer patients used any form of acid-suppressive therapy, most 
notably a proton pump inhibitor (PPI).14 TKIs often cause stomach complaints or GERD, 
which confronts clinicians with a challenge, as the general consensus is to avoid the 
combination of TKIs and acid-suppressive agents. Therefore,  registration authorities 
nowadays recommend investigating this DDI before registration of a new TKI. However, 
for regorafenib, this potential DDI has not been investigated.
In this study we assessed the potential pharmacokinetic interaction between 
esomeprazole and regorafenib . Furthermore, we also assessed the potential influence 
of timing of esomeprazole intake relative to that of regorafenib (three hours before 
regorafenib ingestion or concomitantly).15
METHODS
This study was a randomized, two-armed, three-phase, cross-over clinical trial in 
patients using regorafenib. Between May 2016 and February 2018, the study was 
performed at the Erasmus Medical Center, Rotterdam, The Netherlands. Approval of 
the Medical Ethics Committee and the board of directors from the Erasmus University 
Medical Center, and the competent authorities was obtained. The study was registered 
at the European Clinical Trials Database (EudraCT 2015-005784-17), and clinicaltrials.
gov (NCT02800330).
Patients
Patients were included if they were 18 years or older, had a pathological confirmed 
diagnosis of mCRC or GIST, Eastern Cooperative Oncology Group (ECOG) performance 
status ≤ 1, with  adequate kidney and liver function. Patients were excluded if they 
could not abstain from dietary supplements or medication which could interact with 
regorafenib or esomeprazole, if they could not interrupt acid-suppressive therapy, or 
if they had a known impaired drug absorption or serious illness that could interfere 
with study conduct (e.g. infection, bleeding diathesis or hemorrhage, arterial or venous 
thrombotic or embolic events, uncontrolled hypertension despite optimal medical 
management, HIV, hepatitis, organ transplants, or kidney, cardiac and respiratory 
diseases). All patients provided written informed consent before any study related 
procedure was pursued.
Study design
The main objectives of this study were to compare the area under the curve (AUC) 
of regorafenib alone to regorafenib concomitantly used with esomeprazole, and to 
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regorafenib used with esomeprazole three hours prior in patients with mCRC or GIST. 
Patients started with regorafenib on 120 or 160 mg once daily during a loading phase 
of 14 consecutive days (Figure 1). Regorafenib dose adjustments were only allowed 
during these first two weeks of the trial. However, due to (reversible) toxicity, the study 
was allowed to be temporarily interrupted for a maximum of one full regorafenib dosing 
cycle (i.e. 28 days). After reaching steady-state, patients either used regorafenib alone 
(phase A), or with esomeprazole (40mg once daily) for five consecutive days (phase 
B and C). During phase B of the study regorafenib was administered concomitantly 
with esomeprazole, while during phase C regorafenib was administered three hours 
after esomeprazole intake, presuming a maximally elevated intragastric pH at the time 
of regorafenib ingesture.16 Subjects were randomized into two sequence groups (i.e. 
A-B-C or C-B-A) to rule out sequence and time effects (Figure 1).
FIGURE 1. Study procedures
Pharmacokinetics
Patients were admitted to the hospital on the 21st, the 49th and the 77th day of the trial 
for pharmacokinetic blood sampling. Blood samples were collected before regorafenib 
administration, and at the 0.5h; 1h; 1.5h; 2h, 2.5h; 3h; 3.5h; 4h; 6h; 8h; 12h and 24h time-
point after regorafenib administration (at 10:00 AM). Blood samples were collected in 
4 mL lithium heparin (Li-He) blood collection tubes, and processed into plasma within 
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10 minutes by centrifugation for 10 minutes at 2,500*g (at 4°C) and stored at T<-70°C 
until analysis. Regorafenib, M-2, and M-5 plasma concentrations were measured using 
a validated liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method 
(detailed description in Supplementary Methods). Pharmacokinetic parameters were 
calculated by using Phoenix WinNonlin version 7.0, and included exposure expressed 
as dose corrected area under the curve from pre-intake time point until 24 hours 
(AUC0-24h), maximum observed concentration (Cmax), and time until maximum observed 
concentration (Tmax).
Statistical analysis
A difference in systemic exposure to regorafenib of 30% was determined to be 
clinically relevant. Since two primary comparisons were to be made, i.e. regorafenib 
with esomeprazole concomitant or three hours prior compared to regorafenib alone, 
a Bonferroni correction was applied. The Bonferroni correction was implemented by 
multiplying the obtained p-values by two and calculation of 97.5% confidence intervals 
(CI) which correspond to the alpha of 0.025 with the interpretation of Bonferroni 
corrected 95% CIs. It was assumed that the within patient standard deviation in 
regorafenib pharmacokinetics was 30%. Given a power of 80%, the sample size 
calculation resulted in a required number of 14 evaluable patients 17. Patients were 
considered evaluable when they completed all three phases, including all required 
blood samples.
Analyses of the AUC0-24h and Cmax were performed on log-transformed observations 
since they were assumed to follow a lognormal distribution 18. Estimates for the mean 
differences in (log) AUCs and Cmax of regorafenib, M-2 and M-5 were obtained for the two 
comparisons separately using a linear mixed effect model with treatment, sequence, 
and phase as fixed effects and subject within sequence as a random effect 19. Variance 
components were estimated based on restricted maximum likelihood (REML) methods 
and the Kenward-Roger method of computing the denominator degrees of freedom 
was used. The mean differences and CIs for the differences were exponentiated to 
provide point estimates of the ratio of geometric means and CIs for these ratios, which 
can be interpreted as relative differences in percentages. Tmax was analyzed by means 
of the Wilcoxon signed rank test and described with medians and interquartile ranges.
Toxicity was described as the incidence of toxicity per phase and was corrected for 
baseline toxicity by describing only new or worsened toxicity compared to baseline. 
This study was not powered to detect a difference in toxicity between treatment 
phases, therefore these results only have a descriptive character.
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RESULTS
Patient characteristics
A total of 31 patients were included, of which 14 patients were evaluable for the 
primary endpoint analysis. The evaluable patients were equally distributed over the 
two treatment sequence groups. Patients were not evaluable due to various reasons: 
screen failures (n=4); rapid disease progression during treatment (n=8); and premature 
treatment interruption (n=5). Patients who developed progressive disease during the 
study period were also equally distributed over the two treatment sequences.
TABLE 1. Patient characteristics
Characteristic Total
Gender
Male
Female
10 (71%)
  4 (29%)
Age (years)
Median [IQR] 69 [61-73]
ECOG Performance Status
0
1
  2 (14%)
12 (86%)
Ethnic origin
Caucasian 14 (100%)
BMI (kg/m2)
Median [IQR] 28.6 [24.1-29.9]
eGFR (mL/min)a
Median [IQR] 82 [77-91]
Liver function (median [IQR])
AST
ALT
Bilirubin
39 [27-68]
33 [17-39]
  8 [6-13] 
Prior therapy
Surgery
Radiotherapy
Chemotherapy
Monoclonal antibodiesb    
12 (86%)
  4 (29%)
14 (100%)
  9 (64%)
a eGFR was calculated according to the CKD-EPI
b Treatment with monoclonal antibodies included bevacizumab, panitumumab, and cetuximab
Abbreviations: AST = aspartate aminotransferase; ALT = alanine aminotransferase; BMI = Body Mass Index; eGFR = 
estimated glomerular filtration rate; IQR = interquartile range
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Patient characteristics are detailed in Table 1. All patients suffered from mCRC, were 
of Caucasian origin and predominantly male (71%). Median age was 69 years and most 
patients had an ECOG performance status of 1 (86%). All patients used regorafenib 
120 mg at steady-state on recommendation of the treating physician or due to dose-
reductions in the first two weeks of the trial.
Pharmacokinetics
All obtained pharmacokinetic results are depicted in Table 2. No statistical difference 
in geometric means for regorafenib AUC0-24h was found when regorafenib alone was 
compared to regorafenib and esomeprazole concomitantly (relative difference [RD]: 
-3.9%, 95%CI: -20.5-16.1%, P = 1.0) or when compared to regorafenib and esomeprazole 
three hours before regorafenib intake (RD: -4.1%, 95%CI:      -22.8-19.2%, P = 1.0) (Figure 
2). Furthermore, no differences could be identified in Cmax or Tmax for regorafenib. For 
M-2 and M-5 no differences could be identified either, although the interindividual 
variability (expressed as coefficient of variation; CV) was much higher for all these 
pharmacokinetic parameters compared to regorafenib (Table 2, Supplementary 
Figure 1). No sequence nor period effects were seen for any of the comparisons of the 
AUC0-24h and Cmax (results not shown).
FIGURE 2. Regorafenib AUC. Regorafenib exposure compared between phase A (regorafenib alone) and phase 
B (regorafenib concomitantly with esomeprazole) (figure 2A), and between phase A and C (regorafenib with 
esomeprazole 3 hours prior) (figure 2B)
Abbreviations: AUC0-24 = Area under the curve, timepoint 0h to 24h
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Toxicity
Most common adverse events during the whole study period were hoarseness (79%), 
anorexia (71%), hypertension (71%), hand foot skin reaction (64%), fatigue (71%), 
stomatitis (57%), and nausea (50%). Also, most common blood value disorders included 
transaminase increase (79%), bilirubin increase (50%) and hypophosphatemia (29%). 
The majority of adverse events was of low grade, the incidence of toxicity ≥ grade 3 
occurred mainly as hypertension (64%), anorexia (14%) and hand foot skin reaction 
(14%). The incidence of adverse events seems comparable between different phases. 
Two patients developed major cardiac events, possibly related to regorafenib treatment: 
myocardial infarction and atrial fibrillation. One patient developed hypertrichosis, 
although this rare side effect is seen more often with other TKIs such as erlotinib 20, to 
our knowledge it has not been described for regorafenib. All observed adverse events 
are described in Supplementary Table 1.
DISCUSSION
This randomized, three-phase, cross-over clinical trial did not reveal a significant 
pharmacokinetic interaction between esomeprazole and regorafenib at the two time-
points studied. Therefore we can conclude that esomeprazole  can be combined with 
regorafenib safely, in contrast to other TKIs.
In this study, esomeprazole was used because it exhibits the strongest pH-reducing 
effect of all acid-reducing drugs currently available.8,16 Also, esomeprazole does not 
influence other enzymes or transporters, such as P-glycoprotein (ABCB1), that could 
potentially influence the pharmacokinetics of regorafenib’s active metabolites M-2 
and M-5.21 Therefore, our findings cannot be extrapolated to other PPIs -- such as 
pantoprazole -- which is known to influence P-glycoprotein. We examined two time-
points regarding the intake time of esomeprazole (i.e. concomitantly or three hours 
prior regorafenib intake), because PPIs are assumed to have their maximum acid-
reducing effect three hours after intake and a possible interaction would be the 
strongest at this time-point.15 However, even at this time-point we did not demonstrate 
an influence of esomeprazole on the pharmacokinetics of regorafenib, M-2 and M-5.
Regorafenib exhibits low solubility, which is mainly caused by its chemical structure 
as no strong basic or acidic group is attached (regorafenib: 4-[4-({[4-chloro-3-
(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-
carboxamide).22 Furthermore, to improve the solubility, regorafenib is formulated as a 
solid dispersion consisting of small powder particles in which the drug and excipient are 
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integrated.23 Despite this formulation, regorafenib exhibits low solubility compared to 
other TKIs. As a result regorafenib absorption is, in theory, less affected by intragastric 
pH-alterations and the results of this study were not totally unexpected. However, since 
TKI absorption is multifactorial a drug-drug interaction with PPIs cannot always be fully 
ruled out based on modeling and physiochemical properties alone.11 Therefore, a drug 
interaction should always be verified in an in vivo setting as was done in this study for 
regorafenib.
In order to reach the required sample size of 14 evaluable patients a total of 31 patients 
had to be included in the study, due to the fact that many patients were not able to 
complete three cycles of regorafenib at 160 or 120 mg due to treatment-related adverse 
events or progression of disease. In addition, we aimed to include both mCRC and GIST 
patients, but mainly mCRC patients were included, which resulted in a possible selection 
bias. In general, mCRC patients are in a worse condition and more heavily pre-treated 
compared to GIST patients, which could have resulted in more adverse events and 
a higher drop-out rate. However, we do not think it influenced the pharmacokinetic 
end points. In addition, the CORRECT trial demonstrated a median overall survival 
increase of 1.4 months compared to placebo in mCRC patients.2 Therefore, it was not 
completely surprising that quite some patients developed early disease progression 
during study treatment hampering prolonged study participation. In addition, all 
patients eventually used 120 mg at steady-state instead of 160 mg, due to known 
severe treatment-related adverse events (e.g. hypertension), which also occurred in 
up to 50% of patients in the registration studies.2-4 Furthermore, because this study 
was designed as a pharmacokinetic cross-over study, we could not compare toxicity 
between different cycles. However, because we found no differences in regorafenib 
pharmacokinetics, a difference in exposure-related toxicity seems unlikely.
This study was designed to demonstrate a difference based on two primary comparisons 
on regorafenib exposure depending on esomeprazole intake time (concomitantly or 
three hours prior). Because of the assumption of a difference between those cycles, 
we did not include a bioequivalence analysis. However, the boundaries of the adjusted 
90%-confidence interval of the relative differences of the regorafenib AUC found in this 
study almost fit the limits for bioequivalence (B vs A, RD: -3.9%, 90% CI: -18.2-12.9%, 
and C vs A, RD: -4.1%, 90%CI: -20.3-15.4%)18, which supports the interpretation of our 
results.
In conclusion, we have shown that esomeprazole did not influence regorafenib 
exposure on two different intake time-points, and that these drugs can be combined in 
clinical practice, without the appearance of a significant pharmacokinetic interaction.
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SUPPLEMENTARY INFORMATION
Supplementary Methods
Detailed description assay regorafenib, M-2 and M-5
Regorafenib and the metabolites M-2- and M-5 were simultaneously quantitated by 
a validated liquid chromatography tandem triple quadrupole mass spectrometry 
(UPLC-MS/MS) assay. Aliquots of 25 µL of human lithium heparinized plasma samples 
for the quantitation of regorafenib and its metabolites were deproteinized, after the 
addition of 100 µL of Internal Standard (sunitinib-d10). After vigorously mixing for 5 
seconds and centrifugation for 10 min at 18,000*g, aliquots of 1 µL were injected into 
the UPLC-MS/MS-system. Peak area ratios of analytes versus the Internal Standard 
were a function of the concentration from 20.0 to 5,000 ng/mL. For regorafenib, the 
within and between-run precisions at five tested concentrations, including the LLQ, 
were ≤ 5.94 and ≤ 9.99%, respectively, while the average accuracy ranged from 101.4 
to 112.5%. For regorafenib-M2, the within and between-run precisions at five tested 
concentrations, including the LLQ, were ≤ 5.18 and ≤ 11.4%, respectively, while the 
average accuracy ranged from 91.0 to 96.7% and for regorafenib-M5, the within and 
between-run precisions at five tested concentrations, including the LLQ, were ≤ 6.47 
and ≤ 11.2%, respectively, while the average accuracy ranged from 92.8 to 99.4%.
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Supplementary results
SUPPLEMENTARY FIGURE 1. M-2 and M-5 AUC. M-2 and M-5 exposure compared between phase A (regorafenib 
alone) and phase B (regorafenib concomitantly with esomeprazole) (figure 1A, 1C), and between phase A and 
C (regorafenib with esomeprazole 3 hours prior) (figure 1B, 1D). Abbreviations: AUC0-24 = Area under the curve, 
timepoint 0h to 24h
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SUPPLEMENTARY TABLE 1. Toxicity
Toxicitya
Regorafenib
N (%)
Regorafenib + 
Esomeprazole
Concomitant 
N (%)
Regorafenib + 
Esomeprazole 
3h prior
N (%)
Overallb
N (%)
Gastrointestinal 
Anorexia
All grades
Grade ≥3 
6 (43)
1 (7)
5 (36)
1 (7)
5 (36)
1 (7)
10 (71)
2 (14)
Constipation
All grades
Grade ≥3
2 (14)
0
2 (14)
0
1 (7)
0
4 (29)
0
Diarrhea
All grades
Grade ≥3
0 1 (7)
0
2 (14)
0
2 (14)
0
Nausea
All grades
Grade ≥3
2 (14)
0
5 (36)
0
3 (21)
0
7 (50)
0
Reflux
All grades
Grade ≥3
1 (7)
0
0
0
1 (7)
0
2 (14)
0
Stomatitis
All grades
Grade ≥3
5 (36)
0
6 (43)
0
5 (36)
0
8 (57)
0
Vomiting
All grades
Grade ≥3
2 (14)
0
2 (14)
0
3 (21)
0
5 (36)
0
Respiratory
Cough
All grades
Grade ≥3
0 2 (14)
0
1 (7)
0
2 (14)
0
Dry mouth
All grades
Grade ≥3
0 1 (7)
0
3 (21)
0
3 (21)
0
Dyspnea
All grades
Grade ≥3
3 (21)
0
3 (21)
0
4 (29)
1 (7)
6 (43)
1 (7)
Ear pain
All grades
Grade ≥3
1 (7)
0
2 (14)
0
1 (7)
0
3 (21)
0
Hoarseness
All grades
Grade ≥3
8 (57)
0
11 (79)
0
9 (64)
0
11 (79)
0
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SUPPLEMENTARY TABLE 1. Continued
Toxicitya
Regorafenib
N (%)
Regorafenib + 
Esomeprazole
Concomitant
N (%)
Regorafenib + 
Esomeprazole 
3h prior
N (%)
Overallb
N (%)
Vascular 
Cardiac eventsc
All grades
Grade ≥3
0 2 (14)
0
0 2 (14)
0
Hypertension
All grades
Grade ≥3
4 (29)
3 (21)
4 (29)
3 (21)
5 (36)
5 (36)
10 (71)
9 (64)
Skin & Hair
Erythema
All grades
Grade ≥3
1 (7)
0
2 (14)
0
1 (7)
0
4 (29)
0
Hand foot skin reaction
All grades
Grade ≥3
6 (43)
0
9 (64)
1 (7)
7 (50)
1 (7)
9 (64)
2 (14)
Hypertrichosis
All grades
Grade ≥3
0 1 (7)
0
1 (7)
0
1 (7)
0
General disorders
Fatigue
All grades
Grade ≥3
6 (43)
1 (7)
7 (50)
0
7 (50)
1 (7)
10 (71)
1 (7)
Blood value disorders
AST/ALT increase
All grades
Grade ≥3
7 (50)
0
6 (43)
1 (7)
5 (36)
0
11 (79)
1 (7)
Bilirubin increase
All grades
Grade ≥3
4 (29)
0
3 (21)
0
2 (14)
0
7 (50)
0
Hypophosphatemia
All grades
Grade ≥3
2 (14)
0
1 (7)
0
1 (7)
1 (7)
4 (29)
1 (7)
Platelet count 
decreased
All grades
Grade ≥3
0 1 (7)
0
0 1 (7)
0
Number of patients is scored as individual patients per phase.
a Toxicity was graded according to the NCI CTC-AE classification (version 4.03)
b Overall toxicity was defined as the number of patients during the whole study period (i.e. all three phases)
c Cardiac events included atrial fibrillation and myocardial infarction
Abbreviations: AST = aspartate aminotransferase; ALT = alanine aminotransferase; N = number of patients
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EFFECTS OF PREDNISONE ON 
DOCETAXEL PHARMACOKINETICS 
IN MEN WITH METASTATIC 
PROSTATE CANCER:
A RANDOMIZED DRUG-DRUG 
INTERACTION STUDY
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019 MAY;85(5):986-992
Bodine P.S. Belderbos, Koen G.A.M Hussaarts, Leonie J. van Harten, 
Esther Oomen-de Hoop, Peter de Bruijn, Paul Hamberg, Robbert J. van Alphen, 
Brigitte C.M. Haberkorn, Martijn P. Lolkema, Ronald de Wit, Robert J. van Soest 
and Ron H.J. Mathijssen
90
Chapter 5
ABSTRACT
Aim. Docetaxel has been approved for the treatment of metastatic prostate cancer in 
combination with prednisone. Since prednisone is known to induce the cytochrome 
P450 iso-enzyme CYP3A4, which is the main metabolizing enzyme of docetaxel in the 
liver, a potential drug-drug interaction (DDI) may occur. In this prospective randomized 
pharmacokinetic cross-over study we investigated docetaxel exposure with concomitant 
prednisone, compared to docetaxel monotherapy in men with metastatic prostate 
cancer.
Methods. Patients scheduled to receive at least 6 cycles of docetaxel (75 mg/m2) and 
who lent written informed consent, were randomized to receive either the first 3 cycles, 
or the last 3 consecutive cycles with prednisone (BID 5mg). Pharmacokinetic blood 
sampling was performed during cycle 3 and cycle 6. Primary endpoint was difference 
in docetaxel exposure, calculated as area under the curve (AUC0-inf) and analyzed by 
means of a linear mixed model. Given the cross-over design the study was powered on 
eighteen patients to answer the primary, pharmacokinetic, endpoint.
Results. Eighteen evaluable patients were included in the trial. Docetaxel concentration 
with concomitant prednisone (AUC0-inf 2784 ng*h/mL, 95% CI 2436-3183 ng*h/mL) was 
similar to the concentration of docetaxel monotherapy (AUC0-inf 2647 ng*h/mL, 95%CI 
2377-2949 ng*h/mL). Exploratory analysis showed no toxicity differences between 
docetaxel monotherapy and docetaxel cycles with prednisone.
Conclusion. No significant difference in docetaxel concentrations was observed. In 
addition, we found similar toxicity profiles in absence and presence of prednisone. 
Therefore, from a pharmacokinetic point of view, docetaxel may be administrated with 
or without prednisone.
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INTRODUCTION
Docetaxel, a taxane chemotherapeutic agent, was approved by the Food and Drug 
Administration (FDA) and European Medicines Agency (EMA) in 2004 as first-line 
chemotherapy for metastatic castration-resistant prostate cancer (mCRPC) as a result 
of survival benefit obtained in TAX327.1,2 In that study, mitoxantrone plus prednisone 
treatment was compared to a 3-weekly docetaxel (75 mg/m2) regimen in mCRPC patients. 
Prednisone (5 mg BID) was added to docetaxel to equally compare both treatment 
arms, although the preceding phase 2 trials with docetaxel (36 mg/m2, weekly) in 
mCRPC had been conducted without prednisone.3,4 In the final analysis, treatment with 
docetaxel plus prednisone improved overall survival (OS) with 2.9 months compared 
to the mitoxantrone group. Subsequently, docetaxel and prednisone became first-line 
chemotherapy for mCRPC .
After the registration of docetaxel plus prednisone, the role of corticosteroids in the 
treatment of mCRPC remained controversial. In patients with symptomatic bone 
metastases corticosteroids may have a favorable palliative effect, and a reduction in 
docetaxel-induced toxicity has been suggested.5-7 However, the effect of prednisone on 
OS in mCRPC patients remains unclear.6,8 Of note, prolonged use of corticosteroids may 
lead to the development of multiple severe toxicities including osteoporosis, adrenal 
insufficiency, immune suppression, and may exacerbate comorbidities like diabetes.9 
These side-effects of long-term corticosteroid are a justifiable reason to reconsider the 
addition of prednisone to the docetaxel regimen.
Recently, two large clinical trials, CHAARTED and STAMPEDE, assessed the survival 
benefit of docetaxel combined with androgen-deprivation therapy (ADT) in metastatic 
hormone-sensitive prostate cancer (mHSPC).10,11 In order to avoid long term exposure 
to steroids, the investigators of the CHAARTED trial decided to administer docetaxel 
without prednisone, whereas docetaxel was administered with prednisone in 
the STAMPEDE study. At the time of the initiation of our study, only the results of 
CHAARTED were available, showing a robust survival benefit of 13.6 months compared 
to androgen deprivation therapy alone. Toxicity rates were similar to previously 
published work on docetaxel plus prednisone in mCRPC patients , except for a higher 
febrile neutropenia rate in CHAARTED without prednisone, as compared to TAX327 
where docetaxel was administered with prednisone.1,12 Likewise, a retrospective trial 
by Kongsted et al. showed that the toxicity rates of febrile neutropenia and edema 
were significantly higher in the docetaxel monotherapy group compared to the 
docetaxel plus prednisone-group (for an overview of toxicity rates previously reported 
on docetaxel with or without prednisone, see Table 1).5
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TABLE 1. Literature review of docetaxel toxicities with and without prednisone
Trials Prednisone Neutropenia (Gr3-4) Febrile neutropenia
TAX-327 Yes 32% 3%
Venice Yes 7% <1%
Mainsail Yes 16% 5%
GETUG-AFU15 No 32% 8%
CHAARTED No 12% 6%
STAMPEDE Yes 12% 15%
Kongsted et al. No - 25%
Yes - 10%
As a underlying mechanism, prednisone could influence docetaxel pharmacokinetics via 
the CYP3A4 iso-enzyme. Glucocorticoids are known as CYP3A inducers, and docetaxel 
is mainly metabolized in the liver by the cytochrome P450 iso-enzymes CYP3A4 and 
CYP3A5.13 Consequently, this potential drug-drug interaction could lead to higher 
clearance of docetaxel and therefore diminished docetaxel exposure. In this study, 
we therefore investigated the effects of prednisone on docetaxel pharmacokinetics in 
patients with metastatic prostate cancer.
METHODS
This prospective, randomized, cross-over pharmacokinetic trial was carried out 
between September 2016 and February 2018 at the Erasmus MC Cancer Institute in 
Rotterdam, the Netherlands. The study protocol was approved by the Ethical board 
of the Erasmus MC, and the study was conducted according to the ethical guidelines 
of the Declaration of Helsinki. All participants signed informed consent before start of 
the study. The study was registered at the European Clinical Trials Database (EudraCT 
2016-001269-10) and the Dutch Trial Register (‘www.trailregister.nl’ by NTR-number 
NTR6037 or acronym Doc-Pred).
Patients
We included patients with histologically confirmed metastatic prostate cancer, both 
hormone-sensitive or castration-resistant, who were scheduled to receive a minimum 
of 6 cycles of docetaxel chemotherapy. Eligible patients were 18 years and older, 
with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 
Adequate organ function was required, defined by creatinine clearance > 60mL/min, 
bilirubin levels <1x ULN, ALAT/ASAT <2.5x ULN, alkaline phosphatase (AF) < 5x ULN, 
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absolute neutrophil count > 1,5x10^9/L and platelets > 100x10^9/L. Patients had to be 
castrated either by continued androgen deprivation therapy (ADT) with gonadotropin 
releasing hormone (GnRH) analogues or by surgical orchiectomy. It was preferred ADT 
started four weeks prior to chemotherapy, to reach castration-levels of testosterone 
before treatment start. Prior hormonal treatment, like enzalutamide and abiraterone, 
was allowed. However, these therapies, including prednisone, had to be stopped at 
least 6 weeks before the start of this study. Medication or herbal supplements known 
to induce or inhibit CYP3A pathway were prohibited.
Study Design
Patients received 6 consecutive cycles of 3-weekly docetaxel (75 mg/m2) and 
were digitally randomized to receive either the first 3 docetaxel cycles or the last 3 
cycles with prednisone (cross-over). Prednisone 5 mg BID was administered during 
three consecutive cycles. Prednisone started at day 1 of cycle 1 or cycle 4 and was 
stopped after the last day of cycle 3 or cycle 6 (depending on randomization arm, A 
or B respectively). Prednisone dose-modifications were not allowed during the last 
week before pharmacokinetic sampling (cycle 3 day 1 and cycle 6 day 1) and patient 
compliance was assessed through a patient diary. Docetaxel dose-modifications 
because of hematological or non-hematological toxicities were allowed, and schedule 
modifications were allowed up to one week. Dexamethasone is a strong CYP3A4 
inducer, its use, as premedication, was restricted to only 12 and 3 hours before 
docetaxel-infusion to reduce its influence on docetaxel pharmacokinetics. 
Pharmacokinetic sampling
To have maximum inducible effects of prednisone on the CYP-enzymes and to ensure 
a sufficient wash-out period after prednisone, we decided to undertake PK-samples 
during cycle 3 and cycle 6. Hospital admission during the first day of the 3rd and the 
6th docetaxel cycle was required to obtain 24-hour pharmacokinetic-blood samples. 
Blood/plasma samples for determination of docetaxel pharmacokinetics were taken 
at predefined time points (pre-infusion and at 0.5, 0.92, 1.25, 1.5, 2, 3, 4, 6, 8 and 24 
hours after the start of docetaxel). Plasma concentrations of docetaxel were measured 
using a validated liquid chromatography with tandem mass spectrometry method (UP-
LCMS/MS).14 Pharmacokinetic parameters were docetaxel concentration, expressed as 
dose-corrected area under the curve from pre-infusion time-point to infinity (AUC0-inf), 
maximum drug concentration (Cmax), docetaxel half-life (t1/2) and docetaxel clearance. 
AUC0-inf was calculated using a linear pharmacokinetic curve to estimate the residual 
AUC from the latest measurable pharmacokinetic point (24h-time-point).
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Toxicity
Secondary endpoint was describing toxicity rates during docetaxel monotherapy cycles 
and docetaxel with prednisone cycles. Standard laboratory control was performed prior 
to each docetaxel cycle and when indicated according to the physician. Toxicities were 
scored using the CTCAE (v.4.0) grading. If relevant differences in toxicity rates between 
the treatment arms occurred, these were analyzed by means of McNemar test.
Statistical analysis
A difference in systemic exposure to docetaxel of 25% was determined to be clinically 
relevant and it was assumed that the within-patient standard deviation in docetaxel 
pharmacokinetics was 25%. Given a power of 80% and a two-sided alpha of 5%, 18 
patients were required to detect a difference.15 Since docetaxel dose-modifications 
were allowed, a dose-correction was applied for all docetaxel concentrations to the 
standard dose of 75 mg/m2. All docetaxel cycles with prednisone were compared 
to all docetaxel cycles without prednisone, regardless of the randomization arm. 
Analyses of the AUC0-inf and Cmax were performed on log-transformed values, since 
these parameters were assumed to follow a lognormal distribution.16 Estimates for 
the mean differences in (log) AUC0-inf, Cmax and clearance were obtained using a linear 
mixed effect model with treatment, sequence, and period as fixed effects and subject 
within sequence as a random effect.17 Variance components were estimated based 
on restricted maximum likelihood (REML) methods and the Kenward-Roger method of 
computing the denominator degrees of freedom was used. The mean differences and 
their 95% CIs were exponentiated to provide point estimates of the ratio of geometric 
means and 95% CIs for these ratios, which can be interpreted as relative differences in 
percentages. T1/2 was analysed by means of the Wilcoxon signed rank test and described 
with medians and interquartile ranges.
RESULTS
Patients
Twenty-nine patients were screened, of whom four were screen failures which were 
excluded from study participation (Figure 1). We randomized 25 patients to receive 
either cycles 1-3 with concomitant prednisone, and cycles 4-6 without prednisone (arm 
A, N=11), or vice versa (arm B, N=7). During treatment one patient withdrew consent 
in arm A, and six patients stopped treatment in arm B due to radiologic confirmed 
progression (N=3) or withdrawal of consent (N=3). Baseline patient and disease 
characteristics are shown in Table 2. All patients, except three mHSPC patients, received 
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the first cycle of docetaxel 4 weeks after initiation of ADT, to reach castration levels of 
testosterone. However, all patients received ADT for more than a month before PK 
samples during cycle 3 were withdrawn.
FIGURE 1. Flowchart
a. due to inadequate laboratory values
b. Arm A: Three cycles of docetaxel plusprednisone followed by three cycles of docetaxel alone
c. Arm B: Three cycles of docetaxel alone followed by three cycles of docetaxel plus prednisone
Pharmacokinetic parameters
The geometric mean exposure of docetaxel was not significantly different (1.9%, 95% CI 
-9.9% till 15.2%, P=0.75) during docetaxel with concomitant prednisone treatment (AUC0-
inf of 2784 ng*h/mL, 95% CI 2436-3183 ng*h/mL) compared to docetaxel monotherapy 
(AUC0-inf of 2647 ng*h/mL, 95% CI 2377-2949 ng*h/mL). The pharmacokinetic variation, 
as expressed by coefficient of variation, was slightly higher in the docetaxel with 
prednisone arm as compared to docetaxel monotherapy (27% and 22% respectively). 
All pharmacokinetic parameters are shown in Table 3 and were not significantly 
different for docetaxel with or without prednisone. Additionally, we graphically showed 
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TABLE 2. Patient and disease characteristics
Characteristic N (%)
Patients 18 (100)
Age (Median, IQR) 70 (62-73)
BMI (Median, IQR) 25.8(24.6-28.7)
WHO Performance Status
0
1
8 (44)
10 (56)
Hormone Status
Hormone sensitive
Castration resistant
11 (61)
7 (39)
Metastatic stage at screening
M0
M1a
M1b
M1c
5 (28)
4 (22)
8 (44)
1 (6)
Gleason score at diagnosis
≤ 7
> 7
4 (22)
14 (77)
Type of castration
Bilateral orchidectomy
LHRH analogues
1 (6)
17 (94)
Previous therapy
Radicale prostatectomy
RTx prostate
Hormone therapy
Bicalutamide
Enzalutamide
Radium-223
Experimental therapy
1 (6)
3 (16)
6 (33)
2 (11)
1 (6)
1 (6)
Lab results at baseline
PSA, µg/L
Hb, mmol/L
LDH, U/L
AP, U/L
Albumin, g/L
Median (IQR)
20 (3-87)
8 (7-10)
196 (178-216)
103 (70-160)
44 (43-46)
Abbreviations: IQR = Inter Quartile Range, BMI = Body Mass Index, WHO = World Health Organizations, LHRH = 
luteinizing hormone releasing hormone, RTx = radiotherapy, PSA = prostate specific antigen, Hb = hemoglobin, LDH = 
lactate dehydrogenase, AP = alkaline phosphatase
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differences in exposure of docetaxel in mCRPC patients (blue line) and mHSPC patients 
(red line), separately in arm A and arm B; see Figure 2. We performed a t-test on the 
complete patient group (arm A and arm B combined) and found no significant (P=0.2) 
difference between the exposure in mCRPC patients and mHSPC patients. Of note, we 
found a 13.4% (95% CI 2.1%-23.4%, P=0.025) lower exposure of docetaxel over time, 
independent from randomization or disease setting. This, so called, period-effect shows 
lower measured concentrations of docetaxel in cycle 6 compared to the concentrations 
in cycle 3, regardless of the addition of prednisone (Figure 2).
TABLE 3. Docetaxel pharmacokinetics
Docetaxel PK parameters
Docetaxel 
(N=18)
Docetaxel+Prednisone 
(N=18)
Relative difference 
(95% CI) P-value
AUC0-inf a
geomean ng*h/mL (CV%)
2647 (22) 2784 (27) 1.9% (-9.9 till 15.2) 0.75
Cmaxa
geomean ng/mL (CV%)
2454 (26) 2505 (25) -1.4% (-15.3 till 14.8) 0.85
CLa
geomean, L/h (CV%)
55 (26) 53 (26) -2.3% (-9.5 till 5-6) 0.53
T1/2b
median, h (IQR)
12.6 (10.6-14.5) 13.7 (11.3-16.3) 0.31
Abbreviations: AUC0-inf = Area under curve timepoint zero until infinity, Cmax = maximum concentration, CL = clearance, 
T1/2 = half-life, geomean = geometric mean, CV% = coefficient of variation, CI = confidence interval, 
a= analyzed by 
means of a linear effect model, b= analyzed by means of Wilcoxon signed rank test.
Toxicity
Toxicity rates were similar between the cycles with and without prednisone, see Table 
4, except for neutropenia. A non-significant trend towards a higher rate of all grade 
(gr 1-4) neutropenia (N=12) was observed in patients treated without prednisone as 
compared to with prednisone (44 vs 22%, P=0.22). Seven patients (39%) experienced 
an episode of grade 3 – 4 neutropenia. Three febrile neutropenia hospitalizations 
were observed, two of which happened during co-administration of prednisone. There 
was no difference in the disease setting; toxicity was equally distributed in castration-
resistant and hormone-sensitive setting (data not shown).
98
Chapter 5
TABLE 4. Toxicity with or without prednisone
Toxicity
All grades
With prednisone N (%) Without prednisone N (%)
Nausea 3 (17) 5 (28)
Mucositis 9 (50) 8 (44)
Diarrhea 5 (28) 2 (11)
Sens PNP 6 (33) 6 (33)
Fatigue 12 (67) 13 (72)
Neutropenia 4 (22) 8 (44)
Febrile neutropenia 1 (6) 2 (11)
Nail toxicity 5 (28) 6 (33)
Edema 0 (0) 1 (6)
Dysgeusia 1 (6) 1 (6)
Abbreviations: Sens PNP = sensory polyneuropathy
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FIGURE 2. Docetaxel concentration by disease setting. Each line represents a patient for whom the measured 
docetaxel concentration (geomean AUC0-inf) at cycle 3 and cycle 6 were connected with a line to visualize the 
concentration differences between the cycles. In the majority of the patients the measured concentration 
in cycle 6 is lower than in cycle 3, reflecting the period-effect observed in this study. The red lines represent 
patients in the hormone-sensitive disease setting and the blue lines represent the castration-resistant patients, 
subdivided by randomization arm.
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DISCUSSION
In this randomized study, the effects of prednisone on the pharmacokinetics of 
docetaxel were evaluated. No significant difference in docetaxel exposure with or 
without the administration of prednisone was observed. This is the first randomized 
pharmacokinetic study investigating the effects of prednisone on the pharmacokinetics 
of docetaxel. From a pharmacological perspective, we conclude that prednisone did 
not affect the exposure of the docetaxel regimen.
Glucocorticoids are classified as inducers of the CYP3A enzyme,18 and docetaxel is 
metabolized primarily by this iso-enzyme. Previously, an interaction study of docetaxel 
and prednisone has been published in the Clinical Study Report (CSR) of docetaxel 
and no relevant drug-drug interaction was reported.19 However, that PK-study was not 
randomized and included only two docetaxel cycles; one
with prednisone and one without, possibly not providing enough time for optimal 
CYP-induction by prednisone. Moreover, that study was limited by sparse PK-sampling 
(only 6 samples during each cycle) and by limited pharmacokinetic endpoints of 
docetaxel (clearance only). Therefore, in our study, we used a randomized cross-over 
design including 6 cycles of docetaxel (3 cycles in absence and 3 cycles in presence 
of prednisone), an enriched sampling scheme with more relevant pharmacokinetic 
endpoints.
Although we corrected for dose-reductions due to toxicity over time, we unexpectedly 
did find a significant period-effect in this study. This means that a decrease in 
docetaxel exposure occurred in the consecutive cycles independent of randomization 
or treatment. This might be an explanation for the trend towards an overall higher 
incidence of (febrile) neutropenia seen at the start of chemotherapy cycles. There are 
a few potential explanations for this phenomenon. First, a time-dependent induction 
of CYP3A4 by upregulation of Pregnane X receptor (PXR) due to repetitive docetaxel 
exposure could occur.20-23 This phenomenon is called ‘auto-induction’ and is previously 
described with several other agents, e.g. dabrafenib.24 A second possible explanation 
is an upregulation of ABCB1 (P-glycoprotein) by docetaxel. P-glycoprotein is an active 
drug-efflux transporter at the cell membrane of hepatocytes, kidney cells and intestine 
cells. Its upregulation leads to an increased efflux of docetaxel out of the circulation, 
resulting in decreased plasma concentrations.25 This phenomenon could even lead to 
pharmacokinetic resistance to the drug.26,27 This period effect is unlikely to be caused by 
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castration-levels of the patients, since the maximum induction effect of ADT is reached 
after approximately 4 weeks , whereas in our study patients had received at least nine 
weeks of ADT at the time of PK sampling.
Interestingly, we observed no difference in docetaxel-induced toxicities in the absence 
or presence of prednisone, except for a non-significant difference in neutropenia. 
Because our study was not powered or designed for toxicity related questions, we can 
only conclude from a pharmacokinetic point of view that prednisone could be safely 
omitted from the docetaxel regimen.
The major benefit of administering docetaxel without prednisone could be a reduced 
treatment-period of prednisone for patients with metastatic prostate cancer. Long-
term corticosteroid use, albeit in low dosage, may contribute to the development 
of severe toxicities, as mentioned before.9 By excluding prednisone from the initial 
docetaxel chemotherapy regimen patients will no longer be unnecessarily exposed to 
these side-effects. Especially for those patients in the hormone-sensitive phase, who 
usually have a long life expectancy, excluding prednisone will be of relevance to avoid 
long-term toxicity with unclear antitumor activity. In this light, Ghatalia et al. found no 
positive effect on survival nor on cabazitaxel-induced toxicity in patients with mCRPC.28
Limitations of our study include the administration of the standard pre-medication 
dexamethasone, which is another CYP3A inducer. We aimed to minimize the 
pharmacokinetic effect of dexamethasone on docetaxel by excluding the latest gift of 
dexamethasone before docetaxel infusion. Strengths of our study are the randomized 
design with extensive PK sampling at multiple time points.
In conclusion, we found no influence of prednisone on docetaxel pharmacokinetics. 
Docetaxel is registered with concomitant prednisone in the mCRPC setting. In 
metastatic hormone-sensitive disease, the use of prednisone should be supported by 
other arguments balancing the benefit of prednisone versus the potential long-term 
side effects of corticosteroid use.
101
Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer
5
REFERENCES
1. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, 
Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or 
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-
12.
2. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF, Investigators TAX. Survival and 
PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after 
mitoxantrone or vice versa. Ann Oncol 2008; 19: 1749-53.
3. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in 
hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 2001; 
28: 8-15.
4. Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic 
androgen-independent prostate cancer. Ann Oncol 2001; 12: 1273-9.
5. Kongsted P, Svane IM, Lindberg H, Daugaard G, Sengelov L. Low-dose prednisolone in first-
line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a 
clinical benefit? Urol Oncol 2015; 33: 494 e15-20.
6. De Santis M, Saad F. Practical Guidance on the Role of Corticosteroids in the Treatment of 
Metastatic Castration-resistant Prostate Cancer. Urology 2016; 96: 156-64.
7. Ndibe C, Wang CG, Sonpavde G. Corticosteroids in the management of prostate cancer: a 
critical review. Curr Treat Options Oncol 2015; 16: 6.
8. Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart 
R, De Bono J, Parker C. A randomised phase 2 trial of dexamethasone versus prednisolone in 
castration-resistant prostate cancer. Eur Urol 2015; 67: 673-9.
9. Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G. Impact of prednisone on toxicities and 
survival in metastatic castration-resistant prostate cancer: A systematic review and meta-
analysis of randomized clinical trials. Crit Rev Oncol Hematol 2014; 90: 253-61.
10. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, Ritchie AW, Parker 
CC, Russell JM, Attard G, de Bono J, Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, 
Millman R, Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti P, Chowdhury 
S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD, Hetherington J, Hughes R, Laing R, McKinna 
F, McLaren DB, O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari N, 
Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J, Parmar MK, investigators 
S. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy 
in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, 
platform randomised controlled trial. Lancet 2016; 387: 1163-77.
11. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli 
M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. 
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 
2015; 373: 737-46.
12. Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre 
B, Rolland F, Theodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, 
Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey 
JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. 
102
Chapter 5
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate 
cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149-
58.
13. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dual effect of 
dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of 
glucocorticoid receptor and pregnane X receptor. Eur J Biochem 2001; 268: 6346-58.
14. de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, 
Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, 
Baker SD, Mathijssen RH, Sparreboom A. Influence of polymorphic OATP1B-type carriers on 
the disposition of docetaxel. Clin Cancer Res 2012; 18: 4433-40.
15. D. Schoenfeld MMGCRC. Statistical considerations for a cross-over study where the outcome 
is a measurement. In.
16. European Medicines Agency. Guideline on the investigation of bioequivalence. In.
17. Jones B, Kenward, M.G. Design and Analysis of Cross-Over Trials: Chapman&Hall/CRC 
monographs, 2014.
18. Quattrochi LC, Guzelian PS. Cyp3A regulation: from pharmacology to nuclear receptors. Drug 
Metab Dispos 2001; 29: 615-22.
19. Summary of Product Characteristics - Taxotere. In: EMA.
20. Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of 
cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer 
Chemother Pharmacol 2009; 64: 35-43.
21. Istrate MA, Nussler AK, Eichelbaum M, Burk O. Regulation of CYP3A4 by pregnane X receptor: 
The role of nuclear receptors competing for response element binding. Biochem Biophys Res 
Commun 2010; 393: 688-93.
22. Hilli J, Sailas L, Jyrkkio S, Pyrhonen S, Laine K. NCT01110291: induction of CYP3A activity and 
lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother 
Pharmacol 2011; 67: 1353-62.
23. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, Hamilton G, Rizzo C, Jolley S, Gilbert D, 
Downey A, Mudra D, Graham R, Carroll K, Xie J, Madan A, Parkinson A, Christ D, Selling B, 
LeCluyse E, Gan LS. CYP3A4 induction by drugs: correlation between a pregnane X receptor 
reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 
30: 795-804.
24. Luke JJ, Ott PA. New developments in the treatment of metastatic melanoma - role of 
dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014; 6: 77-88.
25. Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH. PXR-mediated 
induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived 
cell line. Cancer Chemother Pharmacol 2010; 66: 765-71.
26. Kato T, Mizutani K, Kameyama K, Kawakami K, Fujita Y, Nakane K, Kanimoto Y, Ehara H, Ito 
H, Seishima M, Deguchi T, Ito M. Serum exosomal P-glycoprotein is a potential marker to 
diagnose docetaxel resistance and select a taxoid for patients with prostate cancer. Urol 
Oncol 2015; 33: 385 e15-20.
27. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura 
K. Interaction of docetaxel (“Taxotere”) with human P-glycoprotein. Jpn J Cancer Res 1999; 90: 
1380-6.
103
Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer
5
28. Ghatalia P, Pond GR, Templeton AJ, Sonpavde G. Effect of Single-agent Daily Prednisone on 
Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis 
of Prospective Studies. Clin Genitourin Cancer 2018; 16: e277-e87.
CHAPTER 7
INFLUENCE OF PROBENECID ON 
THE PHARMACOKINETICS AND 
PHARMACODYNAMICS OF SORAFENIB
PHARMACEUTICS 2020 AUG 20;12(9):E788.
Koen G.A.M. Hussaarts*, Leni van Doorn*, Karel Eechoute, Jeffrey Damman, 
Qiang Fu, Nadia van Doorn, Eric D. Eisenmann, Alice A. Gibson, Esther Oomen- 
de Hoop, Peter de Bruijn, Sharyn D. Baker, Stijn L.W. Koolen, Teun van Gelder, 
Roelof W.F. van Leeuwen, Ron H.J. Mathijssen, Alex Sparreboom and Sander Bins 
 
* Authors contributed equally
120
Chapter 7
ABSTRACT
Prior studies have demonstrated an organic anion transporter 6 (OAT6)-mediated 
accumulation of sorafenib in keratinocytes. The OAT6 inhibitor probenecid decreases 
sorafenib uptake in skin and might, therefore, decrease sorafenib-induced cutaneous 
adverse events. Here, the influence of probenecid on sorafenib pharmacokinetics and 
toxicity was investigated. Pharmacokinetic sampling was performed in 16 patients 
on steady-state sorafenib treatment at days 1 and 15 of the study. Patients received 
sorafenib (200–800 mg daily) in combination with probenecid (500 mg two times 
daily (b.i.d.)) on days 2–15. This study was designed to determine bioequivalence with 
geometric mean Area under the curve from zero to twelve hours (AUC0–12 h) as primary 
endpoint. During concomitant probenecid, sorafenib plasma AUC0–12 h decreased 
by 27% (90% CI: −38% to −14%; P < 0.01). Furthermore, peak and trough levels of 
sorafenib, as well as sorafenib concentrations in skin, decreased to a similar extent in 
the presence of probenecid. The metabolic ratio of sorafenib-glucuronide to parent 
drug increased (+29%) in the presence of probenecid. A decrease in systemic sorafenib 
concentrations during probenecid administration seems to have influenced cutaneous 
concentrations. Since sorafenib-glucuronide concentrations increased compared with 
sorafenib and sorafenib-N-oxide, probenecid may have interrupted enterohepatic 
circulation of sorafenib by inhibition of the organic anion transporting polypeptides 
1B1 (OATP1B1). Sorafenib treatment with probenecid is, therefore, not bioequivalent 
to sorafenib monotherapy. A clear effect of probenecid on sorafenib toxicity could not 
be identified in this study.
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INTRODUCTION
Over the last two decades, systemic anti-cancer treatment options have been expanded 
from traditional cytotoxic chemotherapy to targeted agents, including tyrosine kinase 
inhibitors (TKIs). TKIs offer a number of important advantages over conventional 
cytotoxic chemotherapy like the oral administration of the drugs, but they are still 
afflicted by some major problems, including large interindividual pharmacokinetic 
variability, a narrow therapeutic window, and debilitating adverse events. 1
Cutaneous adverse events are among the most frequently observed toxicities with 
many TKIs, and their intensity can significantly affect both quality of life and health 
care economics.2 A particularly painful complication seen most frequently during the 
early weeks of use with TKIs, such as sorafenib, sunitinib, and regorafenib, is called 
hand-foot skin reaction (HFSR), in which painful hyperkeratotic plaques develop 
predominantly over sites of pressure or friction 3,4 The clinical incidence of HFSR varies 
among TKIs with a particularly high incidence (20% ≥ grade 3) being observed with 
sorafenib 5, an orally administered multikinase inhibitor, registered for treatment 
of advanced hepatocellular carcinoma and advanced renal cell carcinoma as well as 
iodine-refractory advanced thyroid cancer 3,4,6,7 Furthermore, it is investigated as a 
treatment option for acute myeloid leukemia.8 
The pathogenesis of TKI-induced HFSR remains currently unknown, and the only 
effective treatment options involve either dose reduction or discontinuation of 
therapy, which theoretically may have negative effects on disease management.9,10 
However, previous in vitro and in vivo research showed that sorafenib can accumulate 
in human epidermal keratinocytes mediated by the organic anion transporter 6 (OAT6) 
11, and that sorafenib-induced skin toxicity can be prevented by cotreatment with the 
OAT6 inhibitor probenecid without negatively influencing the antitumor properties of 
sorafenib.11
Probenecid is an uricosuric agent indicated for the maintenance treatment of 
hyperuricemia associated with gout and gouty arthritis. It was also used as an adjuvant 
for therapy with certain antibiotics, such as penicillin, ampicillin, or methicillin, 
because it elevates and prolongs their plasma levels by inhibition of renal excretion.12 
Probenecid is usually well tolerated at a dose of 500 mg two times daily and is usually 
taken for (many) months. Probenecid is also known as a pan- uridine diphosphate 
glucuronosyltransferase (UGT) inhibitor, used in drug registration studies and, 
therefore, could potentially influence pharmacokinetics of several drugs, including 
sorafenib that undergoes cytochrome P450 3A4 (CYP3A4)-mediated oxidation into 
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its active metabolite (pyridine-N-oxide) and UGT1A9-mediated glucuronidation into 
sorafenib glucuronide.13-15 Furthermore, probenecid is known to alter the activity of 
several drug transporters like OAT and the organic anion transporting polypeptides 
(OATP), which play a main role in renal and hepatic excretion.16 However, the extent 
of this possible effect is not yet determined in clinical studies and the safety of the 
combination of these drugs is currently unknown. As part of an ongoing project to 
develop translationally useful prevention strategies for sorafenib-induced HFSR, in the 
current study, we evaluated the pharmacokinetics (PK) and safety of sorafenib when 
concomitantly used with probenecid. 
PATIENTS AND METHODS
This non-randomized, cross-over study was performed between November 2017 and 
November 2019 at the Erasmus University MC Cancer Institute. The study was approved 
by the local ethics committee of the Erasmus University MC (METC-17-490, date of 
approval 16-11-2017) and competent authority and was registered at the European 
Clinical Trials Database (EudraCT 2017-002470-40) and the Dutch trial registry (www.
trialregister.nl; number NL6783).
Patients
Patients who had a confirmed diagnosis of advanced hepatocellular carcinoma (HCC) 
or differentiated thyroid carcinoma with an indication for sorafenib treatment, and who 
were at least 18 years of age, were included in this study. Furthermore, patients had to 
have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 and an 
adequate hematological, renal, and liver function defined as a Common Terminology 
Criteria for Adverse Events (CTCAE) grade of ≤2 at baseline. Besides, patients with 
known contraindications for probenecid use (e.g., history of uric acid kidney stones, an 
acute gouty attack, or blood dyscrasias) and/or the use of drugs that are strong CYP3A4 
or UGT1A9 inducers or inhibitors were excluded. All included patients gave written 
informed consent. 
Study procedures
Patients received sorafenib for at least two weeks to ensure steady-state 
pharmacokinetics of sorafenib. Since sorafenib has linear pharmacokinetics,17 dose 
reductions were allowed after the start of the study. Sorafenib was administered at a 
200–800-mg daily dose during the 15-day study period and was given concomitantly 
with probenecid (500 mg b.i.d.) from day 2 to day 15 of the study. Both sorafenib and 
probenecid were ingested at predefined timepoints at 10:00 a.m. and 10:00 p.m. 
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Pharmacokinetic sampling
Patients were admitted to the hospital on days 1 and 15 of the study for pharmacokinetic 
blood sampling. A total of nine blood samples for the determination of sorafenib, 
sorafenib N-oxide, and sorafenib glucuronide were obtained at predefined time points 
(T = pre, T = 0.5 h, T = 1 h, T = 2 h, T = 4 h, T = 6 h, T = 8 h, T = 10 h, and T = 12 h). Blood 
samples were processed into plasma within 30 min, by vortex mixing and centrifugation 
for 10 min at 2500 g at 4 °C. Plasma concentrations were determined using a validated 
liquid chromatography tandem mass spectrometry (LC-MS/MS) method 18, at both 
the laboratory of Translational Pharmacology in the Erasmus MC, Rotterdam, and the 
laboratory of Pharmaceutics and Pharmaceutical Chemistry, Ohio State University, 
OH. Predefined pharmacokinetic endpoints were the dose-corrected area under the 
curve from preadministration time point until 12 h after sorafenib intake (AUC0–12 h), 
maximum concentration (Cmax), time until maximum concentration (Tmax), and lowest 
plasma concentration (Ctrough) and were determined using WinNonlin v. 7.0 (Phoenix, 
Certara, 5349 AB, Oss, the Netherlands) for sorafenib, sorafenib-N-oxide, and sorafenib 
glucuronide.
Skin biopsies 
A 3-mm skin biopsy was obtained at days 1 and 15 of the study during PK sampling 
days for pharmacokinetic analysis. Skin biopsies were taken from either the forearm 
or the shoulder region, but always from the same region at the same timepoint in an 
individual patient during the two consecutive PK sampling days. If patients had HFSR 
lesions at the hand at the first PK day, an additional skin biopsy was performed from 
the thenar eminence region of the hand for pathologic analysis on days 1 and 15. The 
biopsies were graded according to the scoring for interface dermatitis as used for graft-
versus-host disease by an experienced pathologist (J.D.). There is no other pathologic 
grading scale for HFSR and our grading scale shows the most overlapping features from 
a pathologic perspective 19. Furthermore, concentrations of sorafenib were determined 
from the skin biopsies after dilution in human plasma and homogenization using the 
validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method 
described earlier 18.
In vitro transport assay
Transport assays assessing probenecid’s inhibition of OATP1B1 were conducted 
as previously described 20. The [3H]estradiol-17b-d-glucuronide, a positive control 
substrate for OATP1B1 21, was obtained from American Radiolabeled Chemicals. Water-
soluble probenecid was obtained from Invitrogen (Molecular Probes). The generation 
and characterization of Flp-In T-Rex293 cells expressing inducible OATP1B1 have been 
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reported previously 22, 23. Cells expressing OATP1B1 or vector control (VC) were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen) supplemented with 10% 
Fetal Bovine Serum (FBS), hygromycin B (25 mg/mL; Invitrogen), and blasticidin (37.5 
mg/mL; Biovision, California, United States of America). 
Cells were seeded in 24-well plates in phenol red-free DMEM containing 10% FBS, 
hygromycin (25 mg/mL), blasticidin (37.5 mg/mL), and doxycycline (1 µg/mL) and 
were incubated at 37 °C for 24 h. Cells were then washed with warm PBS and pre-
incubated with the indicated concentration of probenecid in phenol red-free DMEM 
(without FBS and supplements) at 37 °C for 15 min. Cells were then incubated with 
phenol red-free DMEM containing the indicated concentration of probenecid and 0.2 
µM [3H]estradiol-17b-D-glucuronide for an additional 15 min. The experiment was 
terminated by washing three times with ice-cold PBS. Cells were lysed in 1 N NaOH at 4 
°C overnight, and then the solution was neutralized with 2 mol/L HCl. Total protein was 
measured using a Pierce BCA Protein Assay Kit (Thermo Scientific), and total protein 
content was quantified using a microplate spectrophotometer. Drug concentrations 
were determined in the remaining cell lysate by liquid scintillation counting using 
a scintillation counter. OATP1B1-mediated uptake was calculated by dividing the 
disintegrations per minute (dpm) from each replicate by the amount of protein (mg) and 
subtracting the dpm/mg protein in VC cell line from the dpm/mg protein in OATP1B1 
overexpressing cells at each concentration of probenecid. OATP1B1-mediated uptake 
at each concentration of probenecid was then compared with OATP1B1-mediated 
uptake when only an equal volume of vehicle was added without probenecid (i.e., 
% control). The half maximal inhibitory concentration (IC50) was calculated using a 
nonlinear fit comparing concentration of probenecid versus response. 
Toxicity
Toxicity rates were determined at baseline, days 1 and day 15 of the study using 
Common Terminology Criteria for Adverse Events (CTCAE version 4.0, National Cancer 
Institute, Bethesda, Maryland, United States), and by evaluating the patient diaries 
during the sorafenib monotherapy phase and sorafenib concomitant with probenecid 
phase. 
Statistical analysis
The primary objective of this study was to determine bioequivalence between sorafenib 
monotherapy and sorafenib concomitantly with probenecid to determine whether it 
is a safe option in clinical practice. Bioequivalence can be concluded when the 90% 
confidence interval (CI) of the ratio of geometric means is within 80% and 125%. 
Assuming a standard deviation of the difference of 0.25 for log(AUCsorafenib), using a 90% 
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power and two-sided alpha of 5%, the required number of evaluable patients was 16. 
Analyses of AUC0-12h, Ctrough, and Cmax were performed on log-transformed observations 
by means of the paired t-test. The point estimates and CIs were transformed back to 
the original scale in order to give the point estimates for the ratio of the geometric 
means and the CIs. Tmax was analyzed by means of the Wilcoxon signed rank test 
and described with medians and interquartile ranges. Toxicity was described as the 
incidence of toxicity per phase. This was corrected for baseline toxicity and was only 
taken into account in case of an increase in CTCAE grade per PK sampling day. Since 
the design of this study was not appropriate to detect a significant difference in toxicity, 
these results had a descriptive character.
RESULTS
Patient Characteristics
Seventeen patients were included, of whom 16 patients were evaluable due to 
withdrawal of one patient. Most patients (n = 14) were male and had an HCC (n = 12). 
Eight patients with HCC had underlying liver cirrhosis due to alcohol abuse (n = 3) or 
chronic viral hepatitis (n = 5). Other patient characteristics can be found in Table 1.
Pharmacokinetics
When sorafenib was administered with concomitant probenecid, the geometric mean 
sorafenib AUC0–12 h was 26.8% (90% CI: −37.7% to −14.1%) lower than when sorafenib was 
administered alone. Similarly, sorafenib plasma Cmax and Ctrough decreased significantly 
by 25.1% (90% CI: −44.3% to −19.7%) and 26.0% (90% CI: −43.4% to −3.4%), respectively. 
(Table 2 and Figure 1).
Sorafenib metabolites showed a similar decrease in plasma concentration, although 
there was a substantial interpatient variability. The sorafenib-N-Oxide AUC0–12 h decreased 
by 36.3% (90% CI: −52.8% to −14.1%) and Cmax showed a similar significant decrease of 
39.2% (90% CI: −54.6% to −18.7%). Interestingly, cotreatment with probenecid did not 
decrease the sorafenib-glucuronide AUC0–12 h to a similar extent (5.5%; 90% CI: −18.0% 
to 8.9%), did not significantly influence Cmax (6.1%; 90% CI: −21.7% to 12.7%), and, thus, 
shows bioequivalence (Table 2 and Figure 1). The ratio of sorafenib-glucuronide to 
sorafenib increased by 29% when sorafenib was co-administered with probenecid, 
whereas other metabolic ratios did not change significantly. Sorafenib concomitant 
with probenecid is not bioequivalent to sorafenib monotherapy.
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TABLE 1. Patient characteristics.
Characteristic Evaluable patients (n=16)
Sex
Male
Female
14 (88%)
2 (12%)
Age (years) median [IQR] 66.5 [58-75]
Performance
ECOG 0
ECOG 1
ECOG 2
1 (6%)
13 (82%)
2 (12%)
Tumor type
HCC
liver cirrhosis
Pre-existent hepatitis
Thyroid carcinoma
12 (72%)
8 (66%)
5 (42%)
4 (28%)
BMI (kg/m²)  median [IQR] 25.2 [22-30]
Race
Caucasian
African
Arabic
Asian
11 (70%)
1 (6%)
3 (18%)
1 (6%)
Sorafenib daily dose at start of study
200 milligrams
400 milligrams
600 milligrams
800 milligrams
1 (6%)
10 (63%)
2 (12%)
3 (19%)
Abbreviations: BMI= body mass index, ECOG = Eastern Cooperative Oncology Group; HCC = hepatocellular carcinoma, 
n = number of patients; IQR = interquartile range.
FIGURE 1. Pharmacokinetic results are displayed for a) sorafenib-glucuronide concentration, b) sorafenib 
concentration, c) Sorafenib-glucuronide (SG) to sorafenib ratio
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TABLE 2. Pharmacokinetic results.
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P-value
Sorafenib
AUC0-12h (CV %)
geomean μg*h/mL
33457.8
(42)
24476.8
(57)
-26.8%
(-37.7% to -14.1%)
<0.01
Cmax (CV %)
geomean μg/mL
4457.8
(52)
3337.2
(63)
-25.1%
(-44.3% to -19.7%)
<0.01
Ctrough (CV %)
geomean μg/mL
2125.5
(60)
1571.9
(61)
-26.0%
(-43.4% to -3.4%) 
0.07
Tmax (IQR)
median hours
3.7
(1.5-4.15)
2.2
(1.0-2.01)
 NA 0.53
Sorafenib concentration 
in keratinocytes
Geomean ng/mL (CV %)
50.0
(61)
1.49 * 10-3 36.0
(63)
1.47* 10-3 -28.1%
(-46.3% to -3.7%)
0.07
Sorafenib-N-oxide
AUC0-12h (CV %)
geomean μg*h/mL
3442.8
(78)
0.10 2192.3
(77)
0.09 -36.3%
(-52.8% to -14.1%)
0.02
Cmax (CV %)
geomean μg/mL
467.3
(77)
283.9
(74)
-39.2%
(-54.6% to 18.7%)
<0.01
Ctrough (CV %)
geomean μg/mL
271.1
(282)
(71) -35.2%
(-59.7% to 4.3%)
0.13
Sorafenib-glucuronide
AUC0-12h (CV %)
geomean μg*h/mL
120660
(55)
3.61 113995
(59)
4.66 -5.5%
(-18.0% to 8.9%)
0.49
Cmax (CV %)
geomean μg/mL
12704
(51)
11931
(64)
-6.1%
(-21.7% to 12.7%)
0.56
Ctrough (CV %)
geomean μg/mL
9159
(65)
8400
(67)
-8.3%
(-21.3% to 6.9%)
0.34
Abbreviations: AUC0-12h = area under the curve, time point 0h to 12h; CI = Confidence Interval; RD = relative difference; 
Cmax= maximum concentration; Ctrough= minimum concentration; CV = coefficient of variation; h = hours; n = number of 
patients; Tmax = time until maximum concentration, IQR = interquartile range; NA = not applicable.
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Sorafenib concentration in skin decreased in the presence of probenecid by 28.1% (90% 
CI: −46.3% to −3.7%), with a similar plasma sorafenib/sorafenib in skin ratio (Table 2). 
Furthermore, there was no difference between patients with or without liver cirrhosis 
in sorafenib plasma AUC (−6.3%; 90% CI: −32.9% to 30.7%; P = 0.73) and Ctrough (−7.4%; 
90% CI: −46.8% to 61.3%; P = 0.81).
In vitro transport assay
Subsequently, we hypothesized that probenecid interferes with enterohepatic 
sorafenib circulation via OATP1B1 inhibition and, therefore, measured the impact of 
probenecid on the cellular uptake of a probe OATP1B1 substrate, [3H]estradiol-17b-
d-glucuronide, in a cell line overexpressing OATP1B1. Probenecid inhibited OATP1B1 
function with an IC50 of 182 µM (Figure 2). ). Given that probenecid achieves plasma 
concentrations higher than 200 µM at clinically relevant doses,24 the results of this 
experiment support our hypothesis that OATP1B1 contributes to the observed drug–
drug interaction between probenecid and sorafenib. 
FIGURE 2. Inhibition of OATP1B1 function by probenecid in vitro. HEK293 cells expressing OATP1B1 or VC 
were pre-incubated with probenecid at the indicated concentrations for 15 minutes before incubation with 
probenecid and [3H]estradiol-17b-D-glucuronide for 15 minutes. Data represent uptake of OATP1B1-expressing 
cells at each concentration compared against vehicle after subtracting uptake by VC cells (mean ± SEM). Each 
concentration consists of 3-9 technical replicates across 1-3 biological replicates.
Toxicity
There were three serious adverse events, which were assumed to be not related to any 
of the study drugs (gastroenteritis with dehydration and dyspnea grade 3 during the 
probenecid part and atrial fibrillation de novo in the monotherapy part, all complicated 
with unplanned hospitalization). HFSR, rash, anorexia, and fatigue occurred more 
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frequently during probenecid administration (65%) than during sorafenib monotherapy 
(43%)  (Table 3, Supplementary Table 1). HFSR occurred in 10 of 16 patients with five 
patients experiencing HFSR at the first day of PK sampling. Three of these patients 
experienced progression of HFSR symptoms during the study. Most toxicity occurred 
after 3–6 weeks of treatment. Most grades 2 and 3 adverse events were seen when 
sorafenib was administered with probenecid. A total of five patients experienced HFSR 
at PK sampling day 1 and a biopsy of the thenar eminence region was taken in these 
patients on days 1 and 15 of the study. There was no difference in the grading of the 
HFSR between the first and second PK sampling day in these patients.
TABLE 3. Patient reported adverse events during study period.
Sorafenib mono
(N = 16)
Sorafenib concomitantly 
with probenecid
(N = 16)
Adverse event Grade 1-2 Grade 3 Grade 1-2 Grade 3
Rash 1 - 3 1
Nausea 1 - 2 -
Vomiting 0 - 1 -
Oral mucositis 1 - 1 -
Diarrhea 1 - 2 -
Constipation 2 - 3 -
Anorexia 4 - 7 -
Dyspnea - - - 1
Edema - - 1 -
Fatigue 2 - 6 1
fever 1 - - -
Pain 1 1 2 1
Serious adverse events (SAE) 1 2
There were three serious adverse events (Atrial fibrillation de novo, dyspnea grade 3 and severe gastroenteritis with 
dehydration) during sorafenib therapy for which hospitalization was necessary
DISCUSSION
In this study, we investigated the influence of the OAT6 and OATP1B1 inhibitor probenecid 
on sorafenib pharmacokinetics and toxicity in patients, and found a significant decrease 
in the geometric mean of sorafenib plasma exposure and a nearly significant decrease 
in intracutaneous sorafenib exposure during concomitant probenecid administration 
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making sorafenib concomitantly with probenecid not bioequivalent to sorafenib 
monotherapy. Of the metabolites, systemic sorafenib-N-oxide concentrations 
decreased proportionally with the parent drug, but the sorafenib-glucuronide to 
sorafenib ratio increased after probenecid administration, which does not support the 
hypothesis of UGT inhibition. This is in line with our previous findings on enterohepatic 
circulation of sorafenib-glucuronide, which demonstrated that OATP1B inhibition leads 
to an increase in plasma sorafenib glucuronide levels.13,25 Next to the relative increase 
in systemic sorafenib-glucuronide exposure, its reduced hepatocellular secretion 
would also explain the decrease in systemic sorafenib concentrations after probenecid 
administration, as these concentrations are less maintained via enterohepatic 
circulation of deconjugated sorafenib glucuronide. Moreover, as we found probenecid 
to inhibit OATP1B1-mediated transport in vitro at clinically relevant concentrations and 
as we previously showed that OATP1B1 contributes to enterohepatic sorafenib cycling,13 
it is plausible that reduced enterohepatic circulation of sorafenib led to its significant 
decrease in systemic exposure after probenecid. Alternatively, the relative systemic 
accumulation of sorafenib-glucuronide compared with sorafenib and sorafenib-N-
oxide might be caused by decreased tubular secretion in the kidney, where probenecid 
is known to inhibit prominent drug transporters as OAT1 and OAT3.16 However, data 
regarding this potential interaction are lacking. This study was not designed to quantify 
these mechanisms and it should be noted that all patients followed the same sequence 
of treatment, i.e., sorafenib monotherapy followed by concomitant probenecid, which 
complicates the differentiation between effects of probenecid and time. Regardless 
of its etiology, the decrease in systemic sorafenib exposure rather than inhibited 
OAT6-mediated transport seemed to determine cutaneous sorafenib concentrations, 
as systemic and cutaneous sorafenib concentrations decreased proportionally and 
protective effect of probenecid on cutaneous exposure could not be demonstrated. 
This follows a recent population PK analysis in which systemic sorafenib and sorafenib-
N-oxide were associated with earlier occurrence of HFSR.26 
Despite lower sorafenib exposure, adverse events occurred more frequently during 
probenecid cotreatment. It is known that the prevalence of adverse events increases 
during the first weeks of sorafenib treatment.27 The difference in adverse events is, 
therefore, unlikely a result of the drug interaction observed in this study. Patients 
participated in the study at a relatively early stage of the TKI treatment (i.e., maximal 
six weeks after start of sorafenib treatment). Usually sorafenib adverse events such as 
hypertension occur early during TKI treatment 27 and HFSR usually develops 2–4 weeks 
after initiation of sorafenib. Hence, it is not likely that we missed this adverse event in 
our study population.19,27 In the five patients who experienced HFSR at the first day of 
study, pathologic characteristics of skin biopsies from the thenar eminence region did 
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not change during the study, potentially due to the non-specificity for HFSR of the used 
grading scale, i.e., the interface dermatitis score, or due to the absence of high-grade 
HFSR in our study population. Therefore, subtle HFSR specific changes could have been 
missed.
In conclusion, both systemic and cutaneous sorafenib exposure decreased 
proportionally during concomitant probenecid administration, which may have been 
caused by interruption of enterohepatic cycling via OATP1B1 inhibition.
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SUPPLEMENTARY TABLE 1. Toxicity per patient
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Baseline 1 1 1 1
1 14 800 PK day 1 2 1 1 1
800 PK day 2 1 1 1 1
Baseline 1 1 1
2 28 400 PK day 1 1 1
400 PK day 2 1 1 1 1
Baseline 1 1 1
3 9 400 PK day 1 1 2 2 1
400 PK day 2 1 1 1
Baseline 1 1
4 27 600 PK day 1 1 1 1 1
600 PK day 2 1 2 2 1
Baseline 1 1 1
5 23 800 PK day 1 1 1 1 1 1 1
800 PK day 2 2 1 1 1
Baseline
6 35 800 PK day 1 1 1 1
800 PK day 2 3 2 1 2
Baseline 1 1 1 1 1
7 22 400 PK day 1 1 1 1 1
400 PK day 2 2 1 1 1
Baseline 1 1 1
8 8 400 PK day 1 1 1
600 PK day 2 1 1 1 1
Baseline 1 1
9 11 400 PK day 1 1 1 1
400 PK day 2 1 1 1 1 1
Baseline 1 1 1 1
10 23 200 PK day 1 1 1 1 1
200 PK day 2 1 1 2 1 1
Baseline 1 1 1
11 42 400 PK day 1 2 1
400 PK day 2 1 2
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SUPPLEMENTARY TABLE 1. Continued
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Baseline 1 1
12 12 400 PK day 1
400 PK day 2 2 1 1
Baseline 1 1 1 1
13 41 400 PK day 1 1 1 1 3
400 PK day 2 2 1 1 1 3 1
Baseline 1 2 1
14 29 400 PK day 1 1 1 2 1
400 PK day 2 3 2 3 1 1
Baseline 1 1 1
15 24 400 PK day 1 1 1 1
400 PK day 2 1 1 1
Baseline 1 2
16 23 400 PK day 1 1 2
400 PK day 2 2 2 2
Legend: Toxicity per phase per patient according to the CTCAE grading. In general there is an increase in adverse events 
during the study. Fields are left blank if toxicity is scored 0.
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ABSTRACT
Purpose. Antidepressants like the serotonin reuptake inhibitors (SRIs) are often used 
concomitantly with tamoxifen (e.g. for treatment of depression). This may lead to 
an additional prolongation of the QTc-interval, with an increased risk of cardiac side 
effects. Therefore we investigated whether there is a drug-drug interaction between 
tamoxifen and SRIs resulting in a prolonged QTc-interval.
Methods. Electrocardiograms (ECGs) of 100 patients were collected at steady state 
tamoxifen treatment, with or without concomitant SRI co-medication. QTc-interval 
was manually measured and calculated using the Fridericia formula. Primary outcome 
was difference in QTc-interval between tamoxifen monotherapy and tamoxifen 
concomitantly with an SRI.
Results. The mean QTc-interval was 12.4 ms longer when tamoxifen was given 
concomitantly with an SRI (95% CI:1.8–23.1 ms; P = 0.023). Prolongation of the QTc-
interval was particularly pronounced for paroxetine (17.2 ms; 95%CI:1.4–33.0 ms; P 
= 0.04), escitalopram (12.5 ms; 95%CI:4.4–20.6 ms; P < 0.01) and citalopram (20.7 ms; 
95%CI:0.7–40.7 ms; P = 0.047), where other agents like venlafaxine did not seem to 
prolong the QTc-interval. None of the patients had a QTc-interval of >500 ms.
Conclusions. Concomitant use of tamoxifen and SRIs resulted in a significantly higher 
mean QTc-interval, which was especially the case for paroxetine, escitalopram and 
citalopram. When concomitant administration with an SRI is warranted venlafaxine is 
preferred.
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INTRODUCTION
One of the most common causes of cessation of therapeutic use of drugs which have 
already been marketed is prolongation of the QT-interval, which is defined as a QT 
interval > 470 ms in females and > 450 ms in males according to European Society of 
Cardiology (ESC) guidelines1,2. QT-interval or the heart-rate corrected QT (QTc) interval 
prolongation is associated with higher risk of polymorphic ventricular tachycardia or 
Torsade des Pointes (TdP), which may ultimately lead to sudden cardiac death (SCD)1,3. 
The QTc-interval represents the duration between the onset of ventricular depolarization 
and the completion of repolarization of the myocardium. Several risk factors are 
associated with an increased risk for QTc-interval prolongation (e.g hypopotassemia, 
renal impairment, use of diuretics and other QTc-prolonging drugs and unmodifiable 
risk factors such as age > 65 years and female gender)1,4–6. Furthermore, it has become 
evident that several classes of anti-cancer drugs are associated with QT prolongation 
and, therefore, this offers a great challenge in the treatment of cancer patients7–9.
The suggested mechanism of drug-induced QTc-interval prolongation is inhibition or 
reduced expression of the Human ether-a-go-go related (hERG) gene that encodes a 
potassium channel that regulates repolarizing currents (Ikr) in the cardiomyocytes or 
inhibition of late sodium currents 1,10. Inhibition of these Ikr results in a delay in the 
ventricular repolarization causing prolongation of the QT-interval (Fig. 1). Some drugs 
are known Ikr inhibitors, but failed to demonstrate a clinical significant QTc-interval 
prolongation at dosages used in routine clinical practice (e.g. fexofenadine), although 
some of these drugs still give an increased risk of experiencing TdP 1. Therefore, the 
risk of experiencing TdP is not fully linear with the extent of QTc-interval prolongation. 
Combining QTc-prolonging drugs (drug-drug interaction) may also increase the risk of 
SCD 1,8. The combination of two known QTc-prolonging drugs may result in a cumulative 
or synergistic prolongation of the QTc-interval and thus increased risk for TdP 11,12.
QT Interval 
Prolongation
QT Interval
QT Interval 
Prolongation
QT Interval Torsade de 
pointes
SSRI
SSRI
SSRI
hERG channel
Extracellular
Intracellular
Action potential ECG
FIGURE 1. Mechanism of QTc-interval prolongation. Serotonin reuptake inhibitors (SRIs) inhibit the hERG 
channel and therefore the Ikr (repolarizing potassium (K+) current) in the cardiomyocyte. This results in a delay 
of the ventricular repolarization time and therefore in a prolongation of the QTc-interval. Prolongation of the 
QTc-interval may result in cardiac arrhythmias such as TdP.
140
Chapter 8
The risk of drug-induced QTc-interval prolongation is determined according to Adverse 
Drug Event Causality Analysis into QTc-prolonging drugs with a ‘known’, ‘possible’ or 
‘conditional’ risk for TdP 13,14. A drug is categorized as a drug ‘with a known risk of TdP’ 
if there is substantial positive evidence of prolongation of the QTc-interval and an 
association with TdP. The risk is scored as ‘possible’ if there is substantial evidence 
which supports the conclusion that drugs can prolong the QTc interval, but there is 
insufficient evidence that these drugs are associated with TdP. Finally, the risk is scored 
as ‘conditional’ if there is substantial evidence of QT-interval prolongation with an 
association with TdP development but only under certain conditions (e.g. overdosing) 
or because the drug has shown ability to create one or more conditions that facilitate 
induction of TdP (e.g. by inhibiting metabolism of QTc-proloning drugs). Drugs with a 
‘known’ risk for QTc-interval prolongation are escitalopram and citalopram. Venlafaxine, 
imipramine, nortriptyline and tamoxifen are classified as ‘possible’ and paroxetine, 
amitriptyline, sertraline, fluoxetine and fluvoxamine are classified as conditional 
according to Crediblemeds®.
One of the anti-cancer drugs, which is a known Ikr inhibitor, is the selective ER 
modulator (SERM) tamoxifen 8,15,16. Since decades, tamoxifen is used in the treatment 
of breast cancer, where it provides suppression of ER-dependent proliferation of 
breast cancer cells and therefore reduces the risk of disease recurrence and mortality. 
However, tamoxifen may also lead to Ikr inhibition in cardiac tissue and ultimately 
to prolongation of the QTc-interval 15. After absorption tamoxifen is converted into 
several pharmacologically active metabolites of which endoxifen is the most potent. 
The cytochrome P450 enzymes CYP2D6 and CYP3A4 play a dominant role in the 
biotransformation of tamoxifen 17. It has been shown that the use of CYP2D6 or 
CYP3A4 inhibitors or inducers may lead to a significant alteration in tamoxifen and 
endoxifen exposure 18–20. One of the classes of drugs that is known for its ability to 
inhibit CYP2D6 are the serotonin reuptake inhibitors (SRIs) like the selective serotonin 
reuptake inhibitors (SSRI) and the serotonin norepinephrine reuptake inhibitor 
(SNRI) venlafaxine 21. These drugs are frequently used (by breast cancer patients) 
for the treatment of depression, anxiety disorders or (tamoxifen-related) hot flashes 
22. The most potent CYP2D6-inhibiting SRIs are paroxetine and fluoxetine 21. When 
coadministration of an SRI is necessary with tamoxifen therapy, patients are often 
treated with weak CYP2D6-inhibiting SRIs like citalopram or escitalopram to minimize 
the risk of changes in endoxifen plasma concentrations 19,20. However, SRIs such as 
citalopram and escitalopram are also known to cause prolongation of the QTc-interval 
23.
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Since both tamoxifen and SRIs may prolong the QTc-interval, the combined use of these 
drugs may result in an enhanced risk of prolongation of the QTc-interval and therefore 
ventricular arrhythmias, especially in breast cancer patients since they have often more 
additional risk factors (e.g. female gender, often older age). At present it is unknown if 
the effect of combined treatment on the QTc-interval is additive or synergistic. Hence, 
the objective of this study was to determine whether there is a clinically relevant drug-
drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval.
MATERIALS AND METHODS
Study Design
This observational study was performed between February 2012 and October 2018. 
Electrocardiogams (ECGs) were collected in the Erasmus University Medical Center 
in Rotterdam, the Franciscus Vlietland & Gasthuis in Schiedam and the Elisabeth-
Tweesteden hospital in Tilburg, the Netherlands. This study has focused on the QTc-
interval during treatment with tamoxifen monotherapy compared to treatment with 
tamoxifen and SRIs (i.e. SSRIs, SNRIs and tricyclic antidepressants). The study was 
approved by the local ethics committee of the Erasmus Medical Center in Rotterdam 
(MEC12–109).
Study Population
We included a total of 100 adult patients with breast cancer for whom treatment with 
tamoxifen was indicated. Fifty patients also used an SSRI, venlafaxine or a tricyclic 
antidepressant, which also inhibits serotonin reuptake and may increase the risk for 
QTc-interval prolongation (e.g. amitriptyline). ECGs were taken at any time interval 
following drug intake. Patients were on tamoxifen treatment for at least 4 weeks. 
Patients were included either retrospectively or prospectively. Patients should not have 
received chemotherapy or radiotherapy within 4 weeks prior to the ECG-recording. 
If patients were included prospectively, written informed consent was obtained. If 
the ECG of patients showed a left or right bundle branch block (LBBB/RBBB), atrial 
fibrillation or other ECG abnormalities due to cardiac pathology, ischaemia or bigeminy, 
they were excluded from further analysis owing to interference of these factors with 
the QTc-interval. ECGs showing a QRS complex of >120 ms, RR intervals >1800 ms 
(defined as the time between two consecutive R waves) or < 500 ms or ECGs with a 
QTc interval > 700 ms or < 300 ms were also excluded, since the QTc-interval could not 
be reliably measured. In addition, patients who used other strong inhibitors/inducers 
of CYP2D6 and/or CYP3A4 (according to the Flockhart table) were excluded from the 
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analysis 21. Medication with a ‘known’ risk of TdP according to the CredibleMeds list of 
QTc-prolonging drugs, except for tamoxifen and SRIs, was prohibited and considered 
as exclusion criterion 13.
Outcome Measures and Data Collection
The primary outcome measure of this study was the difference in QTc-interval 
duration between tamoxifen monotherapy and tamoxifen therapy with concomitant 
use of SRIs. Secondary outcomes were the difference in the prevalence of QTc-interval 
prolongation between the two groups and the identification of risk factors for QTc-
interval prolongation. QTc-interval prolongation was defined as a QTc-time of >470 
ms in females and > 450 ms in males, based on the ESC guidelines 2. Twelve-lead ECGs 
were recorded and QT-intervals were measured manually by the same researcher for 
all patients, preferably from lead II, from the onset of the QRS complex to the end of 
the T-wave, according to the tangent method, and were corrected for heart rate using 
the Fridericia formula (QTcF) 24. The Fridericia formula is formulated as the QT-interval 
divided by the RR-interval to the power 0.33 (QTcB = QT/(RR0.33)) 25. For each patient 
data on characteristics such as age, sex, medical history, tumor localization, previous 
anti-cancer treatment, laboratory analysis (i.e. liver function [AST, ALT, bilirubin], renal 
function [creatinin, glomerular filtration rate(eGFR)], electrolytes [sodium, potassium, 
calcium, magnesium]) and medication was obtained from electronic patient records 
(HIX, Chipsoft b.v., Amsterdam, the Netherlands). ECGs were obtained during tamoxifen 
or tamoxifen concomitant with an SRI therapy, when steady state therapy for both 
therapies was reached (determined as at least four weeks of use for tamoxifen and one 
week for SRIs). A baseline ECG was determined as an ECG before start of tamoxifen or 
SRI therapy.
Statistical Analysis
QTc-intervals were compared between patients receiving tamoxifen monotherapy and 
patients receiving tamoxifen with concomitant SRI therapy. To detect a difference of 15 
ms, assuming a standard deviation for QTc-interval time of 26 ms, in mean QTc-interval 
between both groups with 80% power, a total of one hundred patients was required. 
Therefore, a total of fifty evaluable patients using tamoxifen monotherapy and fifty 
evaluable patients using tamoxifen concomitant with an SRI were included in the study. 
A p value ≤0.05 was considered statistically significant. Data was analyzed using IBM 
SPSS Statistics version 24 (IBM Corporation, Armonk, NY). A t-test for independent 
samples was used to compare the mean QTc-interval between the treatment groups. 
Furthermore, difference between treatment groups in mean age was also determined 
using a t-test. For the other patient characteristics the chi-square test was used. 
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Moreover for age, renal function, sodium, potassium, calcium and magnesium a 
Pearson correlation coefficient was estimated to determine the correlation with the 
QTc-interval. Correlation for other parameters as tumor localization and previous 
therapy (e.g. anthracyclines, trastuzumab and radiotherapy) was estimated using a 
Spearman correlation coefficient. For the secondary outcome the QTc-interval was 
dichotomized as either prolonged if >470 ms for females or not prolonged if otherwise, 
according to the ESC guidelines 2. Difference in proportion of QT-interval prolongation 
between groups was determined using the Fisher’s exact test. Univariate logistic 
regression analysis was performed to determine associated risk factors. If there were 
any significant risk factors they were put into a multivariate analysis.
RESULTS
Participants
A total of 111 breast cancer patients were initially included in this study. Eleven patients 
were excluded due to a variety of ECG abnormalities at baseline resulting in a total of 
100 evaluable patients. Fifty patients were treated with tamoxifen in combination with 
an SRI (further referred to as index group) and 50 patients were treated with tamoxifen 
without an SRI (further referred to as control group). All patients were female. The 
median age of patients in the control group (60; interquartile range (IQR) = 50–66 
years) was significantly higher than the median age of patients in the index group (50; 
IQR = 45–59 years; P = 0.01). There were no other statistically significant differences 
between the two groups and none of the patients experienced cardiac arrhythmias. The 
most frequently used SRIs in the index group were venlafaxine (30%) and paroxetine 
(20%). A more detailed overview of the patient characteristics is presented in Table  1.
Primary Outcome Measures
Mean QTc interval was 407.5 ± 22.1 ms in the control group and 419.9 ± 24.1 ms in 
the index group. This resulted in a significant difference in mean QTc interval of 12.4 
ms (95%CI 1.8–23.1 ms; P = 0.023) (Table  2). Heart rate was not significantly different 
between the control group and the index group.
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TABLE 1. Patient characteristics
Characteristic
Index group 
(N=50) (%)
Control group 
(N=50) (%)
P-value of the 
difference
Age (Median, IQR)*
<65 years
≥65 years
50 (45-59)
41 (82)
9 (18)
60 (50-66)
37 (74)
13 (26)
0.01*
Sex
Female 50 50
NA
Race
Caucasian
Arabic
African
Latino
45 (90)
4 (8)
1 (2)
-
45 (90)
1 (2)
1 (2)
3 (6)
0.28
Breast cancer localization#
Left
Right
25 (50)
23 (46)
22 (44)
28 (56)
0.54
Trastuzumab pretreatment
Yes
No 
8 (16)
42 (84)
3 (6)
47 (94)
0.20
Anthracycline pretreatment
Doxorubicin
Epirubicin
No
21 (42)
19 (38)
10 (20)
17 (34)
22 (44)
11 (22)
1.0
Radiotherapy
Yes
no
26 (52)
24 (48) 
29 (58)
21 (42)
0.69
Number of drugs 2 (0-6) 2 (0-4) 0.93
Tamoxifen dose
20 mg
40 mg
45 (90)
5 (10)
49 (98)
1 (2)
0.20
Type of antidepressant
Venlafaxine
Paroxetine
Escitalopram
Citalopram
Amitriptyline
Sertraline
Fluoxetine
Other 
15 (30)
10 (20)
5 (10)
5 (10)
5 (10)
4 (8)
3 (6)
3 (6)
NA
Renal dysfunction 1  3 0.30
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TABLE 1. Continued
Characteristic
Index group 
(N=50) (%)
Control group 
(N=50) (%)
P-value of the 
difference
Electrolyte disturbances
Hyponatremia
Hypopotassemia
Hypocalcemia
Hypomagnesemia
2
0
3
1
0
0
2
2
0.50
-
1.0
1.0
Hepatic dysfunction 1 1 1.0
Antidiabetic use 4 (8) 3 (6) 1.0
Loopdiuretic use 0 (0) 1 (2) 1.0
Abbrevations: IQR = interquartile range, NA=not applicable, Other type of antidepressant were fluvoxamine (n=1), 
imipramine (n=1) and nortriptyline (n=1). Renal dysfunction was defined as estimated Glomerular Filtration Rate 
(eGFR) <60m/min/1,73m2, Hyponatremia was defined as a sodium value <136 mmol/l, Hypopotassemia was defined 
as a potassium value <3.5 mmol/l, hypocalcemia was defined as a calcium value < 2.2mmol/l, hypomagnesemia was 
defined as a magnesium value <0.7mmol/l and hepatic dysfunction was defined as increased bilirubin (>16umol/l), 
increased alanine aminotransferase (ALAT) (>40 U/l) or increased aspartate transaminase (ASAT) (>35 U/l). Missing 
values: Hepatic function (N=33), Sodium (N=31), potassium (N=27), calcium (N=60), magnesium (N=66) and renal 
function (N=28);  * = P-value < 0.05. # For breast cancer localization the equation was made for left or right. There 
was 1 patient with breast cancer on both sides at primary diagnosis and 1 patient for which data regarding tumor 
localization was unknown due to lack of information from the referring center. These patients were both excluded 
from this analysis.
TABLE 2. QTc interval
Mean QTc 
(Fridericia) 
time (ms) ± SD
Patients 
with QTc 
prolongation
Mean Difference 
(ms)
(95%CI) P-value
Mean Heart 
rate (beats/
min) ± SD
Tamoxifen 
monotherapy
407.5 ± 22.1 1 (2%) +12.4 (1.8 to 23.1) P=0.023* 70 ± 13.6
Tamoxifen with SSRI
Venlafaxine
Paroxetine
Escitalopram
Citalopram
Amitriptyline
Sertraline
Fluoxetine
419.9 ± 24.1
408.8 ±  21.5
424.7 ±  29.2
420.0 ±  6.0
428.2 ±  16.6
428.8 ±  32.5
424.3 ±  24.1
414.7 ±  25.6
0 (0%)#
+1.3 (-11.4 to 14.0)
+17.2 (1.4 to 33.0)
+12.5 (4.4 to 20.6)
+20.7 (0.7 to 40.7)
+21.3 (-0.1 to 42.5)
+17.0 (-5.6 to 39.6)
+7.2 (-18.7 to 33.1)
0.84
0.04*
0.007*
0.047*
0.054
0.147
0.59
69 ± 10.9
Legend: This table shows the QTc times and difference in QTc-interval between treatment groups. * P-value <0.05. For 
the analysis of the differences an independent samples t-test was used. #Difference in number of patients with QTc 
prolongation was not significant (P=1.0).
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TABLE 3. Risk factors for QTc-interval prolongation
Patients
QTc-interval 
prolongation (N=1)
Correlation coefficient
(P-value)
Age
Age >65 1
0.24 (0.02)*
0.18 (0.07)
Race
Caucasian
Arab
African
Latino
0
0
0
1
0.07 (0.47)
Breast cancer localization*
Left
right
1
0
-0.16 (0.11)
Trastuzumab 0 -0.03 (0.81)
Anthracyclines
Doxorubicin
epirubicin
No
0
0
1
0.14 (0.15)
Radiotherapy 1 0.10 (0.34)
Use of >1 concomitant drug 1 0.23 (0.02)*
SRI use 0 0.25 (0.01)*
Type of SRI
Venlafaxine
Paroxetine
Escitalopram
Citalopram
Amitriptyline
sertraline
Fluoxetine
Other
0
0
0
0
0
0
0
1
0.27 (0.06)
Renal dysfunction 1 -0.24 (0.04)*
Electrolyte disturbances
Hyponatremia
Hypopotassemia
Hypocalcemia
Hypomagnesemia
0
0
0
0
-0.19 (0.12)
-0.28 (0.02)*
-0.14 (0.39)
0.29 (0.09)
Hepatic dysfunction 0 0.20 (0.10)
Antidiabetics 1 -0.12 (0.24) 
Loop diuretics 0 -0.10 (0.32)
Legend: Number of patients which show QTc-interval prolongation (QTc>470ms), when using the Fridericia formula. 
Furthermore the correlation coefficient was calculated and displayed. For breast cancer localization the equation was 
made for left or right. There was 1 patient with breast cancer on both sides at primary diagnosis and 1 patient for 
which data regarding tumor localization was unknown due to lack of information from the referring center. These 
patients were both excluded from this analysis.  * P-value<0.05
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Secondary Outcome Measures
Analysis with the Fridericia formula resulted in 1 patient with a prolonged QTc-interval, 
which was in the control group. This resulted in a prevalence of 2% in the control group 
and a prevalence of 0% in the index group, which was a non-significant difference 
(P = 1.0). None of the patients had a QTc-interval of >500 ms. SRI subgroup analysis 
showed a significant difference in mean QTc-interval time for paroxetine (17.2 ms; 
95%CI 1.4–33.0 ms; P = 0.04), escitalopram (12.5 ms; 95%CI 4.4–20.6 ms; P = <0.01) and 
citalopram (20.7 ms; 95%CI 0.7–40.7 ms; P = 0.047) compared to the control group in 
contrast to the other SRIs, which did not show a significant difference in QTc-interval 
(Table  3).
For the known risk factors for QTc-interval prolongation, only SSRI use (Spearman 
r = 0.25; P = 0.01), age (Pearson r = 0.24; P = 0.02), plasma potassium levels (Pearson 
r = −0.28, P = 0.02), renal dysfunction (Pearson r = −0.24; P = 0.04) and the use of >1 
concomitant drugs used (Spearman r = 0.23, P = 0.02) showed significant correlation 
with QTc-interval duration. There were no other factors which showed a significant 
correlation with QTc-interval in general (Table 3). Furthermore possible risk factors as 
tumor localization (left vs. right) and (pre)treatment with anthracyclines, radiotherapy 
or trastuzumab did not show statistically significant correlation with QTc-interval in 
general. Univariate analysis did not reveal any significant risk factors and therefore a 
multivariate analysis was not performed. The odds ratios for the individual risk factors 
could not be measured reliably, since the prevalence of QTc prolongation was low.
DISCUSSION
To our knowledge, this is the first study that investigated the additional risk of developing 
QTc- prolongation in patients using tamoxifen in combination with an SRI. This study 
showed a significant difference in the mean QTc-interval between patients treated with 
tamoxifen monotherapy and patients treated with tamoxifen therapy concomitantly 
with an SRI, suggesting an additional QTc-prolonging effect if tamoxifen is combined 
with an SRI. Furthermore, in this study 1% of the patients had a prolonged QTc-interval 
(>470 ms). This prevalence is in line with other clinical findings and a recent investigation 
in cancer patients treated with conventional or targeted anti-cancer therapy 26,27.
In this study, ECGs were retrospectively or prospectively collected during tamoxifen 
steady-state monotherapy or tamoxifen therapy combined with an SRI. One of the 
main limitations of this study was the absence of a baseline measurement in most 
of the patients. Therefore, a ‘change from baseline’ analysis could not be performed. 
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There was a significant difference in mean QTc-interval time between the tamoxifen 
monotherapy and tamoxifen with SRI treated patients, which is most likely related to 
the additive effect of the SRI. As mentioned earlier tamoxifen is an assumed QTc-interval 
prolonging agent, especially in higher doses 8,16. Furthermore there is substantial 
evidence regarding QTc-interval prolongation by SRIs, showing an average increase 
in QTc-interval of 10-20 ms. QTc-interval prolonging effects seem most prominent 
in nortriptyline and citalopram with increases of more than 30 ms 28,29. Therefore an 
additive effect of SRIs seems possible on top of the QTc-interval prolonging effects 
of tamoxifen. However, to determine whether the use of an SRI in combination with 
tamoxifen is a significant/clinically relevant factor influencing the QTc-interval, more 
research is needed in patients having both a baseline ECG during tamoxifen use and at 
least a second ECG where tamoxifen is used in combination with an SRI.
Interestingly, a subgroup analysis of the different SRIs showed a significant increase 
of the QTc-interval for citalopram, escitalopram and paroxetine, which is in line with 
the classification on the CredibleMeds list. In this list, citalopram and also escitalopram 
has been clearly associated with QTc-interval prolongation. On this list paroxetine is 
classified as a drug which gives a ‘conditional’ risk of TdP. Several additional factors like 
antidiabetic drug use, renal dysfunction and multiple drug use may have contributed 
to QTc-interval prolongation in some of these patients. Furthermore, patients in 
the control group were significantly older than in the index group. The QTc-interval 
increases with age, and therefore in elderly patients, the criteria for QTc-interval 
prolongation will be met more frequently in the index group. We do acknowledge 
that due to limited sample size in the subgroup our study was underpowered to make 
definitive conclusions regarding individual drugs.
Although QTc-interval prolongation is carefully investigated during early drug 
development, its actual influence on overall survival remains unclear. It is clear that 
QTc-interval prolongation can lead to ventricular tachyarrhythmias (e.g. TdP) and 
SCD 1,3. A recent systematic review from Arunachalam et al. showed that ventricular 
tachyarrhythmias were observed in 2.6% of patients using QTc-interval prolonging 
drugs, however TdP (0.33%) and SCD (0.03%) were relatively rare 27. Since the absolute 
risk of cardiac events is small, physicians always need to weigh the benefits of cessation 
of a QTc-interval prolonging drug to the disadvantage of discontinuation of a potentially 
useful drug. If a QTc-interval prolonging drug can be replaced by a non QTc-interval 
prolonging agent, this should always be considered.
The interaction investigated in this study may be explained at a pharmacodynamic 
or pharmacokinetic level. Both tamoxifen and SRIs inhibit the Ikr and therefore, both 
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may prolong the QTc-interval. Inhibition of CYP2D6 by SRIs results in lower endoxifen 
plasma levels (especially for strong CYP2D6 inhibitors like paroxetine) and possible 
more Ikr inhibition, because of the higher tamoxifen plasma levels. However preclinical 
evidence suggests similar Ikr-inhibition by both tamoxifen and its metabolites, making 
this a less likely explanation 20,30–32. SRIs like fluoxetine and paroxetine are well known 
strong CYP2D6 inhibitors, which could alter endoxifen concentrations and deprive 
patients from optimal oncologic therapy. Escitalopram, citalopram and venlafaxine 
are weak CYP2D6 inhibitors and therefore are considered safe when administered 
concomitantly with tamoxifen 20. However, since escitalopram and citalopram are also 
‘known’ QTc-interval prolonging drugs, the combination with tamoxifen is not desirable 
and venlafaxine may be a better alternative since it seems to prolong the QTc-interval 
in only a minor extent, as was shown in this study (Table  2). However more research is 
needed to verify this point.
In conclusion, this study is the first clinical study that investigated the additional risk 
of QTc-interval prolongation in patients using an SRI concomitantly with tamoxifen. 
There was a significantly longer mean QTc-interval in the patients who used an SRI, 
which tended to be most prominent in patients receiving citalopram, escitalopram 
or paroxetine. The other SRIs, like venlafaxine and fluvoxamine, were not clearly 
associated with QTc-interval prolonging effects. Based on our data we recommend 
avoiding citalopram, escitalopram and paroxetine in tamoxifen treated women, and 
use the others SRIs that do not have this QTc-prolonging effect (e.g. venlafaxine and 
fluvoxamine) to minimize the possible risk of TdP and cardiac arrhythmias. As the 
degree of QTc-interval prolongation was limited, and none of the patients in this study 
reached a QTc-interval of >500 ms, routinely checking ECGs in patients on combined 
tamoxifen+SRI treatment does not seem necessary. For patients who have multiple 
other risk factors for QTc-interval prolongation and are using paroxetine, escitalopram 
and citalopram checking the QTc-interval duration may increase patient safety.
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ABSTRACT
During the past two decades, small-molecule kinase inhibitors have proven to be 
valuable in the treatment of solid and haematological tumours. However, because 
of their oral administration, the intrapatient and interpatient exposure to small-
molecule kinase inhibitors (SMKIs) is highly variable and is affected by many factors, 
such as concomitant use of food and herbs. Food–drug interactions are capable of 
altering the systemic bioavailability and pharmacokinetics of these drugs. The most 
important mechanisms underlying food–drug interactions are gastrointestinal drug 
absorption and hepatic metabolism through cytochrome P450 isoenzymes. As food–
drug interactions can lead to therapy failure or severe toxicity, knowledge of these 
interactions is essential. This Review provides a comprehensive overview of published 
studies involving food–drug interactions and herb–drug interactions for all registered 
SMKIs up to Oct 1, 2019. We critically discuss US Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) guidelines concerning food-drug interactions 
and offer clear recommendations for their management in clinical practice.
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INTRODUCTION
Since the start of this millennium, a new class of anticancer drugs has gained an important 
role in the treatment of solid and haematological tumours: the small-molecule kinase 
inhibitors (SMKIs). SMKIs cause cell-cycle arrest, induce apoptosis, inhibit angiogenesis, 
and modulate tumour immunity by specifically inhibiting cellular signal transduction 
through blocking dysregulated protein kinases.1 Some SMKIs are registered for specific 
oncogenic driver mutations, which need to be determined using molecular diagnostics. 
As a result, this tailored treatment approach often results in better efficacy with a 
favourable risk-benefit balance when compared with chemotherapy.2,3
With the introduction of SMKIs, new challenges have emerged. Different from most 
chemotherapeutic drugs, which are administered intravenously, SMKIs are administered 
orally. Although oral intake improves patient comfort and flexibility of treatment (eg, 
place and timing of intake), the variability in intrapatient and interpatient exposure 
to SMKIs is high4 and is affected by many factors, such as drug-drug interactions, 
concomitant use of food and medicinal herbs, genetic variance, and lifestyle.5 The effect 
of food on drug exposure could be clinically significant. For example, administration of 
lapatinib, combined with a high-fat meal, increases its plasma concentrations more 
than three times.6 Besides a concomitant meal, other specific foods and beverages 
might cause food–drug interactions (FDIs). Additionally, some herbal products that 
are frequently used by patients with cancer have substantial potency to cause herb–
drug interactions (HDIs).7 FDIs and HDIs can affect plasma drug concentration, which 
is a result of the absorption, distribution, metabolism, and elimination of a drug (ie, 
pharmacokinetic interactions). Most patients and clinicians are insufficiently aware 
of possible FDIs and HDIs and their potential risk for treatment inefficacy or toxicity.8 
Hence, it is crucial to have thorough knowledge of these FDIs and HDIs for safe and 
optimal treatment of patients with cancer.
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
provide recommendations for assessing possible FDIs, to ensure optimal dose finding 
and drug labelling.2, 3 To define whether or not food intake clinically relevantly affects 
the plasma concentration of a drug, the FDA applies the bioequivalence range of 80–
125% for the 90% CI of total exposure—known as the area under the curve (AUC)—
or maximal plasma concentration (Cmax). SMKI administration during the fasting state 
serves as the reference.3 Regarding herbs, only EMA states that efforts should be made 
to investigate a possible HDI when reports suggest a clinically relevant interaction.2
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This Review presents a comprehensive overview of published studies regarding FDIs 
and HDIs for all registered SMKIs (until Oct 1, 2019). It discusses the most important 
mechanisms underlying FDIs and HDIs and aims to provide clear recommendations to 
manage clinically relevant interactions in daily practice.
ABSORPTION
Gastrointestinal absorption has a key role in the plasma concentrations of SMKIs. Before 
entering the portal bloodstream, drugs must first dissolve and pass enterocyte cell 
membranes. The solubility of weakly basic drugs, such as SMKIs, is largely dependent 
on the intragastric pH. The intragastric pH is increased by food, acid-suppressing drugs, 
or both.9 Postprandial rise in intragastric pH shifts the drug’s ionised/non-ionised 
equilibrium to the non-ionised form, and reduces SMKI solubility and absorption. Since 
most SMKIs are also lipophilic drugs,10 they probably dissolve better when administered 
concomitantly with a (fat) meal. Additionally, food enhances splanchnic blood flow and 
bile secretion and it increases intragastric and intestinal retention and transit time,11 
thus increasing drug absorption potential.
Besides passive diffusion, multiple drug transporters are important for drug 
permeability. Organic anion and cation (uptake) peptides actively transport the SMKI 
into the enterocyte from which the drug is transported (or can diffuse) to the portal 
vein. Contemporaneous counter (efflux) transport to the intestinal lumen can occur by 
P-glycoprotein (ATP-binding cassette B1; ABCB1) and breast cancer resistance protein 
(BCRP; ABCG2).5 In case of high-passive diffusion, food interactions with transporters are 
not likely to result in clinically significant altered exposures. Various food constituents 
(eg, curcumin, flavonoids, bitter melon) and beverages (eg, tea catechins) are known to 
inhibit P-glycoprotein, whereas St John’s wort is a potent P-glycoprotein inducer, which 
could decrease drug exposure.12
FOOD–DRUG INTERACTIONS
High-fat meal
High-fat test meals consist of 800–1000 kcal of which approximately 500–600 kcal 
is derived from fat and 250 kcal from carbohydrates (eg, a full English breakfast).2,3 
Concomitant SMKI administration with a high-fat meal resulted in a clinically significant 
increase of Cmax and AUC for twelve SMKIs, and in a 29–51% decrease of Cmax and AUC for 
three SMKIs (ie, afatinib, dabrafenib, and sorafenib). We noted the relative changes in 
the Cmax and AUC when an SMKI at its therapeutic dose is administered with a high-fat, 
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moderate-fat, or low-fat meal, compared with the fasted state (Table 1).2, 3, 6, 10, 13-45 On 
the contrary, for seventeen SMKIs, concomitant food intake showed no relevant effect 
on its AUC. However, brigatinib, encorafenib, ruxolitinib, tivozanib, and trametinib had 
decreases in Cmax of 20% or more with a high-fat meal, but had no effect on their AUC.
Moderate-fat and low-fat meals
Moderate-fat test meals contain half the caloric content of a high-fat meal, with fat 
contributing to approximately 150 kcal.2 Low-fat test meals are less consistent between 
studies because they are neither defined by FDA nor EMA,2, 3 but these meals roughly 
consist of less than 100 kcal derived from fat (eg, a continental breakfast). Similar to 
high-fat meals, concomitant SMKI administration with moderate-fat meals did not 
result in clinically significant FDIs for axitinib and sorafenib. The absence of clinically 
relevant FDIs also applies to the low-fat meals that were studied for eight SMKIs. On 
one hand, only when FDIs with a high-fat meal are known to occur, further investigation 
of drug intake with other types of meals (eg, moderate-fat or low-fat meals) is indicated 
to improve patient comfort, or to reduce drug dosage and costs. On the other hand, 
when FDIs do not occur with high-fat diets, doing additional FDI studies with lower fat 
meals is not indicated, because a high-fat meal functions for lipophilic drugs as proof-
of-principle with maximal interacting potential.
General recommendations
Alteration of Cmax or AUC caused by an FDI could potentially alter the drugs’ toxicity and 
effectiveness. Recommendations on food intake should be based on combining optimal 
effectiveness with the lowest toxicity possible. In general, these recommendations 
are straightforward: when food greatly decreases an SMKI’s exposure, patients 
should be instructed to take the SMKI without food, because it could decrease the 
effectiveness of the drug. When food does not affect an SMKI’s AUC, patients should 
be given free choice whether to use the SMKI with or without food. However, when 
food substantially increases a SMKI’s exposure without affecting its tolerability, more 
balanced recommendations should be given. Only when safety has been confirmed, 
SMKIs with FDIs that increase the exposure are allowed to be administered with food. 
For several SMKIs, viable or promising correlations have been reported between 
pharmacokinetic parameters (eg, AUC or plasma trough concentration) and survival 
or response.46 In such a case, the optimal method to individualise SMKI treatment is 
the frequent monitoring of SMKI plasma concentrations, also known as therapeutic 
drug monitoring.47 When plasma concentrations decrease to less than the therapeutic 
threshold, despite a good adherence, patients might be advised to take the SMKI 
concomitantly with a meal.
162
Chapter 9
TABLE 1. Overview of the relative changes in the Cmax and AUC when an SMKI at its therapeutic dose is 
administered with a high-fat, moderate-fat, or low-fat meals, compared with the fasted state
Change 
in Cmax 
(%)
Change 
in AUC 
(%) Importance
FDA or EMA 
recommendation Author recommendation
Afatinib2, 3, 13
High-fat meal −50% −39% Moderate Take without food Take without food
Alectinib2, 14
High-fat meal 170% 192%
to 210%
Major Take with food Take with food*
Axitinib2, 3, 15
High-fat meal 11% 19% Minor Take with or without food Take with or without food
Moderate-fat meal −16% −10% Minor Take with or without food Take with or without food
Binimetinib2, 3
High-fat meal −17% −1% Minor Take with or without food Take with or without food
Low-fat meal −29% No effect Minor Take with or without food Take with or without food
Bosutinib2, 3, 16
High-fat meal 42%
to 80%
54%
to 70%
Major Take with food Take with food
Brigatinib2, 3, 45
High-fat meal −24%
to −13%
−2% Minor Take with or without food Take with or without food
Cabozantinib2, 3, 17
High-fat meal 41% 57% Moderate Take without food Take without food
Ceritinib2, 3, 18, 19
High-fat meal 41% 73% Major Take 450 mg with food 
or 750 mg without food
Take preferably 450 mg with 
food, or 750 mg without food
Low-fat meal 43%
to 45%
54%
to 58%
Moderate Take 450 mg with food 
or 750 mg without food
Take preferably 450 mg with 
food, or 750 mg without food
Low-fat meal (450 
mg dose) versus 
fasted (750 mg dose)
3% 4% Minor Take 450 mg with food 
or 750 mg without food
Take preferably 450 mg with 
food, or 750 mg without food
Low-fat meal (600 
mg dose) versus 
fasted (750 mg dose)
25% 24% Moderate Take 450 mg with food 
or 750 mg without food
Take preferably 450 mg with 
food, or 750 mg without food
Cobimetinib2, 3, 20
High-fat meal 0%
to 7%
0%
to 10%
Minor Take with or without food Take with or without food
Crizotinib2, 3, 21, 22
High-fat meal −14%
to 0%
−14%
to 0%
Minor Take with or without food Take with or without food
Dabrafenib2, 3, 23
High-fat −51% −31% Moderate Take without food Take without food
Dasatinib2, 3
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TABLE 1. Continued
Change 
in Cmax 
(%)
Change 
in AUC 
(%) Importance
FDA or EMA 
recommendation Author recommendation
High-fat meal NA 14% Minor Take with or without food Take with or without food
Low-fat meal NA 21% Minor Take with or without food Take with or without food
Encorafenib2, 3
High-fat meal −36% −4%
to 0%
Minor Take with or without food Take with or without food
Erlotinib24, 25
High-fat meal 33%
to 56%
33%
to 66%
Moderate Take without food Take without food
Gefitinib2, 26
High-fat meal 32% 37% Moderate Take with or without food Take with or without food
Ibrutinib2, 3, 27, 28
High-fat meal 163%
to 400%
62%
to 200%
Major Take with or without food Take with food
Imatinib2, 29
High-fat meal −15%
to −11%
−7% Minor Take with food Take with or without food
Lapatinib2, 3, 6, 30
High-fat meal 166%
to 203%
100%
to 325%
Major Take without food Take with a low-fat meal
Low-fat meal 90%
to 150%
80%
to 200%
Major Take without food Take with a low-fat meal
Lenvatinib2, 3, 31, 32
High-fat meal −4%
to 0%
0%
to +6%
Minor Take with or without food Take with or without food
Nilotinib2, 3, 33
High-fat meal 48%
to 112%
43%
to 82%
Major Take without food Take without food
Low-fat meal 33%
to 55%
15%
to 29%
Moderate Take without food Take without food
Nintedanib2, 3
High-fat meal 19% 21% Minor Take with food Take with or without food
Osimertinib2, 3, 34, 35
High-fat meal −7%
to 14%
6%
to 19%
Minor Take with or without food Take with or without food
Pazopanib2, 3, 36, 44
High-fat meal 108% 134% Major Take without food Take preferably 600 mg with 
food, or 800 mg without food
Low-fat meal 110% 92% Major Take without food Take preferably 600 mg with 
food, or 800 mg without food
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TABLE 1. Continued
Change 
in Cmax 
(%)
Change 
in AUC 
(%) Importance
FDA or EMA 
recommendation Author recommendation
Low-fat meal (600 
mg dose) versus 
fasted (800 mg dose)
12% 9% Minor Take without food Take preferably 600 mg with 
food, or 800 mg without food
Ponatinib2, 3, 37
High-fat meal −6%
to 0%
0%
to 10%
Minor Take with or without food Take with or without food
Low-fat meal −6 %
to 0%
−2%
to 0%
Minor Take with or without food Take with or without food
Regorafenib2, 3
High-fat meal 73% 48% Moderate Take with food or 
low-fat meal
Take without food
Low-fat meal 54% 36% Moderate Take with food or 
low-fat meal
Take without food
Ruxolitinib2, 3, 38
High-fat meal −24% 5% Minor Take with or without food Take with or without food
Sorafenib2, 3
High-fat meal NA −30%
to −29%
Moderate Take without food Take without food
Moderate-fat meal NA no effect Minor Take without food Take without food
Sunitinib2, 3, 39
High-fat meal 0%
to 4%
0%
to 12%
Minor Take with or without food Take with or without food
Tivozanib2, 3, 40
High-fat meal −23% 7% Minor Take with or without food Take with or without food
Trametinib2, 3, 41
High-fat meal −70% −10% Minor Take without food Take with or without food
Vandetanib3, 42
High-fat meal −11%
to 17%
0%
to 10%
Minor Take with or without food Take with or without food
Vemurafenib2, 3, 43
High-fat meal 114%
to 150%
150%
to 400%
Major Take with or without food Take with food
The recommendation for all SMKIs is to reduce dose if intolerable toxic effects occur. Importance of the food-drug interaction is considered 
minor (not clinically relevant) when AUC is <20% decreased or <25% increased, moderate when AUC is ≥20% and <50% decreased or ≥25% 
and <67% increased, and major when AUC is ≥67% increased or ≥50% decreased. Cmax=maximal plasma concentration. AUC=area under 
the curve. SMKI=small-molecule kinase inhibitors.*As alternative for dose reduction, consider administration without food if intolerable 
toxic effects occur.
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Specific recommendations
We noted the relative changes in Cmax and AUC of all SMKIs when taken with a high-
fat meal (Figure 1). FDA and EMA recommendations are expected to be strict: SMKIs 
shown in the grey area can be taken with or without food, whereas SMKIs outside the 
grey area can only be taken without food (ie, fasted). However, for some SMKIs, FDA 
and EMA recommendations are not in accordance with these principles.
-30 -25 -20 -15 -10 -5 5 10 15 20 25 30
-30
-25
-20
-15
-10
-5
5
10
15
20
25
30
Axitinib
Binimetinib
Brigatinib
Cobimetinib
Crizotinib Imatinib
Lenvatinib
Nintedanib
Osimertinib
Ponatinib
Ruxolitinib
Sunitinib
Tivozanib
Vandetanib
Relative change in AUC and Cmax of SMKIs administered with a high-fat meal
400
350 400
Afatinib
Alectinib
Bosutinib
Cabozantinib Ceritinib
Dabrafenib
Encorafenib
Erlotinib
Gefitinib
Ibrutinib
Lapatinib
Nilotinib Pazopanib
Regorafenib
Trametinib
Vemurafenib
C
ha
ng
e
(%
)i
n
C
m
ax
Change (%) in AUC
-100 200100
100
-100
200
FIGURE 1. Relative change in AUC and Cmax of SMKIs administered with a high-fat meal
Data derived from Table 1. The central grey area emphasises the range of 80% to 125% in which no clinically relevant 
FDI occurs. Dabrafenib and sorafenib are not displayed because of unavailable Cmax data. AUC=area under the curve. 
Cmax=maximal concentration. SMKIs=small-molecule kinase inhibitors. FDI=food–drug interaction.
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Gefitinib, ibrutinib, and vemurafenib
Gefitinib, ibrutinib, and vemurafenib are known for having a clinically significant food 
effect, but nonetheless they are recommended by FDA and EMA to be administered 
with or without food (Table 1). Especially for vemurafenib, in which a high-fat meal 
increases its Cmax by 150% and AUC by 400%,
43 this recommendation is remarkable. 
Considering vemurafenib’s plasma concentration to be associated with overall survival 
and developing common terminology criteria for adverse events (CTCAE) grade of 
2 or higher skin rash,48 it is important to reach an effective exposure with minimal 
toxicity. With the current recommendation, 14% of treated patients do not reach 
plasma trough concentrations.48 As vemurafenib has a substantial FDI, and interpatient 
variability is decreased with food by 49%,43 we recommend vemurafenib to be taken 
with food. Awareness and counselling for possible skin rash (CTCAE grade ≥2) are 
also important. Furthermore, therapeutic drug monitoring could be used to establish 
drug concentrations at therapeutic levels in the fasted state. For ibrutinib, there is no 
conclusive evidence for an exposure–toxicity relationship,3, 27, 28 albeit complete target 
receptor occupation (and possibly response) is exposure dependent.49 Therefore, 
we advise ibrutinib to be taken with food. Gefitinib has the most moderate FDI (32% 
increase in Cmax and 37% increase in AUC),
26 which might be the reason for its liberal 
food recommendation (ie, administration irrespective of food intake).
Alectinib, bosutinib, and regorafenib
Although alectinib, bosutinib, and regorafenib are affected by FDIs, they are specifically 
recommended to be administered with food. The registration study of alectinib was 
done with concomitant food administration50 and no differences in side-effects with 
fasted conditions were found,14 therefore patients should be instructed to take alectinib 
with food. Furthermore, bosutinib was shown to be better tolerated with food at 
therapeutic doses because the incidence of gastrointestinal adverse events decreased 
when bosutinib was taken with food.16 EMA’s rationale to recommend administration 
concomitant with a low-fat meal is based on a better exposure to regorafenib’s active 
metabolites.2 However, no toxicity data of these studies are reported.2, 3 Hence, we 
cannot endorse the recommendation of both FDA and EMA to take regorafenib with a 
(light) meal.2, 3 Theoretically, when drug absorption and systemic exposure is increased, 
the residual gastrointestinal drug fraction with accompanied gastrointestinal toxicity is 
reduced. For SMKIs, tolerability depends more on local than systemic adverse events, 
therefore an FDI could optimise efficacy and decrease toxicity simultaneously.16
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Imatinib, nintedanib, and trametinib
In line with this assumption, imatinib and nintedanib are recommended to be taken 
concomitantly with food, even though absorption is not clinically affected by food 
consumption. For both SMKIs toxicity data are lacking. We suggest a recommendation 
based on patient’s preference—ie, intake with or without food. However, even though 
food does not affect trametinib’s AUC, FDA and EMA recommend taking trametinib 
without food. This recommendation is based on extrapolated calculations by Cox 
and colleagues,41 who studied the single-dose pharmacokinetics of trametinib. In our 
opinion, both single-dose pharmacokinetic studies and pharmacokinetic modelling 
studies do not adequately show the in-vivo impact of an FDI. Consistently, because 
trametinib does not have an FDI, trametinib can be administered irrespective of food 
consumption.
Lapatinib
A multiple-dose FDI study with lapatinib showed a major FDI with no unexpected 
toxicity when it was taken 1 h after high-fat food consumption.30 This effect is similar 
to administration concomitant with a low-fat meal.6 Extrapolating these results, we 
recommend lapatinib intake with a low-fat meal. That would additionally allow lapatinib 
to be co-administered with capecitabine, when given as combination treatment for 
HER2-positive breast cancer.2, 3
Ceritinib and pazopanib
The exposure to ceritinib and pazopanib is greatly affected by FDIs. However, multiple-
dose FDI studies compared exposure of standard SMKI dose taken without food with 
reduced dose taken with food.2, 19, 44, 51 To maintain equivalent exposure to 750 mg 
ceritinib taken fasted, 450 mg and 600 mg doses of ceritinib were administered with a 
low-fat meal. Administration of 600 mg ceritinib led to a substantially higher exposure 
compared with 750 mg in the fasted state, but this is however not clinically relevant. 
Although 450 mg resulted in an equal exposure (4% AUC increase) in comparison 
to 750 mg taken fasted, less dose reductions occurred (24% vs 65%) due to less 
gastrointestinal toxicity.19 Conclusively, treatment efficacy in terms of overall response 
rate, disease control rate, and time to response was shown to be consistent as well.51 A 
2019 study44 showed that continental breakfast (ie, low-fat meal) consumption with 600 
mg pazopanib had similar exposure and toxicity to 800 mg pazopanib administered 
without food (9% AUC increase). Additionally, in this study, 68% of patients preferred 
concomitant food intake over fasting. However, the FDA recommendation is intake of 
both SMKIs without food,3 whereas EMA’s advice is to swallow 450 mg ceritinib with 
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food, or 750 mg pazopanib without food.2 Considering the better tolerability and 
economic benefits of a lower dose of ceritinib and pazopanib, both SMKIs (450 mg 
ceritinib and 600 mg pazopanib) could be administered with a low-fat meal.
Clinical implications
Despite these practical recommendations, not all patients will be able to meet them. For 
example, if patients cannot eat food or if they are on a special diet, SMKI administration 
with a meal might be complicated. Fasted intake is possible for SMKIs that are 
recommended to be taken without food or irrespective of food intake. However, for 
SMKIs we advise to take with food (to maximise exposure), dose escalation to initial 
registered doses is an option for ceritinib and pazopanib (Table 1). Efficacy data of 
alectinib and bosutinib, when administered without food, are lacking. Alternative 
administration routes or even alternative therapies should, therefore, be considered. 
Because current labels of ibrutinib, lapatinib, and vemurafenib do not oblige food 
intake, it is still safe to take them without food. Also, for some SMKIs, therapeutic drug 
monitoring should be considered to monitor steady-state exposure and optimise 
dosage.
Ultimately, clinical application of FDIs can be regarded as food-dependent dose 
individualisation—ie, dosing based on a patient’s food consumption. In another 2019 
study,52 by use of therapeutic drug monitoring to determine exposure, pazopanib was 
administered with a low-fat meal and the dose was escalated or reduced after evaluation 
of toxicity. With 64% of the initial registered dose of pazopanib, therapeutic target 
plasma concentrations were reached for multiple cycles.52 Preferably, pazopanib dose 
should have been based on its trough concentration. Food-based dose individualisation 
could then increase SMKI efficacy and lower its drug costs simultaneously. However, 
high-fat meals should be advised with caution, because fatty acids showed harmful 
molecular effects, including increased tumour progression and metastasis.53
Nowadays, several combination treatments of SMKIs with immunotherapy are under 
clinical investigation or already used in clinical practice, for instance the combination 
of axitinib and pembrolizumab in renal cell carinoma.54 Since immunotherapy is 
administered parenterally, an FDI with immunotherapy is not expected to occur. 
However, when food alters the exposure to the co-administered SMKI, total efficacy 
or toxicity of the combined SMKI-immunotherapy could be affected. Therefore, it 
is important to be aware of these FDIs when patients have toxic effects from SMKI-
immunotherapy combinations, but also when new combinations are investigated.
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Most FDI studies use high-fat meals to find the maximal food effect. This effect could, 
however, be far from the average daily practice, considering that not all patients with 
cancer are capable of eating high-fat meals. Furthermore, one study found that 21% 
of patients did not always follow strict fasting recommendations.55 The effects of this 
lack of compliance can be considerable. Illustrative for erlotinib, occasional food intake 
increased its Cmax by 35% and AUC by 33%, whereas missing a concomitant meal led 
to a 14% decrease in Cmax and 15% decrease in AUC.
24 Moreover, other factors, such as 
therapy compliance, will seriously affect exposure.55 Hence, FDIs are an important link 
in the chain to obtain and maintain an adequate systemic drug exposure.
Other pharmacokinetic food effects
The effects of food on the variability and time to reach maximum concentrations of 
SMKIs are presented in Table 2.2, 3, 6, 10, 13-45 Additionally,the absolute bioavailability and 
biopharmaceutical classification system (BCS) classes are reported in Table 3.2, 3, 10
Bioavailability
The absolute bioavailability is the amount of unchanged drug that has been absorbed 
by the gastrointestinal tract and has entered systemic circulation after hepatic first-pass 
metabolism. On one hand, when absolute bioavailability is low, a (high-fat) meal could 
increase absorption and, therefore, could also increase systemic exposure. On the 
other hand, FDIs could cause a decrease in exposure for the three SMKIs (dabrafenib, 
imatinib, and ruxolitinib) with a bioavailability of almost 100%. Food does not affect 
imatinib or ruxolitinib exposure, but decreases the exposure to dabrafenib with 31%.
Biopharmaceutical classification system
The BCS is based on the aqueous solubility of a drug and its intestinal permeability, 
which are the most important elements affecting drug absorption. BCS classes are 
divided in four categories: class I drugs have both high solubility and permeability, class 
II drugs have low solubility and high permeability, class III drugs have high solubility 
and low permeability, and class IV drugs have both low solubility and permeability.3 
Taking into consideration their solubility limited absorption, BCS class II and IV drugs 
could have more FDIs, because high-fat meals can increase drug solubility. The relative 
changes in AUC with a high-fat meal are categorised by BCS class in Figure 2.10 Most 
SMKIs are class II drugs, yet some encounter FDIs, which are both increasing and 
decreasing exposure. FDI prevalence is balanced in the second largest BCS class (IV), 
all giving an increased exposure. Albeit only seven SMKIs are BCS classes I or III, only 
afatinib is negatively affected by food. Hence, high solubility could be associated with 
lower prevalence of FDIs.
170
Chapter 9
TABLE 2. Effect of food on the variability and time to reach maximum concentrations of small-molecule kinase 
inhibitors
Change in Cmax 
variability (%)
Change in AUC 
variability (%)
Change in Tmax 
(%; fed Tmax)
Afatinib2, 3, 13
High-fat meal +63% +2% +130% (6·9 h)
Alectinib2, 14
High-fat meal −20% −6% +100% (4 h)
Axitinib2, 3, 15
High-fat meal −45% −9% +50% (3 h)
Moderate-fat meal −34% +9% +40% (2·8 h)
Binimetinib2, 3
High-fat meal −56% −33% +132% (2 h)
Low-fat meal −50% −8% +43% (1·3 h)
Bosutinib2, 3, 16
High-fat meal −61% −70% +100% (6 h)
Brigatinib2, 3, 45
High-fat meal −31% −11% +250% (5 h)
Cabozantinib2, 3, 17
High-fat meal −5% +4% +50% (6 h)
Ceritinib2, 3, 18, 19
High-fat meal −32% −24% +25% (10 h)
Low-fat meal −55% to −44% −49% to −46% −12% to +33% (7 to 8 h)
Low-fat meal (450 mg dose) 
versus fasted (750 mg dose)
NA NA +2% (6 h)
Low-fat 600 mg versus fasted 750 mg NA NA +2% (6 h)
Cobimetinib2, 3, 20
High-fat meal +29% +22% +300% (6 h)
Crizotinib2, 3, 21, 22
High-fat meal +12% +8% No effect (5 h)
Dabrafenib2, 3, 23
High-fat meal −11% −12% +200% (6 h)
Dasatinib2, 3
High-fat meal NA NA NA
Low-fat meal NA NA NA
Encorafenib2, 3
High-fat meal +37% −9% +130% (3·5 h)
Erlotinib24, 25
High-fat −51% to +9% −38% to +25% +39% to 74% (3·9 to 4·2 h)
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TABLE 2. Continued
Change in Cmax 
variability (%)
Change in AUC 
variability (%)
Change in Tmax 
(%; fed Tmax)
Gefitinib2, 26
High-fat meal −21% −3% No effect (5 h)
Ibrutinib2, 3, 27, 28
High-fat meal −63% to +2% −18% to +2% −53% to +167% 
(1·5 to 4 h)
Imatinib2, 29
High-fat meal −20% −37% +37% (3·7 h)
Lapatinib2, 3, 6, 30
High-fat meal No effect −20% +50% to 67% (5 to 6 h)
Low-fat meal −16% −13% 0% to 30% (3·9 to 4 h)
Lenvatinib2, 3, 31, 32
High-fat meal −52% −24% +100% to 150% (4 to 5 h)
Nilotinib2, 3, 33
High-fat meal −16% to −13% −14% to +25% +20% to 25% (3 to 5 h)
Low-fat meal −5% to +16% +7% to 43% No effect (4 h)
Nintedanib2, 3
High-fat meal +2% +63% +99% (4 h)
Osimertinib2, 3, 34, 35
High-fat meal +16% +9% +33% (8 h)
Pazopanib2, 3, 36, 44
High-fat meal +23% +32% +50% (6 h)
Low-fat meal −6% −5% +50% (6 h)
Low-fat meal (600 mg dose) 
versus fasted (800 mg dose)
+12% +6% +33% (4h)
Ponatinib2, 3, 37
High-fat meal −1% +3% No effect (6 h)
Low-fat meal +4% +5% −17% (5 h)
Regorafenib2, 3
High-fat meal NA NA NA
Low-fat meal NA NA NA
Ruxolitinib2, 3, 38
High-fat meal +45% +9% +150% (2·5 h)
Sorafenib2, 3
High-fat meal NA NA NA
Moderate-fat NA NA NA
Sunitinib2, 3, 39
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TABLE 2. Continued
Change in Cmax 
variability (%)
Change in AUC 
variability (%)
Change in Tmax 
(%; fed Tmax)
High-fat meal −13% +3% +2% (8 h)
Tivozanib2, 4, 40
High-fat meal −23% −1% +683% (23·5 h)
Trametinib2, 3, 41
High-fat meal −12% +3% +169% (4 h)
Vandetanib3, 42
High-fat meal No effect No effect +33% (8 h)
Vemurafenib2, 3, 43
High-fat meal −56% −49% +100% (8 h)
Cmax=maximal plasma concentration. AUC=area under the curve. Tmax=time to reach Cmax. NA=not available.
Relative change in AUC of SMKIs administered with a high-fat meal categorised by BCS-classification
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FIGURE 2. Relative change in AUC of SMKIs administered with a high-fat meal categorised by BCS class. Class I 
drugs have both high solubility and permeability, class II drugs have low solubility and high permeability, class 
III drugs have high solubility and low permeability, and class IV drugs have both low solubility and permeability. 
Data derived from Table 1 and Table 3. The dashed lines represent the minus 20% and plus 25% in AUC wherein 
no FDI is present. AUC=area under the curve. SMKIs=small-molecule kinase inhibitors. BCS=biopharmaceutical 
classification system. FDI=food–drug interaction.
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TABLE 3. Absolute bioavailability and BCS classes of small-molecule kinase inhibitors
BCS class2, 10 Bioavailability (%)2, 3, 10
Afatinib I NA
Alectinib IV 37%
Axitinib II 58%
Binimetinib I or II* 50%
Bosutinib IV 34%
Brigatinib I NA
Cabozantinib II NA
Ceritinib IV NA
Cobimetinib III 46%
Crizotinib IV 43%
Dabrafenib II 95%
Dasatinib II NA
Encorafenib II 86%
Erlotinib II 59%
Gefitinib II 57–60%
Ibrutinib II 2·9%
Imatinib I 98%
Lapatinib IV NA
Lenvatinib II or IV† 85%
Nilotinib IV 30%
Nintedanib II 4·7%
Osimertinib III 70%
Pazopanib II 21%
Ponatinib II NA
Regorafenib II NA
Ruxolitinib I >95%
Sorafenib II NA
Sunitinib IV NA
Tivozanib II or IV† NA
Trametinib IV 72%
Vandetanib II NA
Vemurafenib IV 64%
BCS=biopharmaceutical classification system. NA=not available.* Binimetinib shows low solubility (Class II) at 
physiological pH but higher (Class I) at acidic pH. † Permeability unknown.
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For SMKIs in which absorption is dissolution-limited, a change of formulation to a solid 
dispersion (ie, small one-phase powder drug particles) could optimise absorption. 
Therewith, the effect of food and intragastric pH on solubility is reduced.56
Time to reach Cmax (Tmax)
Tmax is the time when the balance between drug absorption and distribution results 
in the Cmax. High-fat meals increased or had no effect on the average Tmax—eg, for 25 
SMKIs a high-fat meal increased Tmax by 25% or more (Table 2). In contrast, other meal 
types had the potential to decrease Tmax (eg, for lapatinib and ponatinib). A longer Tmax 
could potentially reduce toxicity, because absorption is spread over a longer period. 
Also, this could prolong gastrointestinal food–drug and drug–drug interaction time. 
We, therefore, advise specific counselling when patients use interacting drugs or herbs, 
and administer their SMKI with food.
Variability in exposure
A high-fat meal reduced interpatient variability in AUC by 20% or more for seven 
SMKIs and increased this variability by 25% or more for two SMKIs (ie, nintedanib 
and pazopanib). Interpatient variability was similar for pazopanib when administered 
with a low-fat meal and was regardless of its dose. Furthermore, the majority of 
SMKIs showed no noteworthy change with food consumption. However, this was 
measured in different clinical trials in which timing and caloric intake were monitored 
closely. In real life, the variation in food intake will probably be higher than reported 
in these clinical trials. Minimal interpatient variability might have favourable clinical 
consequences, because efficacy and tolerability could be optimal when exposure is 
within the therapeutic window. As earlier described, food recommendation negligence 
occurs frequently in daily life and might lead to substantial alterations in exposure.24, 
55 Considering the major differences between a study and normal daily life, results of 
interpatient variability should be interpreted with caution.
METABOLISM
After uptake by enterocytes, some SMKIs undergo intestinal metabolism by cytochrome 
P450 (CYP) iso-enzymes. Because most drugs are (largely) metabolised by CYP3A4,5 
most interaction studies are focused on this iso-enzyme. St John’s wort strongly induces 
CYP3A4, therefore, reduces drug bioavailability and exposure. Common foods, such as 
garlic, red wine, and grapefruit, inhibit CYP3A4,57 potentially increasing drug exposure.
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After reaching the portal vein, SMKIs are metabolised in the liver. Hepatic (phase I) CYP 
enzymes are responsible for this oxidative metabolism of the majority of SMKIs. As an 
exception, nintedanib largely undergoes (other phase I) hydrolysis by esterases. Afatinib 
and binimetinib are mainly metabolised by conjugating phase II enzymes. Lenvatinib 
and trametinib show predominantly CYP independent phase I and II metabolism (ie, 
deacetylation, oxidation, and glucuronidation).2, 3
SMKI metabolism by CYP enzymes mainly results in inactive metabolites. On one hand, 
CYP induction hence leads to decreased exposure with potentially reduced efficacy and 
toxicity. On the other hand, CYP inhibition increases exposure, which could result in 
accumulation of potentially life-threatening side-effects. Grapefruit is a widely known 
comestible inhibitor of hepatic CYP3A4 and St John’s is a known inducer of hepatic 
CYP3A4.
SPECIFIC FOODS
Grapefruit (juice)
Grapefruit is considered to be a strong inhibitor of intestinal and hepatic CYP3A4 
and it induces drug efflux by P-glycoprotein transporters.58 Furthermore, grapefruit’s 
flavonoids (naringin) inhibit the uptake transporter OATP1A2, therefore decreasing 
drug bioavailability.59 The high interspecies variability in concentrations of grapefruit’s 
interacting compounds create inconvenient diversity in interaction studies.60 Results 
should be carefully interpreted. In general, one single grapefruit or 200 mL or more of 
grapefruit juice can cause relevant escalation of drug concentrations.61
There is, however, a difference between concomitant grapefruit juice intake, which 
predominantly affects absorption through intestinal CYP inhibition, and chronic (non-
concomitant) grapefruit consumption that inhibits hepatic CYP metabolism.62 The 
known effects of CYP inducing and inhibiting compounds on SMKI bioavailability are 
presented in Table 4.2, 3, 7, 63-70 Both the study of sunitinib in humans70 or the study of 
sorafenib in rats68 showed no noteworthy FDIs with chronic grapefruit usage.
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TABLE 4. The effects of CYP inducing and inhibiting compounds on the bioavailability of small-molecule kinase 
inhibitors
Major CYP
Minor CYP 
and others
Inhibiting 
compound
Inducing 
compound Recommendations
Afatinib2, 3 Mainly due to 
non-enzyme 
catalysed 
Michael adduct 
formation
.. .. .. ..
Alectinib2 CYP3A4 CYP2C8, 
CYP3A5
Grapefruit 
(juice)
St John’s wort When either grapefruit 
(juice) or St John’s wort are 
co-administered, monitoring 
is recommended
Axitinib2, 3 CYP3A4 CYP3A5, 
CYP1A2, 
CYP2C19, 
UGT1A1
Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, decrease 
dose by approximately 50%); 
avoid use of St John’s wort (when 
co-administered, a gradual dose 
increase is recommended)
Binimetinib2 UGT1A1 CYP1A2, 
CYP2C19
.. St John’s wort Avoid use
Bosutinib2, 3 CYP3A4 Mono-
oxygenase 
enzymes
Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice) 
and of St John’s wort
Brigatinib2, 3 CYP2C8, 
CYP3A4
CYP3A5 Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, reduce 
dose by approximately 50%); 
avoid use of St John’s wort
Cabozantinib2, 
3
CYP3A4 CYP2C9 Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, a 
dose decrease with 33% is 
recommended); avoid use 
of St John’s wort (when co-
administered, a dose decrease 
with 33% is recommended)
Ceritinib2, 3 CYP3A4 .. Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice) 
and of St John’s wort
Cobimetinib2, 3 CYP3A4 UGT2B7 Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, 
monitoring is recommended; 
interruption when St John’s 
wort is used for less than 8 
days should be considered); 
avoid use of St John’s wort
Crizotinib2, 3 CYP3A4 CYP3A5, 
CYP2C8, 
CYP2C19, 
CYP2D6
Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice) 
and of St John’s wort
Dabrafenib3 CYP2C8 CYP3A4 .. St John’s wort Avoid use (when co-administered, 
monitoring is recommended)
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TABLE 4. Continued
Major CYP
Minor CYP 
and others
Inhibiting 
compound
Inducing 
compound Recommendations
Dasatinib2, 3 CYP3A4 FMO3, UGT Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, 
monitoring is recommended; 
reducing dasatinib dose by 
20 mg or 40 mg when total 
dose is 120 mg or 140 mg 
daily, respectively, should be 
considered); avoid use of St John’s 
wort (when co-administered, 
monitoring is recommended; 
increasing dasatinib dose 
shoud be considered)
Encorafenib2, 3 CYP3A4 CYP2C19, 
CYP 2D6
Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, reduce 
dose to 33% of the encorafenib 
dose); avoid use of St John’s wort
Erlotinib3, 63 CYP3A4 CYP1A2, 
CYP1A1, 
CYP1B1, 
CYP3A5
Grapefruit 
(juice)
St John’s wort; 
green tea extract 
(Cmax 16% and 
AUC 21%)*
Take caution when grapefruit 
(juice) is co-administered (dose 
reduction should be considered 
when side-effects occur); avoid 
use of St John’s wort; avoid 
use of green tea extract
Gefitinib1, 
2, 3, 64, 65
CYP3A4, 
CYP2D6
CYP3A5, 
CYP2C19
.. St. John’s wort; 
bawu decoction 
(Cmax −79% and 
AUC −61%);* guipi 
decoction (Cmax 
−23% and AUC no 
effect);* ginseng, 
mushrooms, 
and selenium†
Avoid use of St John’s wort 
(dose increase to 500 mg daily 
should be considered when 
coadministered); avoid use of 
bawu decoction; safe to use guipi 
decoction; avoid use of ginseng, 
mushrooms, and selenium
Ibrutinib2, 3 CYP3A4 CYP2D6 Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice) 
and of St John’s wort
Imatinib1, 
3, 7, 66, 67
CYP3A4 CYP2C8, 
CYP3A5, 
CYP1A2, 
CYP2D6, 
CYP2C9, 
CYP2C19
Grapefruit 
(juice)
St John’s wort 
(Cmax −29% to 
−15% and AUC 
−32% to −30%); 
ginseng†
Avoid use of grapefruit (juice); 
avoid use of St John’s wort; 
avoid use of ginseng (when 
co-administered, dose should 
be increased by at least 50% 
and clinical response should 
be carefully monitored)
Lapatinib2, 3, 63 CYP3A4 CYP3A5, 
CYP1A2, 
CYP2D6, 
CYP2C8, 
CYP2C9, 
CYP2C19
Grapefruit 
(juice)
St John’s wort; 
green tea extract 
(Cmax −14% and 
AUC −22%)*
Avoid use of grapefruit (juice); 
avoid use of St John’s wort (when 
co-administered, dose should 
be gradually increased from 
1250 to 4500 mg per day and 
from 1500 to 5500 mg daily); 
avoid use of green tea extract
Lenvatinib2, 3 Aldehyde 
oxidase & 
gluthatione 
conjugation
CYP3A4 .. .. ..
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TABLE 4. Continued
Major CYP
Minor CYP 
and others
Inhibiting 
compound
Inducing 
compound Recommendations
Nilotinib2, 3 CYP3A4 CYP2C8, 
CYP1A1, 
CYP1A2, 
CYP1B1
Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice) 
and of St John’s wort
Nintedanib2, 3 Hydrolysis due 
to esterases
UGT1A1, UGT 
1A7, UGT1A8, 
UGT1A10, 
CYP3A4
.. St John’s wort Avoid use of St John’s wort
Osimertinib2, 3 CYP3A4 CYP3A5, 
CYP1A2, 
CYP2A6, 
CYP2C9, 
CYP2E1
.. St John’s wort Avoid use of St John’s wort
Pazopanib2, 3 CYP3A4 CYP1A2, 
CYP2C8
Grapefruit 
(juice)
.. Avoid use of grapefruit (juice)
Ponatinib2, 3 CYP3A4 CYP2D6, 
CYP2C8, 
CYP3A5
Grapefruit 
(juice)
St John’s wort When grapefruit (juice) is co-
administered, reduce to 30 mg 
daily; avoid use of St John’s wort
Regorafenib2, 3 CYP3A4 UGT1A9 Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice) 
and of St John’s wort
Ruxolitinib2, 3 CYP3A4 CYP2C9 Grapefruit 
(juice)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, 
reduce to 10 mg twice daily); 
concurrent administration 
should be avoided in patients 
with <100 × 109 platelets per 
L; when using St John’s wort 
monitor closely and titrate dose
Sorafenib3, 
68, 69
CYP3A4 UGT1A9 Grapefruit 
(juice) 
(Cmax +10% 
and AUC 
−16%)*; 
triptolide 
(Cmax 
+44% to 
+63% and 
AUC +73% 
to +83%)*
Long-Dan-Xie-
Gan-Tang (Cmax 
−4% and AUC 
−12%);* St 
John’s wort
Avoid use of grapefruit 
(juice), triptolide, Long-Dan-
Xie-Gan-Rang, and St John’s 
wort (when co-administered, 
consider dose increase)
Sunitinib2, 3, 70 CYP3A4 CYP1A2 Grapefruit 
(juice) 
(Cmax+11% 
and AUC 
+11%)
St John’s wort Avoid use of grapefruit (juice; 
when co-administered, dose 
decrease should be considered 
to a minimum of 37·5 mg daily 
for GIST and mRCC or 25 mg daily 
for pNET); avoid use of St John’s 
wort (when co-administered, 
consider dose increase in 12·5 
mg increments up to 87·5 
mg daily for GIST and mRCC 
or 62·5 mg daily for pNET)
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TABLE 4. Continued
Major CYP
Minor CYP 
and others
Inhibiting 
compound
Inducing 
compound Recommendations
Tivozanib2‡ CYP3A4 UGT1A, CYP1A1 .. St John’s wort Avoid use of St John’s wort
Trametinib2, 3 Deacetylation, 
oxidation and 
glucoronidation
CYP3A4 .. .. ..
Vandetanib2 CYP3A4 FMO1, FMO3 .. St John’s wort Avoid use of St John’s wort
Vemurafenib2 CYP3A4 UGT .. St John’s wort Avoid use of St John’s wort
Cmax=maximal plasma concentration. AUC=area under the curve. CYP=cytochrome P450. UGT=UDP-glucuronosyltransferase. FMO=flavine 
mono-oxygenase. GIST=gastro-intestinal stromal tumour. mRCC=metastatic renal cell carcinomas. pNET=pancreatic neuroendocrine 
tumours.* In vivo rat study results. † Case report. ‡ Only EMA approved.
Other foods and beverages can have an effect on SMKI bioavailability (Table 5).2, 9, 27, 
63, 64, 71, 72, 73, 74 Concomitant grapefruit juice intake was studied for ibrutinib (115% AUC 
increase),27 imatinib (2% increase in minimal plasma concentration [Cmin]),
71 and nilotinib 
(29% AUC increase).73 However, since the three study designs are very different, it is 
difficult to extrapolate their results to other CYP3A4-metabolised SMKIs. FDA and EMA 
recommendations for all CYP3A4-metabolised SMKIs are to avoid grapefruit. In case 
of concomitant use, dose reductions are advised for axitinib, brigatinib, cabozantinib, 
dasatinib, encorafenib, ponatinib, ruxolitinib, and sunitinib, thus minimising potentially 
dangerous increases of their blood concentration.2, 3 Even in those cases when evidence 
of FDIs with SMKIs is scarce, we concur with FDA and EMA in the advice to avoid grapefruit 
completely during SMKI treatment of CYP3A4 substrates, because the composition of 
grapefruit and subsequent effect on CYP3A4 is variable and unpredictable.
Beverages
Most beverages are known for their low pH and high-sugar content.75 Because of 
its phosphoric acid ingredient, cola was found to be acidic enough to overcome the 
drug–drug interaction with erlotinib and a proton-pump inhibitor.9 Most soda, fruit, 
and energy drinks have a mean pH less than 4, making them suitable for researching 
similar purposes.75 Likewise, hypothetically exploring erlotinib’s lipophilicity, a potential 
FDI with fatty milk was studied. (ESMO 2019, #1540P)76 Since no FDI was found, erlotinib 
administration with milk is safe. Furthermore, green tea extract caused major FDIs 
with erlotinib, lapatinib, and sunitinib in rats, decreasing their AUCs by 51–74%.63, 74 We 
thus recommend avoiding green tea extract during SMKI therapy until proven safe in 
humans. Nonetheless, some patients with cancer are not capable of taking their SMKI 
with water. In that specific situation, albeit only proven for nilotinib, administration 
with a teaspoon of non-fat plain yoghurt or applesauce is considered safe,2, 72 and we 
would extrapolate those outcomes to all SMKIs.
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TABLE 5. The effects of other foods and beverages on the bioavailability of small-molecule kinase inhibitors
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Erlotinib
Green tea 
(extract)63†
Single-dose 
erlotinib 
immediately after 
green tea extract
−68% 214% −70% −12% No effect
(1 h)
Major Avoid use 
of green tea 
(extract)
Coca-Cola9 Multiple doses 
of erlotinib with 
Coca-Cola
No 
effect
−6% +9% −9% +16%
(NA)
Minor Safe to use
Coca-Cola9 Multiple doses 
of erlotinib with 
esomeprazol 
and Coca-Cola
+42% −26% +39% −25% No effect
(NA)
Major Consider taking 
with Coca-Cola 
when using PPI 
or take PPI >3 h 
after erlotinib
Gefitinib
Bawu 
decoction64†
Single-dose 
gefitinib 5 min and 
1 h after herb
−88%
to −67%
+35%
to 92%
−75%
to −60%
−57%
to −17%
+271%
to 393%
(5·2
to 7·4 h)
Major Avoid use
Guipi 
decoction64†
Single-dose 
gefitinib 5 min and 
1 h after herb
−36%
to −22%
+28%
to 78%
−21%
to −19%
−6%
to +17%
−7%
to +60%
(1·3
to 2·4 h)
Moderate Avoid 
concomitant 
administration
Ibrutinib
Grapefruit 
juice27
Single-dose 
ibrutinib the 
evening before 
and concomitant 
grapefruit juice
+260% +52% +115% +57% −15%
(1·5 h)
Major Avoid use of 
grapefruit 
(juice)
Imatinib
Grapefruit 
juice71
Multiple doses 
of imatinib 
concomitant 
grapefruit juice
−2% NA NA; 
Cmin+2%
NA NA Minor Avoid grapefruit 
(juice), since its 
composition 
is variable and 
unpredictable
Lapatinib
Green tea 
(extract)63†
Single-dose 
lapatinib 
immediately after 
green tea extract
−70% +235% −74% −47% No effect
(1 h)
Major Avoid use 
of green tea 
(extract)
Nilotinib
Grapefruit 
juice73
Single-dose nilotinib 
with grapefruit juice
+60% −26% +29% −14% No effect
(4 h)
Moderate Avoid use of 
grapefruit 
(juice)
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TABLE 5. Continued
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Non-fat plain 
yoghurt2, 72
Single-dose nilotinib 
with non-fat 
plain yoghurt
+31% −6% +8% +2% No effect
(4 h)
Minor Safe to use
Applesauce2, 
72
Single-dose nilotinib 
with applesauce
−5% +3% −3% −8% −25%
(3 h)
Minor Safe to use
Sunitinib
Green tea 
(extract)74†
Single-dose 
sunitinib 
concomitant 
with green tea 
polyphenol 
epigallocatechin-
3-gallate
−48% −46% −51% −24% +37%
(4·9 h)
Major Avoid use 
of green tea 
(extract)
Only small-molecule kinase inhibitors with known interactions are shown in this table. Cmax=maximal plasma concentration. Cmin=minimal 
plasma concentration. AUC=area under the curve. NA=not available. PPI=proton-pump inhibitor. * Importance of the food-drug 
interaction is considered minor (not clinically relevant) when AUC is <20% decreased or <25% increased, moderate when AUC is ≥20% 
and <50% decreased or ≥25% and <67% increased and major when AUC is ≥67% increased or ≥50% decreased. † In vivo rat study results.
HERB–DRUG INTERACTIONS
St John’s wort
St John’s wort (Hypericum perforatum) is frequently used as an antidepressive 
compound. Its active substance, hyperforin, induces hepatic CYP3A4 and inhibits 
P-glycoprotein mediated drug efflux.12, 77 Clinical and pharmacokinetic effects have 
been proven to be positively associated with hyperforin concentrations in different 
studies.77 St John’s wort’s HDI was investigated in two clinical trials that showed a 30–
32% decrease in drug exposure following consumption of St John’s wort (Table 4).7, 67 
Because concentrations of active substances fluctuate by 5–8 times between brands 
or abstracts,77 standardisation of study methods to investigate the HDI for all SMKIs is 
very difficult. Therefore, we recommend avoiding consumption of St John’s wort during 
SMKI treatment, which is in accordance with FDA and EMA recommendations.2, 3
Oriental herbs
Herbal products are used by 13–63% of patients with cancer. Up to 72% of these 
patients do not inform their oncologist about their supplemental herb intake, therefore 
interaction potential with conventional anticancer treatment may be substantial.8 
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Much is unknown about HDIs with SMKIs in clinical practice. Numerous oriental herbs 
can inhibit multiple CYP-enzymes,8 though no standardised HDI studies in humans 
with SMKIs were found (Table 4, Table 5). Two case reports describe reversible severe 
toxicity and therapy failure, probably due to ginseng (potential CYP-inducer) and other 
alternative preparations.65, 66 The decoctions bawu and guipi are traditional oriental 
medicines. Bawu is a mixture of eight herbs and guipi is a mixture of 12 herbs, both 
include ginseng. These traditional medicines are considered to be purifying and are 
used to treat various diseases. Bawu decreased gefitinib’s AUC in rats by 61–75%, 
without regard to administration time.64 Guipi was found not to have an HDI when 
co-administration with gefitinib was avoided, because it caused a 21% decrease in 
gefitinib exposure otherwise.64 Triptolide (derived from Tripterygium wilfordii) escalated 
sorafenib’s AUC with 83% in rats, possibly through CYP3A4 inhibition.69
EMA and FDA recommendations for SMKIs do not specifically mention safe or 
dangerous herbal preparations, but patients are instructed to communicate herb 
use to their health-care provider.2, 3 Because conclusive data are missing, clinicians 
are faced with questions that are practically unanswerable. Current advice is to avoid 
products with possible interacting compounds, to minimise the risk of HDIs. To provide 
clinicians and patients clear recommendations concerning the dangers or safety of 
herbal preparations, more research to HDIs and SMKIs is warranted.
FOOD–DRUG INTERACTION STUDIES
Registered therapeutic doses of SMKI are generally based on the maximum tolerated 
dose that is found in phase I trials. Once a decision is made for SMKI administration in fed 
or fasted state, all consecutive registration studies maintain this food recommendation. 
To change these recommendations, for instance to reduce drug costs by allowing food 
consumption with a reduced dose, solid evidence that FDIs affect drug tolerability or 
anticancer activity must be shown. Since toxicity develops generally after a loading 
phase of several weeks, FDI studies should ideally include multiple drug doses over 
a long period (ie, multiple weeks). Phase I studies can be used for this purpose. In 
studies in which an FDI is present, repeating the drug’s registration studies from phase 
I to phase III can guarantee safety and efficacy. Single-dose FDI studies, which miss 
a reliable safety and efficacy assessment of the loading phase, are thus limited for 
extrapolation of established FDIs to clinical recommendations. Their strength solely lies 
in the exclusion of an FDI, when no clinically significant change in exposure is found. 
The FDA, however, recommends only a single-dose study design to research FDIs.3
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Currently, popularity of calorie-restricted dietary interventions, such as cyclic fasting or 
fasting-mimicking diets, is increasing. Their safety and effectivity are being investigated 
in various clinical trials (NCT03340935, NL5624, and NCT03595540), because much 
is unknown about their efficacy and potential pharmacokinetic effect on anticancer 
drugs.
Animal models are not suited as replacement for human in-vivo studies, because 
interspecies differences can bias FDIs. For example, no FDI for gefitinib (in dogs) and 
pazopanib (in monkeys) was found,2 whereas in humans there is a food effect (Table 1). 
The relevance of in-vitro data for HDIs is limited, although some prediction models that 
mimic HDIs (eg, midazolam as model substrate for CYP3A4) show promising results 
and could be feasible.78 In-vitro research could be used as an indicator to identify herbs 
that should be studied in vivo, as requested by EMA.2 We recommend studying in-vivo 
FDIs and HDIs at steady state, with a multiple-dose instead of a single-dose study, with 
enough patients or healthy volunteers to examine exposure with subsequent efficacy 
and tolerability. Results of such studies would be conclusive for providing useful advice 
for clinical practice.
CONCLUSIONS
FDIs and HDIs can alter the systemic bioavailability and pharmacokinetics of 
many clinically approved SMKIs. The major mechanisms underlying FDIs and HDIs 
concern gastrointestinal drug absorption and metabolism through cytochrome P450 
isoenzymes. FDIs and HDIs might lead to therapy failure or (acute) severe toxicity, 
therefore knowledge of these interactions is essential.
SEARCH STRATEGY AND SELECTION CRITERIA
A literature search for European Medicines Agency-approved small-molecule kinase 
inhibitors (SMKIs) used in haemato-oncology, with the exception of mTOR- and 
CDK4/6-inhibitors, was done in Embase and Pubmed from database inception until Oct 
1, 2019, using the MESH terms: “(food-drug interactions) OR (herb-drug combination) 
OR ((complementary therapies OR combination OR interaction OR supplement) AND 
(diet OR food OR herb OR drink)) AND (drug name)“. In Embase, we applicated “clinical 
studies“, “humans“, and “only in English“ as quick search limits. Prior to full-text screening, 
abstracts and titles were screened. Also, articles concerning pharmacokinetic effects of 
possible in-vivo FDIs or HDIs were included. FDA and EMA assessment reports (including 
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updates) and “Summary of Product Characteristics“ were additionally examined for 
FDIs and HDIs for each SMKI. Practical recommendations were formulated based on 
available evidence and the FDA’s definition of an FDI.
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ABSTRACT
Purpose. Erlotinib depends on stomach pH for its bioavailability. When erlotinib is 
taken concurrently with a proton pump inhibitor (PPI), stomach pH increases, which 
results in a clinically relevant decrease of erlotinib bioavailability. We hypothesized that 
this drug-drug interaction is reversed by taking erlotinib with the acidic beverage cola. 
The effects of cola on erlotinib bioavailability in patients not treated with a PPI were 
also studied.
Patients and Methods. In this randomized, cross-over, pharmacokinetic study 
in patients with non–small-cell lung cancer, we studied intrapatient differences in 
absorption (area under the plasma concentration time curve [AUC0-12h]) after a 7-day 
period of concomitant treatment with erlotinib, with or without esomeprazole, with 
either cola or water. At the 7th and 14th day, patients were hospitalized for 1 day for 
pharmacokinetic sampling.
Results. Twenty-eight evaluable patients were included in the analysis. In patients 
treated with erlotinib and esomeprazole with cola, the mean AUC0-12h increased 39% 
(range, 212% to 136%; P = .004), whereas in patients not treated with the PPI, the mean 
AUC0-12h was only slightly higher (9%; range, 210% to +30%; P = .03) after erlotinib intake 
with cola.
Conclusion. Cola intake led to a clinically relevant and statistically significant increase 
in the bioavailability of erlotinib during esomeprazole treatment. In patients not treated 
with the PPI, the effects of cola were marginal. These findings can be used to optimize 
the management of drug-drug interactions between PPIs and erlotinib.
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INTRODUCTION
Erlotinib is an oral reversible tyrosine kinase inhibitor (TKI) of the epidermal growth 
factor receptor effective in non–small-cell lung cancer (NSCLC). The advantage of the 
oral administration route of erlotinib causes a highly relevant new problem. The GI 
absorption of erlotinib is a complex multifactorial process characterized by a poor and 
variable bioavailability that results in significant intrasubject and intersubject variability 
in exposure.1 One of the most important factors that influences erlotinib absorption is 
intragastric pH.2,3  Because of its weakly basic properties, erlotinib can be present in either 
the ionized or the nonionized form, which depends on the intragastric pH. In the case of 
elevated intragastric pH, equilibrium shifts toward the less-soluble nonionized erlotinib 
form, and drug absorption decreases. The concomitant use of acid-reducing agents, 
such as proton pump inhibitors (PPIs), therefore, leads to a clinically significant drug-
drug interaction (DDI) with erlotinib.2-5 In a study of healthy volunteers, the concurrent 
use of the PPI omeprazole significantly reduced the area under the curve (AUC) and 
maximum serum concentration (Cmax) of erlotinib with 46% and 61%, respectively.
6 As a 
result, the product label of erlotinib states that PPIs should not be taken concurrently 
with erlotinib. Recently, the concomitant use of erlotinib and acid-suppressive agents 
was shown to be associated with decreased erlotinib efficacy in patients with NSCLC.5 
Because a PPI often is indicated during erlotinib therapy, pharmacists and medical 
oncologists are confronted with challenges.2,7 A solution for managing this DDI is not 
yet available. A practical way to bypass the DDI between erlotinib and PPIs could be 
to temporarily lower the stomach pH by taking erlotinib with an acidic beverage, such 
as cola. The classic form of this beverage has a pH of 2.5, which leads to a temporary 
decrease of the stomach pH after intake. Other studies have shown that the absorption 
of weakly basic drugs, such as ketoconazole and itraconazole, is enhanced when taken 
concomitantly with Coca-Cola (The CocaCola Company, Atlanta, GA).8,9 We hypothesize 
that due to similar physicochemical basic properties, this positive effect also is the case 
with erlotinib. We evaluated the impact of cola on the absorption of erlotinib (with and 
without esomeprazole) in patients with lung cancer.
MATERIAL AND METHODS
Study Design and Procedures
This study was an open-label, two-way, randomized, cross-over design in patients 
treated with erlotinib for NSCLC. The study was performed at the Erasmus MC Cancer 
Institute in Rotterdam, the Netherlands, between March 2014 and June 2015. The 
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medical ethics committee of the Erasmus Medical Center (MEC14-046) approved the 
study, which was registered through the Dutch Trial Registry. Twenty-eight patients on 
steady-state erlotinib therapy were assigned to one of two study groups of 14 patients 
each (Figure 1). Study group 1 received erlotinib (Tarceva [Genentech, South San 
Francisco, CA] at any dose, days 1 to 14, 10 AM) taken with 250 mL Coca-Cola Classic 
or 250 mL water. Study group 2 received erlotinib (Tarceva at any dose, days 1 to 14, 
10 AM) and esomeprazole 40 mg (Nexium [AstraZeneca, London, UK], days 5 to 7 and 
12 to 14, 7 AM) taken with 250 mL Coca-Cola Classic or 250 mL water. After allocation 
to one of the study groups, patients were randomly assigned to two sequence arms of 
seven patients each. Sequence arm A first took erlotinib with water for 7 days followed 
by Coca-Cola Classic for 7 days. Sequence arm B took erlotinib with Coca-Cola Classic 
and water in the reversed order. On days 7 and 14, patients were admitted for 24 
h to the hospital for pharmacokinetics (PK) sampling (Fig 1). Before signing informed 
consent, the use of interacting comedications (including over-the-counter drugs, 
herbal/food supplements) was collected in a structured anamnesis with the patient. 
Patient medication use was assessed for DDIs by using the DDI software program 
Micromedex (Truven Health Analytics, Greenwood Village, CO). To ensure steady-state 
concentrations, patients had to use erlotinib for a minimum of 14 days before entering 
the study. In study group 2, esomeprazole 40 mg once daily was given for at least 3 
days before both PK sampling days (3 h before erlotinib intake) to achieve maximum 
elevation in intragastric pH.10,11 Furthermore, patients who used PPIs long term before 
entering the study were allowed to participate as long as they were willing to use 
esomeprazole 40 mg (Nexium) for 3 consecutive days before both PK sampling days 
according to the protocol. Patients fasted overnight before both PK sampling days. On 
the PK sampling days, erlotinib was taken in the hospital. Because the study population 
comprised regular patients with lung cancer with an indication for an epidermal growth 
factor receptor TKI, erlotinib dose reductions due to toxicity were allowed. Compliance 
was assessed through patient diaries.
Eligibility
Eligibility criteria were age 18 years and older, histology or cytology confirmed diagnosis 
of lung cancer for which treatment with erlotinib monotherapy was indicated, use of 
erlotinib monotherapy at any dose for at least 2 weeks before study participation, 
World Health Organization performance status of 0 or 1, and no concurrent use of 
over-the-counter medications or medications known to interact with either erlotinib 
or esomeprazole. Exclusion criteria were pregnancy or lactation and a clear language 
barrier.
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FIGURE 1: Study design. A= sequence arm A; B= sequence arm B; Erlo = erlotinib; PK= pharmacokinetic.
Pharmacokinetics
Blood samples for the analysis of erlotinib were collected before erlotinib dosing and 
at 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, and 24 h (13 samples per hospitalization for 
both sequence arms) after erlotinib administration. Esomeprazole levels were not 
measured. At each time point, blood samples were collected in 6-mL lithium heparin 
blood collection tubes. After collection, blood samples were processed to plasma 
within 10 min by centrifugation (2,000 3 g; 10 min; 4°C). Plasma was transferred into 
polypropylene tubes (1.8-mL Nunc CryoTube [Roskilde, Denmark] vials), which were 
subsequently stored at less than 270°C until the time of analysis at the Laboratory 
of Translational Pharmacology (Josephine Nefkens Institute, Erasmus MC Cancer 
Institute, Rotterdam, the Netherlands). PK parameters of erlotinib were calculated by 
using weighted non-compartmental analyses with Phoenix WinNonlin 6.3 software 
(Pharsight, a Certara Company, Princeton, NJ) and included the area under the plasma 
concentration time curve (AUC0-12h), maximum serum concentration (Cmax), and time to 
Cmax (Tmax).
Statistics
The primary objective was to determine the intrapatient differences in absorption 
(expressed by AUC0-12h and Cmax) after a 7-day period of concomitant treatment of 
erlotinib (with or without esomeprazole for 3 days) taken with cola and 7 days of 
erlotinib taken with water and vice versa. Each patient acted as his or her own control 
subject. In this exploratory study, the primary end point was the relative difference 
(RD) between erlotinib AUCcola and erlotinib AUCwater calculated for each patient as 
follows: RD = (AUCcola – AUCwater) / AUCwater. Cola was considered to have an impact on 
the erlotinib AUC when the absolute value of RD was at least 25% (ie, ≤25% or at least 
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+25%).12 By assuming an intraindividual standard deviation of the difference between 
AUCcola and AUCwater of 30%, 14 evaluable patients per study group (without or with 
esomeprazole) had to be included to obtain 80% power (two-sided significance level a 
= 0.05) to detect this difference of ≥ 25%.13 To evaluate the impact of cola on the AUC (ie, 
compare AUCcola and AUCwater), we used the STATA command pkcross, which analyzes 
cross-over experiments (STATA 13; StataCorp, College Station, TX). This command uses 
analysis of variance models to analyze the data.14 In this way, possible period effects 
(first v second PK sampling period) and sequence effects (A → B v B → A) were taken 
into account by assuming that no carryover effect existed. In case of a dose reduction 
(due to toxicity), PK data were normalized to a dose of 150 mg erlotinib. The P value to 
indicate whether the mean AUC and mean Cmax were significantly different after water 
versus after cola was assigned to the treatment effect by using the pkcross command. 
This was evaluated separately for patients who used esomeprazole and for those who 
did not.
RESULTS
Patient Characteristics
Thirty-five patients were enrolled of whom 28 were evaluable (14 in each study group). 
Seven patients were excluded from the study for various reasons (ie, use of Diet Coke 
[n = 1; The Coca-Cola Company], use of a generic brand of esomeprazole instead 
of Nexium [n = 1], progression of disease before both PK sampling periods [n = 2], 
impossibility of venipuncture [n = 1]) and on patients’ own initiative (ie, withdrawal of 
consent [n = 2]). Baseline characteristics are shown in Table 1. The majority of patients 
were male (61%), and the median age was 63 years.
PK, Safety, and Tolerability
In patients treated with erlotinib and esomeprazole (study group 2; Table 2), the mean 
AUC0-12h was 39% higher (range, 212% to +136%; P = .004) and mean Cmax 42% higher 
(range, 24% to +199%; P = .019) after cola compared with water intake (Fig 2). In patients 
treated with erlotinib without esomeprazole (study group 1; Table 3), the mean AUC0-
12h was 9% higher (range, 210% to +30%; P = .03) and mean Cmax comparable (0%; range, 
219% to +18%; P = .62) after cola intake (Fig 2). Time to Cmax was not significantly altered 
in study group 1 (18%; range, 260% to +194%; P = .75) and study group 2 (0%; range, 
220% to +52%; P = .99).
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TABLE 1. Subject characteristics at baseline
Characteristics No %
No of patients 28  100
Age (years)   
Median (range) 63 (39-77)  
Sex   
    Female 11 39
    Male 17 61
Race   
    Caucasian 24 86
    Asian 4 14
BMI (kg/m
2
)   
    Mean (range) 24,2 (19-31)  
Tobacco use   
    Current (< 1 month) 2 7
    None 26 93
ECOG-performance status   
    0 15 54
    1 13 46
Pre-treatment chemotherapy   
    Yes 8 29
    No 20 71
EGFR mutation
    Yes 14 50
    No 10 36
    Unknown 4 14
Dosage erlotinib   
    50mg 1 4
    100mg 4 14
    150mg 23 82
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor
Adverse events were generally mild and resolved without medical intervention. 
Erlotinib was well tolerated when administered with either cola or water (also in 
patients with known gastroesophageal reflux disease). Grade 3 skin toxicity developed 
in one patient in study group 1, and hospital admission was required. After standard-of-
care treatment, the patient was discharged without sequelae but showed progression 
during erlotinib therapy In this patient, erlotinib was stopped, and the patient was 
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excluded from the study. Erlotinib treatment-related adverse effects primarily affected 
the skin (eg, grade 1 rash) and the GI system (eg, nausea, diarrhea). Details are shown 
in Table 4. There were no known deviations in the patient diaries with regard to study 
adherence.
TABLE 2. Summary of pharmacokinetic parameters study group 2 (Erlotinib+Esomeprazole + water vs. Cola)
Parameter Erlo+Esom+Water (A) Erlo+Esom+Cola (B) Difference % (range)
Erlotinib dose* 150 (100-150) 150 (50-150)
Erlotinib
AUC 0-12h (µg×h/ml), geometric 
mean (geometric mean CV%)
9.0 (19.9%) 11.8 (14.9%) 39% (-12% to +136%),
P=.004
Cmax (µg/ml), geometric mean 
(geometric mean CV%)
1.08 (152%) 1.43 (112%) 42% (-4% to +199%),
P=.019
Abbreviations: A, sequence arm A; AUC0-12h, area under the plasma concentration time curve; B, sequence arm B; Cmax, 
maximum plasma concentration; CV%, percentage of coefficient of variation defined by (standard deviation / mean) 3 
100; Erlo, erlotinib; Esom, esomeprazole 40 mg once daily.
*Median (range).
†In case of a dose reduction (due to toxicity), pharmacokinetic data were normalized to a dose of 150 mg erlotinib.
‡Based on individual patient data.
TABLE 3. Summary of pharmacokinetic parameters for study group 1 (Erlotinib+water vs. Cola)
Parameter Erlo + Water (A) Erlo + Cola (B) Difference % (range)
Erlotinib dose* 150 (50-150) 150 (50-150)
Erlotinib**
AUC 0-12h (µg×h/ml), geometric 
mean (geometric mean CV%)
17.3 (8.5%) 18.6 (7.7%) 9% (-10% to 30%),
P=.03
Cmax (µg/ml), geometric mean 
(geometric mean CV%)
2.10 (68%) 2.09 (64%) 0% (-19% to +18%),
P=.62
Abbreviations: A, sequence arm A; AUC0-12h, area under the plasma concentration time curve; B, sequence arm B; Cmax, 
maximum plasma concentration; CV%, percentage of coefficient of variation defined by (standar deviation /  mean) x 
100;  Erlo, erlotinib; Esom, esomeprazole 40mg once daily
* Median (range)
†In case of a dose reduction (due to toxicity), pharmacokinetic data were normalized to a dose of 150 mg erlotinib.
‡Based on individual patient data.
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FIGURE 2: Pharmacokinetic profile. Mean dose-corrected concentration v time profiles are shown for erlotinib 
alone administered with water or cola (A; n = 14) and erlotinib + esomeprazole with water or cola (B; n = 14).
TABLE 4. Treatment related adverse events during study period
PPI (n=14), No. (%) Non-PPI (n=14), No. (%)
Water Cola Water Cola
Diarrhea* 2 (14%) 2 (14%) 3 (21%) 6 (43%)
Nausea* 1 (7%) 2 (14%) 1 (7%) 1 (7%)
Vomiting* 0 0 1 (7%) 0
Rash†‡ 9 (64%) 11 (79%) 9 (64%) 11 (79%)
Fatigue† 8 (57%) 8 (57%) 7 (50%) 7 (50%)
Abbreviation: PPI, proton pump inhibitor.
*All grade 1 according to Common Terminology Criteria for Adverse Events
(CTCAE) version 4.03.
†Grade 1 or 2 according to CTCAE version 4.03
‡One patient with grade 3 skin toxicity according to CTCAE version 4.03.
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DISCUSSION
We show that the use of cola significantly increases the mean exposure of erlotinib 
in patients treated with esomeprazole probably because of increased solubility and 
absorption. Furthermore, in patients who took the medications with cola instead of 
water, the mean exposure to erlotinib also significantly increased, although this effect 
was clinically irrelevant. The observed PK parameters were comparable to previous 
reports.6 The current study confirms that pH-dependent solubility plays a key role 
in erlotinib absorption and that a 250 mL of cola can enhance erlotinib absorption 
by temporarily lowering intragastric pH. Although H2 antagonists (eg, ranitidine) 
and antacids can substantially affect erlotinib bioavailability, we used esomeprazole 
(Nexium at the regular dosage of 40 mg once daily) in this study because it is currently 
the most effective acid-reducing agent on the market.2,10,11 Furthermore, when using 
esomeprazole instead of other PPIs (eg, pantoprazole), other factors such as inhibition 
of relevant drug transporters that may also alter erlotinib PK (eg, P-glycoprotein) can 
be ruled out.15 To our knowledge, no other interactions (eg, those based on altered 
metabolism or clearance) exist  between erlotinib and esomeprazole, besides those 
based on altered intragastric pH, that may alter erlotinib PK. A 3-day period before 
PK sampling days was assumed to maximize acid-reducing effects and to minimize 
the period a patient was exposed to the unwanted DDI between esomeprazole and 
erlotinib.6,10,11 This assumption was supported by the observation of no significant 
differences in AUC0-12h and Cmax between patients treated with esomeprazole for 3 days 
and those treated longer term. In this study, a large interpatient variability in either 
AUC or other PK parameters was observed. Several factors could explain this variability. 
Most probably, the absorption from the gut itself varies highly between patients. 
Adherence to the protocol during the study period (eg, by drinking other [volumes of] 
acidic beverages or by not taking erlotinib on an empty stomach) is unlikely to be the 
cause of variability because the study protocol was explained thoroughly, and patient 
diaries were heavily protocoled and checked by the investigators. Other probable 
reasons are interpatient differences in gastric emptying and GI motility. Cola may not 
enhance absorption in all patients because gastric pH may also physiologically vary; 
thus, the effects may be lower if the gastric pH is lower in one patient compared with 
another.1
A limitation of this study is that we did not measure intragastric pH. Because some 
patients might experience altered gastric acid secretion (eg, achlorhydria or Zollinger-
Ellison syndrome), large interpatient variations in intragastric pH can be expected. 
Because of the weak basic properties and an acid dissociation constant (ie, the pH 
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at which equilibrium is reached between the ionized and the nonionized form) near 
the stomach pH range of 1 to 4 (erlotinib pKa = 5.4), intragastric pH shifts lead to a 
more significant shift toward the nonionized (less-soluble) form and subsequent lower 
bioavailability compared with TKIs with a higher pKa value (eg, sunitinib, afatinib6). This 
may partly explain the large variation in erlotinib absorption seen in the current study. 
The measurement of the intragastric pH per patient might give additional insights 
into the effect of cola intake on intragastric pH and subsequent absorption. Another 
limitation of this study is that it was not designed to explore the effects of long-term 
cola coadministration on the outcome of anticancer treatment with erlotinib. Because 
of the study design being purely based on PK and chemical parameters (ie, pH effect 
and subsequent erlotinib solubility and absorption) and the relatively short time (ie, 7 
days) that patients were treated with erlotinib and cola (instead of water), the study did 
not allow us to evaluate the impact of cola on erlotinib efficacy. Therefore, the clinical 
impact of cola on erlotinib efficacy should be  unraveled in future research.
In theory, in patients with elevated intragastric pH and subsequent impaired absorption 
(eg, achlorhydria, gastrectomy), the use of cola may increase bioavailability of erlotinib 
or other TKIs with a relatively low pKa value. Because of the nocturnal duodenogastric 
reflux peak during sleep, the intragastric pH at night is, on average, higher than that 
in the morning.11 Many patients take a TKI ante noctem.16 In theory, when a patient 
decides to take erlotinib ante noctem, cola could help to increase bioavailability by 
temporarily lowering intragastric pH. The effect of cola on these subgroups should be 
explored further in future studies.
In clinical practice, a hard indication for the use of PPIs during erlotinib therapy (eg, 
patients treated with corticosteroids and nonsteroidal anti-inflammatory drugs or 
with [recurrent] gastroesophageal reflux disease) often exists. On the other hand, 
physicians are faced with product label guidelines that advise to avoid the combination 
or to switch to less-effective H2 antagonists or antacids (taken 2 h after erlotinib).6 When 
erlotinib and a PPI are given concomitantly, the AUC of erlotinib steeply decreases,6 
which suggests that lower bioavailability due to PPI use (up to 46% for erlotinib6) may 
deprive patients from optimal therapy.5,17 Thus, in the case that the combination of a 
PPI and erlotinib is inevitable, the pH-lowering effects of cola may help physicians to 
optimize erlotinib therapy.
Although ingredients of cola, such as caffeine, may potentially interact with erlotinib PK, 
pH-dependent solubility more likely is the predominant factor in erlotinib absorption.3,18 
Erlotinib is a Biopharmaceutics Classification System19 class II drug characterized by 
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poor solubility but high intestinal permeability, which means that in vivo erlotinib 
bioavailability is predominantly limited by its solubility.3,19 When dissolved, erlotinib is 
rapidly and extensively (> 90%) absorbed across the intestinal membrane.3
Although cola can be associated with several disadvantages, such as dental corrosion 
and gastroesophageal irritation, it is (for most people) a palatable drink readily available 
worldwide. Furthermore, Coca-Cola Classic has the clear advantage of a substantially 
lower pH (approximately 2.5) compared with other acidic beverages, such as orange 
juice (pH approximately 4), 7-Up (pH approximately 3.5; Dr Pepper/Seven Up, Plano, 
TX), and diet (cola) products (pH approximately 3 to 4). In theory, drinks with higher 
pH might not be as effective at enhancing erlotinib absorption as Coca-Cola Classic. 
Furthermore, although not studied, higher volumes of cola might acidify the stomach 
even more, and erlotinib absorption could be further enhanced. However, in the 
current study, 250 mL of cola was well tolerated, and higher volumes might be less 
convenient for the patient (especially in the morning).
In conclusion, the use of cola provides a potential and easyto-implement way to 
significantly improve erlotinib bioavailability, especially during concomitant use of 
esomeprazole. These findings can be used to optimize the management of the existing 
DDI between erlotinib and PPIs. Potentially, the effects of cola on erlotinib exposure 
may be extrapolated to other TKIs with a pH-dependent solubility (eg, dasatinib, 
gefitinib, nilotinib), but this remains to be evaluated in future studies. Furthermore, 
other acidic beverages (ie, orange juice, other carbonated drinks) may have similar 
effects as cola and should be explored in future trials.
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ABSTRACT:
Introduction. Erlotinib’s gastrointestinal solubility and absorption are decreased by 
proton pump inhibitors (PPIs). Since erlotinib is a lipophilic drug, we hypothesized that 
concomitant intake with the fatty beverage milk may be a feasible way to increase 
erlotinib uptake. We performed a two-period, randomized, crossover study to 
investigate the influence of cow’s milk with 3.9% fat on the exposure of erlotinib with 
and without the PPI esomeprazole in patients with non-small cell lung cancer (NSCLC). 
The effect of esomeprazole was studied in an additional intrapatient comparison.
Method. Pharmacokinetic sampling was performed on days 7 and 14 during 24 
consecutive hours. During the 7 days prior to pharmacokinetic sampling, erlotinib was 
taken daily with 250 mL of either water or milk. In the PPI arm, esomeprazole (40 mg 
once daily 3 h prior to erlotinib) was taken for 3 days.
Results. Erlotinib area under the curve from time zero to 24 h (AUC24) did not 
significantly change when administered with milk, compared with water, in both non-
PPI users (n = 14; − 3%; 95% conidence interval [CI] − 12 to 8%; p = 0.57) and patients 
who used esomeprazole (n = 15; 0%; 95% CI − 15 to 17%; p = 0.95). Esomeprazole 
decreased erlotinib AUC24 by 47% (n = 9; 95% CI − 57 to − 34%; p < 0.001) and Cmax 
by 56% (95% CI − 64 to − 46%; p < 0.001). No differences in toxicities were observed 
between milk and water.
Conclusion. Milk with 3.9% fat has no effect on the exposure to erlotinib in NSCLC 
patients, independent of PPI use. The combination with milk is safe and well tolerated. 
Concomitant esomeprazole treatment strongly decreased both erlotinib AUC24 and Cmax 
and should be avoided if possible.
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INTRODUCTION
Erlotinib is a tyrosine kinase inhibitor (TKI) registered for the treatment of epidermal 
growth factor receptor (EGFR) mutated metastatic non-small cell lung cancer (NSCLC) 1, 
2. It is indicated in combination with gemcitabine as firstline therapy for unresectable or 
metastatic pancreatic cancer 1. Erlotinib is orally administered on a daily basis at a dose 
of 150 and 100 mg once daily for NSCLC and pancreatic cancer, respectively. Intra- and 
interpatient variability differs significantly due to interactions with food 3, concomitant 
medication 4, and lifestyle factors (i.e. smoking) 5, 6.
The bioavailability of erlotinib largely depends on its solubility in the stomach and passive 
diffusion and probable active cellular transport in the gastrointestinal tract 7. Optimal 
drug absorption is reached at a physiologically low intragastric pH (i.e. pH value of 1), 
since erlotinib is then protonized and is thus better soluble 8. However, various acid-
reducing drugs, including histamine-2 receptor antagonists (e.g. ranitidine) and proton 
pump inhibitors (PPIs; e.g. omeprazole) may lead to a 40–50% decrease in erlotinib 
absorption due to an increase in intragastric pH 9. It has been previously demonstrated 
that this impaired systemic exposure to erlotinib can be corrected when administered 
in combination with the acidic beverage cola 10. However, daily intake of acidic and 
highly caloric beverages such as cola or orange juice has disadvantages, such as dental 
problems, disrupted bone mineral composition, and weight gain 11. We hypothesized 
that a healthier way to enhance erlotinib bioavailability could be by making use of the 
effects of other food components. The exposure of erlotinib is increased 33–66% when 
administered concomitantly with a high-fat meal 3. We explored this potentially positive 
food effect as a proof-of-principle by optimizing erlotinib absorption in the presence of 
a beverage containing fat. In the past, milk-based drug formulations have shown to 
be equally effective compared with standard formulations in terms of solubility and 
dispersion 12. Milk is consumed worldwide by billions of people. It is a healthy beverage 
that contains essential proteins, vitamins and minerals (e.g. calcium and phosphorus). 
Cow’s milk accounts for more than 80% of the global milk production 13.
This is the first study that investigates the efects of erlotinib administered concomitantly 
with high-fat whole cow’s milk compared with water. In addition, a direct intrapatient 
comparison to study the effects of esomeprazole on the systemic exposure of erlotinib 
has never been made. Therefore, we also explored the potential drug–drug interaction 
of esomeprazole use on the absorption of erlotinib.
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METHODS
Patient eligibility
Adult NSCLC patients were eligible for inclusion in this study if they had an Eastern 
Cooperative Oncology Group (ECOG) performance status 14 of ≤ 1, were treated with 
a stable dose of erlotinib for at least 2 weeks (to guarantee steady-state plasma 
concentrations) and did not use any other (complementary or alternative) medicine or 
compounds that may have the potential to interact with either erlotinib or esomeprazole. 
Patients who concomitantly used any prescribed PPI could only participate in the PPI 
arm of this study when willing to switch to esomeprazole. It was possible for patients to 
participate in both study arms if PPI use was discontinued or if they were willing to take 
esomeprazole as required for this study. All participating patients were asked to sign a 
written informed consent form. The study was approved by the local Ethics Committee 
(Erasmus University Medical Center Rotterdam; MEC 16–590) and was registered in the 
Dutch Trial Registry (number NL5984; NTR6148) 15.
Study design
This was a single center, randomized, two-period, crossover pharmacokinetic study 
with two study arms. Figure 1 shows the study low chart. After signing informed 
consent and after screening, patients were allocated to the non-PPI (arm A) or PPI (arm 
B) study arms. Hereafter, they were randomized to start with erlotinib with 250 mL 
of water (period 1) or cow’s milk containing 3.9% fat (period 2) for 7 consecutive days 
(days 1–7 or 8–14). The 7-day period was chosen to ensure that erlotinib concentrations 
reached steady state. At days 7 and 14, patients were electively admitted for 24-h 
pharmacokinetic blood sampling. During each admission, 13 blood samples were 
collected; < 5 min before erlotinib intake (t = 0 h) and at time points (0.5, 1, 1.5, 2, 2.5, 3, 
3.5, 4, 6, 8, 12 and 24 h) after erlotinib intake. Patients had to take erlotinib according to 
its label, i.e. fasted for at least 2 h prior to and 1 h after administration. Additionally, on 
the day of hospital admission, food intake was prohibited between 4 h prior to and 1 h 
after erlotinib administration. Consumption of beverages was restricted for 1 h before 
and after erlotinib intake. In the PPI arm, patients were required to take esomeprazole 
(40 mg once daily) 3 h prior to erlotinib intake on days 5, 6 and 7 and days 12, 13 and 
14 after the start of the study. The timing of esomeprazole intake was chosen to ensure 
maximal inhibition of gastric acid secretion at the time of erlotinib intake 16. All samples 
were analyzed by a validated liquid chromatography-tandem mass spectrometric assay 
for precise quantiication of erlotinib plasma concentrations 17.
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N = 7 
N = 2 
Figure 1.  
 
Arm A (N = 14) 
Without PPI 
Arm B (N = 15) 
With PPI 
 
Study screening 
Period A1 (N = 7) 
Water; day 1-7 
 
Period A2 (N = 7) 
Milk; day 1-7 
 
 
Period B1 (N = 8) 
Water; day 1-7 
 
Period B2 (N = 7) 
Milk; day 1-7 
 
24 hours hospital admission pharmacokinetic blood sampling (day 7) 
Period A1 
Water; day 8-14 
 
Period B1 
Water; day 8-14 
 
24 hours hospital admission pharmacokinetic blood sampling (day 14) 
 
Period B2 
Milk; day 8-14 
 
Period A2 
Milk; day 8-14 
 
FIGURE 1: Study flowchart. After screening, patients were allocated to the non-PPI (arm A) or PPI (arm B) arms. 
Hereafter, they were randomized to start with administration of either concomitant water (period 1) or cow’s milk 
(period 2). Subsequent participation in both arms was allowed and is illustrated with the arrows between arms 
A and B. Hospital admissions for pharmacokinetic blood sampling took place at days 7 and 14. Esomeprazole 40 
mg once daily was administered in arm B at days 5, 6 and 7, and days 12, 13 and 14. PPI proton pump inhibitor
Study objectives
The primary objective was the diference in geometric mean of the area under the 
curve from time zero to 24 h (AUC24) between periods with concomitant cow’s milk 
compared with water, both with and without esomeprazole. Secondary objectives were 
the effects of esomeprazole intake in patients who were included in both arms, other 
pharmacokinetic outcomes (i.e. clearance, maximum concentration [Cmax] and time to 
Cmax [Tmax]), and comparison of (the incidence and severity of) the adverse effects of 
treatment with erlotinib between periods and study arms.
Adverse event monitoring
Toxicity was scored by the investigator at baseline and during hospital admission in 
accordance with the US National Cancer Institute Common Terminology Criteria for 
Adverse Events (CTCAE) grades, version 4.03 18. Patients were provided with a diary to 
report any (ongoing) adverse events during the study.
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Statistical analyses
Given a clinically relevant difference of 30% in AUC, a within-patient standard deviation 
of 25%, 80% power and a two-sided significance level of 5%, 14 evaluable patients were 
required per study group (i.e. with or without esomeprazole) 19; hence, a total of 28 
patients had to be included.
Analyses of AUC24 and Cmax were performed on logtransformed values, since these 
parameters were assumed to follow a log-normal distribution 20. Estimates for the 
mean differences in (log) AUC24 and Cmax between milk and water were obtained for 
both study arms separately (with or without esomeprazole) using a linear mixed-
effect model with treatment (water or milk), sequence and period as fixed effects, and 
subject-within-sequence as a random effect 21. Variance components were estimated 
based on restricted maximum likelihood (REML) methods, and the Kenward–Roger 
method of computing the denominator degrees of freedom was used. The mean 
differences and their 95% conidence intervals (CIs) were exponentiated to provide 
point estimates of the ratio of geometric means and 95% CIs for these ratios, which 
can be interpreted as relative differences in percentages. Tmax was analyzed using the 
nonparametric Wilcoxon signed-rank test. Analyses to study the effect of esomeprazole 
were performed in a similar way, although they also included the effect of water versus 
milk as a mixed effect and only included patients who participated in both study arms. 
Toxicity was described as the incidence of toxicity per period. This was taken into 
account in case of an increase in CTCAE grade per cycle. Since the design of this study 
was not appropriate to detect a significant difference in toxicity, these results had a 
descriptive character. All statistical analyses were performed using Stata (StataCorp. 
2017. Stata: Release 15.1. Statistical Software. College Station, TX, USA: StataCorp LP).
RESULTS
Patients
A total of 21 unique patients were included between February 2017 and November 
2019. The patient demographics are presented in Table 1. For personal reasons, one 
patient withdrew informed consent after completion of the first period. Nine patients 
were included in both the non-PPI and PPI arms; hence, 29 pairs of study periods were 
completed—14 in the non-PPI arm and 15 in the PPI arm (Figure 1).
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TABLE 1. Patients’ characteristics.
Characteristic Total included (n=20)
Sex
Male
Female
7 (35%)
13 (65%)
Age (years) median [IQR] 67.5 [55-73.5] 
Performance
ECOG 0
ECOG 1
10 (50%)
10 (50%)
Race
Caucasian
Asian
African
16 (80%)
3 (15%)
1 (5%)
Current smoker 0 (0%)
Erlotinib dose
150 milligrams
100 milligrams
50 milligrams 
17 (85%)
2 (10%)
1 (5%)
Abbreviations: ECOG = Eastern Cooperative Oncology Group; n = number of patients; IQR = interquartile range.
Pharmacokinetic effects of milk
The pharmacokinetics of erlotinib when taken with milk or water are presented in 
Table  2. Erlotinib AUC24 decreased non-significantly by 3% (95% CI − 12 to 8%; p = 
0.567) when administered with milk, compared with water, in the non-PPI patients. 
In addition, in those patients who used esomeprazole, erlotinib exposure did not 
signiicantly differ as a result of intake with either water or milk (0%; 95% CI − 15 to 
17%; p = 0.953). Figures 2a and b show the absence of an efect of milk in both study 
arms. Cmax did not difer in non-PPI or PPI users, with relative diferences of a 6% and 
1% increase, respectively (95% CI − 21 to 11%, p = 0.409; and 95% CI − 12 to 17%, p 
= 0.831, respectively). In both study arms, Tmax increased non-significantly at 0.5 h; in 
the non-PPI arm from 2.0 to 2.5 h (p = 0.729) and in the PPI arm from 2.5 to 3.0 h (p = 
0.306). Interpatient variability, measured by the coeicient of variation (CV), was lower 
with milk compared with water in both study periods and for both AUC24 and Cmax. This 
lower variability in AUC24 with milk intake was most pronounced in the PPI arm (CV 38% 
vs. 61%) (Table 2).
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FIGURE 2. Efect of cow’s milk on erlotinib concentrations. Erlotinib taken with 250 mL of cow’s milk or water, a 
without and b with concomitant esomeprazole administration
Effects of esomeprazole on erlotinib pharmacokinetics
Based on data from the nine patients who participated in both study arms, esomeprazole 
decreased erlotinib AUC24 by an average of 47% (95% CI − 58 to − 34%; p < 0.001) 
and  Cmax by 56% (95% CI − 64 to − 46%; p < 0.001) compared with the period in which 
esomeprazole was not used. These results are displayed in Figure 3 and Table 3. Tmax 
seemed longer for both the milk and water periods, especially in the PPI arm (Table 2). 
In the setting of administration with water, the interpatient variability in AUC24 increased 
from 37 to 61% due to esomeprazole co-treatment. When erlotinib was taken with milk, 
the interpatient variability in AUC24 was not afected by esomeprazole co-treatment (CV 
38% vs. 35%) (Table 2).
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FIGURE 3. Efect of esomeprazole on erlotinib concentrations. Erlotinib taken with a 250 mL water or b cow’s 
milk. In the PPI arm, esomeprazole was administered 3 h prior to erlotinib intake. PPI proton pump inhibitor
Toxicity
Table 4 presents all adverse events experienced. Overall, patient-reported adverse 
events during this study did not increase compared with baseline. Independent of study 
arm, no diferences in toxicities were observed between study periods. Furthermore, 
patients reported almost equal adverse event grades in both the non-PPI and PPI 
arms (data not shown). Two grade 3 adverse events occurred—one period of nausea 
that fluctuated for several weeks, and one increase in skin rash during concomitant 
nadroparine treatment. Both patients used erlotinib for more than 3 months prior to 
this increase in toxicity. For the first patient, erlotinib was temporarily discontinued 
several weeks after study completion and restarted at a reduced dosage. For the 
second patient, erlotinib was temporarily discontinued and its dosage reduced. These 
dose reductions were effective in reducing toxicity in both cases. There was one serious 
adverse event (SAE) in this study, namely a CTCAE grade 3 malignant spinal fracture, 
which occurred after randomization and before the first study period. This SAE 
required hospital admission and was considered to be not related to study procedures, 
therefore erlotinib treatment was continued. No eminent study intervention-related 
toxicity occurred.
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TABLE 4. Patient-reported adverse events during study period.
Baseline (N = 30) Water (N = 29) Milk (N = 30)
Adverse event Grade 1-2 Grade 3 Grade 1-2 Grade 3 Grade 1-2 Grade 3
All events 29 (97%) - 28 (97%) - 28 (93%) 2 (6%)
Reported in ≥10% of patients
   Nausea 1 (3%) - 3 (10%) - 3 (10%) 1 (3%)
   Diarrhea 6 (20%) - 3 (10%) - 3 (10%) -
   Constipation 5 (17%) - 1 (3%) - 3 (10%) -
   Fatigue 10 (33%) - 10 (34%) - 6 (20%) -
   Pain 5 (17%) - 7 (24%) - 9 (30%) -
   Rash 23 (77%) - 18 (62%) - 20 (67%) 1 (3%)
   Alopecia 12 (40%) - 11 (38%) - 11 (37%) -
Serious adverse event - 1 (3%)* - - - -
Data are expressed as n (%) Water = both periods wherein patients used water to take erlotinib, both without and with 
a PPI Milk = both periods wherein patients used cow’s milk to take erlotinib, both without and with a PPI. PPI proton 
pump inhibitor * Serious adverse event was a spinal fracture that needed hospital admission during which erlotinib 
was continued
DISCUSSION
This study reports the absence of a pharmacokinetic efect of cow’s milk with 3.9% fat 
on exposure to erlotinib in NSCLC patients, independent of PPI use. Additionally, this 
study showed a decrease in erlotinib AUC24 of almost 50% and a decrease in Cmax of 
more than 50% when erlotinib was administered 3 h after esomeprazole intake.
 A possible explanation for the lack of effect of milk on erlotinib exposure is that the 
3.9% fat content of cow’s milk is not high enough to affect absorption. In absolute 
values, patients were administered 9.75 g (250 mL × 3.9%) of fat from milk. This is 
relatively low in comparison with a high-fat meal, which consists of 500–600 kilocalories 
of pure fat 3 (c.q. 56–67 g). The efect of a high-fat meal on erlotinib disposition ranges 
from a 33% AUC increase when taken 2 h after erlotinib administration 22, to a 66% 
increase in AUC of erlotinib when food and drug are taken concomitantly 23. In theory, 
the negative efect of esomeprazole of almost 50% decrease in AUC24 could be overcome 
by coadministration of a high-fat meal.
An additional reported efect of increasing the bioavailability of erlotinib with 
coadministration of a high-fat meal was a decrease in interpatient variability 3. The 
benefits of less interpatient variability are a more predictable effectivity and toxicity on 
a large scale, since more patients will be administered within the therapeutic window. 
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Our data show that milk also reduced interpatient variability, especially in the PPI arm 
(Table 2). Although, on average, bioavailability did not change, the lower interpatient 
variability would be an argument in favor of erlotinib administration with milk instead 
of water.
Another reason why erlotinib absorption was not affected by milk could be that the 
strong pH buffering capacity of milk 12 prevents the intragastric pH from decreasing. 
Hence, the beneficial efect of the milk’s fat is counteracted by switching erlotinib to 
its less soluble, non-ionized form, which is not an optimal condition for transluminal 
transportation across gastrointestinal cells. Furthermore, there is no evidence of milk 
interacting with drug transporters or hepatic cytochrome P450 isoenzymes.
Average milk consists of 3–4% fat 13. Since we used cow’s milk with the highest fat content 
(3.9%) commercially available, it is unlikely that lighter variants of cow’s milk would 
have a higher efect on the bioavailability of erlotinib. Nevertheless, cow’s milk may be 
of interest for increasing systemic exposure of TKIs with vaster food efects, i.e. lapatinib 
(up to 325% and 200% AUC increase with a high- and low-fat meal, respectively) 3. In line 
with milk, yoghurt (0.4% fat 24) is not expected to interact with erlotinib absorption and 
could also be considered safe. Coadministration with yoghurt was previously studied 
and was considered safe for the TKI nilotinib 3, 25.
Moreover, for the first time, we conducted an intrapatient comparison on the effects 
of esomeprazole on the AUC24 and Cmax of erlotinib, which is in line with previous 
research with erlotinib and omeprazole 9. We hence warn patients and prescribers of 
this possible harmful interaction, which could lead to therapy ineffectiveness. Potential 
solutions for patients who are dependent on PPI use may be a delayed PPI intake 
until erlotinib is fully absorbed or by taking erlotinib concomitantly with cola 10. Albeit 
practical, the most feasible solution is a critical reconsideration of the need to prescribe 
a PPI and discontinuation of the PPI where possible.
Another way to increase the aqueous solubility, and therewith bioavailability, of 
erlotinib could be to improve its formulation 26. A phospholipid formulation showed 
an improved pharmacokinetic proile in rats 27. Before this new formulation could be 
considered to be implemented in clinical practice, further research should first be 
conducted to determine its possible benefits and deficits.
Furthermore, the absence of a milk efect on erlotinib exposure is probably also the 
reason why this study found no differences in patient-reported toxicity. This is not 
surprising as, for erlotinib, the plasma concentration is correlated with the occurrence 
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of the most prevalent adverse efects of skin rash and diarrhea 28. Erlotinib intake with 
milk is just as safe as intake with water, and could thus be advised to patients as an 
alternative for administration with water, for example to mitigate mild gastrointestinal 
reflux complaints or as the patient’s preference.
Interestingly, although esomeprazole reduced erlotinib exposure by half, patients did 
not report less toxicity; however, the 3-day period during which patients had to take 
esomeprazole was most likely too short to have a noticeable effect on toxicity. When 
esomeprazole is taken for a longer period of time, the chronic decrease in erlotinib 
exposure could have a more distinctive effect of less toxicity.
CONCLUSION
Whole cow’s milk with 3.9% fat has no clinically relevant efects on the exposure of 
erlotinib in NSCLC patients, independent of PPI use. The combination with milk instead 
of water is safe and well tolerated, and may be a good alternative for some patients. 
Meanwhile, the use of esomeprazole 3 h prior to erlotinib intake strongly decreased 
both erlotinib AUC24 and Cmax, and should be avoided if possible.
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ABSTRACT
Tamoxifen is a prodrug that is primarily metabolized into the pharmacologically active 
metabolite endoxifen and eventually into inactive metabolites. The herb curcumin 
may increase endoxifen exposure by affecting phase II metabolism. We compared 
endoxifen and tamoxifen exposure in breast cancer patients with or without curcumin, 
and with addition of the bio-enhancer piperine. Tamoxifen (20-30mg q.d.) was either 
given alone, or combined with curcumin (1,200mg t.i.d.) +/- piperine (10mg t.i.d.). The 
primary endpoint of this study was difference in geometric means for the area under 
the curve (AUC) of endoxifen. Genotyping was performed to determine CYP2D6 and 
CYP3A4 phenotypes. The endoxifen AUC0-24h decreased with 7.7% (95%CI: -15.4 to 0.7%; 
P=0.07) with curcumin and 12.4% (95%CI: -21.9 to -1.9%; P=0.02) with curcumin and 
piperine, compared to tamoxifen alone. Tamoxifen AUC0-24h showed similar results. 
For patients with an extensive CYP2D6 metabolism phenotype (EM), effects were 
more pronounced than for intermediate CYP2D6 metabolizers (IM). In conclusion the 
exposure to tamoxifen and endoxifen was significantly decreased by concomitant use 
of curcumin (+/-piperine). Therefore co-treatment with curcumin could lower endoxifen 
concentrations below the threshold for efficacy (potentially 20-40% of the patients), 
especially in EM patients.
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INTRODUCTION
Breast cancer is one of the most commonly diagnosed malignancies worldwide and 
one of the leading causes of cancer related deaths in women.1 Since decades, patients 
with estrogen receptor positive breast cancer are extensively treated with endocrine 
therapy such as tamoxifen. Tamoxifen acts as a selective estrogen receptor modulator 
in breast cancer tissue, thereby reducing the risk of disease recurrence and breast 
cancer specific mortality.2
Currently, there is a trend towards the use of natural herbs and dietary products 
among cancer patients. Nearly 20-30% of all cancer patients, especially breast cancer 
patients, use herbal medicine besides their conventional therapy.3 Curcumin, also called 
´turmeric´; a spice recovered from the roots of the curcuma longa plant, is becoming 
increasingly popular among cancer patients because of its supposed anti-cancer 
effects.4 Curcumin is characterized by a poor bioavailability due to poor absorption 
and rapid metabolism.5 Therefore, curcumin is often used in combination with piperine 
(a component of black pepper). Piperine increases curcumin bioavailability 20-fold by 
increasing curcumin absorption and inhibition of curcumin glucuronidation.6
Tamoxifen shows a complex and multi-pathway metabolism, which mainly occurs in the 
liver. Tamoxifen is metabolized into several (active) metabolites, through several phase 
I and phase II metabolizing enzymes; mainly by the cytochrome P450 (CYP) enzymes 
CYP2D6 and CYP3A4 (Figure 1).7 Based on its relatively high plasma concentrations 
and potency, endoxifen is believed to be one of the most important metabolites in 
the efficacy of tamoxifen therapy.7, 8 Moreover, endoxifen is excreted (mainly in the 
feces) after phase II metabolism through UDP-glucuronyltransferases (UGTs) and 
sulfotransferase (SULT).8
A study in rats demonstrated an increase in tamoxifen plasma concentration of 33-
64%, suggesting an inhibitory effect of curcumin on tamoxifen metabolism.9 Several 
studies (both in vitro and in vivo) demonstrated that curcumin has an inhibitory effect 
on several CYP enzymes among which CYP3A4 and CYP2D6.10 Another important effect 
of curcumin is inhibition of phase II drug metabolism by inhibition of UGT. Furthermore, 
curcumin could potentially inhibit or induce several drug-efflux transporters (e.g. 
P-glycoprotein (P-gp)).10, 11
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FIGURE 1: The major primary metabolite N-desmethyl-tamoxifen and the minor primary metabolite 
4-hydroxytamoxifen are formed by N-demethylation and 4-hydroxylation of tamoxifen, through CYP3A4 
and CYP2D6 metabolism respectively. Further CYP-mediated metabolism of these metabolites results in the 
formation of 4-hydroxy-N-desmetyltamoxifen (endoxifen). Endoxifen is ultimately metabolized through phase II 
metabolism into a.o. endoxifen-glucoronide through UGT and also through SULT enzymes.
In this study, it was hypothesized that endoxifen plasma concentrations may increase 
when tamoxifen is administered with curcumin, mainly through UGT enzyme inhibition. 
In addition, concomitant administration with the bio-enhancer piperine may potentiate 
effects on tamoxifen and endoxifen plasma pharmacokinetics. In a pharmacokinetic 
cross-over study we therefore explored the impact of curcumin --with and without 
piperine-- on tamoxifen and endoxifen pharmacokinetics.
RESULTS
Patient Characteristics
Seventeen patients were included in the study of whom one patient was excluded 
due to voluntary withdrawal, resulting in 16 evaluable patients. Patient characteristics 
can be found in Table 1. DNA analysis showed no variants for CYP3A4*22. As this 
polymorphism is considered most relevant for CYP3A4, a predicted normal CYP3A4 
phenotype for all study patients based on genotype was assumed.12, 13 Based on 
CYP2D6 genotyping, seven patients (44%) showed an extensive CYP2D6 metabolism 
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TABLE 1. Patient characteristics
Characteristic N (%)
Patients 16 (100)
Randomization sequence
ABC
CBA
9 (56)
7 (44)
Age (Median, IQR) 45 (42-58)
Sex
Female
Male
15 (94)
1 (6)
Race
Caucasian
Arabic
15 (94)
1 (6)
Height (Median, IQR) 171 (167-176)
Weight (Median, IQR) 73 (65-91)
BMI (Median, IQR) 25 (23-29)
WHO Performance Status
0
1
13 (81)
3 (19)
Previous chemotherapy
Yes
TAC
AC - paclitaxel
FEC - docetaxel
No
12 (75)
2 (13)
4 (25)
6 (37)
4 (25)
Previous RTx
Yes
No
10 (63)
6 (37)
Tamoxifen dose
20 mg
30 mg
15 (94)
1 (6)
Genotype
CYP3A4*22
EM
CYP2D6
EM
IM
PM
UM
16 (100)
7 (44)
7 (44)
1 (6)
1 (6)
Abbrevations: IQR = interquartile range, TAC = Docetaxel, doxorubicin and cyclofosfamide, AC = doxorubicin, 
cyclofosfamide, FEC = 5FU, epirubicine and cyclofosfamide, RTx = radiotherapy, EM = extensive metabolism phenotype, 
IM = intermediate metabolism phenotype, PM = poor metabolism phenotype, UM = Ultra-rapid metabolism phenotype.
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phenotype (EM), while seven other patients (44%) exhibited intermediate CYP2D6 
metabolism (IM). The other two patients (12%) demonstrated ultra-rapid metabolism 
(UM) and poor CYP2D6 metabolism (PM), respectively.
Pharmacokinetics
In patients treated with tamoxifen and curcumin, the geometric mean AUC0-24h and 
Ctrough of tamoxifen decreased with 8.0%  (95%CI: -14.1% to –1.4%, P=0.02) and 7.1% 
(95%CI: -17.1% to 4.0%, P=0.25), respectively, compared to tamoxifen monotherapy 
(Table 2). Furthermore, AUC0-24h and Ctrough of endoxifen decreased with 7.7% (95%CI: 
– 15.4% to 0.7%, P=0.07), and 5.6% (95%CI: -15.6% to 5.5%, P=0.43), respectively, with 
concomitant curcumin treatment.
When tamoxifen was administered with curcumin and piperine, the effects were more 
pronounced; tamoxifen AUC0-24h and Ctrough decreased with 12.8% (95%CI: -19.2% to 
-5.9%, P<0.01) and 12.2% (95%CI: -21.5% to -1.8%, P=0.02), respectively, compared to 
tamoxifen monotherapy. The endoxifen AUC0-24h decreased with 12.4% (95%CI: -21.9% 
to -1.9%, P=0.02), while the Ctrough decreased with 12.4% (95%CI: -20.9% to -3.0%, P=0.01). 
Further pharmacokinetic results are shown in Table 2. Pharmacokinetic parameters for 
4-hydroxy-tamoxifen and N-desmethyl tamoxifen showed a decrease in almost every 
pharmacokinetic parameter when administered with curcumin --with and without 
piperine-- although only AUC0-24h of N-desmethyl tamoxifen and 4-hydroxytamoxifen 
with curcumin and AUC0-24h of N-desmethyl tamoxifen with curcumin and piperine 
demonstrated a significant difference.
When analyzing the CYP2D6 predicted phenotypes separately, both endoxifen and 
tamoxifen showed a more pronounced decrease for both AUC0-24h and Ctrough (especially 
during treatment with curcumin and piperine) in patients with an extensive metabolism, 
compared to those with an intermediate metabolism (Table 3). In patients with an IM 
treated with curcumin and piperine the AUC0-24h decreased with 5.3% (95%CI: -13.1% to 
+3.1% , P=0.16) and 10.3% (95%CI: -23.5% to 5.3%, P=0.14) for tamoxifen and endoxifen, 
respectively. In patients with an EM treated with curcumin and piperine the tamoxifen 
and endoxifen AUC0-24h decreased with 22.0% (95%CI: -29.0% to -14.2%, P<0.01) and 
18.4% (95%CI: -36.1% to 4.3%, P=0.09), respectively. Ctrough  showed similar results 
(Table 3). Although the interaction term was only significant for tamoxifen AUC0-24h and 
Ctrough with curcumin and piperine. There was no period effect, which implicates no 
decline in tamoxifen nor endoxifen plasma concentrations based on altered tamoxifen 
metabolism over time. Individual tamoxifen and endoxifen AUC0-24h can be found in 
Figure 2.
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FIGURE 2. Endoxifen and tamoxifen AUC0-24h per individual patient per treatment phase: (a) Tamoxifen AUC0-24h 
per individual patients per treatment phase. (b) endoxifen AUC0-24h per individual patients per treatment phase. 
Patients with an Intermediate CYP2D6 metabolism (IM) were colored blue. Patients with an extensive CYP2D6 
metabolism (EM) were colored black. Poor CYP2D6 metabolizers (PM) and Ultra-rapid CYP2D6 metabolizers 
(UR) were colored green and red respectively; *:decrease in AUC0-24h>25% ; a total of 4 patients showed a >25% 
decrease in endoxifen AUC0-24h and 3 patients in tamoxifen AUC0-24h when tamoxifen was administered with 
curcumin and piperine compared to tamoxifen monotherapy
Toxicities
There were no unexpected serious adverse events (SAE) during combined treatment 
with curcumin or curcumin plus piperine related to the study procedures. There 
was one serious adverse event, which was assumed to be not related to any of the 
study drugs (collaps with unknown origin). Toxicity profiles were similar between the 
different treatment phases, although more hot flashes and fatigue were observed 
in patients treated with curcumin +/- piperine compared to tamoxifen monotherapy 
(Table 4). Interestingly, 3 patients suffered from grade 2-3 diarrhea during treatment 
with curcumin and piperine, whereas none of the patients experienced diarrhea when 
treated with tamoxifen monotherapy.
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TABLE 4. Toxicity
Toxicity
Tamoxifen 
monotherapy N (%)
Tamoxifen with 
curcumin N (%)
Tamoxifen with curcumin 
and piperine N (%)
Nausea 2(13) 1(6) 1(6)
Diarrhea 0 1(6) 3(19)
Constipation 2(13) 4(25) 1(6)
Fatigue 2(13) 3(19) 3(19)
Hot flashes 3(19) 5(31) 4(25)
Reflux 1(6) 1(6) 0
Dyspnea 0 1(6) 0
Anorexia 1(6) 0 1(6)
Pain 4(25) 0 2(13)
Rash 1(6) 0 1(6)
Hypophosphatemia 0 0 1(6)
Hyperlipidemia 1(6) 1(6) 1(6)
Legend: Number of patients with all CTCAE grade toxicity when treated with tamoxifen with or without curcumin and 
piperine expressed as number of patients (% of total number of patients).
DISCUSSION
In this study, a modest but significant decrease was found in both tamoxifen and 
endoxifen plasma concentrations during concomitant administration of tamoxifen and 
curcumin, compared to tamoxifen monotherapy. This effect was even more pronounced 
when tamoxifen was administered with curcumin and piperine. Furthermore, patients 
with an extensive CYP2D6 phenotype seem to be at greater risk of experiencing this 
herb-drug interaction, compared to CYP2D6 intermediate metabolizers.
Since tamoxifen metabolism and excretion is complex and involves multiple enzymes 
and transporter-proteins, the likelihood of a drug-drug interaction (DDI) with modulators 
and inhibitors of enzymes and drug-transporters (e.g. CYP3A4 and P-glycoprotein) 
involved in tamoxifen metabolism is high.7, 8 Based on preclinical data, curcumin is a 
compound which could potentially lead to such a DDI.10 When designing our study, we 
based our hypothesis on preclinical data, as no studies in cancer patients studying the 
effects of curcumin on the pharmacokinetics of anti-cancer drugs were available in the 
literature. Cho et al. demonstrated an increase in tamoxifen exposure and a decrease 
in 4-hydroxy-tamoxifen/tamoxifen AUC ratio, suggesting a decrease in CYP-mediated 
metabolism or P-glycoprotein mediated efflux of tamoxifen.9 In vitro results indicate 
an inhibitory effect of curcumin on phase II metabolism, in which enzymes such as 
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UGT are involved.10, 14 UGTs are also involved in the metabolism of tamoxifen (Figure 
1), in theory resulting in increased endoxifen plasma concentrations.10 In contrast to 
the study in rats by Cho et al., we found both a decrease in tamoxifen and endoxifen 
plasma concentrations. We do not have a conclusive explanation for this observation, 
as several mechanisms might be involved. As endoxifen plasma concentrations did not 
increase during concomitant treatment with curcumin and piperine, an inhibitory effect 
on phase II metabolism is unlikely as these results rather indicate phase II induction. 
A more likely explanation is inhibition of CYP2D6 –which is underlined by the larger 
effect in EM patients—although this cannot be the only explanation, as tamoxifen 
concentrations also decreased due to curcumin co-treatment. Another explanation 
may be found in a potential interaction with P-glycoprotein. This transporter, which 
is responsible for the efflux of tamoxifen out of the epithelial cells into the gut and 
bile, was studied before in vitro and led to contrasting results (both induction and 
inhibition).10, 15, 16 In case curcumin acts as a P-glycoprotein inducer, tamoxifen and 
metabolite plasma concentrations would all decrease, which is in line with our findings, 
resulting from a diminished absorption of tamoxifen into the blood stream.
One of the main problems of clinical research with curcumin is to standardize the 
formulation of curcumin. There are many curcumin formulations available. Potentially 
these formulations may differ in bio-availability, which makes it difficult to determine 
the individual impact of these formulations and to give a general advise.17 Moreover, 
many of these formulations exist of multiple non-standardized ingredients. In this 
study  standardized formulations of both curcumin and piperine of 1200mg and 10mg 
capsules respectively were used from a single production batch.
Moreover curcumin knows low bio-availability and the suggested interpatient 
variability is high.4, 18  We only measured tamoxifen pharmacokinetics and did not 
determine plasma levels of curcumin, which gives a possible limitation of this study 
since the magnitude of a possible interaction may differ between patients depending 
on curcumin plasma levels.18 However a curcumin dose of 3.6 g q.d. is considered 
to reach significant plasma concentrations and is therefore most likely to achieve a 
significant drug-interaction.18
Furthermore the interaction term for CYP2D6 metabolism only reached significance for 
tamoxifen AUC0-24h and Ctrough when coadministered with curcumin and piperine. Since 
the design of this study was not sufficient to detect a significant difference in other 
pharmacokinetic endoxifen and tamoxifen comparisons this result must be confirmed 
in future clinical trials.
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Besides curcumin, piperine might also influence pharmacokinetics of tamoxifen 
and endoxifen by itself.19 Piperine affects the structure of the intestinal lumen and 
wall resulting in a higher passive drug influx. Concomitant piperine use might alter 
gastric emptying time use in a dose- and time dependent manner, and in addition, 
piperine is known to be a P-glycoprotein inhibitor in vivo.19, 20 Moreover piperine might 
enhance plasma concentrations of several drugs due to inhibition of CYP enzymes 
(e.g. CYP3A4 , CYP2D6).19 Therefore the effect of piperine on tamoxifen and endoxifen 
pharmacokinetics may not be underestimated and the results in this study could not 
be solely attributed to curcumin.
Although the relatively small effects on tamoxifen and endoxifen pharmacokinetics 
and the high inter-patient variability of endoxifen (CV= 50-60%) this study may seem 
of limited clinical relevance. However, individual patients may be deprived from an 
optimal therapy, since tamoxifen and endoxifen concentrations may drop below the 
threshold for efficacy (~16 nM for endoxifen) due to co-treatment with curcumin.7, 21 
Especially, considering the fact that 20-30% of all treated patients have an endoxifen 
plasma concentration below this threshold and an additional 20% has endoxifen plasma 
concentrations just above this threshold.21-23 This scenario is in particular the case in 
patients with an extensive metabolism CYP2D6 phenotype, as effects of curcumin with 
and without piperine were most pronounced in this group of patients.
This was the first study, which investigated the influence of curcumin (with and without 
piperine) on tamoxifen pharmacokinetics. The use of curcumin (with and without 
piperine significantly decreased tamoxifen and endoxifen pharmacokinetics, especially 
in EM patients. Patients may be deprived from optimal tamoxifen treatment and 
endoxifen plasma levels may even drop below the threshold for treatment efficacy. 
Therefore patients should be advised to stop curcumin use during tamoxifen treatment 
or treatment efficacy of tamoxifen should be adequately monitored.
MATERIALS AND METHODS
This 2-arm, 3-period, randomized, cross-over study was performed between January 
2017 and May 2018 at the Erasmus University Medical Center. The study was approved 
by the local ethics committee and competent authority in accordance to the declaration 
of Helsinki and was registered at the European Clinical Trials Database (EudraCT 2016-
004008-71) and the Dutch trial registry (www.trialregister.nl; number NTR6149).
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Patients
We included patients who had a histological or cytological confirmed diagnosis of 
breast cancer with an indication for tamoxifen treatment and who were at least 18 
years of age. In addition, an Eastern Cooperative Oncology Group (ECOG) performance 
status of 0 or 1, adequate hematological, renal, and liver function defined as a CTCAE 
grade of ≤ 1 were required, and patients should be able and willing to abstain from 
curry, grapefruit (juice), (herbal) dietary supplements, herbals or over-the-counter 
medication (except for paracetamol and ibuprofen) for the duration of the study. 
Patients were excluded if they had known impaired drug absorption (e.g. gastrectomy), 
serious illness or medical unstable conditions requiring treatment (e.g. infection, heart 
failure) or if they used strong CYP3A4, CYP2D6, UGT or P-glycoprotein inhibitors or 
inducers. All included patients gave written informed consent.
Study procedures
Patients received tamoxifen at the same dose for at least 28 days before entering the 
study to ensure steady-state pharmacokinetics. No dose alterations were allowed after 
inclusion in the study. Patients were digitally randomly assigned into two sequence 
groups, using block randomization, to rule out sequence effects. Tamoxifen was 
administered at a constant dose (20-30 mg q.d.) during three consecutive cycles. During 
cycle 1, patients received tamoxifen monotherapy; in cycle 2, patients swallowed 
tamoxifen concomitant with curcumin (three times daily 1,200 mg), and in cycle 3, 
tamoxifen was taken concomitantly with curcumin and piperine (three times daily 
1,200 mg and three times daily 10 mg,  respectively) in the first sequence group or vice 
versa in the other group. Curcumin and piperine were taken at predefined time points 
(10 AM, 4 PM, and 10 PM). Patient compliance was assessed through a patient diary 
until end of study after three consecutive cycles. Furthermore CYP2D6 and CYP3A4*22 
mutational analysis was performed.
Pharmacokinetic sampling
Patients were admitted to the hospital on days 28, 56, and 84 of the study for 
pharmacokinetic blood sampling. Blood samples for determination of tamoxifen, 
4-hydroxytamoxifen, n-desmethyl-tamoxifen, and endoxifen pharmacokinetics were 
obtained at predefined time points (t=0 (before tamoxifen intake); and 0.5h; 1h; 1.5h; 
2h, 2.5h; 3h; 3.5h; 4h; 6h; 8h; 12h, and 24h after tamoxifen intake). Blood samples were 
processed into plasma within 30 minutes by vortex mixing and centrifugation for 10 
min at 2,500-3,000 g at 4°C. Plasma concentrations were measured using a validated 
liquid chromatography with tandem mass spectrometry method (UP-LCMS/MS).24 
Predefined pharmacokinetic parameters were tamoxifen and endoxifen exposure 
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(expressed as dose corrected area under the curve from pre-infusion time point until 
24h (AUC0-24h)), maximum concentration (Cmax), time until maximum concentration (Tmax) 
and lowest plasma concentration (Ctrough).
Toxicity
Toxicity rates during tamoxifen monotherapy and tamoxifen concomitantly with 
curcumin with or without piperine were determined during patient follow-up until 
the end of the study using  Common Terminology Criteria for Adverse Events (CTCAE 
version 4.0), and by evaluating the patient diaries.
Statistical analysis
A difference in systemic exposure (AUC0-24h) to endoxifen of 25% between treatment 
cycles was considered to be clinically relevant. It was assumed that the within patient 
standard deviation in endoxifen pharmacokinetics was 20%.25 Given a power of 80%, 
this resulted in a sample size of 16 evaluable patients.26
Analyses of AUC0-24h , Ctrough and Cmax were performed on log-transformed observations 
since these were assumed to follow a log-normal distribution.27  Estimates for the mean 
differences in (log) AUC0-24h, Ctrough and Cmax were obtained for the two comparisons (i.e. 
curcumin versus tamoxifen monotherapy, and curcumin plus piperine versus tamoxifen 
monotherapy) separately using a linear mixed effect model with treatment, sequence, 
and period as fixed effects and subject within sequence as a random effect.28 Variance 
components were estimated based on restricted maximum likelihood (REML) methods, 
and the Kenward-Roger method of computing the denominator degrees of freedom 
was used.28 Since two primary comparisons were made, a Bonferroni correction 
was applied to correct for multiple testing (two-sided alpha of 5%/2=2.5%). Tmax was 
analyzed by means of the Wilcoxon signed rank test and described with medians and 
interquartile ranges .
For a comparison between extensive and intermediate CYP2D6 phenotype an 
interaction term between metabolism and treatment was added to the linear mixed 
effects models. Only if the interaction term turned out to be significant, subsequent 
subgroup analyses were performed.
Toxicity was described as the incidence of toxicity per phase. This was corrected for 
baseline toxicity and was only taken into account in case of an increase in CTCAE grade 
per cycle. Since the design of this study was not appropriate to detect a significant 
difference in toxicity, these results had a descriptive character.
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CONCLUSION
In conclusion, this is the first study in patients, which investigated the influence of 
curcumin (with and without piperine) on tamoxifen pharmacokinetics. Curcumin 
(with and without piperine) significantly decreased tamoxifen and endoxifen 
pharmacokinetics, especially in EM patients. Therefore patients using curcumin should 
be adequately monitored or should be advised to stop curcumin use during tamoxifen 
treatment.
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ABSTRACT
Background. Many cancer patients use additional herbs or supplements in combination 
with their anti-cancer therapy. Green tea – active ingredient epigallocatechin-3-gallate 
(EGCG) – is one of the most commonly used dietary supplements among breast cancer 
patients. EGCG may alter the metabolism of tamoxifen. Therefore, the aim of this study 
was to investigate the influence of green tea supplements on the pharmacokinetics of 
endoxifen; the most relevant active metabolite of tamoxifen.
Methods. In this single center, randomized cross-over trial, effects of green tea 
capsules on endoxifen levels were evaluated. Patients treated with tamoxifen for at 
least 3 months were eligible for this study. After inclusion, patients were consecutively 
treated with tamoxifen monotherapy for 28 days and in combination with green tea 
supplements (1 g twice daily; containing 300 mg EGCG) for 14 days (or vice versa). Blood 
samples were collected on the last day of monotherapy or combination therapy. Area 
under the curve (AUC0-24h), maximum concentration (Cmax) and minimum concentration 
(Ctrough) were obtained from individual plasma concentration-time curves.
Results. No difference was found in geometric mean endoxifen AUC0-24h in the period 
with green tea versus tamoxifen monotherapy (-0.4%; 95% CI: -8.6 – 8.5%; p=0.92). 
Furthermore, no differences in Cmax (-2.8%; -10.6 – 5.6%; p=0.47) nor Ctrough (1.2%; -7.3 
– 10.5%; p=0.77) were found. Moreover, no severe toxicity was reported during the 
whole study period.
Conclusions. This study demonstrated the absence of a pharmacokinetic interaction 
between green tea supplements and tamoxifen. Therefore, the use of green tea by 
patients with tamoxifen does not have to be discouraged.
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INTRODUCTION
Breast cancer is the most commonly diagnosed type of cancer among women.1 In 
the adjuvant treatment of hormone sensitive breast cancer, tamoxifen is the most 
frequently used and an effective oral endocrine therapy.2 Many cancer patients – with 
estimates up to 80% – use complementary and alternative medicines in combination 
with their anti-cancer therapy.3–7 One of the most popular herbal supplements among 
breast cancer patients are green tea (camellia sinensis) supplements.4,5,8
Green tea contains a large number of bioactive compounds, such as catechins and 
flavonoids.9,10 The active pharmacological ingredient of green tea is epigallocatechin-
3-gallate (EGCG).11 EGCG is believed to contribute to various cancer-preventive effects 
resulting from its high antioxidant potential.11–14 In vitro and animal studies reported 
a number of cancer-preventative effects of EGCG including: attenuation of oxidative 
stress, inhibition of angiogenesis, induction of apoptosis and alterations in expression 
of cell cycle regulatory proteins.11,12,14–17 None of these effects have been proven 
clinically. However, there are also signs that green tea and associated substances can 
influence other prescribed drugs. For example, it has been reported that EGCG could 
significantly reduce the systemic exposure of nadolol, folic acid and digoxin in subjects 
with approximately 85%, 39% and 31%, respectively.18–20 Moreover, EGCG significantly 
increased the bioavailability of for example simvastatin and verapamil in rat studies.21,22 
The described interactions with these drugs are the result of altered bioavailability or 
decreased metabolism, and can mechanistically be explained by inhibition of influx 
transporter organic anion transporter polypeptide (OATP) or efflux transporter 
P-glycoprotein  and several phase I and II metabolizing enzymes (e.g. cytochrome P450 
(CYP) 3A and UDP-glucuronosyltransferase (UGT)).18–27 Simultaneous administration 
with green tea is therefore not recommended for these drugs.  However, the impact of 
green tea on tamoxifen pharmacokinetics remains unclear.
Tamoxifen pharmacokinetics depend on a multi-pathway biotransformation (Figure 1).28 
After hepatic uptake by – among others – OATP1B1, the cytochrome P450 iso-enzymes 
CYP2D6 and CYP3A4 metabolize tamoxifen into the main metabolite endoxifen.28–31 
Endoxifen is ultimately glucuronidated by UGT into an inactive metabolite and excreted 
through bile and feces.30 In view of the involvement of drug transporting proteins 
and metabolizing enzymes, green tea could potentially interfere with the tamoxifen 
metabolism. Herb-drug interactions with tamoxifen could negatively impact the 
pharmacokinetic profile, as was previously shown with the combination of tamoxifen 
and curcumin.32 Therefore, the primary objective of this study was to evaluate the 
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possible pharmacokinetic interaction between green tea supplements and tamoxifen. 
The secondary objective was to assess the safety profile of green tea in combination 
with tamoxifen.
Phase II metabolism Phase I metabolism
P-gp
OATP
Absorption into 
circulatory tract
Blood vesselIntestine
Liver
Basal 
membrane
Apical 
membrane
CYP3A4
CYP2D6
UGT
Excretion of
 inactive metabolites
Tamoxifen
EndoxifenEndoxifen
FIGURE 1: Main metabolism pathway of tamoxifen. After absorption tamoxifen is metabolized mainly by 
CYP2D6 in its active metabolite endoxifen. Tamoxifen relies on phase II metabolism before it can be excreted 
from the body. Endoxifen is ultimately glucuronidated into endoxifen-glucuronide mainly by UGTs. Several in 
vitro studies suggest inhibition by green tea of several phase I enzymes (CYP2D6 and CYP3A4) and inhibition 
of several drug-transporters which the efflux transporter P-gP (ABCB1) and sever influx-transporters like 
OATP. P-gP, P-glycoprotein; CYP, cytochrome P450; OATP, organic anion transporting polypeptide; UGT, UDP-
glucuronosyltransferase.
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METHODS
Study design
This single-center, randomized, two-armed, open-label, pharmacokinetic cross-over 
trial aimed to investigate the endoxifen exposure in breast cancer participants using 
tamoxifen with or without green tea. The study protocol was written in conformity with 
the declaration of Helsinki and approved by the local medical ethics committee and 
registered at the Netherlands Trial Registry (number NL8144). Enrollment took place 
after written informed consent at the Erasmus University Medical Center, Rotterdam, 
The Netherlands. Patients with a confirmed histological or cytological diagnosis of 
primary breast cancer, a World Health Organization (WHO) performance status of ≤ 1 
and on tamoxifen treatment at a stable dose of 20 or 40 mg q.d. for at least 3 months 
(ensuring steady-state concentration) were included. Participant demographics, 
medical history, CYP2D6 phenotype status and serum biochemistry were assessed 
before study entry. Participants were excluded if they were CYP2D6 poor or ultra-rapid 
metabolizers or if they had an impaired drug absorption. Furthermore, all participants 
were required to abstain from herbal or dietary supplements and strong inhibitors or 
inducers of CYP3A4, CYP2D6, UGT and P-glycoprotein. Depending on randomization, 
participants either started with tamoxifen monotherapy (20 or 40 mg q.d.; 10 AM) for 
28 consecutive days or tamoxifen and green tea (1000 mg b.i.d.; containing 150 mg of 
EGCG; 10 AM and 10 PM) concomitantly for 14 consecutive days. This dose of green 
tea capsules is equivalent to approximately 5-6 cups of regular green tea and is also 
in line with previous clinical studies. Thereafter, participants received tamoxifen and 
green tea concomitantly for 14 consecutive days or tamoxifen monotherapy for 28 
days, respectively. The green tea capsules were manufactured by a qualified Dutch 
Pharmacy (NatuurApotheek, Pijnacker, the Netherlands) and the batch was provided 
with a certificate of analysis for verification of the EGCG content. Participants were 
hospitalized for 24-hour pharmacokinetic blood sampling on days 14 and 42, after 
one night of fasting. Blood samples were collected periodically at 13 predefined time 
points (t=0; 0.5; 1.5; 2; 2.5; 3; 3.5; 4; 6; 8; 12 and 24 h after tamoxifen intake) and after 
processing to plasma stored at -80 °C until analysis. Plasma samples were analyzed by 
a validated liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method 
in accordance with U.S. Food and Drug Administration (FDA) bioanalytical method 
validation guidelines.33 Adverse events were graded using the Common Terminology 
Criteria for Adverse Events version 5.0 (CTCAEv.5, National Cancer Institute, Bethesda, 
MD, USA).
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Pharmacokinetic analysis
A non-compartmental pharmacokinetic analysis of steady-state concentrations was 
performed using Phoenix WinNonlin version 8.1 (Pharsight, a Certara Company, 
Princeton, NJ, USA). Main pharmacokinetic parameters including area under the 
curve (AUC0-24h), maximum observed concentration (Cmax) and minimum observed 
concentration (Ctrough) were constructed by individual plasma concentration-time 
curves.
Statistical analysis
The main objective of this trial was to compare the concentration of endoxifen with 
and without green tea supplements by comparing the AUC0–24h between days 14 and 
42, where one comparison was made: endoxifen monotherapy versus combined with 
green tea supplements. A relative difference in AUC0–24h of at least 25% was considered 
to be clinically relevant and the within-patient deviation was assumed to be 20%. 
Given a power of 90% and a two-sided alpha of 5%, this resulted in a sample size of 
14 evaluable patients (7 in both treatment arms). Analyses of AUC of tamoxifen, and 
Ctrough and Cmax of both endoxifen and tamoxifen were performed on log-transformed 
observations since these are assumed to follow a log-normal distribution. Estimates for 
the mean differences in Ctrough and Cmax were obtained for one comparison (tamoxifen 
concomitantly with green tea monotherapy versus tamoxifen monotherapy) separately 
using a linear mixed effect model treatment with sequence, and period as fixed effects 
and subject within sequence as a random effect. Variance components were estimated 
based on restricted maximum likelihood (REML) methods, and the Kenward-Roger 
method of computing the denominator degrees of freedom was used. The antilog were 
taken from the effect estimate and corresponding 95% confidence interval boundaries 
for the comparisons of tamoxifen concomitantly with green tea versus tamoxifen 
monotherapy to interpret the results (interpreted as ratios of the geometric means).
RESULTS
Trial participants
Between October 2019 and February 2020, a total of 14 breast cancer patients were 
enrolled. All participants completed this trial and were evaluable. An overview of 
baseline characteristics is presented in Table 1. Participants were predominantly 
of Caucasian origin (86%) and were extensive metabolizers of CYP2D6 (79%). All 
participants were treated with adjuvant tamoxifen in this trial. The vast majority of 
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patients used tamoxifen in a dose of 20 mg once daily (93%) and one patient used 
tamoxifen in a dose of 40 mg once daily (7%). In addition, the median duration of 
tamoxifen use before enrollment in this trial was 11.8 (range 6.0 – 12.9) months.
TABLE 1.  Baseline characteristics of evaluable participants (n=14).
Characteristic N (%) or median (range)
Sex
Female
Male
14
0
(100%)
(0%)
Age, years 58.5  (50.8 – 68.3)
BMI, kg·m-2 27.4 (23.9 – 28.5)
WHO performance status
0
1
12
2          
(86%)
(14%)
Ethnic origin
Caucasian
Afro-Caribbean
12
2 
(86%)
(14%)
CYP2D6 phenotype
EM
IM
11
3       
(79%)
(21%)
Biochemistry
AST (U/L)
ALT (U/L)
ALP (U/L)
GGT (U/L)
Total bilirubin (µmol/L)
Albumin (g/L)
LD (U/L)
Hb (mmol/L)
Creatinine (µmol/L)
21
15
53.5
21
6
36
189
8.1
76.5   
(17.8 – 27.0)
(11.8 – 21.0)
(43 – 67)
(16.5 – 29.5)
(5.3 – 8.5)
(35 – 37)
(181.5 – 196.5)
(7.7 – 8.3)
(71.8 – 87.3)
Previous treatment
Surgery
Radiotherapy
Chemotherapy
14
9
3       
(100%)
(64%)
(21%)
Tamoxifen dose
20 mg
40 mg
13
1         
(93%)
(7%)
Duration of adjuvant tamoxifen use, months 11.8   (6.0 - 12.9)
BMI, body mass index; EM, extensive metabolism; IM, intermediate metabolism; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyltransferase; LD, lactate dehydrogenase; 
Hb, hemoglobin.
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Pharmacokinetics
Tamoxifen and endoxifen levels were detectable in all collected blood samples. 
Estimates of main pharmacokinetic parameters for tamoxifen monotherapy versus 
tamoxifen with green tea supplements are presented in Table 2. The individual AUC 
values for endoxifen and tamoxifen exposure without and with green tea supplements 
are displayed in Figure 2 and 3. The geometric mean of endoxifen AUC0-24h during 
concomitant administration of green tea was comparable to tamoxifen monotherapy 
(746 nmol.h.L-1 ; coefficient of variation (CV): 38.6% vs 749 nmol.h.L-1; CV 41.1%). The 
corresponding relative difference (RD) in endoxifen AUC0-24h between the cycle with and 
without green tea was -0.4% (95% CI: -8.6 – 8.5%; p=0.92). Endoxifen geometric means 
of Cmax  38.5 nmol/L; CV 37.3% vs 39.6 nmol/L; CV 41.7% and Ctrough 32.2 nmol/L; CV 
34.1% vs 31.9 nmol/L; CV 39.8% also did not significantly differ between with or without 
green tea.
The plasma pharmacokinetic parameters of tamoxifen showed a clear resemblance in 
AUC0-24h with and without green tea (RD 4.1% (95% CI: -6.6 – 16.1%; p=0.44). Likewise, 
the determined relative difference of tamoxifen Cmax (RD -2.2% (95% CI: -11.8 – 8.4%; 
p=0.64) and Ctrough (RD 6.2% (95% CI: -6.8 – 20.9%; p=0.34) also shared similar results 
between both treatments. No differences between CYP2D6 phenotype groups and 
endoxifen exposure was found.
TABLE 2. Main pharmacokinetic parameters of tamoxifen and endoxifen.
PK parameters
Tamoxifen 
monotherapya
Tamoxifen with 
green teaa p-value
Relative difference (%)
(95% CI)
Endoxifen
AUC0–24h (nmol·h·L
-1) 749 (41.1) 746 (38.6) 0.92 -0.4 (-8.6 – 8.5)
Cmax (nmol/L) 39.6 (41.7) 38.5 (37.3) 0.47 -2.8 (-10.6 – 5.6)
Cmin (nmol/L) 31.9 (39.8) 32.2 (34.1) 0.77  1.2 (-7.3 – 10.5)
Tamoxifen
AUC0–24h (nmol·h·L
-1) 6867 (26.1) 7150 (22.9) 0.44 4.1 (-6.6 – 16.1)
 Cmax (nmol/L) 401.5 (28.1) 392.6 (25.1) 0.64 -2.2 (-11.8 – 8.4)
Cmin (nmol/mL) 257.1 (35.6) 273.0 (24.4) 0.34 6.2 (-6.8 – 20.9)
PK, pharmacokinetic; CI, confidence interval; AUC, area under the plasma-concentration time curve; Cmax, maximum 
observed concentration; Cmin, minimum observed concentration.
a = values are geometric mean (% coefficient of variation).
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FIGURE 2: Pharmacokinetics of endoxifen without and with concomitant green tea supplements.
FIGURE 3: Pharmacokinetics of tamoxifen without and with concomitant green tea supplements.
Treatment-related adverse events
An overview of treatment-related adverse events is presented in Table 3. Headache, 
gastro-intestinal side-effects (e.g. constipation and dyspepsia) and polyuria were 
reported more often during the treatment with green tea vs tamoxifen monotherapy. 
A few changes in liver biochemical parameters (AST, ALT, GGT) occurred during 
administration with green tea, as well as a creatinine increase and platelet count 
decrease. Hot flashes were the most reported side-effects, but its occurrence count 
remained the same independent of green tea consumption. Adverse events were mild 
and serious adverse events (grade 3 or higher) were not observed during the study 
period.
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TABLE 3. Treatment-related adverse events, graded according to CTCAEv.5
Adverse event Tamoxifen monotherapy (N) Tamoxifen with green tea (N) 
Grade 1  
General 
Abdominal pain 2
Headache 2 4
Hot flashes 5 5
Restlessness 1
Gastro-intestinal 
Nausea  1
Dyspepsia 1
Gastroesophageal reflux 1
Constipation 1
Belching 1
Bloating 1
Urogenital 
Polyuria 3
Irregular menstruation 1
Menorrhagia 1 1
Biochemistry
ASAT increased 1
ALAT increased 1
GGT increased 1
Creatinine increased 1
Platelet count decreased 2
Grade ≥3 0 0
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; GGT, gamma-glutamyltransferase.
DISCUSSION
This randomized, cross-over, pharmacokinetic study clearly demonstrated that 
green tea supplements did not cause a pharmacokinetic interaction with tamoxifen 
or endoxifen in breast cancer patients. Therefore, we can conclude that tamoxifen 
absorption and metabolism were not affected by green tea from a pharmacokinetic 
point of view. Furthermore, serious or severe green tea related adverse events were 
not reported during the whole study period.
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These results were unexpected as preclinical studies showed that green tea did 
modify important targets of tamoxifen metabolism (e.g. OATP, P-glycoprotein, UGT 
and CYP enzymes).23,25–27,34 Several mechanisms for drug interactions resulting in 
an altered bioavailability or metabolism have been reported, including inhibition of 
influx- or efflux-transporters and cytochrome P450 enzymes.18–22 Furthermore, other 
green tea-drug combinations were previously studied in humans, and significant 
herb-drug interactions with clinical implications were found.18,20 Consequently, it 
was hypothesized that green tea would induce changes in the systemic exposure of 
tamoxifen and endoxifen, but no differences in endoxifen and tamoxifen exposure 
between the phase with and without green tea were found in this study.
The non-significant effect is not consistent with the outcomes of a study that reported 
EGCG (range 3 to 10 mg/kg) significantly altered the pharmacokinetic parameters 
of tamoxifen in rats.35 This animal study suggested that EGCG might be effective to 
obstruct CYP3A4-mediated metabolism and P-glycoprotein mediated efflux pathways 
in the intestine and liver. However, a lower dose EGCG (0.5 mg/kg) did not significantly 
alter the metabolite formation of tamoxifen in rats.35 This phenomenon suggests a 
dose-dependent effect of EGCG on the pharmacokinetic profile of tamoxifen. In this 
trial,  the EGCG dose used is equivalent to a dose of approximately 4 mg/kg.
In this study a commercially available green tea extract was administered, in what is 
considered a high, but safe dose for humans (2000 mg green tea per day of which 
300 mg is EGCG) and in line with dosages used in previous clinical studies and with 
what we observe in breast cancer patients in our out-patient clinic. 10,35–39 This EGCG 
dose is equivalent to approximately about 5-6 cups of green tea.  According to the 
European Food and Safety Association (European agency funded by the European 
Union) 300 mg EGCG is comparable to the maximum mean daily EGCG intake from the 
consumption of regular green tea in beverage form.38 However, it is worth noting that 
routes of administration other than green tea supplements (e.g. green tea beverages) 
may in theory affect green tea absorption and bioavailability and therefore may affect 
tamoxifen pharmacokinetics. Therefore, it is possible that green tea beverages show 
a different bioavailability of EGCG  compared with green tea capsules. However a 
possible interaction with the green tea beverage less likely since similar EGCG levels 
are likely to be obtained in human plasma.    Apparently, administration of green tea 
capsules influence the phase II metabolism of tamoxifen to a very limited extend.
The main reported adverse events in this trial were headaches, hot flashes, gastro-
intestinal toxicity, polyuria and minor abnormalities in liver biochemical parameters. 
The incidences of headache, polyuria, gastro-intestinal adverse events and minor liver 
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biochemical disturbances were increased in the green tea phase, whereas abdominal 
pain was more present without green tea. All reported adverse events during this 
study were mild (grade 1). Previous studies found similar gastro-intestinal and hepatic 
adverse events related to the administration of high doses of green tea.36,37,40 In 
addition, headache, polyuria and restlessness are well-known side-effects of caffeine, 
one of the substituents of green tea supplements (140 mg per day, equivalent to 
approximately 200 mL of filtered coffee). These green tea related adverse events 
suggest that green tea was sufficiently absorbed, which is important because of its low 
oral bioavailability.13,41,42 To ensure adequate green tea absorption, we administered 
the daily dose in two dosages and patients with known impaired drug absorption were 
excluded.
In conclusion, this study clearly indicated that tamoxifen and endoxifen pharmacokinetics 
were not affected by green tea supplements. Concomitant treatment with green tea 
and tamoxifen was well-tolerated in this real-life breast cancer cohort. Therefore, the 
use of green tea among breast cancer patients does not have to be actively discouraged 
by physicians.
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In this thesis pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) 
and drug-food interactions (DFIs) with several commonly prescribed anti-cancer 
drugs have been addressed. This chapter gives a general overview of this thesis with 
an in-depth discussion of the individual chapters. Furthermore, recommendations and 
future perspectives on the management and investigation of these interactions will be 
presented.
PART I: DRUG-DRUG INTERACTIONS (DDIS)
A drug interaction is defined as the pharmacological or clinical response to the 
administration or co-exposure of a drug with another substance that modifies the 
patient’s response to the drug.1 In the case of a drug-drug interaction, the interacting 
substance is another drug used by the patient. There are several risk factors for 
experiencing a drug interaction in clinical practice such as age and polypharmacy, but 
also cancer patients in general are at an increased risk, because they often use multiple 
drugs as part of their cancer treatment or for the management of comorbidity.2,3
Drug interactions intervene with the pharmacokinetic or pharmacodynamic 
mechanisms of drugs. Pharmacokinetic drug interactions involve the absorption, 
distribution, metabolism and/or excretion of drugs resulting in altered plasma 
concentrations, which results in possible wanted (e.g. increased efficacy) or unwanted 
effects (e.g. increase of side-effects). Pharmacodynamic drug-interactions occur when 
two drugs have similar molecular targets, which may result in an increase in toxicity 
or response to these agents.1,4 In Chapter 2 the drug-drug interaction potential of 29 
small molecule kinase inhibitors (SMKIs), including the tyrosine kinase inhibitors (TKIs) 
is described. The main interaction categories are pH-dependent drug-interactions, 
drug-transporter interactions and interactions with drug metabolism. Many SMKIs 
show pH-dependent solubility resulting in a decreased plasma exposure when co-
administered with acid-suppressive medication like proton pump inhibitors (PPIs). For 
example gefitinib, a TKI used in the treatment of non-small cell lung cancer (NSCLC), 
shows a decrease in plasma exposure of 47% when co-administered with the PPI 
lansoprazole or esomeprazole.5 However, for many TKIs like tivozanib and ruxolitinib, 
clinical data is missing and the current advice regarding these interactions is only 
based on chemical (Pka, acid-dissociation constant) data. Also for drug-transporter 
interactions clinical data is frequently missing. These interactions may have a major 
impact on drug pharmacokinetics as is the case for the SMKIs lapatinib and vemurafenib 
(P-gp inhibitors), regorafenib (BCRP-inhibitor) and nintedanib (a P-gp substrate). 
Finally, SMKIs are prone to drug interactions involving drug metabolism, which gives 
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either inhibition or induction of phase I (cytochrome P450 enzymes) or phase II drug 
metabolism (e.g. glucuronidases and sulfatases). Especially bosutinib, cobimetinib, 
crizotinib, gefitinib, ibrutinib, and nilotinib are highly prone for clinically relevant drug 
interactions regarding drug metabolism. In conclusion, most SMKIs are prone for DDIs, 
which may result in an altered systemic exposure. Taken into account that about 34% of 
all the treated patients is underdosed during treatment,6 it is important to accomplish 
optimal individual exposure to SMKIs and to provide the right dose for each individual 
patient. Therefore, clinicians always need to pay attention to DDIs since they may have 
a major impact on drug pharmacokinetics and thus efficacy and/or toxicity. One of the 
possible solutions for the management of these interactions is the use of therapeutic 
drug monitoring (TDM).7,8 TDM has proven its additional value for several drugs like 
tamoxifen and pazopanib, where a significant recurrence benefit was found when drug 
concentrations were above a certain threshold.9,10 Overall, there is lack of decent clinical 
drug interaction studies with SMKIs, especially for drug-transporter interactions and 
interactions with acid-suppressive medication. Therefore, it is necessary to perform 
more clinical studies to better understand the underlying mechanisms and advise both 
clinicians and patients.
There is some evidence suggesting a survival benefit for patients treated with SMKI 
monotherapy compared to SMKI therapy concomitantly taken with a PPI. For example, 
Mir et al. 11 found a significant difference in median overall survival (OS) in patients 
treated with pazopanib using acid-suppressive agents compared to patients without 
an acid-suppressive agent of 8.0 vs 12.6 months (HR, 1.81; 95% CI, 1.31–2.49; P < 0.01), 
with duration of treatment with acid-suppressive agents as a significant risk factor for 
a worse outcome. There are other examples of anti-cancer drugs besides the SMKIs, 
which also show a decrease in survival when treated with acid-suppressive agents. For 
example, Chu et al.12 demonstrated a significant survival difference for capecitabine, 
an oral chemotherapeutic agent used in the treatment of colorectal cancer among 
others, when co-administered with PPIs compared to capecitabine without PPIs. 
They found that patients treated with a PPI had a worse progression free survival 
(PFS) (HR: 1.68; 95% CI, 1.42-1.94; P < 0.001) and overall survival (HR: 1.41; 95% CI, 
1.11-1.71; P = 0.001) compared to capecitabine without a PPI suggesting a significant 
DDI between capecitabine and PPIs. However, Chapter 3 describes many remarks 
to this study by Chu et al. PPI use was defined as 20% or more overlap between PPI 
prescription and trial treatment duration. However, total PPI duration was not taken 
into account in the primary analysis. Furthermore, both PPI dose and type of PPI were 
not taken into account, even though there is a significant difference in acid suppression 
among various PPI variants and also the PPI dose is positively correlated with both 
magnitude and duration of gastric acid suppression.13,14 Moreover, time of intake of 
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both capecitabine and PPIs was not taken into account, which is of clinical relevance 
since PPIs reach their maximum pH elevating effects 2-4 hours after administration and 
their pH-elevating effects change during the day.15 Because of the complex mechanism 
involved in this interaction, there is a need for a more standardized research method 
for the investigation of a possible drug-interaction with PPIs.
An example of a new method to investigate a potential drug-interaction with PPIs is 
provided in Chapter 4 of this thesis. Regorafenib, a multi-kinase inhibitor used in the 
treatment of several tumor types such as colorectal carcinoma and hepatocellular 
carcinoma, has a predicted pKa of around 2, suggesting a minor influence of the 
gastrointestinal pH on the absorption of the drug.16-18 In this pharmacokinetic 
cross-over study, fourteen patients were consecutively treated with regorafenib 
monotherapy, regorafenib concomitantly with esomeprazole, and regorafenib three 
hours after esomeprazole intake (in this order or vice versa). In this study, no difference 
in regorafenib plasma area under the curve (AUC0-24h) was found for regorafenib 
monotherapy compared with concomitant esomeprazole (relative difference: −3.9%; 
95%CI: −20.5 to 16.1%; P = 1.0) or compared with regorafenib with esomeprazole three 
hours prior to regorafenib intake (relative difference: −4.1%; 95% CI: −22.8 to 19.2%; 
P = 1.0). These findings indicate that regorafenib can be safely combined with PPIs at 
all timepoints. This study demonstrates that this study design can serve as a template 
for future studies investigating the influence of PPIs on the pharmacokinetics of anti-
cancer agents. This was not unexpected since regorafenib exhibits a low solubility in 
general, which is due to its complex chemical structure where no acidic or basic group 
is attached.18 As esomeprazole was used, which is the strongest pH-elevating  PPI,15,19 
we expect these findings to be generalizable for other PPIs. Nevertheless, results 
of this study are not by definition applicable to other acid-suppressive compounds. 
Esomeprazole is a known inhibitor of CYP2C19, but it is not known to induce or inhibit 
drug-transporters or enzymes involved in the pharmacokinetics of regorafenib, making 
a potential DDI most likely caused by an alteration in stomach pH. For example H2-
receptor antagonists, such as pantoprazole may still cause a DDI with regorafenib, 
since regorafenib is a substrate for P-gp (ABCB1) and pantoprazole inhibits this drug-
transporter.20 By inhibition of this transporter, a significant alteration in regorafenib 
plasma exposure may still occur.
Unlike interactions at the level of drug absorption, there is more clinical evidence 
regarding drug metabolism interactions, i.e. interactions that involve phase I or phase II 
metabolism. Most drugs are metabolized in the liver by enzymes of the cytochrome P450 
system of which CYP3A4 usually is the most important. Many anti-cancer agents, such 
as the taxanes (e.g. docetaxel and cabazitaxel) display CYP3A4-dependent metabolism 
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in the liver and are thus prone for DDIs with drugs that induce or inhibit the CYP3A4 
enzyme. For example enzalutamide, used in combination with taxanes in the treatment 
of metastatic castration-resistent prostate cancer (mCRPC), amongst others decreases 
the AUC0-24h with 22% for cabazitaxel compared to cabazitaxel monotherapy.
21 Another 
taxane, which is often prescribed in the treatment of metastatic prostate cancer, is 
docetaxel.22 Two large trials investigated the value of docetaxel in the hormone-
sensitive setting; one trial used docetaxel in combination with prednisone and one trial 
used docetaxel without prednisone.23,24 Both trials showed a similar overall survival 
benefit of 13.4 and 15.0 months respectively, which raised the question whether 
prednisone could be removed from the regular docetaxel treatment. Furthermore 
prednisone, like many corticosteroids, is a mild CYP3A4 inducer and therefore may 
decrease docetaxel exposure.25,26 In Chapter 5 our cross-over study in 18 patients with 
metastatic hormone-sensitive prostate cancer showed similar docetaxel concentrations 
with (AUC0-inf 2784 ng*h/mL, 95%CI: 2436-3183 ng*h/mL) or without (AUC0-inf 2647 ng*h/
mL, 95%CI: 2377-2949 ng*h/mL) concomitant prednisone treatment. Furthermore, 
no difference in toxicity between the treatment regimens was observed. Therefore it 
can be stated that, from a pharmacokinetic point of view, prednisone can be safely 
removed from the treatment with docetaxel in patients with mCRPC. The major benefit 
of administering docetaxel without prednisone is the prevention of long-term side-
effects of prednisone such as osteoporosis and adrenal insufficiency.27,28 However, 
this study was only designed to detect a difference in pharmacokinetics and therefore 
more research is needed to detect a possible difference in toxicity or survival. In the 
literature there is an ongoing debate about the utility of prednisone, since prednisone 
may have an anti-tumor effect by itself and decreases the PSA level in about 15% of the 
patients.29 Furthermore prednisone is believed to reduce taxane-induced toxicity such 
as fatigue.30 However a clear survival benefit from the addition of prednisone is not 
yet found, when combined with chemotherapy in mCRPC patients.23,31 Additionally, no 
difference in toxicity was observed when treating patients with or without prednisone 
and also long-term prednisone use is thought to promote resistance mechanisms to 
taxane therapy. 23,32
A narrow therapeutic window can increase the risk of a significant DDI, especially 
when this applies to both interacting drugs. SMKIs, for example, are known to have 
a small therapeutic window and an increase or decrease in plasma exposure may 
therefore have a significant impact on both therapy efficacy and patient wellbeing.33 
An example of a clinical situation where this balance is very delicate, is the oncological 
treatment of transplanted patients with SMKIs and immunosuppressant drugs (e.g. 
tacrolimus). Immunosuppressant drugs often show similar pharmacokinetic pathways 
as several anti-cancer drugs among which the SMKIs and are highly prone to clinically 
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relevant drug interactions.34 For instance, patients with hepatocellular carcinoma (HCC) 
sometimes undergo liver transplantation as an initial treatment for their HCC, after 
which immunosuppressant therapy is started.35 Unfortunately, 20% of these patients 
develop an HCC recurrence in the transplanted liver and need systemic anti-cancer 
treatment.36 In the case of a recurrence, patients are often treated with sorafenib, 
which may lead to severe toxicity (e.g. rash, hypertension) despite the known survival 
benefit.37,38 Sorafenib, similar to most immunosuppressants, is mainly metabolized by 
CYP3A4 into several metabolites, which increases the risk for a DDI since both drugs 
are a substrate of the same enzyme. Chapter 6 describes four patients who used 
sorafenib in combination with immunosuppressant drugs. We found that the sorafenib 
concentration decreased over time when combined with immunosuppressant drugs, 
without major effects on tacrolimus plasma levels. Treatment of patients with HCC 
recurrence after liver transplantation remains controversial, since there is a clear lack 
of knowledge in managing this interaction. An explanation for the interaction is auto-
induction of CYP3A4 by sorafenib, which results in an increased sorafenib metabolism 
over time. This principle was shown for imatinib and may apply to sorafenib as well.39,40 
This study offers the first evidence, although it has to be confirmed in a larger clinical 
study, that combining immunosuppressant drugs with sorafenib decreases sorafenib 
plasma exposure over time. Interestingly, all patients in this study experienced severe 
side-effects when administered more than 400 mg of sorafenib daily, probably due to a 
pharmacodynamic DDI between sorafenib and tacrolimus. Since side-effects are more 
prone in patients with a liver transplantation, starting with a dose of 200 mg twice a 
day seems a better and safer option in these patients than the regularly advised dose 
in non-transplant patients.41
As described in Chapter 2 of this thesis, drug transporters are important in the 
pharmacokinetics of many drugs among which the SMKIs. Drug transporters are 
divided in solute carrier (SLC) and ATP-binding cassette (ABC) transporters.42 These 
transporters are involved in either the uptake (e.g. OCT; SLC22A and OATP; SLCO) or 
efflux (e.g. P-glycoprotein; ABCB1 and BCRP; ABCG2) of drugs in and out of the cell.42,43 
Many SMKIs are substrate for specific drug transporters and are therefore prone 
to drug-transporter interactions. For example nintedanib, a TKI which is exclusively 
metabolized by phase II enzymes, shows a 61% increase in plasma exposure, when 
treated concomitantly with the strong P-glycoprotein (P-gp) inhibitor ketoconazole. 
Furthermore, treatment with rifampicin, a strong P-gp inducer, decreased nintedanib 
plasma exposure by 50%.44 Similar to nintedanib, sorafenib is also prone for interactions 
with drug-transporters, such as inhibition of OATP1B by rifampicin, which results in an 
increase in sorafenib-glucuronide plasma levels in mice.45 Besides the advantage of 
sorafenib therapy on survival, it also knows many side-effects of which hand-foot skin 
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reaction (HFSR) is the most common and debilitating.37,46 HFSR is a painful complication 
of the hands and feet in which hyperkeratotic plaques develop predominantly over sites 
of pressure or friction, which occurs in 20-40% of sorafenib-treated patients.47,48 There 
is currently no good treatment option for HFSR except for dose reduction or cessation 
of sorafenib therapy. Zimmerman et al.49 found that accumulation of sorafenib in 
keratinocytes is the possible mechanism behind HFSR in mice. The uptake of sorafenib 
is facilitated by the OAT6 (SLC22A20) transporter and inhibition of this transporter with 
probenecid, a drug used in the treatment of gouty arthritis, resulted in prevention 
of the HFSR. However probenecid is a known pan-UGT inhibitor and may therefore 
alter sorafenib pharmacokinetics, since sorafenib is metabolized by UGT1A9. In 
Chapter 7 we investigated the influence of probenecid on sorafenib pharmacokinetics 
and toxicity in patients treated with sorafenib. Probenecid decreased the sorafenib 
AUC0-12h 26.8% (90%CI: -37.7% to -14.1%; P < 0.01). Furthermore peak concentrations 
(-25.1%, 90%CI: -44.3% to -19.7%; P < 0.01) and trough levels of sorafenib (-26.0%, 
90%CI: -43.4% to -3.4%; P < 0.01) decreased. Moreover, sorafenib concentrations in 
keratinocytes decreased in the presence of probenecid with 28.1% (90%CI: -46.3% to 
-3.7%, P = 0.07). Unfortunately, there was no clear difference in skin toxicity between 
sorafenib monotherapy and sorafenib concomitantly with probenecid. Nonetheless, 
this study demonstrates that probenecid is likely to alter sorafenib concentrations, 
due to OATP1B1 inhibition, which alters the hepatic circulation of sorafenib and 
therefore changes systemic sorafenib concentration. These results offer probenecid 
as a new inhibitory agent for clinical interaction studies.50,51 In short, both systemic and 
cutaneous sorafenib exposure decreased proportional during concomitant probenecid 
administration, which may have been caused by interruption of enterohepatic cycling 
via OATP1B1 inhibition.
Besides pharmacokinetic DDIs there are also pharmacodynamic DDIs. A well-known 
example of the latter interaction is prolongation of the QTc-interval, which is associated 
with sudden cardiac death and (fatal) arrhythmias.52 The suggested mechanism of 
drug-induced QTc-interval is the inhibition of the potassium channel encoded by 
the human ether-a-go-go related gene (hERG). Inhibition of this potassium channel 
leads to a delay in ventricular repolarization and therefore a prolongation of the QTc-
interval.52,53 Prolongation of the QTc-interval is one of the most common causes of 
cessation of therapeutic use of drugs that have already been marketed.52 There are 
many drugs known to prolong the QTc-interval among which the (selective) serotonin 
reuptake inhibitors, which are frequently used by (cancer) patients for the treatment 
of depressive symptoms.54,55 Another drug that is known to prolong the QTc-interval, 
is tamoxifen.56,57 Tamoxifen is a selective estrogen receptor modulator (SERM) used in 
the adjuvant treatment of breast cancer. Tamoxifen inhibits the estrogen-dependent 
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proliferation of breast cancer cells and therefore reduces the risk of disease 
recurrence and mortality. Combining drugs that prolong the QTc-interval may result 
in a synergistic prolongation of the QTc-interval with an increased risk of cardiac side-
effects as a consequence.58 Chapter 8 presents an observational study in 50 patients 
using tamoxifen monotherapy and 50 patients using tamoxifen in combination with 
a serotonin reuptake inhibitor (SRI). In our study, concomitant use of tamoxifen with 
SRIs significantly prolonged the mean QTc-interval with 12.4 ms (95%CI 1.8 to 23.1 
ms; P = 0.023) when analyzed with the Fridericia formula. This prolongation was most 
prominent for patients using paroxetine, escitalopram or citalopram. Taken into account 
the pharmacokinetic drug interaction profile of both tamoxifen and SRIs, it should be 
advised to administer tamoxifen concomitantly with venlafaxine or fluvoxamine, which 
are not likely to result in QTc-interval prolongation. In contrast to other SRIs, these 
agents do not influence tamoxifen pharmacokinetics.59 In the general population there 
is a large interindividual variability of the QTc-interval making it hard for physicians to 
determine the clinical relevance of the QTc-interval prolongation on a single ECG.60 In 
the case of the combination of tamoxifen and SRIs like venlafaxine and fluvoxamine, 
monitoring of the ECG is not warranted, since the additional prolongation of the QTc-
interval is only minor. However, when using SRIs like paroxetine and escitalopram, 
monitoring is adviced since the prolongation of the QTc-interval may approach clinical 
significance. Furthermore, there are many individual risk factors like polypharmacy 
and age, that increase the risk of clinically relevant QTc-prolongation and explain the 
large interindividual variability in patients.
In conclusion, multiple DDIs are of major clinical relevance. In daily clinical oncology 
practice DDIs are common and need to be investigated further since sufficient clinical 
data is frequently lacking.
PART II: FOOD-DRUG INTERACTIONS (FDIS)
Besides co-medication there are many other factors that can influence the 
pharmacokinetics of drugs, such as lifestyle and food. Nowadays there is an increasing 
trend in the use of complementary and alternative medication (CAM) as a treatment 
strategy. This especially applies to cancer patients who use CAM increasingly more often 
as an alternative for the treatment of cancer and the complaints of both the disease 
and therapy-related side-effects.61 In total 48-88% of all cancer patients use alternative 
medication or food (supplements) next to their regular anti-cancer therapy.61,62 Besides 
the possible anti-cancer effects of food and supplements, these substances can also 
have a significant impact on the pharmacokinetics of several drugs and may therefore 
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deprive patients from optimal therapy. This is for instance the case for St. John’s wort, 
a herb used for treatment of depressive symptoms. The intake of this herb decreased 
the plasma levels of the active metabolite of irinotecan (SN-38) , a chemotherapeutic 
agent used in several tumor types among which colorectal carcinoma, by 42% (95%CI: 
14%-70%) by alteration of irinotecan metabolism.63 Food and herbs can also alter drug 
absorption. A well-known example is the influence of a fat meal on the absorption of 
the chemotherapeutic agent abiratarone, which is used in the treatment of prostate 
cancer. Administration of abiratarone with a high-fat meal resulted in a 10-fold 
increase in abiratarone plasma exposure compared to abiratarone intake without 
food.64 Chapter 9 gives an overview of known food interactions with SMKIs. We 
found that many SMKIs show a significant increase in both maximum concentration 
(Cmax) and AUC. For example, lapatinib showed an increase in the AUC of 100%-325% 
when administered with a high-fat meal compared to intake of lapatinib on an empty 
stomach. Furthermore, some food substances like grapefruit juice (an inhibitor of 
intestinal and hepatic CYP3A4) can alter SMKI exposure in a significant extent due to 
an interaction with TKI metabolism. Coadministration of grapefruit juice with ibrutinib 
showed an increase in AUC of 115% compared to ibrutinib with water.65 Additionally, 
intake with other beverages like green tea can alter SMKI pharmacokinetics as was 
shown for erlotinib, lapatinib, and sunitinib in rats resulting in a decrease in AUC of 
these drugs ranging from 51-74%.66,67 Besides food substances, herbs can also alter 
metabolism of SMKIs with St. John’s wort being the most familiaras was mentioned 
earlier.68 Therefore it is advised to abstain from St. John’s wort when using SMKIs in 
general. This review also found that the advices of the European Medicines Agency 
(EMA) and the Food and Drug Administration (FDA) were not always consistent, making 
the management of these interactions challenging for clinicians. A more uniform 
advise is necessary when interpreting a possible FDI with SMKIs and is presented in this 
review. It is difficult to estimate the impact of a particular diet of an individual patient 
on the pharmacokinetics of anti-cancer drugs since the interpatient variability is high. 
When an SMKI is advised to be administered without food, patients have strict dietary 
instructions. However, about 21% of the patients treated with a SMKI does not always 
follow these instructions resulting in altered pharmacokinetics of the SMKIs in these 
patients compared to patients who comply to the dietary instructions.68 This lack of 
compliance could potentially lead to a significant alteration in plasma pharmacokinetics 
as was shown for erlotinib, as missing a concomitant meal led to a decrease in erlotinib 
AUC of 15%.69 Moreover, individual SMKI variability is high and many other factors may 
influence its exposure. Besides the negative effects of intake with food, food can also 
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be used for food-dependent dose individualization. By taking SMKIs with food, some 
SMKI plasma levels increase, due to which the dose of these SMKIs can be lowered, 
which has many other advantages such as a reduction in drug costs simultaneously.
In chapters 2 to 4 of this thesis the DDIs of drugs with PPIs were already described. An 
SMKI which is known for its interaction with PPIs and other gastric acid suppressive 
agents, is erlotinib. Co-administration with PPIs results in a significant decrease in 
erlotinib plasma levels and ultimately reduces therapy efficacy.-12, 70, 71 However, many 
patients have an indication for the use of PPIs and cannot stop PPI therapy. A practical 
way to bypass this interaction is the intake of erlotinib with an acidic beverage to 
temporarily lower stomach pH and increase erlotinib absorption, as the TKI will dissolve 
better in this acidic environment. An acidic beverage which is frequently used in the 
modern society, is cola. The brand Coca-cola has a pH-value of 2.5 and can therefore act 
as a pH-lowering beverage. In patients using ketoconazole, the intake of ketoconazole 
with cola resulted in a significant increase in the AUC of ketoconazole.72 In Chapter 10 
we investigated the concomitant intake of erlotinib with Coca-Cola with and without a 
PPI in 28 patients. When erlotinib and esomeprazole were administered with Coca-Cola 
instead of water, this resulted in a significant and clinically relevant increase of 39% 
(95%CI: −12% to +136%; P = .004) in the AUC0-12h of erlotinib. This means that it partly 
corrects the negative effect of PPIs on the erlotinib AUC. This study therefore offers a 
practical way of using a beverage to improve erlotinib therapy in patients using a PPI. 
However, the almost 50% decrease in plasma levels of erlotinib with concomitant use of 
a PPI can also be bypassed using separate intake times of the PPI and erlotinib as was 
suggested in chapter 2 of this thesis.73 This suggestion also bypasses the disadvantages 
such as irritation of the stomach and long term side-effects as dental problems that 
adding an acidic beverage offers to the treatment with an SMKI.74,75
In Chapter 11 a healthier way of managing the interaction between erlotinib and PPIs is 
presented. Erlotinib, as most TKIs, knows a high solubility in a fatty environment as was 
also discussed in Chapter 9 of this thesis. Therefore, a fatty beverage may also increase 
the erlotinib absorption to bypass the interaction with PPIs. In Chapter 11, erlotinib 
was administered in 29 patients with either cow’s milk or water, both with and without 
a PPI. High-fat cow’s milk has proven to significantly interact with drugs depending 
on various mechanisms. For example, several antibiotic drugs (e.g. minocycline and 
tetracyclin) show a significantly decreased absorption, due to calcium binding of the 
drugs resulting in a decrease in plasma exposure.76 We found no significant difference 
in plasma pharmacokinetics of erlotinib when it was combined with high-fat cow’s milk 
(both with and without PPIs). Based on the results of this study, we can conclude that 
erlotinib intake with milk is safe and well-tolerated, but not sufficient to bypass the 
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decrease in plasma exposure when combining erlotinib with PPIs. When erlotinib was 
taken with a fatty meal, the AUC increased with 33-66% indicating a moderate FDI. 
High-fat cow’s milk has a caloric content of 68 kcal/ 100 mL and contained 3.9 g of 
fat per 100 mL. Patients took erlotinib with a total of 170 kcal in this study, whereas a 
standardized high-fat meal contains 800-1000 kcal.77 Since the total amount of calories 
and fat is (much) lower compared to a standardized high-fat meal, this could explain 
the absence of a significant interaction.
Besides FDIs at the absorption phase, there are many other substances (e.g. 
grapefruit juice and St. John’s wort) that can alter drug pharmacokinetics due to an 
interaction with drug metabolism. The use of food (supplements) and herbs is very 
popular among cancer patients, and curcumin is probably one of the most popular 
herbs, especially among breast cancer patients.61,62 This herb is derived from the root 
of the curcuma longa plant and is believed to have anti-tumor effects.78,79 However, 
curcumin can also alter pharmacokinetics of drugs as was shown by Cho et al.80 in 
rats using tamoxifen. Tamoxifen acts as a prodrug and needs to be metabolized into 
several active metabolites of which endoxifen is the most important one.81 Metabolic 
enzymes involved in tamoxifen metabolism are mainly CYP2D6 and CYP3A4. Next, 
UDP-glucuronosyltransferase (UGT) enzymes inactivate endoxifen into endoxifen-
glucuronide.81,82 This complex metabolic route makes tamoxifen prone for drug 
interactions as was shown previously with e.g. several SSRIs and rifampicin.55,83 In 
Chapter 12 the FDI between curcumin and tamoxifen was investigated in 16 patients. 
Compared to tamoxifen alone, we found a significant decrease in endoxifen AUC0–24h of 
7.7% (95%CI: −15.4 to 0.7%; P = 0.07) with curcumin and a decrease of 12.4% (95%CI: 
−21.9 to −1.9%; P = 0.02) with curcumin and piperine (a bio-enhancer used to increase 
curcumin plasma concentration). These effects were most prominent in patients with 
an extensive (normal) functioning metabolizing CYP2D6 enzyme. The decrease in AUC 
seems relatively small, but taking into account that a large part of patients is under or 
just marginally above the therapeutic threshold of endoxifen, using curcumin may still 
result in subtherapeutic endoxifen concentrations.9,84 This study emphasizes that the 
concurrent use of additional food or herbs is not by definition safe. The effect of curcumin 
on the exposure of endoxifen may be explained by a decreased absorption in the gut 
resulting in ultimately lower endoxifen plasma levels, but decent clinical evidence is not 
yet available.85 Moreover, a difference was seen in patients with an extensive CYP2D6 
metabolism phenotype and an intermediate metabolism phenotype. This difference 
can only partly be explained by the inhibitory potential of curcumin on CYP2D686, since 
CYP2D6 inhibition only results in a decrease in endoxifen concentrations in patients 
with a normal functioning CYP2D6 phenotype. More research is needed to determine 
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the exact mechanisms behind the effects of curcumin on the pharmacokinetics of 
tamoxifen. Meanwhile, patients should be discouraged to take curcumin supplements 
next to their tamoxifen therapy.
Another substance used extensively by cancer patients is green tea, which can be 
administered as either a hot drink, or in high concentrations as a capsule. Green tea is 
believed to have anti-cancer effects resulting from catechins, a class of flavonoids that 
exert potent antioxidant activity, of which (-)-epigallocatechin-3-gallate (EGCG) has the 
highest antioxidant and thus anti-cancer potential.87,88 However, in contrast, several 
flavonoids such as green tea may cause significant unwanted FDIs as was shown for 
the beta blocker nadolol, where co-administration with green tea resulted in a huge 
decrease in nadolol plasma concentration of 85%.89,90 In Chapter 13, we studied the 
effects of green tea capsules on tamoxifen and endoxifen concentrations in a cross-over 
design in 14 patients who were on steady state tamoxifen. We found no significant effect 
in endoxifen plasma concentration suggesting that administration of tamoxifen with 
green tea is safe from a pharmacokinetic point of view. We were unable to demonstrate 
a meaningful effect probably due to the lack of clinically relevant inhibition of phase 
I and II metabolizing enzymes. The effect on nadolol pharmacokinetics was probably 
due to OATP1B inhibition, which is a drug-transporter with no effect on tamoxifen or 
endoxifen pharmacokinetics. In general, the results in literature regarding green tea 
are in contradiction with these findings.89 There are several preclinical studies in cell 
cultures and mice that suggest an inhibitory effect on several pharmacokinetic levels, 
among which the phase I and II metabolizing enzymes.89,91 However, these effects could 
not be demonstrated in human subjects in this study. This underlines the need for 
clinical studies to investigate the magnitude of a certain interaction.
CONCLUSIONS AND IMPLICATIONS
Over the years, treatment of cancer has developed rapidly with a raise in treatment 
options and treatment strategies. It is important to ensure an optimal treatment for every 
individual patient by using personalized treatment strategies, where ideally individual 
patient characteristics should be taken into account. As mentioned thoroughly in this 
thesis, there are many factors that may interfere with anti-cancer therapy through 
alteration of drug pharmacokinetics, making DDIs and FDIs major influencing factors 
in daily oncology practice since they can influence anti-cancer drug pharmacokinetics 
and therefore efficacy and patient well-being.1,2 Drug interactions are responsible for 
20-30% of all the adverse reactions to drugs and account for up to 5% of the total 
hospital admissions.1,92 These interactions may lead to an altered drug exposure based 
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on several mechanisms – as discussed in this thesis –  usually leading to either a decline 
in therapy efficacy or an increase in side-effects. Most interactions take place during 
either the absorption phase, or the metabolism phase of an anti-cancer drug. There 
is a substantial amount of evidence about the interaction with strong inhibitors or 
inducers of metabolizing CYP enzymes and absorption interactions with high-fat meals. 
However, there is a clear lack of decent clinical research in the field of other drugs or 
substances, like compounds that can inhibit or induce drug transporters. The exact role 
of drug transporters is not fully determined, but is nevertheless considered to be of 
major clinical relevance.42 Drug transporters are located throughout the body and may 
have an influence in different ways. They can act as a barrier mechanism preventing 
drugs from entering organs such as the brain and they can even cause drug-resistance, 
because drug efflux transporters such as P-gp may be upregulated in tumor cells.93
The inhibition or induction of drug transporters on the exposure and pharmacokinetics 
of anti-cancer agents may potentially be an even larger clinical problem than 
interactions with drug metabolism (in terms of side-effects and efficacy). because of 
the wide spread of these drug-transporters in the body. Nevertheless, as there is only 
a limited number of clinical studies investigating these interactions, more research is 
definitely needed to better understand and predict the impact of inhibition or induction 
of these transporters on drug pharmacokinetics. Drug interactions can sometimes 
also be beneficial. For example, co-administration of a P-gp inhibitor can increase the 
sensitivity of a drug-resistant tumor and therefore improve the response of a patient 
to the particular anti-cancer agent.94,95 Furthermore, inhibition of specific transporters 
involved in the blood-brain barrier can alter the uptake of a drug in the brain, which 
leads to potentially better treatment of brain metastases and tumors.96,97
The most often implemented form of DDI research used for the registration of drugs, 
is inhibition of several metabolizing enzymes with strong CYP3A4 inhibitors or inducers 
(i.e. ketoconazole or rifampicin). However, clinical data is lacking for moderate or 
mild inhibitors and inducers or the interaction potential of several substances like 
herbs used by patients, even though these still could have clinically relevant effects. 
Currently, a trial aimed at exploring such an interaction is ongoing regarding the effects 
of the moderate CYP3A4 inhibitor erythromycin on the pharmacokinetics of palbociclib 
in cancer patients (Dutch Trial Registry number NL7549). Furthermore, it is important 
to acknowledge the fact that patients want to treat their cancer by using alternative 
medication or herbs. Nowadays, there are many (new) interesting substances that 
are becoming more and more popular under cancer patients such as cannabis. To 
better advice patients in clinical practice it is important to keep investigating possible 
interactions with these substances.
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In conclusion, drug-drug and food-drug interactions are of major clinical relevance, but 
more research is needed to better understand the mechanism and impact of these 
interactions on patients quality of life and therapy.
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In dit proefschrift worden verschillende onderzoeken beschreven over de wisselwerking 
tussen anti-kankermedicatie en (veelgebruikte) andere medicatie en voedingsmiddelen. 
In deze onderzoeken wordt gekeken naar de manier waarop het lichaam omgaat 
met het geneesmiddel (‘farmacokinetiek’), dan wel naar de manier waarop het 
geneesmiddel een effect heeft op het lichaam of de tumor (‘farmacodynamiek’). 
Binnen de geneesmiddelenleer, ook wel de farmacologie genoemd, bepalen deze twee 
onderdelen de uiteindelijke effecten van een geneesmiddel, zowel gewenst (een betere 
werking van je therapie) als ongewenst (meer bijwerkingen). Het overkoepelende 
doel van alle deelonderzoeken in dit proefschrift is om eventuele wisselwerkingen te 
identificeren waarmee de bijwerkingen (toxiciteit) van een medicijn kunnen worden 
geminimaliseerd of de effectiviteit van de behandeling kan worden verbeterd. Op die 
manier kan de behandeling van kanker verder worden geoptimaliseerd.
Deel 1: Wisselwerking tussen anti-kankermedicatie en comedicatie
De behandeling van kanker is in de afgelopen decennia drastisch verbeterd, wat heeft 
geleid tot een langere levensverwachting voor patiënten met kanker. Doordat de 
overleving toeneemt, neemt echter ook het aantal patiënten met langetermijnklachten 
van de kanker (of de behandeling van de ziekte) toe. Hierdoor gebruiken kankerpatiënten 
vaak meerdere soorten medicijnen tegelijkertijd, wat de kans op een wisselwerking (of 
interactie) enorm vergroot. Deze wisselwerkingen kunnen zowel voordelig als nadelig 
werken.
Een wisselwerking vaak invloed op de farmacokinetiek van een middel. De 
farmacokinetiek bestaat uit 4 stappen: 1) de opname of absorptie van een medicijn uit 
het maagdarmkanaal, 2) de verdeling of distributie van een medicijn via de bloedbaan, 
3) het metabolisme; oftewel de verwerking c.q. afbraak van een medicijn (meestal door 
de lever) en 4) de uitscheiding van een medicijn via de gal en/of de urine. Medicatie heeft 
vaak een invloed op de absorptie dan wel het metabolisme van een anti-kankermedicijn. 
In hoofdstuk 2 is een uitgebreid overzicht beschreven van alle bekende wisselwerkingen 
van de zogenaamde small-molecule kinase inhibitors (SMKI’s) met andere medicatie. 
SMKI’s worden gebruikt in de behandeling van verschillende soorten kanker, zoals 
long- en darmkanker. Deze middelen grijpen in op verschillende processen in de 
kankercel, waardoor deze niet meer goed kan functioneren en uiteindelijk doodgaat. 
Deze anti-kankermiddelen worden via de mond (oraal) ingenomen en moeten dus alle 
vier de stappen van het farmacokinetische proces doorlopen. Hierdoor lopen SMKI’s, 
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vergeleken met intraveneus toegediende anti-kankermiddelen, dan ook een grotere 
kans op wisselwerking met andere middelen, zoals ook blijkt uit het uitgebreide 
overzicht in hoofdstuk 2.
Een bekend voorbeeld van een wisselwerking in de absorptiefase heeft betrekking 
op maagbeschermers, zoals proton pomp remmers (PPI’s). Deze middelen worden 
door ongeveer een derde van alle kankerpatiënten gebruikt voor de behandeling 
van verschillende klachten zoals maagzuurbranden. PPI’s zorgen ervoor dat de 
maaginhoud minder zuur wordt, waardoor het maagzuur minder irritatie en pijn geeft. 
Sommige geneesmiddelen zoals de SMKI’s hebben echter een zure omgeving van de 
maag nodig om goed en volledig op te lossen. Als maagbeschermers ervoor zorgen 
dat de maag minder zuur wordt, kan het zijn dat de SMKI’s minder goed oplossen 
en daardoor uiteindelijk ook minder goed worden opgenomen in het bloed. Voor de 
SMKI dasatinib kan dit bijvoorbeeld zelfs tot meer dan een halvering van de opname 
leiden. Wanneer minder van het anti-kankermedicijn in het bloed terechtkomt, 
leidt dit mogelijk ook tot een mindere werking van het medicijn. Patiënten die het 
anti-kankermiddel capecitabine, dat o.a. wordt gebruikt voor de behandeling van 
darmkanker, tegelijkertijd innemen met een maagbeschermer leven bijvoorbeeld 
minder lang dan patiënten die geen maagbeschermer gebruiken. In hoofdstuk 3 is 
onze reactie op dit onderzoek met capecitabine en maagbeschermers beschreven, 
met daarin een opsomming van enkele tekortkomingen van deze studie. Tevens is een 
voorstel voor een nieuwe onderzoeksmethode naar deze wisselwerking beschreven. 
Deze nieuwe onderzoeksmethode is vervolgens toegepast in het onderzoek dat is 
beschreven in hoofdstuk 4 van dit proefschrift. Zoals gezegd zijn SMKI’s over het 
algemeen erg gevoelig voor de wisselwerking met maagbeschermers. Een SMKI, 
waar dit nog niet voor was uitgezocht bij mensen is regorafenib. Dit is een relatief 
nieuwe SMKI die wordt gebruikt voor de behandeling van onder andere darm- en 
leverkanker. In het onderzoek hebben we gekeken of de PPI esomeprazol invloed heeft 
op de blootstelling aan regorafenib. Bij 14 patiënten, die zowel regorafenib zonder 
esomeprazol als regorafenib met esomeprazol (op 2 verschillende momenten) hebben 
gekregen, zagen we geen verschil in blootstelling aan regorafenib. Op basis van dit 
onderzoek hebben we geconcludeerd dat de wisselwerking met maagbeschermers 
niet opgaat voor regorafenib en dat deze dus veilig samen gebruikt kunnen worden.
Naast de wisselwerkingen op het gebied van absorptie vinden de meeste 
wisselwerkingen plaats op het gebied van het metabolisme van medicatie, dat meestal 
in de lever plaatsvindt. De meeste medicijnen worden door bepaalde eiwitten (ook wel 
(CYP-)enzymen genoemd) in het lichaam afgebroken tot zogenaamde metabolieten. 
Deze eiwitten kunnen door andere medicatie worden gestimuleerd of afgeremd, 
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wat kan zorgen voor een lagere of hogere blootstelling aan het medicijn. Een bekend 
voorbeeld hiervan is het anti-schimmelmiddel ketoconazol. Dit medicijn remt het enzym 
CYP3A4, waardoor de blootstelling aan medicamenten dramatisch kan toenemen, 
zoals het geval is bij ibrutinib, een SMKI gebruikt bij chronische leukemie. Wanneer 
ibrutinib tegelijk wordt ingenomen met ketoconazol, wordt een 23 keer (!) hogere 
concentratie van ibrutinib in het lichaam bereikt dan zonder ketoconazol. Er zijn nog 
zeer veel andere medicijnen die in meer of mindere mate invloed hebben op CYP-
enzymen, waaronder de corticosteroïden (zoals prednison). Deze middelen worden 
gebruikt voor bijvoorbeeld het remmen van het immuunsysteem en worden veelvuldig 
in combinatie met chemotherapie gegeven. Zo worden patiënten met uitgezaaide 
prostaatkanker vaak behandeld met een chemotherapeuticum, docetaxel genaamd, 
in combinatie met prednison. Uit grote onderzoeken is echter gebleken dat er geen 
duidelijk verschil is in effectiviteit en bijwerkingen wanneer docetaxel met of zonder 
prednison gebruikt wordt. Prednison geeft daarnaast veel bijwerkingen, met name 
bij langdurig gebruik, waardoor het weglaten van prednison uit het behandelschema 
wellicht gunstiger is voor de patiënt. In hoofdstuk 5 is gekeken naar de invloed van 
prednison op de blootstelling aan docetaxel om te onderzoeken of prednison veilig 
uit het normale behandelschema kan worden geschrapt. In deze studie onder 18 
patiënten met prostaatkanker is er geen verschil in de blootstelling aan docetaxel te 
zien tussen patiënten die daarnaast worden behandeld met prednison ten opzichte 
van docetaxel zonder prednison. Hieruit kan worden geconcludeerd dat – op basis van 
de farmacokinetiek – prednison veilig kan worden weggelaten uit het behandelschema.
Een relevant probleem met anti-kankermedicijnen is het nauwe evenwicht (ook wel 
‘therapeutisch venster’ genoemd) tussen enerzijds de mogelijke bijwerkingen en 
anderzijds te weinig blootstelling aan het medicijn om effectief te zijn. Dit principe 
geldt ook voor de SMKI’s waarbij deze balans erg smal is. Wanneer in dit geval een 
wisselwerking plaatsvindt met andere medicatie, zeker als die andere medicatie 
ook nog eens een smal therapeutisch venster heeft, dan heeft dit potentieel grote 
klinische consequenties. Dit is bijvoorbeeld te zien bij patiënten met leverkanker na 
een eerdere levertransplantatie. Deze patiënten worden over het algemeen behandeld 
met de SMKI sorafenib en hebben vaak meer last van bijwerkingen van dit medicijn 
dan patiënten zonder een levertransplantatie. Dit kan komen doordat ze vaak 
middelen gebruiken die het immuunsysteem onderdrukken om afstoting van de lever 
te voorkomen (zogenaamde immunosuppressiva) zoals tacrolimus. Deze middelen 
kunnen potentieel het metabolisme van sorafenib en daarmee de concentratie ervan 
veranderen. In hoofdstuk 6 is gekeken naar de blootstelling aan zowel sorafenib als de 
immunosuppressiva in 4 patiënten die deze specifieke combinatie van geneesmiddelen 
gebruikten. Bij deze patiënten wordt in de loop van de tijd een duidelijke daling van 
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de blootstelling aan sorafenib waargenomen, maar tegelijkertijd lijden deze patiënten 
aan veel bijwerkingen van de behandeling met sorafenib waardoor ophogen van 
het medicijn erg lastig is. Het advies is dan ook om deze patiënten geen hoge dosis 
sorafenib te geven, omdat dit meestal leidt tot te veel bijwerkingen waardoor patiënten 
(tijdelijk of definitief) moeten stoppen met de behandeling.
Sorafenib kent veel bijwerkingen, zoals een hoge bloeddruk en allerlei bijwerkingen 
met betrekking tot de huid. Het hand-voetsyndroom is hiervan misschien wel de 
belangrijkste bijwerking met ook een grote impact op de kwaliteit van leven van deze 
patiënten. Het hand-voetsyndroom kenmerkt zich door pijnlijke blaar- en eeltvorming 
op de handpalmen en voetzolen. Er is geen andere behandeling voor deze bijwerking 
voorhanden dan het verlagen van de dosering dan wel het (tijdelijk) staken van de 
toediening van sorafenib. Onderzoek in muizen heeft laten zien dat het ontstaan van 
het hand-voetsyndroom kan worden voorkomen door het remmen van de functie van 
een geneesmiddel-transporter die zorgt voor de opname van sorafenib in huidcellen. 
Een bekende remmer van deze transporter is probenecid; een oud medicijn dat soms 
wordt gebruikt in de behandeling van jicht. De combinatie van probenocid met sorafenib 
is echter nog nooit in mensen getest. In hoofdstuk 7 is het resultaat beschreven van 
een onderzoek onder 16 patiënten naar de potentiële invloed van probenecid op de 
farmacokinetiek van sorafenib. Gelijktijdige inname van sorafenib met probenecid 
geeft een aanzienlijk lagere blootstelling aan sorafenib en de afbraakprodukten 
(metabolieten) ervan, zonder een duidelijk effect op de bijwerkingen. Deze combinatie 
is dan ook niet goed toepasbaar in de dagelijkse praktijk, maar toont wel aan dat 
probenecid een wisselwerking kan geven en dus wellicht kan worden gebruikt in 
toekomstig onderzoek naar interacties.
Ook op het gebied van farmacodynamiek kunnen er interacties optreden. Twee 
middelen kunnen bijvoorbeeld eenzelfde soort effect hebben en daardoor additief 
of zelfs synergistisch werken, maar ze kunnen elkaar ook juist tegenwerken 
(antagonistisch). Een voorbeeld van zo’n interactie is verlenging van het QTc-interval op 
het elektrocardiogram (ECG); oftewel de tijd van de ontspanning van de hartkamers, wat 
een risico geeft op hartritmestoornissen. Bekende medicijnen die dit effect hebben zijn 
de zogenaamde serotonine reuptake blokkers (SRI’s), oftewel antidepressiva. Een groep 
patiënten die veel last heeft van depressieve klachten, en daarvoor worden behandeld 
met antidepressiva, zijn borstkankerpatiënten. Deze patiënten worden vaak behandeld 
met tamoxifen; een (anti-)hormonale therapie die ook een QTc-intervalverlenging kan 
veroorzaken. In hoofdstuk 8 is gekeken of gelijktijdige toediening van een SRI met 
tamoxifen de QTc-intervalverlenging versterkt t.o.v. tamoxifen alleen. In dit onderzoek 
is een duidelijke toename in verlenging van het QTc-interval gevonden, met name bij 
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de anti-depressiva paroxetine, escitalopram en citalopram. De verlenging was niet 
dusdanig groot dat bij iedere patiënt actie is vereist. Echter, op basis van ons onderzoek 
verdient het wel de voorkeur om een SRI te geven die geen sterke QTc-verlening geeft 
en ook niet inwerkt op het metabolisme van tamoxifen, zoals venlafaxine.
Deel 2: Wisselwerking tussen anti-kankermedicatie en voeding
Naast het gebruik van comedicatie is er de laatste decennia ook een grote toename te 
zien in het gebruik van alternatieve medicatie en/of voedingssupplementen. Ongeveer 
48-88% van alle kankerpatiënten gebruikt tegenwoordig voedingsmiddelen en kruiden 
als een alternatieve of aanvullende strategie voor de behandeling van kanker. Naast de 
veronderstelde gunstige effecten op de ziekte kunnen voeding en kruiden helaas ook 
een nadelige invloed hebben op de farmacokinetiek van anti-kankermedicatie door 
een wisselwerking. Een voorbeeld hiervan is het middel abiratarone, gebruikt voor 
de behandeling van prostaatkanker. Inname met vette voeding geeft maar liefst een 
10 keer hogere blootstelling van abiratarone vergeleken met inname zonder voedsel. 
Zoals eerder genoemd zijn SMKI’s erg gevoelig voor een wisselwerking met medicatie 
en voeding. Een uitgebreid overzicht van voor SMKI’s bekende interacties met voeding 
en kruiden is gepresenteerd in hoofdstuk 9 van dit proefschrift. Het valt met name 
op dat er veel verschillen tussen de SMKI’s zijn in hoeverre ze goed oplossen in een 
vet milieu. Daarnaast zijn er ook voedingsmiddelen en kruiden die een wisselwerking 
op het niveau van het metabolisme veroorzaken. De bekendste voorbeelden hiervan 
zijn St. Janskruid en grapefruit(sap), die respectievelijk het enzym CYP3A4 stimuleren 
(inductie) en het enzym CYP3A4 remmen (inhibitie) en daardoor de bloostelling aan 
SMKI’s veranderen.
Zoals reeds genoemd in het eerste deel van dit proefschrift, zijn SMKIs erg gevoelig 
voor verschillende interacties met name een wisselwerking met PPI’s. Een bekend 
voorbeeld van een SMKI die erg gevoelig is voor deze interactie, is erlotinib. Dit middel 
wordt gebruikt in de behandeling van longkanker en lost het best op bij een erg lage 
zuurgraad van de maag. Aangezien PPI’s de maag minder zuur maken lost dit middel 
bij gebruik daarvan veel minder goed op, wat een lagere blootstelling tot gevolg heeft. 
Wanneer de pH van de maag tijdelijk verlaagd wordt tijdens de absorptiefase, omzeilt 
dat potentieel het negatieve effect van PPI’s. Een veelgebruikte frisdrank met een lage 
pH is cola (Coca-Cola; pH-waarde = 2.5). In hoofdstuk 10 is onderzocht wat inname van 
erlotinib met cola t.o.v. water doet met de opname van erlotinib in patiënten die al dan 
niet een maagbeschermer gebruiken. We zagen in deze patiënten dat het negatieve 
effect van de PPI’s nagenoeg wordt opgeheven door de tijdelijke verlaging van de pH 
door cola.
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Hoewel cola een duidelijk voordeel geeft ten aanzien van de opname van erlotinib, is 
inname met cola niet ideaal. Langdurig gebruik van cola kan namelijk ook resulteren 
in tandproblemen en gewichtstoename. Daarnaast moet erlotinib in de ochtend op 
een nuchtere maag met cola worden ingenomen wat ook niet voor iedere patiënt is 
weggelegd. Een alternatieve oplossing ligt mogelijk in gelijktijdige inname met een vette 
drank, omdat erlotinib tevens goed oplost in een vet milieu (zoals met vette voeding). 
In hoofdstuk 11 is een dergelijke strategie met volle koemelk (ongeveer 4% vet) 
besproken. In deze studie met 28 patiënten werd echter geen duidelijk effect van volle 
melk op de opname van erlotinib gezien, wat deze strategie geen geschikt alternatief 
voor het gebruik van cola maakt. Daarnaast is in deze studie gekeken naar het effect 
van de PPI esomeprazol op de blootstelling van erlotinib. Het blijkt dat esomeprazol 
een zeer forse daling geeft van de blootstelling aan erlotinib. Dit onderzoek bevestigt 
dus het grote probleem van gelijktijdige toediening. Patiënten kunnen erlotinib veilig 
met melk innemen indien dit gewenst is, omdat er geen duidelijke wisselwerking op 
het gebied van de farmacokinetiek is, maar het gelijktijdig gebruik van PPI’s wordt wel 
afgeraden.
Het gebruik van alternatieve medicatie wordt steeds populairder onder 
kankerpatiënten. Daarmee neemt ook het risico op een significante wisselwerking 
met anti-kankermedicatie toe. Een bijzonder populair kruid is kurkuma, dat wordt 
gewonnen uit de wortel van de curcuma longa plant en wordt gebruikt in de traditionele 
Aziatische keuken en geneeskunde. Onderzoek in muizen heeft laten zien dat kurkuma 
ook een effect kan hebben op het metabolisme van tamoxifen. Tamoxifen moet 
door verschillende enzymen (met name CYP2D6 en CYP3A4) in verschillende stappen 
worden omgezet in de actieve stof endoxifen. Hoofdstuk 12 beschrijft een studie in 16 
patiënten met borstkanker die tamoxifen met en zonder kurkuma (en een periode met 
kurkuma en zwarte-peperextract, dat er waarschijnlijk voor zorgt dat kurkuma beter in 
het bloed wordt opgenomen). Gelijktijdige inname van tamoxifen met kurkuma zorgt 
voor een significante daling van 12% in de blootstelling aan endoxifen. Hoewel dit een 
relatief klein effect is, kan dit een potentieel gevaarlijke wisselwerking zijn, aangezien 
voor de werkzaamheid van tamoxifen een bepaalde concentratie nodig is die door 
deze wisselwerking wellicht niet kan worden bereikt. Dit effect van kurkuma op de 
blootstelling aan tamoxifen en endoxifen is met name te zien in patiënten waarbij het 
metabolisme normaal functioneert, wat het merendeel van de patiënten betreft.
Naast kurkuma is er een ander supplement dat veel door borstkankerpatiënten wordt 
gebruikt, namelijk groene thee (capsules). Groene thee bevat namelijk zogenaamde 
flavinoïden (een stikstofvrije organische structuur die in planten voorkomt) waarvan 
epigallocatechine gallaat (EGCG) het belangrijkste is en mogelijk een anti-kankerwerking 
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heeft. Echter, EGCG kan ook een significante wisselwerking geven met medicatie, zoals 
eerder is aangetoond bij het geneesmiddel nadolol (een medicijn dat wordt gegeven 
aan patiënten met een ritmestoornis). Gelijktijdige toediening met groene-theecapsules 
gaf een afname van 85% van de blootstelling aan nadolol. Deze wisselwerking geldt 
mogelijk ook voor patiënten die worden behandeld met tamoxifen. In hoofdstuk 
13 is een onderzoek onder 14 patiënten gepresenteerd dat laat zien dat gelijktijdige 
toediening van tamoxifen met groene thee geen invloed heeft op de blootstelling aan 
endoxifen t.o.v. toediening zonder groene thee. Gelijktijdige toediening van tamoxifen 
met groene thee is dus veilig vanuit een farmacologisch gezichtspunt.
Al met al kunnen wisselwerkingen met medicatie en voeding een belangrijke invloed 
hebben op de werking van anti-kankertherapie. Potentieel kan er veel goed, maar ook 
veel fout gaan. Het is daarom belangrijk dat er voldoende aandacht en kennis is voor 
deze interacties met andere geneesmiddelen en voeding in de klinische praktijk en 
dat er veel onderzoek plaats blijft vinden. Op die manier kan patiënten een optimale 
gepersonaliseerde behandeling worden geboden, waarbij rekening wordt gehouden 
met (of advies gegeven kan worden over) alle medicatie en voeding/kruiden die een 
patiënt gebruikt.
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Dit proefschrift is uiteraard niet het werk van mij alleen. Zonder de hulp en steun 
van velen had dit werk nooit af kunnen komen. Allereerst wil ik alle patiënten en hun 
naasten bedanken voor alle toewijding en hun belangeloze inzet voor de verschillende 
onderzoeken in een fase van hun leven waarin ik zelf waarschijnlijk heel andere 
prioriteiten zou hebben. Zonder deze inzet zou (medisch-)wetenschappelijk onderzoek 
niet uitgevoerd kunnen worden en zou de geneeskunde niet staan waar zij nu staat. 
Daarnaast wil ik ook nog een hoop andere mensen in het bijzonder bedanken.
Allereerst wil ik mijn beide promotoren bedanken. Professor dr. Mathijssen, beste 
Ron, jij hebt ooit het vertrouwen in mij uitgesproken en mij over weten te halen om 
onder jouw hoede een promotietraject aan te gaan. Gelukkig heb ik hier geen spijt 
van gekregen en heb ik enorm veel geleerd in deze betrekkelijk korte tijd. Jouw 
enthousiasme en toewijding werken aanstekelijk en met name de tijd en moeite die je 
ondanks je drukke agenda telkens weer vrij hebt kunnen maken om stukken te lezen 
en lastige vragen te beantwoorden, hebben ervoor gezorgd dat dit proefschrift af is 
gekomen en ook dat jouw onderzoeksgroep zo floreert. Ik weet dat je het privé niet 
altijd makkelijk hebt gehad, maar als promovendus heb ik dit nooit gemerkt waarvoor 
ik alleen maar respect kan hebben. Wat mij betreft had je de 'promotor van het jaar' 
award zeker moeten winnen.
Professor Dr. Van Gelder, beste Teun, we hebben elkaar niet heel veel gezien tijdens 
onze promotie, maar desondanks heb ik veel aan je gehad. Je stond klaar voor alle 
(onderzoeksgerelateerde) vragen en dacht ook actief mee over het vormgeven van 
mijn toekomst. Uiteraard vind ik je transfer naar het LUMC een groot gemis voor het 
Erasmus MC, maar ik weet zeker dat ze daar erg blij met je zijn. Hopelijk kun je daar nu 
eindelijk wat mensen vinden die wel voor je favoriete voetbalclub zijn.
Beste Roelof, onze samenwerkingsperiode was een tumultueuze aangezien we beiden 
veel hebben meegemaakt, met en los van elkaar. Ik hoop dat je je ambities waar kunt 
gaan maken zonder daarbij jezelf voorbij te lopen, ik gun het je in ieder geval van harte! 
Daarnaast is het natuurlijk een eer om je eerste echte promovendus te zijn en we gaan 
het mooi afsluiten straks tijdens (en na) de verdediging.
Prof. Dr. Gelderblom, Prof. Dr. Dingemans, Prof. Dr. Huitema, bedankt dat jullie de 
moeite en tijd hebben genomen om dit manuscript te beoordelen. Daarnaast wil ik 
alle overige leden van de commissie, Prof. Dr. Sparreboom, Prof. Dr. Reyners, Prof. Dr. 
Aerts en Dr. Frank Jansman bedanken voor het plaatsnemen in de oppositie.
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Ruben, mijn EE-19 maatje, zonder jou had mijn algemene muziek-, sport- en 
Rotterdamkennis nooit geweest wat het nu is. Jouw verbluffend mooie(?) muzieksmaak 
van nog steeds legendarische artiesten als Snelle, Frenna en Josylvio heeft duidelijk 
zijn sporen nagelaten. Een locomotief zal nooit meer hetzelfde zijn. En uiteraard mis ik 
onze vrijdagmiddag afterparty, die altijd een mooi begin van het weekend was. Laten 
we dit, nadat je me hebt bijgestaan bij de promotie, snel nog maar eens overdoen.
Edwin, samen zijn wij gestart met ons promotietraject. Als AE-306 nomaden voelden 
we ons vaak een beetje geïsoleerd van de groep, maar we hebben ons er maar mooi 
doorheen geslagen. Nogmaals dank voor alle gezellige momenten en hulp (met name 
met technische zaken als computers). Leuk dat je nu weer terug bij de groep bent na je 
coschappen en ik weet zeker dat je je promotie nu ook goed af gaat sluiten. Daarnaast 
vind ik het erg fijn dat jij me tijdens de promotie een steuntje in de rug wil geven.
Femke, lieve Fem, jouw georganiseerde aanpak en doorzettingsvermogen heeft velen 
van ons geholpen en geïnspireerd bij onze promotie. Niet voor niks is jouw opbouw 
van de persoonlijke mappen nog steeds heilig en ben je cum laude gepromoveerd. 
Onze gesprekken bij een bak koffie waren altijd een fijne start van de dag. Ik weet zeker 
dat je het nog heel ver gaat schoppen als oncoloog en als kersverse echtgenote. Dat 
speciaalbiertje in Delft moet er binnenkort toch maar eens van komen!
Lieve Flo, op het eind waren wij toch mooi ineens de ervaren promovendi, maar jij 
natuurlijk veruit de oudste. Ik heb altijd erg genoten van jouw naïviteit, je chaotische 
buien en soms toch een beetje onhandige momenten. Zelf heb ik hier graag misbruik 
van gemaakt en je (samen met Ruben) veelvuldig voor de gek gehouden. Gelukkig 
hebben we er samen altijd goed om kunnen lachen en heb ik aan jou een geweldige 
collega gehad. Het meest legendarische moment voor mij blijft toch wel het shoppen 
bij Macy’s in Chicago (ik bedoel, hoe dan!).
Bodine, lieve Bo, ondanks dat je toch heel anders bent dan ik, lijken we toch ook veel 
op elkaar. Helaas heb ik nooit lang bij je op de kamer mogen zitten, maar ondanks dat 
hebben we toch veel leuke gesprekken gehad en vooral lekker over sport en flauwekul 
geluld. Jouw heerlijk fanatieke en eerlijke houding heb ik enorm gewaardeerd en deze 
gaat je zeker nog ver brengen als mens en als uroloog. Daarnaast vind ik het ergens 
ook een fijn idee dat ik later met al mijn plasproblemen bij je terecht kan.
Marijn, jouw persoonlijkheid is uniek. Je hebt een eigen mening en komt daar ook 
gewoon lekker voor uit. Gelukkig heb ik je in de loop van de tijd ook wat beter leren 
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kennen en ben ik erachter gekomen dat je stiekem toch wel een klein hartje hebt. 
Uiteraard hebben we samen veel gelachen en heb ik altijd erg fijn met je samengewerkt, 
met de publicatie in Lancet Oncology als hoogtepunt.
Porrazzo, als niet-promovendus toch lid worden van de promovendigroep is natuurlijk 
een topprestatie. Sowieso heb ik bewondering voor hoe je bent opgeklommen de 
afgelopen jaren. Je bent een goede vriend geworden en we hebben samen veel leuke 
dingen meegemaakt. Bijna overvallen op Rotterdam Zuid, legendarische potjes FIFA, 
pizza eten en uiteraard je carnaval ontmaagding (als je je dat tenminste nog kunt 
herinneren). Ik hoop dat er nog veel van dit soort momenten mogen volgen.
Louwrens, ik heb jouw ontwikkeling vanaf dag 1 mee mogen maken. Eerst student in 
AE-306 en daarna doorgegaan met een promotietraject bij onze groep. Jouw kennis 
over tamoxifen is ongeëvenaard en je bent intussen de apotheker met het meeste 
directe patiëntencontact van Nederland. Je gaat je promotie zeker goed afsluiten met 
een mooi proefschrift waarin de TEA-studie uiteraard het hoogtepunt gaat zijn.
Daan, jij was gelijk een unieke aanwinst voor de club van promovendi met al je 
levenservaring, er is volgens mij niks wat jij niet hebt meegemaakt. Altijd gezellig 
aanwezig en ik heb veel met je gelachen (als je dan uiteindelijk op het werk verscheen 
tenminste). Ondanks dit alles heb je ook tijd gevonden om je promotie in relatief korte 
tijd af te ronden en dat gaat sowieso leiden tot een erg mooi proefschrift en vast ook 
een mooie vervolgcarrière.
Nikki, wat hebben wij stiekem al veel meegemaakt samen. We gaan uiteraard terug tot 
het COLA-studie dreamteam en we zijn (jij weliswaar via een omweg) ook allebei in een 
promotietraject binnen de klinische farmacologie terecht gekomen. Ik heb altijd erg fijn 
met je kunnen werken en vooral ook goed kunnen praten. Je bent echt een vriendin 
voor me geworden in al die jaren. Onze dubbeldate in Haarlem moeten we maar snel 
plannen, al is het maar voor wat extra triatlonadviezen.
Leni, wat heb ik fijn met jou mogen samenwerken tijdens mijn promotie met name 
bij onze gezamenlijke sorafenib-projecten. De klinische ervaring die jij meebrengt, is 
gigantisch en daardoor ook onmisbaar in het functioneren van de onderzoeksgroep 
en de afdeling oncologie van het Erasmus MC. Naast het werk was er ook altijd tijd 
voor een informeel (uitgebreid) gesprek of activiteit met de silent disco toch wel als 
hoogtepunt. Je gaat het zeker fantastisch doen tijdens jouw promotie.
Mirjam, in de korte tijd die we hebben samengewerkt, heb ik een heel fijne collega aan 
je gehad. We moesten als streekgenoten de Brabantse eer toch altijd hooghouden en 
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dat is volgens mij prima gelukt. De ESMO van 2019 was ons gezamenlijke hoogtepunt 
waarbij we naast de gezelligheid onze kamergenoten toch echt hebben moeten 
opvoeden. Ik ga er uiteraard vanuit dat je dit ook blijft doen met al je huidige mannelijke 
collega’s, dan blijft de onderzoeksgroep toch een beetje in het gareel als Ron er niet is. 
Heel veel succes met je verdere carrière.
Stefan, als mijn opvolger van de interactie-lijn binnen de onderzoeksgroep weet ik zeker 
dat je een mooi traject en uiteindelijk een mooie promotie tegemoet gaat. Daarnaast 
gaan we elkaar zeker in de gaten houden op Strava.
Wesley, jij bent een erg leuke en unieke aanvulling voor de promovendi groep. Helaas 
snap ik niet heel goed waar je onderzoek over gaat, maar je kunt er in ieder geval 
altijd goed over vertellen. We hebben daarnaast samen veel kunnen lachen bij alle 
gezamenlijke besprekingen en borrels. Verder ben ik erg blij dat je nu af en toe even 
op mijn vriendin past.
Inge, Lindsay, Lisanne, Pauline en Melissa, oftewel de meiden van de overkant. Ik heb 
jullie altijd heel fijne en gezellige collega’s gevonden en met name op de ASCO en ESMO 
hebben we heel veel leuke momenten samen beleefd. Bedankt voor de gezelligheid 
en het ga jullie goed! Lieve Inge, wat is jouw leven enorm veranderd sinds je weg 
bent gegaan uit het Erasmus MC. Een nieuwe baan, getrouwd en natuurlijk een klein 
menneke erbij! Het geluk lacht je toe en ik kom snel maar eens die kant op om bij te 
kletsen, zoals we altijd hebben gedaan tijdens onze vele koffieafspraakjes.
Esther, bedankt voor al je hulp bij de vele statistische berekeningen en vraagstukken 
die ik je heb voorgelegd. Op de een of andere manier maak je statistiek altijd een 
stukje simpeler. Bedankt voor de geweldige inzet en betrokkenheid bij de verschillende 
projecten en nogmaals heel veel geluk met je zoontje.
Stijn, Bedankt voor al je input bij mijn verschillende onderzoeken. Ik heb erg veel van 
je geleerd de afgelopen jaren. Naast werk was je ook altijd in voor gezelligheid zoals in 
Chicago tijdens de ASCO in ons grote appartement.
Azi, thanks for all the ‘gezellige’ coffee moments. We have had a lot of interesting 
conversations and also helped each other during difficult times. I hope you can 
finish your PhD-trajectory on short notice and continue your career in Belgium, in 
the beautiful city of Antwerp. When the COVID-19 pandemic is attenuated, we must 
certainly catch up.
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Peter, Inge en Mei, zonder jullie zou dit hele boekje slechts een kaft met wat tekst 
zijn. Ik heb altijd fijn met jullie samengewerkt en vind het elke keer weer bijzonder 
wat er eigenlijk allemaal kan met die ingewikkelde machines. In de loop van de jaren 
heb ik jullie gelukkig ook op een betere manier leren kennen tijdens de labuitjes en 
gesprekken bij een bak koffie.
Bimla en Carla, ook jullie werk wordt vaak onderschat maar met een stappenteller zou 
al snel duidelijk worden hoeveel jullie doen voor het lab. Bimla, jij was mijn tweede 
moeder de afgelopen jaren en ik heb altijd erg genoten van je Surinaamse kookkunsten 
en temperament. Carla, het was altijd gezellig om samen op de kamer te zitten tijdens 
PK-dagen en te carpoolen naar labuitjes en barbecues vanuit het zuiden van Nederland.
Sander, ik heb jou heel lang als voorbeeld gezien wat betreft kennis over farmacokinetiek 
en onderzoek doen. Jouw enthousiasme werkt inspirerend, maar misschien heb ik nog 
wel meer genoten van je vaak verschrikkelijk droge humor. Bedankt voor je uitgebreide 
bijdrage in de afrondende fase van mijn proefschrift, want dat is met een opleiding en 
twee kleintjes wel het laatste waar ik mee bezig zou zijn.
Veel van het werk dat bij klinisch onderzoek komt kijken zou niet mogelijk zijn zonder 
alle baliemedewerkers, secretaresses en verpleegkundigen die achter de schermen veel 
voor ons doen en regelen. Jullie zijn met te veel om allemaal afzonderlijk te bedanken, 
maar ik ben jullie allen ontzettend dankbaar voor de hulp en inzet de afgelopen jaren. 
In het bijzonder Petra, Chantal, Willy, José en Eline, bedankt voor alles.
Ook moet ik natuurlijk alle oncologen en AIOS in het Erasmus MC en daarbuiten 
bedanken voor het doorsturen en benaderen van een heleboel patiënten. Zonder jullie 
hadden we de studies nooit vol gekregen. Ook heb ik op klinisch en communicatief 
vlak ook veel van jullie kunnen leren. Verder heb ik genoten van alle gezelligheid buiten 
het Erasmus MC op de verschillende congressen en tijdens de jaarlijkse marathon van 
Rotterdam.
Een bedankje voor Leonie, Stan, Niels en Nadia is uiteraard ook op zijn plaats in dit 
boekje. Jullie hebben als studenten veel werk uit handen genomen en hebben met 
veel enthousiasme meegeholpen aan verschillende van mijn onderzoeken. Jullie gaan 
er allemaal stuk voor stuk komen en wellicht kan ik op termijn een boekje van jullie 
tegemoet zien.
Zonder goede uitlaatklep nooit een goed boekje. Voor mij is dat altijd sport geweest en 
daarom nog een shout out naar de leden van groep 1 van AVO83 voor de gezelligheid 
en de fysieke uitdaging tijdens deze periode. Ook wil ik mijn vrienden van TOGA 
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bedanken, jullie hebben zonder dat jullie het misschien zelf beseffen heel veel voor mij 
betekent in een heel moeilijke periode. Ik kijk ernaar uit om te knallen volgend jaar in 
de tweede divisie.
Alle collega ANIOS, verpleegkundigen en SEH-artsen van de spoedeisende hulp van het 
Bravis ziekenhuis, bedankt voor de gezelligheid en geweldige collegialiteit de afgelopen 
maanden. Ik heb veel geleerd en meegemaakt in de afgelopen maanden en had nog 
veel langer willen blijven. We houden zeker contact!
Jos, Marjo en met name Debbie bedankt voor de vele jaren aan steun en vertrouwen. 
Jullie support is voor mij überhaupt de reden geweest om aan dit hele avontuur te 
beginnen. Het is allemaal anders verlopen dan gepland, maar zonder deze steun had 
het toch beduidend minder makkelijk geweest en was ik er misschien wel nooit aan 
begonnen. Linda bedankt voor alle gezelligheid en steun de afgelopen jaren. Ik weet 
zeker dat het goed gaat komen met jou.
Mark, Luc, Bram, Pim en René, we spreken eigenlijk chronisch te weinig af, maar de 
keren dat we het doen, zijn altijd weer legendarisch. Jullie zijn topvrienden en mede 
dankzij de ontspanning die ik vond als we wel afspraken, heb ik dit traject tot een 
goed einde kunnen brengen. Marco, voor jou geldt eigenlijk hetzelfde, na de COVID-
pandemie moeten we snel maar weer afspreken en bijkletsen.
Melvin, we kennen elkaar al sinds de brugklas en hebben nagenoeg hetzelfde pad 
bewandeld. Over een paar jaar zijn we collega-huisartsen en ik weet zeker dat we 
hierna nog vele jaren samen op zullen trekken. Bedankt voor al die jaren vriendschap, 
dat heeft me uiteindelijk gebracht waar ik nu ben.
Lieve René, Angelique en Marlou, ik had me geen betere schoonfamilie kunnen wensen! 
Ik heb me vanaf het begin af aan thuis gevoeld en jullie interesse in mijn bezigheden 
doet me altijd erg goed. Het ‘afstandsprobleempje’ komt zeker goed in de toekomst en 
dan gaan we elkaar echt vaker zien.
Lieve pa, ma, Noortje, Tijs en Hanneke (en Silven en Joris), jullie zijn de afgelopen jaren 
altijd de stabiele rots in de branding geweest. Zonder jullie steun had ik nooit zover 
kunnen komen met mijn universitaire traject en had ik niet gestaan waar ik nu sta. We 
gaan er nog een leuk feestje aan vast plakken, want daar zijn we nu eenmaal goed in!
Lieve Liza, ruim een jaar geleden hebben we elkaar gevonden als koffiemaatje. Hierna 
is het erg snel gegaan en ondertussen ben je mijn beste vriend, mijn luisterend oor 
en vooral mijn geliefde. Als jij er niet was geweest had mijn leven er nu heel anders 
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uitgezien en had ik me niet gevoeld zoals ik me momenteel voel, kortom bedankt voor 
alles, maar echt. Ik kijk uit naar al het leuks en de vele mooie dingen, die we samen nog 
gaan beleven.
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